

ANNUAL REPORT & ACCOUNTS



>> EMPOWERING THE FUTURE





YOU ARE THE REASON WE EXIST!





At Fidson Healthcare Plc, we know that quality is never an accident. That is why we operate a world-class company and a WHO compliant state-of-the-art manufacturing facility with cutting-edge technology to produce high-quality pharmaceutical products across major therapeutic classes.

We also collaborate with global partners to bring you premium products insisting on these same values across our entire value chain because...

...we value life



♠ +234 807 700 8888

info@fidson.com

268, Ikorodu Road, Obanikoro, Lagos, Nigeria.











COMPANY PROFILE



The Company

Fidson currently manufactures from its ultramodern, Current Good Manufacturing Practice (CGMP) compliant factory in Sango Ota, Ogun State. The company is one of a few local pharmaceutical manufacturers that are candidates for pre-qualification by the World Health Organization. By leveraging our relationships and collaborating with various overseas manufacturers, most of whom are market leaders in their areas of specializations, we are able to deliver hundreds of high quality medicines to Nigerians. Today, Fidson is one of the largest employers of pharmacists in Nigeria, outside of government institutions, and we constantly employ global best practices in our operations.

About Us

Fidson Healthcare Plc started operations on March 1, 1995 as a local distributor of pharmaceutical products. Barely a year after, the company moved into an importation of its own brand of finished medicines. The company set up its first local manufacturing facility in July 2002. In March 2005, Fidson became the first company in sub-Saharan Africa to manufacture Antiretroviral (ARVs) drugs.

In February 2007, Fidson set up a second manufacturing facility and ceded the former manufacturing facility to an international joint venture project, which led to setting up of Ecomed Pharma Limited. In November of the same year, the company received the NIS ISO 9001:2000 certification of its Quality Management System from the Standards Organization of Nigeria (SON). In 2008, the company was listed on the floor of the Nigerian Stock

Exchange, NSE to become a publicly quoted company. In 2009, the company won the Financial Standard Sector Leader Award and received the NIS ISO 14001: 2015 Certification in 2018.

The tremendous and phenomenal growth of Fidson, without a doubt has been guided by providence and a team of young, passionate, dedicated and goal-driven field personnel, seasoned managers and a visionary management team driven by a passion for excellence and credibility.



VISION, MISSION & CORE VALUES



VISION

To be the preferred healthcare provider.



MISSION

To be the preferred company that adds value to life with brands that deliver sustainable, profitable growth.

Our Core Values



Our drive to achieve outstanding results without compromising our integrity remains unparalleled. This unequalled consistency in quality of our delivery stands out amongst our peers.



The zeal and tenacity in improving our quality standards for customer satisfaction has continually sustained our brand within the competitive environment. This drives the energy and dedication of our team in striving to deliver and build consumer loyalty.



We reflect this creed in the products, people and information provided by our organization. This has endeared our brand to the public as a premium (quality) pharmaceutical company.



Our pursuit for continuous innovative and affordable healthcare products that would touch practically every household has been the platform for product development.



We take ownership of the challenges in the industry and provide leadership to advance the science and practice of pharmacy. Some of our most heralded breakthroughs, such as the unprecedented Astymin, is a result of our ground-breaking efforts.

CONTENTS

- 6. Notice of 23rd Annual General Meeting
- 8. Corporate information
- 9. Results at a glance
- 18. Report of the Directors
- 21. Corporate governance report
- 29. Statement of Directors' Responsibilities
- 30. Audit committee's report
- 35. Independent Auditors' report
- 40. Statement of profit or loss and other comprehensive income
- 41. Statement of financial position
- 42. Statement of changes in equity
- 43. Statement of cash flows
- 82. Value added statement
- 83. Five-year financial summary
- **Unclaimed Dividends** 89.

NOTICE OF THE 23RD ANNUAL GENERAL MEETING

Notice is hereby given that the 23rd Annual General Meeting of Fidson Healthcare Plc will hold on Thursday, the 28th of July 2022 at the Conference Centre 2nd Floor, Fidson Towers, 268 Ikorodu Road, Obanikoro, Lagos at 10.00 a.m. to transact the following businesses:

Ordinary Business

- To lay before the meeting the audited accounts for the year ended 31st December 2021 together with the reports of the Directors, Auditors and Audit Committee thereon
- 2. To declare a dividend of 50 kobo per 50 kobo ordinary shares amounting to a total of N1,043,180,125 (one billion and forty-three million, one hundred and eighty thousand, one hundred and twenty-five naira, only).
- 3. To re-elect Mr. Olusegun Adebanji who is aged over 70 years as a Director pursuant to Sections 261 and 282 of the Companies and Allied Matters Act, 2020, special notice being hereby given and to re-elect other Directors who are due for re-election.
- 4. To authorize the Directors to fix the remuneration of the Auditors.
- To disclose the remuneration of the Managers of the Company.
- 6. To elect members of the Audit Committee in accordance with Section 404(3) of the Companies and Allied Matters Act, 2020.

Special Business

7. To consider and if thought fit to pass the following as an ordinary resolution:

(I) ISSUANCE OF BONUS SHARES

"That in line with the recommendation of the Board of Directors and to comply with the provisions of Section 124 of the Companies and Allied Matters Act 2020 and Regulation 13 of the Companies Regulations 2021 with respect to the company's unallotted shares, a bonus issue of **one new** ordinary share of 50 kobo **for every ten** ordinary shares held as at the close of business on the **8th of July 2022**, and totaling **208,636,025** ordinary shares be and are hereby issued to rank pari-pasu in all respects with the existing ordinary shares of the company.

- (ii) 'That, in furtherance of the above and pursuant to Section 430(5) of the Companies and Allied Matters Act, 2020, the sum of N104,318,012.50 (one hundred and four million, three hundred and eighteen thousand and twelve naira, fifty kobo) out of the total balance of N4,933,932,000 (four billion, nine hundred and thirtythree million, nine hundred and thirty-two thousand naira) only standing to the credit of share premium account be and it is hereby applied for the bonus issue.'
- (iii) "That the Directors be and are hereby authorized to allot any outstanding amount of shares after the bonus issue whether by way of Employee Shares schemes or in any manner as they may deem fit for consideration that shall be fixed by them"
- (iv) "That the Directors be and are hereby authorized to do all things necessary to give effect to the allotments with

the relevant Regulators by way of registration and/or listing.'

- 8. To fix the remuneration of Directors.
- 9. To consider and if thought fit, to pass the following as an ordinary resolution: "That, pursuant to Rule 20.8 of the rulebook of Nigerian Exchange Limited, 2015: Issuers Rule, the general mandate given to the Company to enter into recurrent transactions with related parties for the Company's day-to-day operations, including amongst others the procurement of goods and services, on normal commercial terms be and is hereby renewed."

NOTES

1. Proxy

A member entitled to attend and vote at the Annual General Meeting is entitled to appoint a proxy to attend and vote in his/her stead. A proxy form is attached. All instruments of proxy should be duly completed and deposited at the registered office of the company at No 268 Ikorodu Road, Obanikoro, Lagos or the office of the Registrars, Meristem Registrars and Probate Services Limited, 213 Herbert Macaulay Way, Adekunle Yaba, Lagos or by email to info@meristemregistrars.com not later than 48 hours before the commencement of the meeting to enable the Company to stamp the proxy forms at its expense.

PROXY:

In view of the COVID-19 pandemic and the directives issued by relevant authorities on physical distancing and the ban on large gathering, the Corporate Affairs Commission has approved that attendance to the meeting shall only be by proxies. Consequently, Members are required to appoint any of the under-listed persons who are also shareholders of the Company including the Chairman as proxies to attend and vote in his/her/its stead:

- 1. Mr. Segun Adebanji
- 2. Dr. Fidelis Ayebae
- 3. Chief Matthew Akinlade, FCA
- 4. Alhaii Abdulkabir Babatunde Sarumi
- 5. Mr. Solomon S. Akinsanya
- 6. Sir Sunny Nwosu
- 7. Dr. Anthony O. Omojola
- 8. Mrs. Adebisi Bakare
- 9. Mr. Owolabi Peters.
- 10. Mr. Tunji Bamidele
- 11. Mr. Godwin Ede.
- 12. Barrister. Ganiyat Adetutu Siyanbola
- 13. Mr. Nonah Awoh.
- 14. Mrs. Efunyemi Obideyi
- 15. Mr. Badmus Tunde

2. Dividend Payment

If the dividend recommended by the Directors is approved by members at the Annual General Meeting, payment would be made on Friday, 29th of July 2022 to members whose names appeared in the Register of members at the close of business on the 8th of July 2022. In line with the directives of the Securities and Exchange Commission to pay dividends electronically by direct credit to the bank accounts of shareholders, the dividend would be paid accordingly.

3. Closure of Register of Members

The Register of Members and Transfer Books of the company will be closed from 11th to 15th of July 2022 (both dates inclusive) for the annual general meeting's notice and payment of dividend.

4. Nomination of members of the Audit Committee

Any member may nominate a shareholder as a member of the Audit Committee by giving notice in writing of such nomination to the Company Secretary at least 21 days before the date of the Annual General Meeting.

Section 404 (5) of the Companies and Allied Matters Act 2020 provides that all members of the Audit Committee shall be financially literate and at least one member shall be a member of a professional accounting body established by an Act of the National Assembly in Nigeria. It may therefore be necessary to attach curriculum vitae to every nomination for verification.

5. E-Dividend

Pursuant to the directive of the Securities and Exchange Commission notice is hereby given to all shareholders to respectively open a bank account, stockbroking account and CSCS account for e-dividend. Forms are attached to this annual report for completion by all shareholders to furnish the particulars of these accounts to the Registrars (Meristem Registrars and Probate Services Limited) as soon as possible.

6. Securities holders' rights

In compliance with rule 19.12 (c) of Nigerian Exchange Limited, a member and other securities holders of the

company may ask questions not only at the annual general meeting but also in writing before the meeting. Such questions should be submitted at least one week before the date of the meeting.

7. LIVE STREAMING OF THE AGM

To enable Shareholders and other Stakeholders who will not be able to attend the meeting physically to follow the meeting proceedings the Annual General Meeting will be streamed live. Link for the live streaming will be made available on the Company's website: **www.fidson.com** in due course.

BY ORDER OF THE BOARD



J. ABAYOMI ADEBANJO, FCIS COMPANY SECRETARY 268, Ikorodu Road, Lagos

Dated this 21st day of June 2022 FRC/2013/ICSAN/00000002161



CORPORATE INFORMATION

DIRECTORS Mr. Segun Adebanji, FCA Independent Non-Executive Director/Chairman - Appointed 2018

Dr. Fidelis A. Ayebae Managing Director/ Chief Executive Officer Mrs. Olufunmilola O. Avebae Non- Executive Director

Mr. Emmanuel E. Imoagene Non- Executive Director Mrs. Aishatu P. Sadauki Independent Non- Executive Director Dr. Vincent Ahonkhai Independent Non- Executive Director

Mr. Ekwunife Okoli Independent Non- Executive Director Mr. Olugbenga O. Olayeye Executive Director, Strategy and Marketing Mr. Abiola A. Adebayo Executive Director, Technical

Mr. Ola Ijimakin Executive Director, Commercial

COMPANY SECRETARY Mr. J. Abayomi Adebanjo, FCIS

Obanikoro, Lagos. Tel: 234 807 700 8888

www.fidson.com, e-mail: info@fidson.com

AUDITORS

SOLICITORS

53-57, Bamqbose Street Lagos Island, Lagos Tel: 2348093131158

BANKERS Access Bank Plc

FSDH Merchant Bank Limited

First Bank of Nigeria Limited

Guaranty Trust Bank Plc

Unity Bank

Zenith International Bank Plc

REGISTRARS Meristem Registrars

213, Herbert Macaulay Way

Adekunle, Yaba

Lagos

Tel: 234 18920491

Email: info@meristemregistrars.com

- Pioneer

- Appointed 2001

- Appointed 2011 - Appointed 2011

- Appointed 2021

- Appointed 2021

- Appointed 2011

- Appointed 2011

- Appointed 2021

REGISTERED OFFICE 268, Ikorodu Road,

Deloitte & Touche

(Chartered Accountants)

Civic Towers, Plot GA1 Ozumba Mbadiwe Street,

Victoria Island, Lagos.

Adesokan & Adesokan

Bank of Industry Fidelity Bank Plc

First City Monument Bank Plc

Union Bank Plc Wema Bank Plc

RESULTS AT A GLANCE

	Dec-21 ₦¹000	Dec-20 ₦'000	% Change
Revenue	30,860,817	 18,275,856	69%
Profit before tax	4,717,644	1,772,802	166%
Profit for the year	3,719,913	1,205,039	209%
Retained earnings	7,774,138	4,561,808	70%
Minimum share capital	1,200,00	1,200,000	0%
Issued share capital	1,043,180	1,043,180	0%
Shareholder's fund	13,751,835	10,539,435	30%
PER SHARE DATA			
Earnings per share (Kobo)			
Basic and diluted	178	58	207%
Net asset per share (Kobo)	659	506	30%
Stock exchange quotation at 31 December (Naira)	7.11	4.50	58%
Number of employees	478	405	18%

CHAIRMAN'S STATEMENT



Mr. Segun Adebanji, FCA

Chairman

INTRODUCTION

Esteemed members, representatives of regulatory bodies, my colleagues on the Board, gentlemen and ladies of the press, ladies and gentlemen, I am delighted to welcome you all to the 23rd Annual General Meeting (AGM) of our great Company, Fidson Healthcare Plc, the leading pharmaceutical company in Nigeria.

As a pharmaceutical company, and in line with our corporate slogan: 'We value life', this meeting is once again being held in a hybrid manner, in spite of the relaxation of the covid 19 rules relating to social gatherings. We believe the situation must still be closely watched to avoid any incident of infection, however remote. Consequently, many of our members are participating in this meeting through their proxies who are physically attending this meeting along with other Shareholders and the Directors. We highly commend your understanding and cooperation in this regard.

OPERATING ENVIRONMENT

The limited improvements in the state of infrastructure in the country, coupled with the challenges of insecurity and poor power supply, made it extremely daunting for businesses to operate during the year under review. The incessant closure of markets, especially in the Southeastern part of the country on account of IPOB agitation, disrupted our supply chain; thereby affecting regular supplies of our products into markets around the country. Unfortunately, the situation remains challenging till date.

Nevertheless, according to the Nigerian Bureau of Statistics, Nigeria's economy grew in 2021 at the fastest annual pace in eight years, relying more on the non-oil sector. The Gross Domestic Product expanded at 3.4% last year, the most since 2014 when it grew at 6.22%. In absolute terms, GDP in 2020 was reported as USD432.3 billion and USD 514 billion in 2021, an increase of 18.2%. The non-oil sector recorded a growth of 6.74% in the second quarter of 2021. The sector's aggregate contribution to real GDP, which stood at N92.58 billion as at quarter 2 of 2021, was driven by agriculture, manufacturing, road transportation, telecommunications, and trade sub-sectors. The oil sector's contribution during the year under review suffered a decline as a result of the reduction of Nigeria's output quota by OPEC.

The rate of unemployment rose to 35%, according to a report by a credit rating agency, Agusto & Co. in January 2022. In like manner, inflation rate in 2021 was 16%, compared to 15.75% in December 2020. Inflation rate rose to 15.9% in March, 2022, higher than the 13% average assumed in the government budget.

The foreign exchange situation worsened during the year. This development, in no small measure, put pressure on a lot of businesses, especially those in the manufacturing sector (like ours) who depend heavily on importation of material inputs. The situation appears to be getting worse and worrisome and unlikely to improve, unless appropriate proactive monetary and fiscal policies are implemented to achieve a stable exchange rate and contain the pace of inflation in the country.

No doubt, the Nigerian economy needs to look inwards for self-sustenance. Efforts made by Government to promote agribusiness are quite commendable, but more positive actions are still required to ensure food security and keep in check food price inflation.

Rising operating costs, coupled with high inflation, mass unemployment and rampant insecurity across the nation, portends nothing but looming hardship on the masses, and this challenge must be urgently addressed.

The war between Russia and Ukraine, which started in the first quarter of 2022, has seriously disrupted supply chains and heightened the risk of export restrictions in some commodity producing countries; resulting in an upsurge in international commodity prices, with significant implications for Nigeria.

The Board and Management have reflected on the severe impact of these macro-economic challenges on a lot of Nigerian families and are taking appropriate steps to improve on staff welfare through a package of incentives and review of compensations.

THE HEALTHCARE INDUSTRY

The Regulators for our sector, the National Agency for Food and Drug Administration and Control (NAFDAC), remained alert to their responsibilities for ensuring high quality standards by industry players through stringent compliance assessments. They also implemented the '5 plus 5' policy. This policy is expected to accelerate the growth in capacity and manufacturing expertise of the pharmaceutical industry in Nigeria. It is hoped that complementary government policies in support of this initiative will be enacted to facilitate the realization of the potential benefits expected by industry players from this good initiative.

It is also noteworthy that the National Drug Distribution Guidelines (NDDG) of the Federal Government are being

implemented by a number of State Governments. This initiative has culminated in many state governments buying drugs directly from manufacturers through Drug Revolving Funds (DRF) to cater for the needs of their people. It is hoped that key players in the industry will ultimately benefit from the laudable initiative.

The ever-increasing population in the country imposes on government the urgent need to create an enabling environment for pharmaceutical companies to thrive in order to secure access to essential drugs at affordable prices. Access to good health-care facilities, affordable locally manufactured drugs and a properly regulated health insurance sector should be essential planks of Government's policies and strategies for the health sector.

Despite the industry challenges, partly due to poor government funding of the health sector, the Board and Management of our company remain determined to sustain our industry position as the pharma company of choice, not only in Nigeria but also in the entire African continent. We will continue to champion innovation and capacity expansion in order to meet the strategic goals and priorities of our company to address our customers' need for affordable and high-quality drugs. Our efforts at continuous improvement on our GMP and capacity building are already yielding good results, with the increase in the contribution to revenues from locally manufactured products compared to imported finished products. This positive trend is expected to continue going forward.

PERFORMANCE AND OPERATING RESULTS

Turnover in the year ended 31st December 2021 was N30.860 billion, compared with N18.275 billion in 2020, representing an increase of 69%. Operating profit grew from N3.097 billion in 2020 to N5.862 billion in 2021, representing an increase of 89%. Profit before tax increased from N1.772 billion in 2020 to N4.717 billion in the year under review, representing 166% increase. Profit after tax also increased from N1.205 billion in 2020 to N3.097 billion during the year under review, representing an increase of 157%.

The improved performance year-on-year continued as a result of consistent improvements in operational efficiency in the face of the challenging operating environment, introduction of new products, sustained investments in brand building, and good teamwork between various functions within the business, resulting in significant volume growth.

OPERATING FACILITIES

The medium-term strategic expansion of the factory, which started three years ago, continued throughout the year. The scope of the expansion has been enlarged and is on track and in line with our strategic ambition. Hopefully, before the end of 2022, the first phase of the project will be completed.

The objectives of the expansion programme are, among others, to increase volume and the portfolio of our locally manufactured products and become less dependent on imported products. The expansion will also enable us to position the factory for better efficiency and eventually for WHO prequalification.

THE BOARD

The Board remained stable since the last annual general meeting. The current structure and composition of the Board align with the company's aspirations and strategic objectives. There is an effective collaboration between the Board and Management, with the desired oversight functions in place. The Directors are seasoned professionals in their private capacities.

In line with the requirements of the law and good corporate governance, three of the Directors, namely Mrs. Olufunmilola O. Ayebae, Mr. Olugbenga O. Olayeye and myself retire by rotation and will be presented for re-election at this meeting.

DIVIDEND AND BONUS ISSUE

Given the outstanding performance recorded in the year under review, the Board is pleased to recommend a dividend of 50 kobo per 50 kobo ordinary share, which is double the 25 kobo dividend declared in 2020. The dividend is subject to the deduction of appropriate statutory withholding tax. If approved, payments will be made on 29th July 2022.

In addition to the proposed dividend, your Board has also considered it necessary to propose a bonus of 1 new ordinary share for every 10 ordinary shares of 50 kobo held by our members as at the record date. This proposal is in recognition of the level of our share premium account and is also to comply with Section 124 of the Companies and Allied Matters Act, 2020 vis-à-vis Regulation 13 of the Companies Regulations 2021. The bonus shares would be credited as fully paid by debiting our share premium account balance with the sum of N104,318,012.50k. A resolution will be proposed at the annual general meeting to approve this.

FUTURE OUTLOOK

As we continue driving our vision for the company through constant strategic reviews and with the commitment of the Board and Management, the Board expects the trend of good performance recorded in the last few years to continue, barring any significant deterioration in macroeconomic conditions and the operating environment. The young, vibrant, and well-motivated management team already in place is also a source of confidence that the future of the company remains bright.

CONCLUSION

I would like to appreciate all our stakeholders, particularly our numerous Customers, Shareholders, and the public for your continued interest in the Company. The great work of the Executive Management team, the staff, as well as the cooperation and commitment of my colleagues on the Board is immensely appreciated. I count on your continued support, as we face the future with hope and faith in divine guidance to accelerate the growth of our company.

I give glory to God Almighty for allowing us to witness this

Ladies and gentlemen, I thank you for your attention.



MANOLL

Restores Health and Vitality Naturally

Flavonoids, Vitamins, Minerals, Immunity Boosters, Adaptogens

Benefits

- ✓ Hastens recovery from illness
- Rejuvenates and stregthens the body
- ✓ Boosts immunity
- ✓ Combat Stress
- Builds up heamoglobin levels
- © +234 807 700 8888



Enriched

Honey



BOARD OF DIRECTORS



MR. SEGUN ADEBANJI, FCA Chairman (Independent Non-Executive Director)

Mr Adebanji attended Yaba College of Technology and obtained his Ordinary National Diploma (Accounting) in 1973. He completed the Chartered Association of Certified Accountants' examinations in June 1975 and served his articles with Peat, Marwick Cassleton Elliot & Co in Nigeria between June 1973 and May 1976. He was admitted a Fellow of both the Chartered Association of Certified Accountants (FCCA) and the Institute of Chartered Accountants of Nigeria (FCA) in December 1982 and November 1988 respectively.

Mr Adebanji joined UAC of Nigeria in 1976 and carried out various assignments within the UAC Group until he was seconded to Unilever Plc, London as Management Group Accountant in 1988. He returned to UAC at the end of 1990 as the Group Treasurer. In 1992, Mr Adebanji was seconded to Unilever South Africa as Audit Manager with sub-regional responsibilities for Unilever Plc subsidiaries in South Africa, Zimbabwe, Malawi, Tanzania, Kenya and Ghana.

He returned to Nigeria in October 1995 to serve as the Financial Director of Nigerian Breweries Plc (appointed in January 1996), and was later seconded to Heineken International in the Netherlands as Group Treasurer from 1998 to 2001. He also served Heineken as Managing Director of Ghana Breweries Ltd and Namibia Breweries Ltd between 2001 and 2007. He retired from the Heineken Group after his assignment in Namibia, and practiced as a Financial Consultant until he joined African Capital Alliance in January 2011 as a Principal. He retired from African Capital Alliance in January, 2019.

Mr Adebanji is a Non-Executive Director of Daraju Industries Ltd, Cornerstone Insurance Plc, Multimedia Ghana Ltd, and ARM Holdings Ltd. He also serves as the Chairman of Filmhouse Ltd and Crest Agro Products Ltd. He was until 2018 a Non-Executive Director of Nigerian Breweries Plc.



DR. FIDELIS AYEBAE Managing Director / Chief Executive Officer

Fidelis Ayebae graduated from the Mainland Institute of Technology in 1976 with a Diploma in Civil Engineering. He obtained Advanced Diploma in Business Administration from the University of Lagos in 1999.

He is an Associate of the Chartered Institute of Administration and also a member of the Nigeria Institute of Management.

After working in various capacities in a number of organizations, including Citibank Limited, he started as the Founder and Pioneer Chief Executive Officer at Fidson Healthcare Limited in 1995. He is also the Chairman and Director of many other companies.

He has attended many courses, both locally and internationally including banking operation, organisation development skills, selling skills e.t.c.



MRS. OLUFUNMILOLA AYEBAE

Non-Executive Director

Mrs. Olufunmilola O. Ayebae completed her Professional Secretaries Diploma from The London College of Secretaries in the United Kingdom.

She worked in many organizations in various capacities for a number of years before establishing her own business - Goodness Supermarket in 1995 and served as the Managing Director/CEO for 3 years, she is also the MD/CEO of Townhouse Limited.

She became a director of Fidson Healthcare Plc in 2001.



CHIEF (MRS.) AISHATU SADAUKI, OON Independent Non-Executive Director

(Chief) Mrs. Sadauki holds a Bsc. Degree in Home Economics with a Major in Community Nutrition from Iowa State University, Iowa USA in 1968. She has attended several courses and seminars on board development evaluation within and outside the country.

She was an accomplished civil servant who rose from the position of Chief Agricultural Officer (State Home Economist) in 1964 to the position of Chief Agricultural Officer (State Home Economist) in 1986.

She was appointed Kaduna State Commissioner, Social Development, Youth and Sports in 1988, Commissioner of Education in 1989 and Deputy Governor kaduna State from 1990 to 1992. Chief Mrs Sadauki is a Director of many companies including Zazzau Ginnery Limited, D. A. Sadauki Investments Limited, Hillside Company Limited and MTN Foundation amongst others.

She was conferred with Merit Award by Nigerian Veterinary Medical Association of Farmers in 1999 and National Honour of Officer of the Order of the Federal Republic of Nigeria (OON) in 2000.



MR. EMMANUEL IMOAGENE

Non-Executive Director

Mr. Emmanuel Imoagene was appointed to the Board of Directors effective February 2011. He is the Founder and Lead Consultant of Multivaluedge Consulting Limited, a firm that is focused on working with the leadership and management teams of largely indigenous businesses with aspirations for sustainable long term value.

He has diverse experience spanning over three decades in several bluechip companies including Shell Petroleum Development Company of Nigeria Limited, Nigerian Breweries Plc, Unilever Ghana Limited, Cadbury Nigeria Plc, Dangote Cement Plc, amongst others. In the course of his career, he held several senior leadership positions in human resources, logistics and procurement. He also has significant experience in corporate governance and general management practice.

Mr. Imoagene received his undergraduate degree from the University of Benin, and his graduate degree from the University of Ibadan. He is a fellow of the Chartered Institute of Personnel Management of Nigeria.



DR. VINCENT AHONKHAI, FAAP Non-Executive Director

Dr. Ahonkhai is an expert in Global Health and Bio-pharmaceutical Research and Development. His passion and focus are in producing innovative health products for the prevention, treatment and elimination of infectious diseases for all persons who need them worldwide, particularly in resourceconstrained countries.

His contributions and leadership for over 3 decades in top tier multinational and global pharmaceutical companies have delivered numerous drugs for different disease groups, as well as vaccines and biologicals which are widely accessible.

He has served on the United States Institute of Medicine's Forum on Emerging Infections, as Board Chair of the American Academy of

Pharmaceutical Physicians, Member, Nigerian Academy of Science Forum on Evidence-Based Health Policymaking, as Senior Advisor at the Bill & Melinda Gates Foundation, as Scientific Advisor to the US Food and Drug Administration Commissioner, to the International Vaccine Institute of South Korea, on the GSK Ebola Vaccine Initiative, the Advisory Boards of Quality, MD, VYZR Technologies, and played key scientific roles in several other organizations.

On the Civic and Social responsibility front, Dr. Ahonkhai has served as National Chairman of the Nigerian Peoples' Forum USA, as President, Ora-Ekpen Association, USA, and on the Board of the Association of Scientists and Physicians of African Descent.

He obtained his medical degree at the University of Lagos College of Medicine, is Fellow of the American Infectious Disease Society and has published over 60 scientific and medical papers in international journals.

Dr. Ahonkhai is an independent consultant and Principal, Gwynedd Consultancy, LLC in the Philadelphia area, USA.



MR. EKWUNIFE OKOLI Non-Executive Director

Mr. Okoli is versatile in the field of Sales and Marketing, having worked for many years in the FMCG industry.

He was an Executive Director, Marketing at Diageo Plc. He was also Managing Director of the same company in Cameroun and Ghana and Managing Director for Africa and Regional Markets.

He is an experienced Non-Executive Director who sits on the Board of Cornerstone Insurance Plc. He is married to Mrs. Unoma Okoli and blessed with four children.

He is expected to enrich the expertise in the Sales and Marketing department.




MR. OLUGBENGA OLAYEYE Strategy & Marketing Director

A Pharmacist educated at Nigeria's premier University- the University of Ibadan and the Stanford Graduate School of Business.

He has pursued a career in the pharmaceutical industry since graduation with Fidson Healthcare Plc. He has worked across diverse functions (Sales and Marketing, Business development, Manufacturing, Research and Development and Operations) in the company since inception and has been pivotal in determining her policy direction, strategy execution and has managed organizational change and transformation over the period.

His current responsibilities involve the development and implementation of Corporate and Marketing Strategies.

An exciting person to have on a team, he is committed to team building and development of leadership skills and ability which he believes is the critical requirement for organizational growth and corporate success.



MR. BIOLA ADEBAYO Technical Director

Mr Adebayo graduated from the School of Pharmacy, University of Lagos in 1988. He also has a Diploma in Advanced Computer Techniques and Applications (1998) from the University of Ibadan (Consultancy Unit). He worked with the Federal Ministry of Health in Lagos as an intern pharmacist. He began his career with Glaxo Nigeria Plc in April 1991 as a medical representative. He later on joined the pharmaceutical division of CAP PLC in July 1994 where he developed his skills and competencies in the sales and marketing of healthcare products and FMCGs.

He continued his career with Fidson Healthcare Plc in 1996 and held various positions in the sales and marketing division and rose through the ranks to become the Sales and Marketing Manager in April 2001. In 2004, he became the Sales and Marketing Director, the position he occupied till July 2009. He is currently the Technical Director in the company.

He is a member of the Institute of Directors (IOD). He also completed a top executive leadership programme jointly organized by Nigeria Institute of Management (NIM) and Manchester Business School in Manchester, England, United Kingdom in 2007.



MR. OLA IJIMAKIN Commercial Director

Mr. Ijimakin joined the organization (Fidson Healthcare Ltd) in July 2002 as Regional Manager in the Northeastern region.

He graduated from the University of Jos in 1994 where he was awarded a Bachelor of Pharmacy (B.Pharm) degree. He won the prize for the best graduating student in Pharmacy among other prestigious awards. He holds a Master of Business Administration (MBA) degree from the Business School Netherlands, Buren (2014) where he finished with a distinction.

Ola is a seasoned professional who has grown through the ranks over the years. He served as Group Marketing Manager from May 2005 to December 2006; General Manager, Marketing from April 2011 to May 2016 and General Manager, Sales and Marketing from May 2016 till date.

Over the years, as GM Sales & Marketing, his drive for results reflected in more than a 100% revenue sales growth from N7.6bn to over N17bn.

He is vastly experienced, having served in large corporations both at home and abroad. He is a fellow of the Pharmaceutical Society of Nigeria.

His appointment as Commercial Director is a testament to the hard work and commitment he has shown consistently over the years.

REPORT OF THE DIRECTORS

The Directors have pleasure in submitting to the members of the Company their report together with the audited financial statements for the year ended 31 December 2021.

PRINCIPAL ACTIVITIES 2.0

The principal activities of the Company are the manufacture and distribution of pharmaceutical products which includes drugs, infusion and injectables. The Company commenced local manufacturing of pharmaceutical products in July 2002.

3.0 **LEGAL FORM**

The Company operated as a Private Limited Liability Company until June 5, 2008 when it was re-registered as a Public Limited Liability Company. The shares are currently quoted on the floor of the Nigerian Exchange Limited (NGX).

4.0 STATE OF AFFAIRS

In the opinion of the Directors, the state of the Company's affairs is satisfactory and there has been no material change since the reporting date, which would affect the financial statements as presented.

5.0 DIVIDEND

The Directors propose to pay a dividend of No.50k amounting to N1,043,180,125.00 out of the profit for the year ended 31 December 2021 (31 December 2020: No.25k, N521, 590,562.50). Proposed dividend will only be recognised as a liability after approval by the shareholders at the Annual General Meeting.

MAJOR CUSTOMERS 6.0

LAGOS

Omere-Oil Pharm Limited/Zimaco Elvis-Madu and Son Enterprise Safeline Pharmaceutical Ltd Cemcee Pharmacv Great Dan-White Int'l Ltd

EAST

John Medicals Okwytex International Concept Limited Jaymorr Pharmacy LTD

Peton Investment (Nig) Limited Grams Pharmacy

WEST

Fiolu Pharmacy Kunle Ara Pharm Elgra Pharmacy Ridaz Pharmacy and Store Goodall Pharmacy

NORTH

Latnas Pharmacy Gozeb Pharceuticals Nig. Limited Klen Pharmacy Limited. New Health Pharm Goodall Pharmacy

7.0 **MAJOR SUPPLIERS**

Overseas Suppliers

TIL Exports Pvt Limited India V.S International Mevish Export Ltd. India Medinomics Healthcare Pvt Ltd) Themis Medicare Ltd Sukhesh Marketing pvt. Ltd Sterimax Limited Thermax Limited M/S Espee Pharma chen Pvt Ltd Sinobright Import and Export Co. Ltd Quest Vitamins Ltd Charack Pvt Ltd.

Local Suppliers

Sankil Pharm Ltd Beta Glass Plc Caxton Joe Nigeria Ltd Dowell Resources & Logistics Ltd Top pan printing Co. Nigeria Ltd Vijibuks Nigeria Limited Shongai Technologies Ltd Twinstar Ind. Ltd Sagar Overseas Ltd Tempo Paper Pulp & Packaging Ltd Jackpackk Industries Nigeria Ltd Fiyique Venture Ltd

DIRECTORS

The names of the Directors at the date of this report and of those who held office during the year are as follows:

1.	Segun Adebanji, FCA	Chairman (Independent Non-Executive Director)	 Appointed 2018
2.	Dr. Fidelis A. Ayebae	Managing Director/ Chief Executive Officer	- Pioneer
3.	Mrs. Olufunmilola O. Ayebae	Non- Executive Director	- Appointed 2011
4.	Mr. Emmanuel E. Imoagene	Non- Executive Director	- Appointed 2011
5.	Mrs. Aishatu P. Sadauki	Independent Non-Executive Director	- Appointed 2011
6.	Dr. Vincent Ahonkhai	Independent Non-Executive Director	- Appointed 2021
7.	Mr. Ekwunife Okoli	Independent Non-Executive Director	- Appointed 2021
8.	Mr. Olugbenga O. Olayeye	Executive Director, Strategy and Marketing	- Appointed 2011
9.	Mr. Abiola A. Adebayo	Executive Director, Technical	- Appointed 2011
10.	Mr. Ola Ijimakin	Executive Director, Commercial	- Appointed 2021

DIRECTORS' INTERESTS

The Directors' interests in the issued share capital of the Company as at 31 December 2021 are as follow:

	Numbers of shares 2021	%	Numbers of shares 2020	%
Mr. Olusegun Adebanji				
Dr. Fidelis A. Ayebae	689,585,227	33.05	689,585,227	33.05
Mrs. Olufunmilola O. Ayebae	67,845,000	3.25	67,845,000	3.25
Mr. Olugbenga O. Olayeye	19,581,040	0.94	19,581,040	0.94
Mr. Abiola A. Adebayo	16,626,609	0.80	16,626,609	0.80
Mr. Emmanuel E. Imogene	34,012,000	1.63	34,012,000	1.63
Mrs. Aisha P. Sadauki	781,550	0.04	781,550	0.04
Dr. Vincent Ahonkhai	163,600	0.01	-	-
Mr. Ola Ijimakin	2,130,000	0.10	-	-
Mr. Ekwunife Okoli		-	-	-
Indirect interest				
Glorious Haven Ltd – on behalf of				
Dr. Fidelis A. Ayebae	1,000,000	0.05	1,000,000	0.05

10.0 BOARD OF DIRECTORS

In accordance with the provisions of Section 285 of the Companies & Allied Matters Act, 2020, one third of the Directors of the Company shall retire from office. The Directors to retire every year shall be those who have been longest in office since their last election. Accordingly, Mr. Segun Adebanji, Mrs. Olufunmilola O. Ayebae and Mr. Olugbenga O. Olayeye retired by rotation and being eligible, offer themselves for re-election.

11.0 DIRECTORS' INTEREST IN CONTRACTS

None of the Directors has notified the Company for the purpose of Section 303 of the Companies and Allied Matters Act, 2020, of any disclosable interest in contracts with which the Company is involved as at 31 December 2021.

12.0 SUBSTANTIAL INTEREST IN SHARES

The registrar has advised that according to the register of members as at 31 December 2021, the following held more than 5% of the issued share capital of the Company:

Shareholder	No of Shares	% Holding
Dr. Fidelis Ayebae	689,585,227	33.05%
Stanbic IBTC Nominee Ltd	514,747,303	24.67%

13.0 CORPORATE SOCIAL RESPONSIBILITIES

The Company made contributions as part of its corporate social responsibility. The beneficiaries are as follows:

	2021 N	2020 N
Religious organisations	210,000	350,000
Hospitals/Health institutions	70,008,725	19,613,521
Schools/Communities	43,711,262	38,407,878
	113,929,987	58,371,399

EVENTS AFTER THE REPORTING PERIOD

As stated in Note 44, no material events have occurred between the end of the reporting period and the date of this report which could have had a material effect on the state of affairs of the Company as at 31 December 2021.

15.0 ANALYSIS OF SHAREHOLDERS

Analysis of shareholdings as at 31 December 2021

Range	No. of	%		%
G	Holders	Members	Units	Holding
1-50,000	5,761	 88	50,367,242	2
50,001 - 100,000	327	5	25,858,954	1
100,001 - 1,000,000	384	6	105,084,343	5
1,000,001 and above	60	1	1,905,049,711	91
	6,532	100	2,086,360,250	100

16.0 **EMPLOYMENT AND EMPLOYEES**

Employment of disabled Persons a.

It is the Company's policy that there is no discrimination in considering applications for employment including those from disabled persons. All employees whether or not disabled are given equal opportunities to develop their expertise and knowledge and to qualify for promotion in furtherance of their careers. As at 31 December 2021, there were two disabled employees working in the administrative section of the factory.

b.

The Company has retainership agreement with a number of private hospitals to whom cases of illness are referred for treatment and/or admission.

The Company provides subsidy to employees in respect of transportation, lunch, housing, and healthcare. Incentive schemes designed to meet the circumstances of each individual are implemented wherever appropriate and some of these schemes include bonus, promotions, and wage review.

C. **Training**

The Company attaches great importance to training and all categories of staff attend courses or seminars as considered necessary by the Company's management. This was extended to member of the statutory audit committee during the year under review.

AUDIT COMMITTEE

Pursuant to Section 404 of the Companies and Allied Matters Act, 2020, the Company has in place an Audit Committee comprising of Directors and shareholders, namely:

Chief Matthew Akinlade, FCA Shareholders 'Chairman Shareholders' representative Alhaji Abdulkabir Sarumi, Mr. Solomon S. Akinsanya Shareholders' representative Mrs. Olufunmilola O. Ayebae Directors' representative Mr. Emmanuel E. Imoagene Directors' representative

The functions of the Audit Committee are laid down in Section 404(7) of the Companies and Allied Matters Act, 2020.

AUDITORS

Messrs Deloitte and Touche (Chartered Accountants) have indicated their willingness to continue in office in accordance with section 401 (2) of the Companies and Allied Matters Act, 2020 Nigeria. A resolution will be proposed at the 23rd Annual General Meeting for the authority to fix their remuneration by the directors.



BY ORDER OF THE BOARD J. ABAYOMI ADEBANJO, FCIS COMPANY SECRETARY FRC/2013/ICSAN/00000002161 24 March 2022

CORPORATE GOVERNANCE REPORT

The governance imperatives for businesses' sustainability became obvious since the outbreak of COVID-19 in 2019. Like many other companies, we remained resolute and strengthened the internal capacity to meet the challenges in the business and regulatory environment. We maintained the zerotolerance for non-compliance on all governance matters throughout the year under review.

We recognized the importance of Environment, Social and Governance (ESG) and imbibed the culture of environmental preservation. This let to our ISO 14001:2015 certification during the year under review while maintaining the principle of full disclosure as required by Principle 28 of the Nigerian Code of Corporate Governance and the provisions of the Listing Rules particularly Rule 17.5 and other rules of the exchange bordering on transparency and effective communication with stakeholders and the investing public.

Good governance and fair-trade practices remain at the heart of our business activities. In this report, reviews were made to existing principles where necessary while sustaining them, namely:

People: Our stakeholders are at the center of our Corporate Governance practices. Demands of our stakeholders whether directly or indirectly impacting our operations are constantly considered and promptly attended to. In this area of our operations are robust Corporate Social Responsibility policies, remuneration and motivation schemes that are second to none in the industry and concern for our end users. We realize that our shareholders are important, and all efforts were made throughout the year to reach out to them in a bid to ensure an amicable shareholder-management relationship. Aside from the statutory register of members, we created a directory of notable members for the purposes of engagement and operational reporting whenever the need arises.

Prices: Our pricing policies are geared towards optimizing our resources for continued growth and development without exploiting the market. We have continued to consider the general inflationary trend and affordability to the common man before arriving at our prices.

Planet: Because we value life, our operations are conducted in a way that minimizes negative externalities. At the heart of this is our robust policy on Health, Safety, and Environment (HSE). We conducted regular HSE training throughout the year in addition to appointing Safety Officers in each of our locations and the Office. Obsolete equipment is disposed of in order to allow for recycling. Expired drugs are also destroyed under the supervision of regulators and each time this is done a Certificate of Destruction is received from the relevant Government Agency. We have imbibed best practices and ethical standards in all our dealings.

Probity: We reviewed our governance principles, and we imbibed the 'probity' as one of the essentials of good governance. All officers, including directors, are requested to give an honest account of all company resources in their custody as and when due.

In addition to the above, we have strengthened our risk management team and the general practice of risk awareness and control consciousness company wide.

OUR CORPORATE GOVERNANCE PLATFORM

Our corporate governance strategy and initiatives are geared towards complying with the Nigerian Code of Corporate Governance 2018 and maintaining an amicable relationship with the various stakeholders on which our continued existence relies. Our second approach to Corporate Governance is to use the doctrines of good governance to engender the sustainability of our business.

We have continued to subject our operations to periodic examinations and audits by independent auditors which include current Good Manufacturing Practice (GMP) and National Agency for Food and Drugs Administration and Control (NAFDAC). Each audit/examination report is made the subject for consideration by a committee headed by an executive director for proper review and implementation.

Overseen by the Board of Directors, Corporate Governance practices are constantly under review in line with the dynamics of the business environment. The Corporate Governance policies adopted by the Board of Directors are designed to ensure that the company's business is conducted in a fair, honest and transparent manner that conforms to high ethical standards.

The day-to-day affairs of the company are run by the Executive Management with regular meetings to brainstorm on the company's operations and to also give departmental reports for reviews.

The framework for our corporate governance is hinged on:

- 1. The Nigerian Code of Corporate Governance 2018
- 2. Various Standard Operations Procedure (SOP) and the International Standard Organisations compliance requirements
- 3. Provisions of the Companies and Allied Matters Act, 2020
- 4. Financial Reporting Council Act, 2011
- 5 International Financial Reporting Standards (IFRS)
- 6. The listing rules of the Nigerian Exchange Limited
- 7. Rules of the Securities and Exchange Commission.
- 8. Good Manufacturing Practices.
- 9. International best practices.

BOARD COMMITTEES

Board committees during the year under review were constituted as follows:

S/N	NAME OF COMMITTEE	MEMBERS
1.	Governance, Nomination and Remuneration Committee	Mrs. A. P. Sadauki (Chairman) Mr. E. E. Imoagene Mrs. O. O. Ayebae Mr. Ekwunife Okoli Dr. Vincent Ahonkhai
2.	Finance and General purposes committee	Mr. E. E. Imoagene (Chairman) Mr. O. S. Adebanji Dr Vincent Ahonkhai Mr. Ekwunife Okoli Mr. O. O. Olayeye Mr. A. A. Adebayo Mr. Ola Ijimakin Dr F. A. Ayebae
3.	Risk, Audit & Credit Control Committee	Mr. O. S. Adebanji (Chairman) Mr. E. E. Imoagene Mr. Ekwunife Okoli Mrs. O. O. Ayebae Mr. O. O. Olayeye Mr. A. A. Adebayo Dr. F. A. Ayebae
4.	Strategy and Business Development	Mr. Ekwunife Okoli (Chairman) Dr. Vincent Ahonkhai Mrs. A. P. Sadauki Mr. Emmanuel Imoagene Mr. O. O. Olayeye Mr. A. A. Adebayo Mr. Ola Ijimakin Dr. Fidelis Ayebae
5.	Statutory Audit Committee.	Mrs. O. O. Ayebae Mr E. E. Imoagene

COMMITTEES' TERMS OF REFERENCE

The terms of reference for all the committees are in line with the provisions of the Nigerian Code of Corporate Governance 2018 and generally accepted best practices. The Committee's terms of reference, in summary, are as follows:

1. Governance, Nomination and Remuneration Committee (GNRC): The committee's main responsibility is to assist the Board in developing policies to fill any vacancy on the Board, however, occasioned and to ensure at all times that competence gaps are closed so that the company is not short of the required skills.

In doing this, the committee considers the need to attract, motivate and retain suitably qualified individuals to the Board. The Committee ensures the sustainability of the business by ensuring that at all times the company maintains its good governance structure, probity, accountability, transparency, good ethical conduct and responsible leadership.

The responsibility of the committee includes the recommendation of a competitive remuneration package for the executive management and the Board. In doing this, the committee considers the need to maintain both internal and external competitiveness. It is also the responsibility of the committee to ensure that remunerations paid to the employees of the company are adequate and commensurate with performance.

- 2. Finance and General Purposes Committee: The committee assists the Board in ensuring that the company's strategic initiatives and objectives are translated into actions and processes. In doing this, the committee considers and makes recommendations to the Board with regards to:-
 - (a) the annual estimates of revenue and expenditure (income statement).
 - (b) capital expenditure requirements including loans.
 - (c) investment and borrowing policies
 - (d) any other matters referred to the Committee by the Board.

Strategy and Business Development

Committee: The Committee's function is to assist the board in the development of a strategic planning process and ensure a periodic review of the process and report to the Board on implementation. To achieve its objectives, the Committee, amongst others:

- (a) ensure that the business sets stretch but realisable long-term and annual business goals consistent with market opportunities, and capable of delivering the company's vision and mission statements.
- (b) review, input, and recommend to the Board long-term and annual business strategy to deliver the business goals and consistently outperform the competition.
- (c) ensure that the annual plans and long-term strategy is communicated across the organisation to ensure alignment and ownership.
- (d) ensure that the long-term strategy and annual plans are tracked twice annually and quarterly respectively and a dashboard is used to communicate status to key stakeholders.
- (e) ensure that a Strategic planning cycle is developed and embedded into the corporate calendar so that adequate time is created for the process.
- Risk, Audit and Credit Control Committee: The 4. committee assists the Board in the monitoring, reviewing and administration of the credit policy and risk management. Its terms of reference include the following:
 - (a) Consider the nature, extent, and categories of the risks facing the Company, and the likelihood of such risks materializing, the Company's ability to reduce the incidence and the impact on its business, if the risks do materialize.
 - (b) Advise the Board on the cost of operating particular controls relative to the benefits thereby obtained in managing the related risks:
 - (c) Ensure that the Company's policy on ethics adequately impacts positively on its business partners and stakeholders e.g. Customers, Shareholders, Community, Government, Suppliers and the public;
 - (d) Prescribe new standards and mechanisms related to ethics and make the recommendations to the Board.
 - (e) Review the risk register and to notify the Board of changes in the status and control evaluation of risks.
 - Keep under review and monitor the effectiveness of the Company's system of internal control, non-financial activities of management, including operational and compliance controls and risk management, environment, health and safety and report to the Board on annual basis and;

- (g) Monitor compliance with the provisions of the Companies and Allied Matters Act as they affect the operations of the business and adherence to the rules and regulations of relevant regulatory bodies.
- (h) To obtain Board approval for any policy changes, actions or decisions of the Committee that require such approval. The communication path shall be through the Company Secretary and/or the Chairman.
- (i) The Committee shall be responsible for putting in place a structure for risk management.
- To review the implementation of the company's processes as they relate to risk management framework and recommend best practice.
- (k) To consider the likely impact on breaches in the company's operations.
- To put in place a Business Continuity Plan (BCP) for the company. These committees meet on a regular basis to discharge their functions and report to the Board.

THE BOARD

Frequency of meetings:

The Board of Directors holds at least 4 (four) meetings in each financial year. Each meeting is scheduled to receive quarterly operating results among other reports on the company's operations. All matters reserved for the Board are duly considered and resolved. These include consideration and approval of budgets, major capital expenditures, corporate strategy, review of policies on internal risk management, review of performance and generally direct the affairs of the company's operations.

Attendance at Board meetings during the year under review was impressive. In line with Section 284 (2) of the Companies and Allied Matters Act, 2020, the record of Director's attendance at Board meetings is available at the annual general meeting for inspection.

In compliance with Section 275 of the Companies and Allied Matters Act, 2020, two additional Independent Non-executive Directors were added to the Board with effect from 01/01/21 to have a minimum of three (3) required by the Law.

Responsibilities of the Board of Directors:

It is the responsibility of the Board of Directors to:

- ensure that the company's operations are conducted in a fair and transparent manner that conforms with high ethical standards;
- 2. ensure the integrity of the company's financial and internal control policies;
- 3. ensure the accuracy, adequacy and timely rendition of the statutory returns and financial reports to the regulatory authorities, namely, The Nigerian Exchange Limited (NGX), Securities and Exchange Commission (SEC), Corporate Affairs Commission (CAC), National Agency for Food and Drug Administration and Control (NAFDAC) and shareholders through the Company Secretary;

- ensure value creation for the shareholders, employees and other stakeholders;
- review and approve corporate policies, strategies, 5. annual budgets and business plans;
- 6. monitor implementation of policies and strategic direction of the company.
- 7. set performance objectives, monitor implementation and corporate performance.
- 8. review and approve all major capital expenditure of the company.
- 9. ensure that the statutory rights of all stakeholders are protected at all times; and,
- institute an appropriate mechanism for measuring 10. adherence by management to all regulations.

Information flow to the Board:

The executive management ensures that the Board received adequate information on a timely basis. Board papers are circulated at least two weeks before every Board meeting.

As part of the Board's resolve to ensure adequate compliance with and to engender good corporate governance, at every Board meeting Corporate Governance Report is presented by the Company Secretary for consideration by the Board. This way, the Board is abreast of the regulatory, statutory and ethical requirements expected of listed companies in Nigeria.

Board Charter: In order to ensure good governance is engendered in the company, the Board is run by a Charter which amongst other things make provisions concerning:

- Frequency of Board meetings a)
- Process for adoption and circulation of Board b) minutes
- Disclosure of interest c)
- Guidelines for ensuring the integrity and independence of directors.
- Commitment to comply with the Corporate e) Governance Code

Board Structure: The Board currently consist of 10 (ten) directors. They are made up of four (4) Executive Directors, two (2) Non-Executive Directors and four (4) Independent Non-Executive Directors. The structure has engendered a culture of objective and professional inputs at Board level.

In structuring the Board, there was consideration for diversity in terms of gender and core competencies of individual directors, hence there are three women and five men on the Board. Among the Board members are experts in Human Resources, corporate governance, medical sciences, finance, agriculture, marketing and strategy.

Directors during the year under review were:

1. Mr. O. S. Adebanji Chairman (Independent Non-Executive Director)

2. Dr. Fidelis A. Ayebae Managing Director/ Chief Executive Officer Mrs. Olufunmilola O. Ayebae Non- Executive Director 3.

Mr. Emmanuel E. Imoagene Non- Executive Director 4. Mrs. Aishatu P. Sadauki Independent Non-Executive Director

Mr. Vincent Ahonkhai Independent Non-Executive Director 6. Mr. Ekwunife N. Okoli Independent Non-Executive Director 7.

Executive Director, Strategy and Marketing 8. Mr. Olugbenga O. Olayeye

Mr. Abiola A. Adebayo Executive Director, Technical 9 Mr. Ola Ijimakin Executive Director, Commercial 10.

Board evaluation and appraisal: The Board has decided to conduct an evaluation of its members before the end of the 2022 financial year. Related party transaction: Though the shareholders gave an anticipatory approval at the last annual general meeting, there was no material related party transaction throughout the year under review.

THE STATUTORY AUDIT COMMITTEE

In accordance with section 404 (3) of the Companies and Allied Matters Act, 2020, the audit committee is made up of five (5) members, three representatives of the shareholders and two (2) representatives of the Board of directors. Members of the audit committee are elected at the annual general meeting. The committee was engaged maximally in all aspects of its responsibility as stipulated by the law. In addition, the committee was encouraged to take on other assignments that may be of benefit to the company.

Members of the committee during the year under review were:

1. Chief Matthew Akinlade, FCA, Shareholder Chairman Alhaii Abdulkabir B. Sarumi 2. Shareholder

Mr. Solomon S Akinsanya 3. Shareholder

Mrs. Olufunmilola O. Ayebae Director 4. Mr. Emmanuel E. Imoagene Director 5.

Attendance of Board Members, Board Committees and Audit Committee at meetings during the twelve months ended 31st December 2021.

BOARD MEETINGS		25-3-21	22-04-21	28-07-21	21-10-21	10-12-21	%
Mr. Segun Adebanji		✓	✓	✓	✓	✓	100
Dr. F. A. Ayebae		─ ✓	100				
Mrs. A. P. Sadauki			─ ✓	─ ✓	─ ✓	√	100
Mrs. O. O. Ayebae		X	─	─	√	─	80
Mr. E. E. Imogene				√	─ ✓	√	100
Dr. Vincent Ahonkhai			X	√	─ ✓	√	80
Mr. Ekwunife Okoli		─ ✓	√	√	─ ✓	√	100
Mr. O O. Olayeye				<u> </u>			100
Mr. A. A. Adebayo				<u>✓</u>			100
Mr. Ola Ijimakin		<u> </u>		<u> </u>	<u> </u>	<u> </u>	100
AUDIT COMMITTEE		02-02-21	24-03-21	2-04-21	15-07-21	19-10-21	%
Chief Matthew Akinlade							100
Alhaji A. B Sarumi			✓				100
Mrs. O. O. Ayebae		X					80
Mr. S. S Akinsanya							100
Mr. E. E. Imoagene		✓		✓			100
GOVERNANCE, NOMINATION AND REMUNERATION COMMITTEE			31-03-21	26-07-21	20 07 21	20-10-21	%
					28-07-21		100
Mrs. A. P. Sadauki			✓	✓	✓	✓	100
Mrs. O. O. Ayebae			✓	√	✓		100
Mr. E. E. Imogene Mr. Ekwunife Okoli				√	✓	√	100
			✓	√	√	√	
Dr. Vincent Ahonkhai						✓	100
FINANCE AND GENERAL							
PURPOSES COMMITTEE	28-01-21	25-03-21	22-04-21	14-07-21	18-10-21	03-12-21	%
Mr. E.E. Imogene	√		─ ✓	√	─ ✓	√	100
Dr. F. A. Ayebae	✓	<i>─</i>	─	√	√	─ ✓	100
Mr. O. S Adebanji	✓	✓	✓	√	✓	─	100
Dr. Vincent Ahonkhai	NA	NA	X		─ ✓		75
Mr. Ekwunife Okoli	NA	NA	─ ✓	─ ✓	─ ✓	─ ✓	100
Mr. O O. Olayeye	✓	─	─	─	─	─	100
Mr. A. A. Adebayo	NA	NA	✓	─	✓	─	100
Mr. Ola Ijimakin	√				X		75
-							
RISK MANAGEMENT AND AUDIT CO	OMMITTEE			13-07-21	12-10-21	30-11-21	%
Mr. Segun Adebanji				✓			100
Dr. F. A. Ayebae							100
Mr. Ekwunife Okoli							100
Mrs. O. O. Ayebae						X	67
Mr. O O. Olayeye				✓		✓	100
Mr. E.E. Imogene				✓	✓	✓	100
Mr. A. A. Adebayo				✓	✓	✓	100

STRATEGY AND BUSINESS DEVELOPMENT COMMITTEE	08-07-21	14-10-21	02-12-21	%
Mr. Ekwunife Okoli	✓	✓	X	67
Mrs. A. P. Sadauki	✓	✓	X	67
Mr. E.E. Imogene	✓	✓	✓	100
Dr. Vincent Ahonkhai	√	✓		100
Dr. Fidelis. Ayebae	X	─ ✓	─ ✓	67
Mr. O O. Olayeye	<i>_</i>	─ ✓	─ ✓	100
Mr. A A. Adebayo		─ ✓	─	100
Mr. Ola Ijimakin		X	<i>─</i>	67

Key ✓ - Present

X - Absent

N/A - Not Applicable

Board induction programme

With the expansion of the Board in January 2021, a robust Directors' induction programme was instituted. The induction took one month and covered all aspects of the business in addition to the basic training of directors on compliance with their disclosure obligations and more. The benefit of the induction was apparent in the quick understanding of the business by the Directors and reflected in their contributions at Board meetings.

Securities Trading

The company directors are constantly reminded and they are aware of the restrictions imposed on them with regards to trading in the shares of the company during closed periods. The policy in place is obeyed by the directors and other senior employees who by virtue of their position constantly come in contact with price-sensitive information.

Enquiries have been made and it is hereby stated that in respect of these financial statements and the interim accounts submitted in the year under review none of the directors violated the rules relating to securities trading.

Payment of penalty

The company paid no penalty to the Nigerian Exchange Limited or any other regulator during the year under review.

Compliance with the code of corporate governance

The Company complied with the 2018 Code of Corporate Governance for public companies during the year under review. Detailed explanations were given in the annual corporate governance return (Form SEC 1) made to the Securities and Exchange Commission in January 2022.

The complaints management policy of the company

The company has in place a policy document on complaints management to support the existing policies dealing with allied matters.

SHAREHOLDING STRUCTURE / FREE FLOAT STATUS

	31-12-21		31-12-20	
Description	Unit	Percentage	Unit	Percentage
Issued Share Capital	2,086,360,250	100%	2,086,360,250	100%
Substantial Shareholdings (5% and above)				
Dr. Fidelis A. Ayebae	689,585,227	33.05%	689,585,227	33.05%
Stanbic IBTC Nominees Limited	514,747,303	24.67%	514,747,303	24.67%
Total Substantial Shareholdings	1,204,332,530	57.72%	1,204,332,530	57.72%
Directors' Shareholdings (direct and indirect), excluding of	lirectors with subs	stantial intere	ests	
DR. Fidelis A. Ayebae (indirect)	1,000,000	0.05%	1,000,000	0.05%
Mr. Emmanuel E. Imoagene	34,012,000	1.63%	34,012,000	1.63%
Mrs. Olufunmilola O. Ayebae	67,845,000	3.25%	67,845,000	3.25%
Mrs. Aishatu P. Sadauki	781,550	0.04%	781,550	0.04%
Dr. Vincent Ahonkhai	162,600	0.01%	0	0.00%
Mr. Olugbenga O. Olayeye	19,581,040	0.94%	19,581,040	0.94%
Mr. Abiola A. Adebayo	16,625,609	0.80%	16,625,609	0.80%
Mr. Ola Ijimakin	2,130,000	0.10%	2,130,000	0.10%
Mr. Ekwunife Okoli	0	0.00%	0	0.00%
Mr. Segun Adebanji	0	0	0	0
Total Directors' Shareholdings	142,137,799	6.81%	141,975,199	6.80%
Other Influential Shareholdings				
NIL				
Total Other Influential Shareholdings	0	0.00%	0	0.00%
Free Float in Units and Percentage	739,889,921	0	740,052,521	35.47%
Free Float in Value	₦ 4,180,378,	.053.65		

Declaration:

- (A) FIDSON HEALTHCARE PLC with a free float percentage of 35.47% as at 31 December 2021, is compliant with The Exchange's free float requirements for companies listed on the Main Board.
- (B) FIDSON HEALTHCARE PLC with a free float value of N4,180,378,053.65 as at 31st December 2021, is compliant with The Exchange's free float requirements for companies listed on the Main Board.

NB: Average share price in 2020 was N2.99 and N5.65 in 2021.



J. Abayomi Adebanjo, FCIS Company Secretary FRC/2013/ICSAN/00000002161 25 March 2022

STATEMENT OF CORPORATE RESPONSIBILITY AND CERTIFICATION OF ACCOUNT PURSUANT TO SECTION 60 (2) OF THE INVESTMENTS AND SECURITIES ACT, 2007 AND SECTION 405 OF THE COMPANIES AND ALLIED MATTERS ACT 2020

We, Dr. Fidelis Ayebae and Mr. Imokha Ayebae, being the Chief Executive Officer and the Head of Finance respectively of Fidson Healthcare Plc in compliance with section 60 of the Investments and Securities Act, 2007 and with regard to the unaudited accounts for the YEAR ended 31st December 2021 now submitted to the Commission, hereby certify that:

- We have reviewed the report; (a)
- (b) based on our knowledge, the report does not contain;
 - any untrue statement of a material fact, or
 - ii) omit to state a material fact, which would make the statement, misleading in the light of the circumstances under which such statement was made:
- (c) Based on our knowledge, the financial statements and other financial information included in the report fairly present in all material respects the financial condition and results of operations of the company as of, and for the period presented in the report.
- (d) We:
 - are responsible for establishing and maintaining internal controls.
 - have designed such internal controls to ensure that material information relating to the company and its consolidated subsidiaries is made known to us by others within the company particularly during the year ended
 - have evaluated the effectiveness of the company's internal controls as of date within 90 days prior to the report;
 - iv) have presented in the report our conclusions about the effectiveness of our internal controls based on our evaluation as of that date;
- We have disclosed to the Auditors of the company and audit committee: (e)
 - all significant deficiencies in the design or operation of internal controls which would adversely affect the company's ability to record, process, summarize and report financial data and have identified for the company's Auditors any material weakness in internal controls.
- (f) We have identified in the report whether there were significant changes in internal controls or other factors that could significantly affect internal controls subsequent to the date of their evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

Certified by:

Dr. Fidelis Ayebae (Managing Director)

Dated this 24th day of March 2022.

Mr. Imokha Ayebae (Chief Financial Officer)

STATEMENT OF DIRECTORS' RESPONSIBILITIES FOR THE PREPARATION AND APPROVAL OF THE FINANCIAL STATEMENTS

The Directors of Fidson Healthcare Plc accept responsibility for the preparation of the financial statements that give a true and fair view of the financial position of the as at 31 December 2021, and the results of its operations, cash flows and changes in equity for the year then ended, in compliance with International Financial Reporting Standards ("IFRS") and in the manner required by the Companies and Allied Matters Act, 2020 and Financial Reporting Council of Nigeria Act, 2011.

In preparing the financial statements, the Directors are responsible for:

- properly selecting and applying accounting policies;
- presenting information, including accounting policies, in a manner that provides relevant, reliable, comparable and understandable information;
- providing additional disclosures when compliance with the specific requirements in IFRSs are insufficient to enable users to understand the impact of transactions, other events and conditions on the Company's financial position and financial performance.

Going Concern:

The Directors have made an assessment of the Company's ability to continue as a going concern and have no reason to believe the Company will not remain a going concern in the year ahead.

Abiola Adebayo Director

FRC/2013/PSNIG/00000002162 24 March 2022

Fidelis Ayebae

MD/CEO

FRC/2014/CIANG/00000002376

24 March 2022

AUDIT COMMITTEE'S REPORT

In the course of the financial year 2021, the statutory Audit Committee of Fidson Healthcare Plc met five times as illustrated in the table below.

AUDIT COMMITTEE	02-02-21	24-03-21	2-04-21	15-07-21	19-10-21	%
Chief Matthew Akinlade	─	✓	✓	√	✓	100
Alhaji A. B Sarumi	<i>_</i>	<i>─</i>	─ ✓	✓	✓	100
Mrs. O. O. Ayebae	X	─	─ ✓	─ ✓	✓	80
Mr. S. S Akinsanya	<i>_</i>	✓	<u> </u>	<i>─</i> ✓	─ ✓	100
Mr. E. E. Imoagene	<i>_</i>	─ ✓	√	─ ✓	─ ✓	100

Key

- Present

- Absent

Our terms of reference include but are not limited to the following:

- Assist in the oversight of the integrity of Fidson Healthcare Plc ("the Company") financial statements, compliance with legal and other regulatory requirement, assessment of qualifications and independence of external auditor, and performance of the company's internal audit functions well as that of external auditors.
- 2. Ensure the development of a comprehensive internal control framework for the Company, obtains assurance and report annually in the financial report, on the operating effectiveness of the Company's internal framework.
- 3. Oversee management's process for the identification of significant fraud risks across the Company and ensure that adequate prevention, detection, and reporting mechanism are in place.
- 4. Discuss the annual audited financial statements with management and external auditors.
- 5. Discuss policies and strategies in respect to risk assessment and management.
- 6. Review and ensure that adequate whistle blowing procedures are in place and that a summary of issues reported are highlighted to the Chairman.
- 7. Review, with the external auditor, any audit scope limitations or problems encountered and management responses to same. In addition, to review the independence of external auditors and ensure that where non- audit services are provided by the external auditors, there is no conflict of interest.
- 8. Preserve auditor independence, by setting clear hiring policies for employees or former employees of independent auditors
- Invoke its authority to investigate ant matter within its terms of reference for which purpose the Company must make 9. available the resources to the internal auditors with which to carry out these functions, including access to external advice where necessary.

Consequently, in accordance with the provisions of section 404(4) and (7) of the Companies and Allied Matters Act 2020, the members of the statutory Audit committee of Fidson Healthcare Plc hereby report that we have exercised our statutory functions under this act, and we acknowledge the cooperation of the Management and staff of the conduct of these responsibilities.

Specifically, we confirm that:

- The accounting and reporting policies of the Company are consistent with the legal requirements and ethical practices.
- 2. The internal audit programmes are extensive and provide a satisfactory evaluation of the efficiency of the internal controls systems; and
- 3. We have considered the independent auditor's post audit report and management responses thereon, and are satisfied with responses to our question as well as the state of Fidson Healthcare Plc.

Chief Matthew Akinlade, FCA FRC2013/ICAN/00000002111

Chairman

Statutory Audit Committee

23 March 2022

Members of the Statutory Audit Committee are:

Chief Matthew Akinlade, FCA Shareholder representative (Chairman)

Alhaji Abdulkabir Sarumi, Shareholders' representative Mr. Solomon S. Akinsanya Shareholders' representative Mrs. Olufunmilola O. Ayebae Directors' representative Mr. Emmanuel E. Imoagene Directors' representative

CORPORATE SOCIAL RESPONSIBILITY

Fidson healthcare plc has remained unwavering in its commitment to adding value to lives.

While we ensure the security of shareholders' investment and deliver quality healthcare products and services to across Nigeria and West Africa, we also integrate social and environmental concerns in our business goals and operations.

This passion for humanity is essentially the basis of our existence as a healthcare organization. For almost 3 decades, this philosophy influenced the way we go about our business, whether it is manufacturing or marketing of quality pharmaceutical products.

Our work makes the best use of Fidson's resources—our people, products, partnerships, and funding-to address social and healthcare challenges. Our commitment to humanity is demonstrated in the company's efforts at treating employees well, preserving the environment, developing sound corporate governance, supporting humanity causes, as well as fostering the good health and general wellbeing of the people.

Our approach

Fidson's Corporate Social Responsibility efforts would not be possible without strategic partnerships with nonprofit organizations, governments, and foundations. Together, we work to identify and allocate the most appropriate resources to help the underserved communities around us. This gives life to our vision and mission statements, as well as our corporate slogan -" we value life".

Though our CSR initiatives focus on three core pillars namely Children's health, Education, Community service and development, we also combine innovative approaches with traditional philanthropic methods to create enduring and meaningful impact on humanity and under-served communities. We adopted a corporate sustainability approach that aligns with the United Nation Sustainable Development Goals 12 and 15, which focus on Responsible Production and Consumption as well as protection of the Environment, respectively.

In the past year, we have sustained our commitment to maintain and enforce an effective Health, Safety and Environment (HSE) programme which entails company wide measures put in place to avert risks to occupational health or damage to the environment. In the same vein, Fidson Healthcare Plc. maintains an Environmental Management System (EMS) in compliance with IS0 14001:2015 Standard, which is the world's most widely recognized standard for Environmental Management Systems, Our adherence to this system minimizes the impact of our operations, activities, products, and services on the environment. For example, we have improved our safe waste management processes at our ultra-modern cGMP compliant manufacturing and sustains the use of natural gas for alternative power generation to mitigate against harmful occurrences like pollution in the host community.

It is important to reiterate that Fidson's maintenance of the EMS standards, is not only to enhance our environmental performance and manage legal compliance with environmental responsibilities, but we also demonstrate our commitment to humanity and environmental preservation setting an example for other manufacturing companies in a society where organizations and the citizens pay less attention to the impact of their activities on the environment.

We are pleased to present the following CSR projects carried out in 2020.

EDUCATIONAL AND PROFESSIONAL I. **DEVELOPMENT PROGRAMMES**

A. **ASTYMIN SCHOOL PROGRAMMES (ASP)** INITIATIVE

This is a catch-them-young programme which started in 2010 with the aim of developing mental and academic performance by rewarding hard work and academic excellence amongst Primary School pupils. The programme reaches out to children and young adults via various school/academic activities and other events to enrich their mental and academic development.

We have endeavoured to achieve these objectives through 2 main activities:

- 1. Astymin Genius of the Month [AGOM], which rewards the best pupils in schools across the country who engage in monthly essay competition.
- 2. Astymin Brilliance Reward [ABR] an annual event that rewards hard work and academic excellence amongst Primary School pupils.



Through these programmes, Fidson has reach over 10,000 pupils in 5000 schools by providing cash prizes, products sampling, and souvenirs distribution during different times/ events of academic years. This makes Fidson the only pharmaceutical manufacturing company that actively identifies with schools in both private and public sectors in the country.

In 2021, Fidson Healthcare Plc. held the monthly Astymin Genius of the Month [AGOM] which witnessed the submission of entries from 250 schools - both Government and private - across the Northern, Southwest and South-east regions. We rewarded top performers with educational materials that will help them in their next level of study on their journey to a bright future.

Also, 304 students across the nation were rewards for their exceptional academic performance through the Astymin Brilliance Reward [ABR] programme. The event themed: "Empowering the Future: Rewarding Excellence" held with strict adherence to COVID 19 protocols on Saturday 21st August 2021 at the Fidson Corporate head office, Lagos with both onsite and online attendance.

Astymin Brilliance Reward [ABR] is our attempt to bring back the glory days of our education by throwing our weight behind the children's drive for academic excellence. We believe it is better to catch them young and put them on the right path to success. Therefore,



Fidson with her Astymin themed initiative, will continue to support brilliant primary school kids in a way that will motivate them to stay focused on their studies, believing that merit and hard work can still be rewarded.

Free Medical Webinars

Aside from programmes to improve academic development of children. Fidson also prioritises the development of medical professionals. In 2021. Fidson hosted 6 medical webinars engaging seasoned resource persons from various medical specialties to educate the medical practitioners on topical issues and global trends and best practices that will help the attendees deliver better healthcare services to Nigerians. These webinars were free and was attended by hundreds of health workers across the country. In addition, through our partnership with Premier Medical System (PMS) - a Digital Health company focusing on leveraging IT to improve access to quality and affordable healthcare in Africa - attendees received CME points to boost the career progression.

II. **Blood Donation Advocacy**

Due to the poor blood donation culture in Nigeria and the realization of the ever-increasing need for Nigerians to have access to safe blood for health reasons Fidson have made the advocacy for Voluntary blood donation one of its focal points for Corporate Social

Responsibility. This advocacy will create awareness of the need for people to take responsibility and support the drive to make blood safe, available, accessible, and affordable. In 2021, we partnered with Timilehin Leukemia Foundation and the Lagos State Blood Transfusion Service to hold Blood Donation drive at different times within the year. Aside from massively sensitizing the public, we also gave out several samples of Ferobin – the ideal blood building brand by Fidson and other "Saving Lives" branded souvenirs to reward voluntary blood donors. The organization has also committed to hosting such sensitization and advocacy event every quarter.



Fidson team at the Blood Donation drive in partnership with Timilehin Leukaemia Foundation.



Fidson team at the Blood Donation drive in partnership with Lagos State Blood Transfusion Service



Fidson team at the Blood Donation drive in partnership with Lagos State Blood Transfusion Service

Grants to Children Emergency Relief Foundation (CERF)

In 2020, Fidson healthcare Plc. continued her partnership with Children Emergency Relief Foundation (CERF) – a faith-based non-governmental organization committed to the survival, protection, welfare, rights, relief and support of vulnerable children and by extension, their caregivers through outreaches and sensitization programmes.

Fidson collaborates with CERF by providing scholarship support to pupils as well as health interventions to indigents of the Ikorodu community and other rural communities in Lagos and Ogun States. Over the years, we have supported many vulnerable children with Scholarship fund for their Primary and Secondary education through this collaboration. Some of children have also pursued further studies in various higher institutions of learning. Till date we receive reports that confirm that our grants and donations are not in vain as the children grow into adulthood, attaining the required and desired educational heights.

Fidson also partners with CERF to support medical treatment for indigents with dire medical needs. This year, Fidson in collaboration with the foundation supported the medical bills of two surgery cases including a limbs surgery to correct a defect caused by sickle cell.

IV. **Donations to Support Children Developmental** Centre (CDC)

In the year 2021, Fidson continued her commitment to funds donation aimed at bringing succor to the lives of the special needs children at the Children Developmental Centre. The company made financial donations towards the establishment of the "Little School Programme." - an initiative of the CDC which builds on sibling-to-sibling learning, applying learning resources for children with Special Education Needs and Disabilities (SEND). This learning resources specifically developed by the CDC was designed to help the

children with Special Education Needs and Disabilities to keep on learning taking into consideration a range of learning challenge they experience as a result of their disability.

Partnership with CDC aligns with our Corporate Social Responsibility (CSR) focus of Children's health and education, especially for the vulnerable ones. Children Developmental Centre is a safe home where Autistic and Down Syndrome children are well catered for and strongly empowered to achieve remarkable feats with all needed support, love, and attention by professional and passionate care givers. This is the reason Fidson Healthcare Plc has and will continue to support by way of funds and drugs donations, while encouraging the Centre and the children to achieve their potentials even in their disabilities.

V. **Corporate Philantrophy**

Α. Hospital Ward Building in the Catholic Church Hospital, Agenebode. Fully funded by Fidson Healthcare



ESSENTIAL PRODUCTS

affordable and widely lable for today and future erations of Nigerians. think radically and that conform to global best



We aim to provide quality, affordable **healthcare** for every socio-economic class



About H.E.L.P

- Affordability
- Corporate Social Responsibility (CSR)
- Quality
- Essential medicines

ABOUT FIDSONFidson Healthcare Plc is a leading pharmaceutical manufacturing company in Nigeria. Founded in 1995, we have relentlessly pursued our goal of becoming a leading player in the pharmaceutical landscape in Nigeria.

OUR CORE VALUES

on, Passion, Excellence, Integrity and Ownership

SYRUPS & SUSPENSIONS



Mist Magnesium Trisilicate 200ml



Ibuprofen 100ml



Sulbutamol Sulphate 100ml



Metronidazole 60ml



Hyoscine N-Butylbromide 60ml



Sulfamethoxazole, Trimethoprim 50ml



Fitulin



Fidvite 100ml



Vitamin C 100ml



Vitamin B Complex 100ml



Multivitamin 100ml



TABLETS & CAPSULES



Metronidazole 200mg



Metronidazole 400mg



Chloramphenicol 250mg



Tetracycline 250mg



Ibuprofen 400mg



Co-trimoxazole 480mg



Ciprofloxacin 500mg



Independent Auditor's report To the Shareholders of Fidson Healthcare Plc Report on the Audit of the Financial Statements

Deloitte & Touche Civic Towers
Plot GA 1, Ozumba Mbadiwe Avenue
Victoria Island
P.O.Box 965, Marina Lagos Tel: +234 (1) 904 1700 www.deloitte.com.ng

Opinion

We have audited the financial statements of Fidson Healthcare Plc set out on pages 5 to 67, which comprise the statement of financial position as at 31 December 2021, the statement of profit or loss and other comprehensive income, the statement of changes in equity the statement of cash flows for the year then ended and the notes to the financial statements, including a summary of significant accounting policies.

In our opinion, the financial statements give a true and fair view of financial position of Fidson Healthcare Plc as at 31 December 2021, and its financial performance and cash flows for the year then ended in accordance with International Financial Reporting Standards, the requirements of the Companies and Allied Matters Act and Financial Reporting Council Act, 2011.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the requirements of the International Ethics Standards Board for Accountants' (IESBA) International Code of Ethics for Professional Accountants (including International Independence Standards) (IESBA code) and other independence requirements applicable to performing audits of financial statements in Nigeria. We have fulfilled our other ethical responsibilities in accordance with the IESBA Code and other ethical requirements that are relevant to our audit of Financial Statements in Nigeria.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matter

Key audit matter is the matter that, in our professional judgment, was of most significance in our audit of the financial statements of the current year. This matter was addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on the matter.

Key Audit Matter

Revenue

As at 31 December 2021, the Company's revenue was N30.86 billion representing an increase of 69% from N18.28 billion as at 31 December 2020. Further assessment revealed that significant part of the increase relates to infusion products which increased by 52%.

Given the materiality of the increase in the account balance, and the extent of audit procedures performed, we have considered this a Key Audit Matter.

Details of the Key Audit Matter (KAM) are disclosed in note 5 of the financial statements.

How the matter was addressed in the audit

In evaluating the reasonableness of the increase in the account balance, we performed the following procedures:

- 1. Performed analytical procedures to determine the relevant risks as at year end.
- 2. Assessed and obtained understanding of key controls over revenue recognition
- Reconciled revenue to the general ledger to ensure proper recording, completeness, accuracy, occurrence, and classification of revenue
- Obtained the sales report and reconciled it to the general ledger.
- 5. Selected samples of sales transactions and reviewed the sales invoices and customer acknowledged waybills to ascertain the goods were sold to third parties, and control passed before recognition
- 6. Performed analysis of revenue, receivables, and payments from customers during and after year end to ascertain that the recorded revenue was paid for by the customers.
- 7. Performed cut off procedures to ensure revenue transactions were recorded in the appropriate period
- 8. Ensured appropriate disclosure of the revenue balance in the financial statements.

The result of procedures performed shows that the increase in the account balance is reasonable.

Other Information

The Directors are responsible for the other information. The other information comprises the Directors' Report, the Audit Committee's Report the Corporate governance Report, and other national disclosures which we obtained prior to the date of this report, and the Annual Report, which is expected to be made available to us after that date. The other information does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not and will not express an audit opinion or any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If, based on the work we have performed on the other information obtained prior to the date of this auditor's report, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the Directors for the Financial **Statements**

The Directors are responsible for the preparation and fair presentation of the financial statements in accordance with International Financial Reporting Standards, the requirements of the Companies and Allied Matters Act, the Financial Reporting Council of Nigeria Act and for such internal control as the Directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Directors either intend to liquidate the Company or to cease operations, or have no realistic alternative but to do so.

Auditor's Responsibilities for the Audit of the **Financial Statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor is report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Directors.
- Conclude on the appropriateness of the Directors' use of the going concern basis of accounting and based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with the audit committee and Directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide the audit committee with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, actions taken to eliminate threats or safeguards applied.

From the matters communicated with the audit committee, we determine those matters that were of most significance in the audit of the financial statements of the current year and are therefore the key audit matters. We describe the matter in our auditor's report unless law or regulation precludes public disclosure

about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

In accordance with the Fifth schedule of the Companies and Allied Matters Act we expressly state that:

- i) We have obtained all the information and explanation which to the best of our knowledge and belief were necessary for the purpose of our audit.
- The Company have kept proper books of account, so far as appears from our examination of those books.
- iii) The Company's financial position and its statement of profit or loss and other comprehensive income are in agreement with the books of account and returns.

Chigozie Okoro, FCA-FRC/2013/ICAN/00000004457 For: Deloitte & Touche **Chartered Accountants** Lagos, Nigeria 31 March, 2022





...high-quality solution to achieving smooth skin.

For More Enquiries: Customer Care Line: 0807 700 8888 website: www.fidson.com

FINANCIALS

STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

	Notes	Dec-21 ₩'000	Dec-20
Revenue Cost of sales	5 6	30,860,817 (15,757,782)	18,275,856 (9,694,516)
Gross profit Other operating income Administrative expenses Selling and distribution expenses	7 8 9	15,103,035 596,552 (6,416,079) (3,421,283)	8,581,340 349,745 (3,734,059) (2,099,537)
Operating profit		5,862,225	3,097,489
Finance costs Finance income	10 11	(1,222,299) 77,718	(1,333,927)
Profit before tax Income tax	12 13a	4,717,644 (997,731)	1,772,802 (567,763)
Profit for the year		3,719,913	1,205,039
Other comprehensive income: (OCI) Items to be reclassified to profit or loss in subsequent years: Fair value profit on available for sale financial instruments	34	70	1,240
Net other comprehensive income to be reclassified to profit or loss Items not to be reclassified to		70	1,240
profit or loss in subsequent years: Re- measurement gain on defined benefit plans Income tax effect	25 13c	20,011 (6,004)	36,838 (11,051)
Net other comprehensive income not to be reclassified to profit or loss		14,007	25,787
Other comprehensive income, net of tax		14,077	27,027
Total comprehensive income, net of tax		3,733,990	1,232,066
Earnings per share – basic (in kobo) Basic and diluted	43	178	58

The notes and accounting policies form an integral part of these financial statements.

STATEMENT OF FINANCIAL POSITION

ASSETS	Notes	Dec-21	Dec-20
Non-current assets	4.4	14.000.004	10.007.010
Property, plant and equipment	14	14,892,994	13,387,810
Right of use assets	15	486,271	595,194
Investment property	16	31,823	32,742
Intangible assets	17	21,722	23,530
Available-for-sale investments	18a	5,030	4,960
Loans and receivables	18b	14,027	12,871
Other non-current financial asset	19	173,162	171,673
		15,625,029	14,228,780
Current assets Inventories	20	11,154,535	6,780,766
Trade and other receivables	21	2,979,867	2,731,272
Prepayments	22	1,389,825	296,312
Cash and cash equivalents	23	1,956,154	3,205,354
Oash and Cash equivalents	20	1,930,134	3,203,334
		17,480,381	13,013,704
		33,105,410	27,242,484
Total assets			
Equity and liabilities Equity			
Issued share capital	32	1,043,180	1,043,180
Share premium	33	4,933,932	4,933,932
Retained earnings	00	7,774,138	4,561,808
Available for sale reserve	34	585	515
Available for sale reserve	04		
Non-current liabilities		13,751,835	10,539,435
Interest bearing loans and borrowings	24	6,210,729	4,050,683
Lease liabilities	25	63,590	164,459
Retirement benefit obligation	26	268,185	447,792
Government grant	27	660,764	938,248
Deferred revenue	28	1,583	4,751
Deferred tax liability	13c	1,177,063	1,548,311
Deletted tax hability	100		
Current liabilities		8,381,914	7,154,244
Trade and other payables	29	4,447,130	2,177,568
Interest bearing loans and borrowings	24	2,200,119	6,636,268
Bank Overdraft	23	259,662	232,229
Other financial liabilities	30	2,150,000	252,229
	25	87,350	95,982
Lease liabilities			,
Government grant	27 28	356,651	244,229
Deferred revenue		3,167	3,168
Income tax payable	13b 31b	1,379,367	120,424
Unclaimed dividend	310	88,215	38,937
		10,971,661	9,548,805
Total liabilities		19,353,575	16,703,049
Total equity and liabilities		33,105,410	27,242,484

SIGNED ON BEHALF OF THE BOARD OF DIRECTORS ON 24 March 2022

Fidelis Ayebae Managing Director/CEO FRC/2014/CIANG/00000002376 Imokha Ayebae Chief Financial Officer

Abiola Adebayo Director

FRC/2013/PSNIG/00000002162

The Notes and accounting policies form an integral part of these financial statements.

The Financial Reporting Council of Nigeria (FRC), through a letter dated 11 November 2021, granted a waiver which allows the Chief Financial Officer to sign the financial statements for the year ended 31 December 2021 without indicating any FRC registration Number.

STATEMENT OF CHANGES IN EQUITY

	Share capital	Share premium	Retained earnings	Available- for–sale reserve	Total
	₩000	₩000	₩000	₩000	₩000
At 1 January 2020 Profit for the year Other comprehensive income for the year, net	1,043,180 - -	4,933,932 - -	3,643,921 1,205,039 25,787	(725) - 1,240	9,620,308 1,205,039 27,027
Total Comprehensive Income for the year Dividends (Note 31)	- -	:	1,230,826 (312,939)	1,240 -	1,232,066 (312,939)
At 31 December 2020	1,043,180	4,933,932	4,561,808	515	10,539,435
At 1 January 2021 Profit for the year Other comprehensive income for the year, net	1,043,180 - -	4,933,932 - -	4,561,808 3,719,913 14,007	515 - 70	10,539,435 3,719,913 14,077
Total Comprehensive Income for the year Dividends (Note 31)	:	-	3,733,920 (521,590)	70 -	3,733,990 (521,590)
At 31 December 2021	1,043,180	4,933,932	7,774,138	585	13,751,835

STATEMENT OF CASH FLOWS

Operating activities:	Notes	Dec-21 ₩'000	Dec-20 ₩'000
Profit before tax		4,717,644	1,772,802
Adjustments to reconcile profit before tax to net cash flows			
Depreciation of property, plant and equipment	14	654,108	668,435
Depreciation - Right of use assets	15	105,850	106,911
Impairment loss/(gain)	8	245,050	276,028
Gain on disposal of plant, property, and equipment	7	(83,264)	(8,785)
Net exchange difference (Unrealized)	8	667,645	309,345
Net exchange difference (Realized)	8	1,609,954	-
Depreciation of investment property	16	919	919
Grant income	7	(474,951)	(200,088)
Amortization of Intangible assets	17	40,358	37,769
Interest income on loans and receivables	11	(36,898)	(3,383)
Interest on other non-current assets	11 11	(11,730)	(4,034)
Interest income on fixed deposit Finance costs	10	(25,090) 1,222,299	(1,823) 1,333,927
Employee benefit expense	26	20,011	36,838
Amortization of deferred revenue	28	(3,167)	(3,167)
Changes in working capital:	20	(3,107)	(3,107)
(Increase)/ decrease in trade and other receivables		(248,595)	532,435
Decrease / (increase) in prepayments		(1,093,514)	(128,842)
(Increase) in inventories		(4,291,199)	(3,405,327)
Increase in government grant		(165,062)	814,602
(Decrease)/increase in other financial liabilities		2,150,000	(65,000)
increase in trade and other payables		2,269,566	914,276
	-	7,269,934	2,983,838
Income tax paid	13b	(116,039)	(95,465)
Benefits paid	26	(3,958)	(6,390)
Net cash flow from operating activities	20	7,149,937	2,881,983
	-	7,140,007	2,001,000
Cash flows from investing activities:			
Purchase of property, plant & equipment	14	(2,646,191)	(2,070,861)
Additions to intangible assets	17	(38,550)	(33,563)
Interest received	11	25,090	1,823
Interest on other non-current assets	11	11,730	4,034
Proceeds from sale of property, plant, and equipment	19	570,166	21,358
Investment in other financial assets	19	-	272,030
Liquidation of investment in other financial asset		(0.077.755)	(4.005.470)
Net cash utilised by investing activities	-	(2,077,755)	(1,805,179)
Cash flows from financing activities:			
Payments of finance lease liabilities		(109,501)	(269,068)
Interest paid on loans & borrowings	10	(1,222,299)	(1,333,927)
Dividend paid	31	(512,590)	(312,939)
Payment of unclaimed dividend	31b	49,278	-
Proceed from loans & borrowings	24a	3,500,000	6,768,450
Loan repayment	24a	(5,776,105)	(2,404,163)
Net cash provided by financing activities	-	(4,071,217)	2,448,353
Net increase/(decrease) in cash and cash equivalents		1,000,966	3,525,155
Net foreign exchange difference		(2,277,599)	(309,345)
Cash and cash equivalents at the beginning of the year		2,973,125	(242,685)
Cash and cash equivalents at the end of the year	23	1,696,492	2,973,125

NOTES TO THE FINANCIAL STATEMENTS

1.0 Corporate information

The Company was incorporated as a private limited liability Company on 13 March 1995 and commenced business activities on 15 March 1995. The principal activities of the Company include manufacturing and distribution of pharmaceutical products. The Company's shares were quoted the Nigerian Stock Exchange on 5 June 2008. The issued share capital is held as to 38.86% directly by the Directors, 5.74% indirectly by the Directors and 54.94% by the Nigerian Public.

Composition of the financial statements 1.1

The Financial statements are drawn up in Naira, the functional currency of Fidson Healthcare Plc. In accordance with IFRS accounting presentation, the Financial Statements comprise:

- Statement of Profit or Loss and Other Comprehensive Income
- Statement of Financial Position
- Statement of Changes in Equity
- Statement of Cash flows
- Notes to the Financial Statements.

1.2 Financial period

These Financial Statements cover the financial year ended 31 December 2021 with comparative amounts for the year ended 31 December 2020.

2.0 Significant accounting policies

2.1 Basis of preparation and measurement

These financial statements have been prepared in accordance with the International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB).

The financial statements have been prepared on a historical cost basis, except for certain available-for-sale financial assets which have been measured at fair value. The financial statements are presented in the Nigerian Naira and all values are rounded to the nearest thousands (₦'000), except when otherwise indicated.

Summary of significant accounting policies

The following are the significant accounting policies applied by the Company in preparing its financial statements:

2.2.1 Current versus non-current classification

The Company presents assets and liabilities in statement of financial position based on current/noncurrent classification. An asset is current when it is:

- Expected to be realised or intended to sell or consumed in normal operating cycle.
- Held primarily for the purpose of trading.
- Expected to be realised within twelve months after the reporting period.

Or

Cash or cash equivalents unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. All other assets are classified as non-current.

A liability is current when:

- It is expected to be settled in normal operating
- It is held primarily for the purpose of trading.
- It is due to be settled within twelve months after the reporting period.

Or

There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period.

The Company classifies all other liabilities as noncurrent.

Deferred tax assets and liabilities are classified as noncurrent assets and liabilities.

2.2.2 Fair value measurement

The Company measures some financial instruments and non-financial assets at fair value at each reporting date. Also, fair values of financial instruments measured at amortized cost are disclosed in Note 41a.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- In the principal market for the asset or liability, or
- In the absence of a principal market, in the most advantageous market for the asset or liability.

The principal or the most advantageous market must be accessible by the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the relevant observable inputs and minimizing the use of unobservable inputs. Refer to Note 42b for fair value hierarchy.

2.2.3 Revenue recognition

Revenue is recognised to depict the transfer of promised goods or services to the customer in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.

Revenue is recognised by applying a five-step approach:

Identify the contract

- Identify the separate performance obligations in the contract
- Determine the transaction price
- Allocate the transaction price to separate performance obligations
- Recognise revenue when (or as) each performance obligation is

The Company recognises revenue from the following major sources:

- Sale of Ethical Products
- Sale of Over the Counter (OTC) products.

Revenue is measured based on the consideration to which the Company expects to be entitled in a contract with a customer and excludes amounts collected on behalf of third parties. The Company recognises revenue when it transfers control of a product or service to a customer.

Interest income

For all financial instruments measured at amortised cost, interest income or expense is recognised using the effective interest rate (EIR), which is the rate that exactly discounts the estimated future cash payments or receipts through the expected life of the financial instrument or a shorter year, where appropriate, to the net carrying amount of the financial asset or liability. Interest income is included in finance income in the profit or loss.

Dividends

Dividends are recognised when the Company's right to receive the payment is established, which is generally when shareholders approve the dividend.

2.2.4 Government grants

Government grants are recognised where there is reasonable assurance that the grant will be received, and all attached conditions will be complied with. When the grant relates to an expense item, it is recognised as income on a systematic basis over the period that the related costs, for which it is intended to compensate, are expensed. When the grant relates to an asset, it is recognised as income in equal amounts over the expected useful life of the related asset.

When the Company receives grants of non-monetary assets, the asset and the grant are recorded at fair value amounts and released to the profit or loss over the expected useful life in a pattern of consumption of the benefit of the underlying asset by equal annual instalments. When loans or similar assistance are provided by governments or related institutions, with an interest rate below the current applicable market rate, the effect of this favourable interest is regarded as a government grant. The loan or assistance is initially recognised and measured at fair value and the government grant is measured as the difference between the initial carrying value of the loan and the proceeds received. The loan is subsequently measured as per the accounting policy in Note 2.2.12 (ii).

2.2.5 Taxes

Current income tax

The income tax assets or liabilities for the current year are measured at the amount expected to be recovered from or paid to the tax authorities. The tax rates and tax laws used to compute the amount are determined in accordance with the Companies Income Tax Act (CITA) 2007 at 30% of total profit after deducting capital allowances and loss relief. Education tax is also assessed at 2% of the assessable profits.

Current income tax relating to items recognised outside the profit or loss are recognised outside profit or loss.

Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.

Deferred tax

Deferred tax is provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.

Deferred tax liabilities are recognised for all taxable temporary differences, except:

- When the deferred tax liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss.
- In respect of taxable temporary differences associated with investments in subsidiaries, associates, and interests in joint ventures, when the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future.

Deferred tax assets are recognised for all deductible temporary differences, the carry forward of unused tax credits and any unused tax losses. Deferred tax assets are recognised to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilised, except:

- When the deferred tax asset relating to the deductible temporary difference arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss.
- In respect of deductible temporary differences associated with investments in subsidiaries, associates and interests in joint ventures, deferred tax assets are recognised only to the extent that it is probable that.

The temporary differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilised.

The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilised.

Unrecognised deferred tax assets are re-assessed at each reporting date and are recognised to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date.

Deferred tax on items recognised in the profit or loss is also recognised in the profit or loss, while deferred tax on items recognised outside the profit or loss is also recognised outside the profit or loss.

The Company offsets deferred tax assets and deferred tax liabilities if and only if it has a legally enforceable right to set off current tax assets and current tax liabilities and the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same tax authority on the same taxable entity.

Value Added Tax (VAT)

Revenues, expenses and assets are recognized net of the amount of Value Added Tax (VAT), except:

- Where the VAT incurred on a purchase of assets or services is not recoverable from the taxation authority, in which case the VAT is recognised as part of the cost of acquisition of the asset or as part of the expense item as applicable.
- Receivables and payables are stated with the amount of VAT included.

The net amount of VAT recoverable from, or payable to, the tax authority is included as part of receivables or payables in the statement of financial position.

2.2.6 Foreign currency transaction

Foreign currency transactions are converted into the functional currency, the Nigerian Naira at the rate of exchange prevailing at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies are retranslated at the functional currency interbank rate of exchange ruling at the reporting date in accordance with the Central Bank of Nigeria guidelines. Any exchange gains or losses arising on settlement or translation of monetary items are recognised in the profit or loss. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates as at the dates of the initial transactions.

2.2.7 Property plant and equipment

Property, plant and equipment are stated at cost of purchase or construction, net of accumulated depreciation and/or accumulated impairment loss, if any. Such cost includes the cost of replacing component parts of the property, plant and equipment and borrowing costs for long term projects if the recognition criteria are met

When significant parts of property, plant and equipment are required to be replaced at intervals, such parts are recognised as individual assets with specific useful lives and depreciated accordingly. Likewise, when a major inspection is performed, its cost is recognised in the carrying amount of the plant and equipment as a replacement if the recognition criteria are satisfied. All other repair and maintenance costs are recognised in the profit or loss as incurred.

Depreciation on the categories of property, plant and equipment is calculated to write off the cost less the residual value of the asset, using the straight-line basis, over the assets' expected useful lives. Land and capital work-in-progress are not depreciated. The attributable cost of each item of capital work-in-progress is transferred to the relevant asset category immediately the asset is available for use and depreciated accordingly. The normal expected useful lives for the major categories of property, plant and equipment are:

	Years
Land	Nil
Buildings	50
Plant and machinery	4 to 25
Office equipment	4 to 10
Furniture and fittings	8
Motor vehicles	4 to 6
Capital work-in-progress (WIP)	Nil

An item of property, plant and equipment and any significant part initially recognised is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the profit or loss when the asset is derecognised.

The assets 'residual values, useful lives and methods of depreciation are reviewed at each financial year end and adjusted prospectively, if appropriate. Impairment reviews are performed when there are indicators that the carrying amounts may not be recoverable.

Impairment losses and reversals of impairment losses are recognised in the profit or loss. An item of property, plant and equipment is derecognised upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. The gain or loss arising on the disposal or retirement of an asset is determined as the difference between the sales proceeds and the carrying amount of the asset and is recognised in profit or loss.

2.2.8 Leases

The Company assesses whether a contract is or contains a lease, at inception of the contract. The Company recognises a right-of-use asset and a corresponding lease liability with respect to all lease arrangements in which it is the lessee, except for shortterm leases (defined as leases with a lease term of 12 months or less) and leases of low value assets (such as tablets and personal computers, small items of office furniture and telephones). For these leases, the Company recognises the lease payments as an operating expense on a straight-line basis over the term of the lease unless another systematic basis is more representative of the time pattern in which economic benefits from the leased assets are consumed. The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted by using the rate implicit in the lease. If this rate cannot be readily determined, the Company uses its incremental borrowing rate.

Lease payments included in the measurement of the lease liability comprise:

Fixed lease payments (including in-substance fixed payments), less any lease incentives receivable.

- Variable lease payments that depend on an index or rate, initially measured using the index or rate at the commencement date.
- The amount expected to be payable by the lessee under residual value guarantees.
- The exercise price of purchase options, if the lessee is reasonably certain to exercise the options; and
- Payments of penalties for terminating the lease if the lease term reflects the exercise of an option to terminate the lease.

The lease liability is presented as a separate line in the statement of financial position. The lease liability is subsequently measured by increasing the carrying amount to reflect interest on the lease liability (using the effective interest method) and by reducing the carrying amount to reflect the lease payments made.

The Company remeasures the lease liability (and makes a corresponding adjustment to the related right-of-use asset) whenever:

The lease term has changed or there is a significant event or change in circumstances resulting in a change in the assessment of exercise of a purchase option, in which case the lease liability is remeasured by discounting the revised lease payments using a revised discount rate.

The lease payments change due to changes in an index or rate or a change in expected payment under a guaranteed residual value, in which cases the lease liability is remeasured by discounting the revised lease payments using an unchanged discount rate (unless the lease payments change is due to a change in a floating interest rate, in which case a revised discount rate is used).

A lease contract is modified, and the lease modification is not accounted for as a separate lease, in which case the lease liability is remeasured based on the lease term of the modified lease by discounting the revised lease payments using a revised discount rate at the effective date of the modification. The Company did not make any such adjustments during the periods presented.

The right-of-use assets comprise the initial measurement of the corresponding lease liability, lease payments made at or before the commencement day, less any lease incentives received and any initial direct costs. They are subsequently measured at cost less accumulated depreciation and impairment losses.

Whenever the Company incurs an obligation for costs to dismantle and remove a leased asset, restore the site on which it is located or restore the underlying asset to the condition required by the terms and conditions of the lease, a provision is recognised and measured under IAS 37. To the extent that the costs relate to a right-ofuse asset, the costs are included in the related right-ofuse asset, unless those costs are incurred to produce inventories.

Right-of-use assets are depreciated over the shorter period of lease term and useful life of the underlying asset. If a lease transfers ownership of the underlying asset or the cost of the right-of-use asset reflects that the Company expects to exercise a purchase option, the related right-of-use asset is depreciated over the useful life of the underlying asset. The depreciation starts at the commencement date of the lease.

The right-of-use assets are presented as a separate line in the statement of financial position.

The Company applies IAS 36 to determine whether a right-of-use asset is impaired and accounts for any identified impairment loss as described in the 'Property, Plant and Equipment' policy.

Variable rents that do not depend on an index or rate are not included in the measurement the lease liability and the right-of-use asset. The related payments are recognised as an expense in the period in which the event or condition that triggers those payments occurs.

As a practical expedient, IFRS 16 permits a lessee not to separate non-lease components, and instead account for any lease and associated non-lease components as a single arrangement. The Company has not used this practical expedient. For contracts that contain a lease component and one or more additional lease or nonlease components, the Company allocates the consideration in the contract to each lease component based on the relative stand-alone price of the lease component and the aggregate stand-alone price of the non-lease components.

The Company as a lessee

Finance leases transfer to the Company substantially all the risks and rewards incidental to ownership of the leased asset.

The assets are measured at the commencement of the lease at the fair value of the leased property or, if lower, at the present value of the minimum lease payments. Lease payments are apportioned between finance charges and reduction of the lease liability to achieve a constant rate of interest on the remaining balance of the liability. Finance charges are recognised as finance costs in the profit or loss.

The capital element of assets under finance lease is capitalised along with the Company's property, plant and equipment and depreciated at the same rates for assets of that category, or over the lease term, where the lease term is shorter than the assets' useful lives.

Operating lease payments are recognised as an operating expense in the profit or loss on a straight-line basis over the lease term.

Leases - as a lessor

Leases for which the Company is a lessor are classified as finance or operating leases. Whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessee, the contract is classified as a finance lease. All other leases are classified as operating leases.

Rental income from operating leases is recognised on a straight-line basis over the term of the relevant lease. Initial direct costs incurred in negotiating and arranging an operating lease are added to the carrying amount of the leased asset and recognised on a straight-line basis over the lease term.

Amounts due from lessees under finance leases are recognised as receivables at the amount of the Company's net investment in the leases. Finance lease income is allocated to accounting periods so as to reflect a constant periodic rate of return on the Company's net investment outstanding in respect of the leases.

When a contract includes both lease and non-lease components, the Company applies IFRS 15 to allocate the consideration under the contract to each component.

2.2.9 Borrowing costs.

Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period to get ready for its intended use or sale are capitalised as part of the cost of the respective assets. All other borrowing costs are expensed in the year in which they occur. Borrowing costs consist of interest and other costs that the Company incurs in connection with the borrowing of funds.

2.2.10 Investment properties

Investment properties are measured initially at cost, including transaction costs. Subsequent to initial recognition, investment properties are stated at cost less accumulated depreciation and accumulated impairment losses.

The investment properties are subject to annual depreciation charge of 2% on a straight-line basis. If Investment properties are derecognized when either they have been disposed of or when the investment property is permanently withdrawn from use and no future economic benefit is expected from its disposal. The difference between the net disposal proceeds and the carrying amount of the asset is recognized in the profit or loss in the year of derecognition.

Transfers are made to or from investment property only when there is a change in use. For a transfer from investment property to owner-occupied property, the deemed cost for subsequent accounting is the fair value at the date of change. Owner-occupied property becomes an investment property, the Company accounts for such property in accordance with the policy stated under property, plant and equipment up to the date of change in use.

2.2.11 Intangible assets

Product licenses are measured on initial recognition at cost. Following initial recognition, intangible assets are carried at cost less any accumulated amortisation and any accumulated impairment losses. The Company makes upfront payments to purchase product licences.

The product licenses are held on various pharmaceutical products sold by the Company and have licence years that range from 2 to 5years. The licences may be renewed by the Company at the expiration of the license period.

Intangible assets with finite lives are amortised over the useful economic lives. The amortisation period and the amortisation method for an intangible asset with a finite useful life are reviewed at least at each financial year

Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are accounted for by changing the amortisation period or method, as appropriate, and treated as changes in accounting estimates. The amortisation expense on intangible assets with finite lives is recognised in the profit or loss in the expense category consistent with the function of the intangible asset.

Amortisation is calculated using the straight-line basis to write down the cost of intangible assets to their residual values over their estimated useful lives.

An intangible asset is derecognised on disposal or when no future economic benefit is expected from use or disposal. The gain or loss arising from the derecognition of an intangible asset is determined as the difference between the net disposal proceeds and the carrying amount of the intangible asset and recognised in the statement of profit or loss when the asset is derecognised.

Research and development costs

Research costs are expensed as incurred. Development expenditures on an individual project are recognised as an intangible asset when the Company can demonstrate:

- The technical feasibility of completing the intangible asset so that the asset will be available for use or sale.
- Its intention to complete and its ability and intention to use or sell the asset.
- It is probable that the asset will generate future economic benefit.
- The availability of resources to complete the asset.

Following the completion of research and development, it is transferred to another asset which is then depreciated, the asset is carried at cost less any accumulated amortisation and accumulated impairment losses. Amortisation of the asset begins when development is complete, and the asset is available for use. It is amortised over the period of expected future benefit.

Amortisation is recorded in cost of sales. During the period of development, the asset is tested for impairment annually.

Licences

The Company made upfront payments to purchase licences. Licences for the use of intellectual property are granted for periods ranging between five and ten years depending on the specific licences.

Trademark

The Company made upfront payments to purchase trademarks. The trademarks have been granted for a period of 5-10 years by the relevant government agency with the option of renewal at the end of this period. Licences for the use of intellectual property are granted for periods ranging between five and ten years.

A summary of the policies applied to the Company's intangible assets is, as follows:

	Licences	Trademarks	Software
Useful lives	Finite (Over 5 years)	Finite (Over 5-10 years)	Finite (Over 4 years)
Amortisation method used	Amortised on a straight-line basis over the period of the licence amortisation	Amortised on a straight-line basis over the period of the trademark amortisation	Amortised on a straight-line basis over the period of the software amortisation
Internally generated acquired	Acquired	Acquired	Acquired

2.2.12 Financial instruments

- Financial assets
 - A financial asset is any asset that is:
- an equity instrument of another entity.
- a contractual right to receive cash or another financial asset (e.g., receivables); or
- a contractual right to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to GSK (e.g., derivatives resulting in an asset, bonds, and investments)

(ii) **Financial liability**

A financial liability is any liability that is:

- a contractual obligation to deliver cash or another financial asset (e.g., payable);
- a contractual obligation to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the Company (e.g., payables, loans and derivatives resulting in a liability).

Amortised cost (iii)

Most of Fidson's financial assets and liabilities are measured at amortised cost, including, most trade receivables and trade payables. The amortised cost of a financial asset or financial liability is the amount at which the asset or liability is measured at initial recognition

minus principal repayments to date, and minus any reduction for impairment.

If there is a difference between the initial amount and the maturity amount (arising from reasons other than impairment), amortised cost will also be plus or minus the cumulative amortisation using the effective interest method.

Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included in finance income in the profit or loss. The losses arising from impairment are recognised in profit or loss as finance costs.

Effective interest method (iv)

The effective interest method calculates amortised cost by allocating the interest payment or expense over the relevant period. This calculation only applies if a premium has been paid or a discount received. The effective interest rate is the rate that exactly discounts estimated future cash payments or receipts through the expected life of the financial instrument. When estimating cash flows, all contractual terms are considered but expected future credit losses are not taken into account unless the financial instrument is credit impaired.

Expected credit loss (ECL)

The expected credit loss is the difference between the cash flows due under the contract and the cash flows expected to be received, discounted at the original effective interest rate. An expected credit loss allowance is similar to an impairment provision.

(vi) **Expected credit loss allowance**

An allowance for expected credit losses (ECLs) on all financial assets measured at amortised cost, e.g. most trade and other receivables, is set up through the Income Statement at initial recognition of the asset. The ECL is deducted from the carrying value of the asset on the balance sheet. Subsequent movements in the ECL (including release of the ECL if the asset is recovered in full) are reported in the Income Statement.

All ECL (impairment) allowances must be reviewed at least quarterly.

In applying the IFRS 9 impairment requirements, an entity needs to apply one of the following approaches:

- The simplified approach, which will be applied to trade receivables.
- The general approach, which will be applied to other receivables, including royalty receivables, and to loan assets and investments in debt securities.

The simplified impairment approach

The simplified approach applied to trade receivables requires the recognition of lifetime ECLs at all times. Fidson uses a provision matrix as a practical expedient for determining ECLs on trade receivables, including non-overdue balances. The provision matrix should incorporate forward-looking information into historical customer default rates and, where appropriate, group receivables into customer segments that have similar loss patterns, such as Distributors, Sales representatives, and Institutions.

b) The general impairment approach

Under the general approach, prior to an asset actually being credit-impaired, entities recognise expected credit losses (ECLs) in two stages. For assets for which there has not been a significant increase in credit risk since initial recognition (i.e. 'good' exposures), entities are required to provide for ECLs that would result from default events that are possible within the next 12 months (a 12-month ECL). For assets for which there has been a significant increase in credit risk since initial recognition, a loss allowance for ECLs expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL), is required. "

Indicators of a significant increase in credit risk include:

- An actual or expected significant change in the financial asset's external or internal credit rating.
- Existing or forecast adverse changes in business, financial or economic conditions that are expected to cause a significant change in the debtor's ability to meet its debt obligations, such as an increase in interest rates or a significant increase in unemployment rates;

- An actual or expected significant change in the operating results of the debtor;
- Significant increases in credit risk on other financial instruments of the debtor;
- An actual or expected significant adverse change in the regulatory, economic, or technological environment of the debtor that results in a significant change in the debtor's ability to meet its debt obligations, such as a decline in the demand for the debtor's sales product because of a shift in technology;
- Expected changes in the loan documentation (i.e. changes in contract terms) including an expected breach of contract that may lead to covenant waivers or amendments, interest payment holidays, interest rate step-ups, requiring additional collateral or guarantees, or other changes to the contractual framework of the instrument;
- Significant changes in the expected performance and behaviour of the debtor, including changes in the payment status of debtor in the group (e.g., an increase in the expected number or extent of delayed contractual payments); and
- Past due information on debtors.

For current assets (expected to be recovered in less than 12 months), there will be no difference between the 12-month ECL and the lifetime ECL.

Impairment on available-for-sale financial (vii) investments

Available-for-sale financial assets are impaired if there is objective evidence of impairment, resulting from one or more loss events that occurred after initial recognition but before the reporting date, that have an impact on the future cash flows of the asset.

In the case of equity investments classified as availablefor-sale, objective evidence would include a significant or prolonged decline in the fair value of the investment below its cost. 'Significant' is evaluated against the original cost of the investment and 'prolonged' against the year in which the fair value has been below its original cost.

When there is evidence of impairment, the cumulative loss - measured as the difference between the acquisition cost and the current fair value, less any impairment loss on that investment previously recognized in the profit or loss - is reclassified from equity and to the profit or loss. Impairment losses on equity investments are not reversed through the profit or loss; increases in their fair value after impairment are recognized in other comprehensive income.

(viii) Derecognition of financial assets

A financial asset (or, where applicable a part of a financial asset or part of a group of similar financial assets) is derecognised when:

- The rights to receive cash flows from the asset have expired
- The Company has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full

without material delay to a third party under a 'pass-through' arrangement; and either

- (a) the Company has transferred substantially all the risks and rewards of the asset, or
- (b) the Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When the Company has transferred its rights to receive cash flows from an asset or has entered into a passthrough arrangement, and has neither transferred nor retained substantially all of the risks and rewards of the asset nor transferred control of it, the asset is recognised to the extent of the Company's continuing involvement in it.

In that case, the Company also recognises an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Company has retained. Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration that the Company could be required to repay.

Derecognition of financial liabilities (ix)

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as a derecognition of the original liability and the recognition of a new liability, and the difference in the respective carrying amounts is recognised in the profit or loss.

(x) Offsetting of financial instruments

Financial assets and financial liabilities are offset and the net amount reported in the statement of financial position if, and only if, there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, or to realise the assets and settle the liabilities simultaneously.

2.2.13 Inventories

Inventories are valued at the lower of cost and net realisable value.

Costs incurred in bringing each product to its present location and condition is accounted for as follows:

- Raw materials are stated at purchase cost on the weighted average basis.
- Finished goods and work in progress: Cost in this case consists of direct purchase cost, conversion cost (materials, labour and overhead) and other costs incurred to bring inventory to its present condition and location. Finished goods are valued using weighted average cost
- Goods in transit are valued at the invoiced price.

Net realisable value is the estimated selling price in the ordinary course of business, less estimated costs of

completion and the estimated costs necessary to make the sale.

2.2.14 Impairment of non-financial assets

The Company assesses at each reporting date, whether there is an indication that an asset may be impaired. If any indication exists, or when annual impairment testing for an asset is required, the Company estimates the asset's recoverable amount. An asset's recoverable amount is the higher of an asset's or cash-generating units (CGU) fair value less costs of disposal and its value in use. Recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or group of assets. When the carrying amount of an asset or CGU exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount.

In assessing value in use, the estimated future cash flows are discounted to their present value using a pretax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining fair value less costs of disposal, recent market transactions are taken into account. If no such transactions can be identified, an appropriate valuation model is used. These calculations are corroborated by valuation multiples, quoted share prices for publicly traded companies or other available fair value indicators.

Impairment losses of continuing operations are recognised in the profit or loss in expense categories consistent with the function of the impaired asset.

An assessment is made at each reporting date to determine whether there is an indication that previously recognised impairment losses no longer exist or have decreased. If such indication exists, the Company estimates the asset's or CGU's recoverable amount. A previously recognised impairment loss is reversed only if there has been a change in the assumptions used to determine the asset's recoverable amount since the last impairment loss was recognised. The reversal is limited so that the carrying amount of the asset does not exceed its recoverable amount, nor exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognised for the asset in prior years. Such reversal is recognised in the profit or loss.

2.2.15 Cash and cash equivalents

Cash and cash equivalents comprise cash at bank and in hand and short-term deposits with an original maturity of three months or less, as shown in the statement of financial position. For the purpose of the statement of cash flows, cash and cash equivalents comprise cash at bank and in hand and short-term deposits with an original maturity of three months or less, as shown in the statement of financial position, net of outstanding bank overdrafts as they are considered an integral part of the Company's cash management.

2.2.16 Provisions

Provisions are recognized when the Company has a

present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Where the Company expects some or all of a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when the reimbursement is virtually certain. The expense relating to any provision is recognized in profit or loss net of any reimbursement.

If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, where appropriate, the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost.

2.2.17 Pension and other post-employment benefits

Retirement benefit Schemes

The gratuity scheme is a defined benefit plan. The cost of providing the benefits under the defined benefit plan is determined using the projected unit credit method. Actuarial gains and losses are recognized immediately in the statement of financial position with a corresponding debit or credit to retained earnings through other comprehensive income in the year in which they occur.

Actuarial gains and losses are not reclassified to the profit or loss in subsequent years.

Pension

The Company operates a defined contribution plan in line with the provisions of the Pension Reform Act 2014 as amended. This plan is in proportion to the services rendered to the Company by the employees with no further obligation on the part of the Company. The Company and its employee contribute 10% and 8% respectively of employees' current salaries and designated allowances to the scheme. Staff contributions to the scheme are funded through payroll deductions while the Company's contribution is recorded as personnel expenses in the profit or loss.

Past service costs are recognized in the profit or loss on the earlier of:

- the date of the plan amendment or curtailment,
- the date that the Company recognizes restructuring-related costs

Net interest is calculated by applying the discount rate to the net defined benefit liability or asset. The Company recognizes the following changes in the net defined benefit obligation under 'cost of sales', 'administration expenses' and 'selling and distribution expenses' in statement of profit or loss (by function):

- Service costs comprising current service costs, past-service costs and gains and losses on curtailments
- Net interest expense or income

Short term benefits

Short term employee benefits are measured on an undiscounted basis and are expensed as the related service is provided. A provision is recognized for the amount expected to be paid under short term cashbonus plans if the Company has a present and constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be measured reliably.

Termination benefits

Termination benefits are recognized as an expense when the Company is demonstrably committed without realistic possibility of withdrawal, to a formal detailed plan to terminate employment before the normal retirement date.

2.2.18 Dividends

Dividends on ordinary shares are recognised as a liability when they are approved by the Company's shareholders at the Annual General Meeting. Dividends are recognised, when they are paid. Dividends for the year that are approved after the reporting date are disclosed in the financial statements as a non-adjusting event.

2.2.19 Segment reporting

For management purposes, the Company is organised into business units based on its products and has two reportable segments as follows:

- The over-the-counter segment, which represent the products that may be sold directly to the consumer without a prescription.
- Ethical products segment, which are drugs, injectables and infusion which would be sold to the consumer only on the possession of a valid prescription.
- Consumer segment, which represent household items was introduced in 2016.

No operating segments have been aggregated to form the above reportable operating segments. The Executive Management Committee monitors the operating results of its business units separately for the purpose of making decisions about resource allocation and performance assessment. Segment performance is evaluated based on revenue and cost of sales. The Executive Management Committee monitors the operating results of the whole business for the purpose of making decisions about resource allocation and performance assessment.

SIGNIFICANT ACCOUNTING JUDGMENTS, **ESTIMATES AND ASSUMPTIONS**

The preparation of the financial statements requires management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the accompanying disclosures, and the disclosure of contingent liabilities. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of the asset or liability affected in future years.

Other disclosures relating to the Company's exposure to

risks and uncertainties includes:

- Capital management Note 43
- Financial risk management and policies Note 41

3.1 **Judgments**

In the process of applying the Company's accounting policies, management has made the following judgments, which have the most significant effect on the amounts recognized in the financial statements:

Operating lease commitments — Company as lessor

The Company has entered commercial property leases on its investment property portfolio. The Company has determined, based on an evaluation of the terms and conditions of the arrangements, such as the lease term not constituting a substantial portion of the economic life of the commercial property, that it retains all the significant risks and rewards of ownership of these properties and accounts for the contracts as operating leases.

3.2 **Estimates and assumptions**

The key assumptions concerning the future and other key sources of estimation uncertainty at the reporting date, that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are described below. The Company based its assumptions and estimates on parameters available when the financial statements were prepared. Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising beyond the control of the Company. Such changes are reflected in the assumptions when they occur.

Taxes

Uncertainties exist with respect to the interpretation of complex tax regulations, changes in tax laws, and the amount and timing of future taxable income. Given the wide range of international business relationships and the long-term nature and complexity of existing contractual agreements, differences arising between the actual results and the assumptions made, or future changes to such assumptions, could necessitate future adjustments to tax income and expense already recorded. The Company establishes provisions, based on reasonable estimates, for possible consequences of audits by the tax authorities.

Retirement benefits The cost of defined benefit gratuity scheme is determined using actuarial valuations. An actuarial valuation involves making various assumptions, which may differ from actual developments in the future. These include the determination of the discount rate, future salary increases, mortality rates and future pension increases. Due to the complexity of the valuation, the underlying assumptions and its long-term nature, a defined benefit obligation is highly sensitive to changes in these assumptions. All assumptions are reviewed at each reporting date. Refer to Note 2 for assumptions relating to retirement benefits.

Fair value measurement of financial instruments When the fair value of financial assets and financial liabilities recorded in the statement of financial position cannot be derived from active markets, their fair value is determined using valuation techniques including the discounted cash flow model. The inputs to these models are taken from observable markets where possible, but where this is not feasible, a degree of judgment is required in establishing fair values. The judgments include considerations of inputs such as liquidity risk, credit risk and volatility. Changes in assumptions about these factors could affect the reported fair value of financial instruments. See Note 41 for further disclosures.

Available-for-Sale financial instruments

The Company assesses at each reporting date whether there is any objective evidence that the available for sale financial assets is impaired. Available-for-sale financial assets is deemed to be impaired if, there is objective evidence of impairment as a result of one or more events that has occurred after the initial recognition (an incurred 'loss event') and that loss event has an impact on the estimated future cash flows of the Available-forsale financial assets that can be reliably estimated. The objective evidence the Management relies upon in assessing the Available-for-sale financial assets for impairment includes information about significant changes with an adverse effect that have taken place in the technological, market, economic or legal environment in which the issuer operates, and indicates that the cost of the investment in the equity instrument may not be recovered. A significant or prolonged decline in the fair value of an investment in an equity instrument below its cost is also seen as an objective evidence of impairment.

The Company judges that the impairment is significant if the fair value declined is between 20% and 30% and prolonged when it is between 9 and 12 months.

When the fair value of available-for-sale financial assets cannot be derived from active markets, their fair value is determined using valuation techniques including the discounted cash flow model. The inputs to these models are taken from observable markets where possible, but where this is not feasible, a degree of judgment is required in establishing fair values. The judgments include considerations of inputs such as liquidity risk. credit risk and volatility. Changes in assumptions about these factors could affect the reported fair value of financial instruments. Refer to Note 19 on the details of available for sale financial assets.

Property, plant and equipment

The Company carries its property, plant and equipment at cost in the Statement of Financial Position. Estimates and assumptions made to determine their carrying value and related depreciation are critical to the Company's financial position and performance. The charge in respect of periodic depreciation is derived after determining an estimate of an asset's expected useful life and the expected residual value at the end of its life. The useful lives and residual values of the assets are determined by management at the time the asset is acquired and reviewed periodically. The lives are based on historical experience with similar assets as well as anticipation of future events, which may impact their life,

such as changes in technology. The Company reviews the estimated the useful lives and residual values of its property, plant and equipment, and accounts for any changes prospectively. Refer to Note 15 on property plant and equipment.

Allowance for uncollectible accounts receivable

Trade receivables do not carry any interest and are stated at their nominal value as reduced by appropriate allowances for estimated irrecoverable amounts. Estimated irrecoverable amounts are based on the aging of the receivable balances and historical experience based on the facts and circumstances prevailing as at reporting date. In addition, a large number of minor receivables is grouped into homogeneous groups and assessed for impairment collectively. Individual trade receivables are written off when management considers them to be uncollectable.

Property, plant and equipment

The Company own a property with dual purpose. The portion not occupied by the Company cannot be separately sold or leased out under a finance lease arrangement. Management believe it occupies a significant portion of the property; hence the whole property has been classified as property, plant & equipment.

Application of new and revised International 4.0 Financial Reporting Standards (IFRSs)

New and amended IFRS Standards that are effective for the current year

Impact of the initial application of Interest Rate Benchmark Reform amendments to IFRS 9 and IFRS 7.

In September 2019, the IASB issued Interest Rate Benchmark Reform (Amendments to IFRS 9, IAS 39 and IFRS 7).

These amendments modify specific hedge accounting requirements to allow hedge accounting to continue for affected hedges during the period of uncertainty before the hedged items or hedging instruments affected by the current interest rate benchmarks are amended as a result of the on-going interest rate benchmark reforms.

The amendments is not relevant to the Company given that it does not apply hedge accounting to its benchmark interest rate exposures.

Impact of the initial application of Covid-19-Related **Rent Concessions Amendment to IFRS 16**

In May 2020, the IASB issued Covid-19-Related Rent Concessions (Amendment to IFRS 16) that provides practical relief to lessees in accounting for rent concessions occurring as a direct consequence of COVID-19, by introducing a practical expedient to IFRS 16. The practical expedient permits a lessee to elect not to assess whether a COVID- 19-related rent concession is a lease modification. A lessee that makes this election shall account for any change in lease payments resulting from the COVID-19-related rent concession the same

way it would account for the change applying IFRS 16 if the change were not a lease modification.

The practical expedient applies only to rent concessions occurring as a direct consequence of COVID-19 and only if all of the following conditions are met:

- The change in lease payments results in revised a) consideration for the lease that is substantially the same as, or less than, the consideration for the lease immediately preceding the change;
- b) Any reduction in lease payments affects only payments originally due on or before 30 June 2021 (a rent concession meets this condition if it results in reduced lease payments on or before 30 June 2021 and increased lease payments that extend beyond 30 June 2021); and
- There is no substantive change to other terms c) and conditions of the lease.

The standard is not applicable to the Company in current financial year as it has not received any rent concessions. The Company has applied the amendment to IFRS 16 (as issued by the IASB in May 2020) in the prior period.

Impact of the initial application of other new and amended IFRS Standards that are effective for the current year

In the current year, the Company has applied the below amendments to IFRS Standards and Interpretations issued by the Board that are effective for an annual period that begins on or after 1 January 2020. Their adoption has not had any material impact on the disclosures or on the amounts reported in these financial statements.

Amendments to References to the Conceptual Framework in IFRS Standards

The Company has adopted the amendments included in **Amendments to References to the Conceptual** Framework in IFRS Standards for the first time in the current year. The amendments include consequential amendments to affected Standards so that they refer to the new Framework. Not all amendments, however, update those pronouncements with regard to references to and quotes from the Framework so that they refer to the revised Conceptual Framework. Some pronouncements are only updated to indicate which version of the Framework they are referencing to (the IASC Framework adopted by the IASB in 2001, the IASB Framework of 2010, or the new revised Framework of 2018) or to indicate that definitions in the Standard have not been updated with the new definitions developed in the revised Conceptual Framework. The Standards which are amended are IFRS 2, IFRS 3, IFRS 6, IFRS 14, IAS 1, IAS 8, IAS 34, IAS 37, IAS 38, IFRIC 12, IFRIC 19, IFRIC 20, IFRIC 22, and SIC-32.

Amendments to IFRS 3 Definition of a business

The amendments clarify that while businesses usually have outputs, outputs are not required for an integrated set of activities and assets to qualify as a business. To be considered a business an acquired set of activities and assets must include, at a minimum, an input and a

substantive process that together significantly contribute to the ability to create outputs. The amendments remove the assessment of whether market participants are capable of replacing any missing inputs or processes and continuing to produce outputs. The amendments also introduce additional guidance that helps to determine whether a substantive process has been acquired. The amendments introduce an optional concentration test that permits a simplified assessment of whether an acquired set of activities and assets is not a business. Under the optional concentration test, the acquired set of activities and assets is not a business if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar assets. The amendments are applied prospectively to all business combinations and asset acquisitions for which the acquisition date is on or after 1 January 2020. The amendments to IFRS 3 is not applicable to the Company in the current year, there was no acquisition.

Amendments to IAS 1 and IAS 8 Definition of material

The amendments make the definition of material in IAS 1 easier to understand and are not intended to alter the underlying concept of materiality in IFRS Standards. The concept of 'obscuring' material information with immaterial information has been included as part of the new definition. The threshold for materiality influencing users has been changed from 'could influence' to 'could reasonably be expected to influence'. The definition of material in IAS 8 has been replaced by a reference to the definition of material in IAS 1. In addition, the IASB amended other Standards and the Conceptual Framework that contain a definition of 'material' or refer to the term 'material' to ensure consistency. The Company has adopted the amendments to IAS 1 and IAS 8 for the first time in the current year.

New and revised IFRS Standards in issue but not yet effective

IFRS 17 Insurance Contracts

IFRS 17 establishes the principles for the recognition, measurement, presentation and disclosure of insurance contracts and supersedes IFRS 4 Insurance Contracts. IFRS 17 outlines a general model, which is modified for insurance contracts with direct participation features, described as the variable fee approach. The general model is simplified if certain criteria are met by measuring the liability for remaining coverage using the premium allocation approach.

The general model uses current assumptions to estimate the amount, timing and uncertainty of future cash flows and it explicitly measures the cost of that uncertainty. It takes into account market interest rates and the impact of policyholders' options and guarantees.

In June 2020, the IASB issued Amendments to IFRS 17 to address concerns and implementation challenges that were identified after IFRS 17 was published. The amendments defer the date of initial application of IFRS 17 (incorporating the amendments) to annual reporting periods beginning on or after 1 January 2023. At the

same time, the IASB issued Extension of the Temporary Exemption from Applying IFRS 9 (Amendments to IFRS 4) that extends the fixed expiry date of the temporary exemption from applying IFRS 9 in IFRS 4 to annual reporting periods beginning on or after 1 January 2023. IFRS 17 must be applied retrospectively unless impracticable, in which case the modified retrospective approach or the fair value approach is applied.

For the purpose of the transition requirements, the date of initial application is the start if the annual reporting period in which the entity first applies the Standard, and the transition date is the beginning of the period immediately preceding the date of initial application.

Amendments to IFRS 10 and IAS 28 - Sale or Contribution of Assets between an Investor and its **Associate or Joint Venture**

The amendments to IFRS 10 and IAS 28 deal with situations where there is a sale or contribution of assets between an investor and its associate or joint venture. Specifically, the amendments state that gains or losses resulting from the loss of control of a subsidiary that does not contain a business in a transaction with an associate or a joint venture that is accounted for using the equity method, are recognised in the parent's profit or loss only to the extent of the unrelated investors' interests in that associate or joint venture. Similarly, gains and losses resulting from the remeasurement of investments retained in any former subsidiary (that has become an associate or a joint venture that is accounted for using the equity method) to fair value are recognised in the former parent's profit or loss only to the extent of the unrelated investors' interests in the new associate or joint venture. The effective date of the amendments has yet to be set by the Board; however, earlier application of the amendments is permitted. The Directors of the Company anticipate that the application of these amendments may have an impact on the financial statements in future periods should such transactions arise.

Amendments to IAS 1 - Classification of Liabilities as Current or Non-current

The amendments to IAS 1 affect only the presentation of liabilities as current or non-current in the statement of financial position and not the amount or timing of recognition of any asset, liability, income or expenses, or the information disclosed about those items. The amendments clarify that the classification of liabilities as current or non-current is based on rights that are in existence at the end of the reporting period, specify that classification is unaffected by expectations about whether an entity will exercise its right to defer settlement of a liability, explain that rights are in existence if covenants are complied with at the end of the reporting period, and introduce a definition of 'settlement' to make clear that settlement refers to the transfer to the counterparty of cash, equity instruments, other assets or services.

The amendments are applied retrospectively for annual periods beginning on or after 1 January 2023, with early application permitted.

Amendments to IFRS 3 - Reference to the **Conceptual Framework**

The amendments update IFRS 3 so that it refers to the 2018 Conceptual Framework instead of the 1989 Framework. They also add to IFRS 3 a requirement that, for obligations within the scope of IAS 37, an acquirer applies IAS 37 to determine whether at the acquisition date a present obligation exists as a result of past events. For a levy that would be within the scope of IFRIC 21 Levies, the acquirer applies IFRIC 21 to determine whether the obligating event that gives rise to a liability to pay the levy has occurred by the acquisition date. Finally, the amendments add an explicit statement that an acquirer does not recognise contingent assets acquired in a business combination. The amendments are effective for business combinations for which the date of acquisition is on or after the beginning of the first annual period beginning on or after 1 January 2022. Early application is permitted if an entity also applies all other updated references (published together with the updated Conceptual Framework) at the same time or earlier.

Amendments to IAS 16 - Property, Plant and Equipment—Proceeds before Intended Use

The amendments prohibit deducting from the cost of an item of property, plant and equipment any proceeds from selling items produced before that asset is available for use, i.e. proceeds while bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management. Consequently, an entity recognises such sales proceeds and related costs in profit or loss. The entity measures the cost of those items in accordance with IAS 2 Inventories. The amendments also clarify the meaning of 'testing whether an asset is functioning properly'. IAS 16 now specifies this as assessing whether the technical and physical performance of the asset is such that it is capable of being used in the production or supply of goods or services, for rental to others, or for administrative purposes. If not presented separately in the statement of comprehensive income, the financial statements shall disclose the amounts of proceeds and cost included in profit or loss that relate to items produced that are not an output of the entity's ordinary activities, and which line item(s) in the statement of comprehensive income include(s) such proceeds and cost.

The amendments are applied retrospectively, but only to items of property, plant and equipment that are brought to the location and condition necessary for them to be capable of operating in the manner intended by management on or after the beginning of the earliest period presented in the financial statements in which the entity first applies the amendments. The entity shall recognise the cumulative effect of initially applying the amendments as an adjustment to the opening balance of retained earnings (or other component of equity, as appropriate) at the beginning of that earliest period presented. The amendments are effective for annual periods beginning on or after 1 January 2022, with early application permitted.

Amendments to IAS 37 - Onerous Contracts-Cost of Fulfilling a Contract

The amendments specify that the 'cost of fulfilling' a contract comprises the 'costs that relate directly to the contract'. Costs that relate directly to a contract consist of both the incremental costs of fulfilling that contract (examples would be direct labour or materials) and an allocation of other costs that relate directly to fulfilling contracts (an example would be the allocation of the depreciation charge for an item of property, plant and equipment used in fulfilling the contract). The amendments apply to contracts for which the entity has not yet fulfilled all its obligations at the beginning of the annual reporting period in which the entity first applies the amendments. Comparatives are not restated. Instead, the entity shall recognise the cumulative effect of initially applying the amendments as an adjustment to the opening balance of retained earnings or other component of equity, as appropriate, at the date of initial application. The amendments are effective for annual periods beginning on or after 1 January 2022, with early application permitted.

Annual Improvements to IFRS Standards 2018–2020

The Annual Improvements include amendments to four Standards, IFRS 1 First-time Adoption of International Financial Reporting Standards. The amendment provides additional relief to a subsidiary which becomes a first-time adopter later than its parent in respect of accounting for cumulative translation differences. As a result of the amendment, a subsidiary that uses the exemption in IFRS 1:D16 (a) can now also elect to measure cumulative translation differences for all foreign operations at the carrying amount that would be included in the parent's consolidated financial statements, based on the parent's date of transition to IFRS Standards, if no adjustments were made for consolidation procedures and for the effects of the business combination in which the parent acquired the subsidiary. A similar election is available to an associate or joint venture that uses the exemption in IFRS 1:D16 (a).

The amendment is effective for annual periods beginning on or after 1 January 2022, with early application permitted.

IFRS 9 Financial Instruments

The amendment clarifies that in applying the '10 per cent' test to assess whether to derecognise a financial liability, an entity includes only fees paid or received between the entity (the borrower) and the lender, including fees paid or received by either the entity or the lender on the other's behalf. The amendment is applied prospectively to modifications and exchanges that occur on or after the date the entity first applies the amendment. The amendment is effective for annual periods beginning on or after 1 January 2022, with early application permitted.

IFRS 16 Leases

The amendment removes the illustration of the reimbursement of leasehold improvements. As the amendment to IFRS 16 only regards an illustrative example, no effective date is stated.

IAS 41 Agriculture

The amendment removes the requirement in IAS 41 for entities to exclude cash flows for taxation when measuring fair value. This aligns the fair value measurement in IAS 41 with the requirements of IFRS 13 Fair Value Measurement to use internally consistent cash flows and discount rates and enables preparers to determine whether to use pretax or post-tax cash flows and discount rates for the most appropriate fair value measurement. The amendment is applied prospectively, i.e. for fair value measurements on or after the date an entity initially applies the amendment. The amendment is effective for annual periods beginning on or after 1 January 2022, with early application permitted.

5.	Revenue	Dec-21 ₩'000	Dec-20 ₦'000
	Sales of goods		
	Consumer Healthcare (Toll Manufacturing)	117,366	-
	Ethical	20,109,605	10,672,684
	Over The Counter (OTC)	10,633,846	7,603,172
		30,860,817	18,275,856
Reve	enue represents total value of goods invoiced to third parties locally.		
6	Coat of color	Dec 21	Dec 21
6.	Cost of sales	Dec-21 ₩'000	Dec-21 N '000
	Consumer Healthcare (Toll Manufacturing)	72,499	-
	Ethical	7,952,280	4,827,129
	Over The Counter (OTC)	5,453,662	3,354,446
	Depreciation of factory PPE (Note 8a)	569,922	499,496
	Energy	549,226	317,563
	Personnel Cost	625,483	418,157
	Other Factory Overheads	534,710	277,725
		15,757,782	9,694,516
		Dec-21	Dec-20
7.	Other operating income	₩'000	₩'000
	Amortization of government grant	474,951	200,088
	Other operating income	5,763	10,926
	Gain on disposal of property, plant and equipment	83,264	8,785
	Rental income	3,167	3,167
	Sale of scrap	29,407	47,741
	Toll Manufacturing Income	<u>-</u>	79,038
		596,552	349,745
		596,552	349,745

8.	Administrative expenses	Dec-21 ₩'000	Dec-20 ₩'000
	Association and Membership	12,940	9,613
	Audit fee	14,000	14,000
	Conferences and Workshop	3,209	1,770
	Consultancy fees	120,161	128,268
	Corporate social responsibility	113,930	58,371
	Depreciation and amortization (Note 8a)	231,313	314,538
	Diesel and fuel	60,116	47,812
	Impairment of receivables (Note 21a)	245,050	276,028
	Insurance	110,510	99,380
	Legal	10,558	12,858
	Office supplies	25,929	17,645
	AGM Expenses	4,656	3,659
	Directors' expenses (Non-Executives)	47,290	27,368
	Bank administrative fee	154,366	52,646
	Newspapers and periodicals	6	124
	Personnel costs (Note 8b)	1,936,207	1,531,459
	Printing & stationery	115,741	24,611
	Repairs and maintenance	303,325	352,255
	Outsourced Cleaning and Security Expenses	45,512	36,475
	Telephone & postage	53,351	38,863
	Training	40,652	17,733
	Travelling and Entertainment	198,380	183,682
	Permit and Dues	87,765	29,045
	Auxiliary materials & Tools	115,531	96,294
	Canteen expenses	87,982	50,217
	Exchange loss (Realized)	1,609,954	-
	Exchange loss (Unrealized)	667,645	309,345
		6,416,079	3,734,059
8a.	Depreciation and amortization		
	Depreciation of property, plant and equipment (Note 14)	654,108	668,435
	Depreciation of Rights of use assets (Note 15)	105,850	106,911
	Depreciation of property, plant and equipment included in cost of sales (Note 6)	(569,922)	(499,496)
		190,036	275,850
	Depreciation of investment property (Note 16)	919	919
	Amortization of intangible assets (Note 17)	40,358	37,769
		231,313	314,538
8b.	Personnel costs		
0.0.	Gratuity	20,011	36,838
	Pension cost	56,331	47,322
	Salary and wages	1,859,865	1,447,299
		1,936,207	1,531,459
9.	Selling and distribution expenses		
		660 004	040.000
	Promotion and advertisement	663,261	340,986
	Sales expenses	2,758,022	1,758,551
		3,421,283	2,099,537

10.	Finance cost	Dec-21	Dec-20
	Intercet on bould have	₩'000	₩'000
	Interest on bank loans	1,183,768	1,248,601
	Interest on finance lease	38,531	85,326
		1,222,299	1,333,927
11.	Finance income		
	Interest earned on loans and receivables	36,898	3,383
	Interest earned on other non-current financial asset	15,730	4,034
	Interest on fixed deposit	25,090	1,823
		77,718	9,240
12.	Profit before tax		
	This is stated after charging:		
	Amortization of intangibles (Note 17)	40,358	37,769
	Audit fee	14,000	14,000
	Depreciation of property, plant and equipment (Note 14)	654,108	668,435
	Depreciation of right of use assets (Note 15)	105,850	106,911
	Depreciation of investment property (Note 16)	919	919
	Gain/loss on disposal of PPE	83,264	8,785
	Personnel costs	1,936,207	1,531,459
	Exchange gain/loss	2,277,599	309,345

13. **Taxation**

13a Income tax expense

The major components of income tax expense for the year ended 31 December 2021:

	Dec-21	Dec-20
Current income tax:	₩'000	₩'000
Current year income tax charge	1,221,532	46,042
Current education tax charge	153,450	69,996
Total current tax	1,374,982	116,038
Deferred tax		
Relating to origination of temporary differences	(377,251)	451,725
Total income tax expense reported in the profit or loss	997,731	567,763
Reconciliation of tax charge:		
Profit before tax	4,717,644	1,772,802
Tax at Nigerian statutory income tax rate of 30%	1,415,293	531,841
Disallowable expenses	(155,718)	(458,134)
Income exempted from tax	(83,264)	(8,785)
Education tax @ 2% of assessable profit	153,450	35,456
Investment allowance	45,221	15,660
Effect of deferred tax balance	(377,251)	451,725
-	997,731	567,763
Effective tax rate	21%	32%

13b.	Income tax payable Current tax payable			Dec-21 N '000	Dec-20 ₩'000
	At 1 January			120,424	99,851
	Charge for the year			1,374,982	116,038
	Payments during the year			(116,039)	(95,465)
	At 31 December			1,379,367	120,424
13c.	Deferred tax liability				
	At 1 January			1,548,311	1,085,534
	Amounts recorded in profit or loss			(377,252)	451,726
	Amounts recorded in other comprehensive incom	ne		6,004	11,051
	At 31 December			1,177,063	1,548,311
	Deferred tax recognised in other comprehensive Re-measurement gain on defined benefit plan	income:		6,004	11,051
	Total deferred tax recognised in other Comprehe	nsive		6,004	11,051
13c		Opening	Recognised in	Recognised in	Closing
	2021	balance	profit or loss	OCI	balance
	5.4.4.4.4.4.4.4.4.4.4.4.4.4.4.4.4.4.4.4	₩'000	M '000	₩'000	₩'000
	Deferred tax assets /(liabilities) in relation to:				
	Property, plant & equipment	1,819,921	(27,914)	-	1,792,007
	Employee benefit	(143,293)	(143,293)	-	(286,586)
	Impairment of trade receivables	(80,496)	(92,910)	-	(173,406)
	Unrealised exchange loss	(98,990)	(102,083)	-	(201,073)
	Unutilised capital allowance	11,051	(11,051)	6,004	6,004
	Impairment on Inventory	40,118			40,118
		1,548,311	(377,251)	6,004	1,177,062
		Opening	Recognised in	Recognised in	Closing
	2020	balance	profit or loss	OCI	balance
		₩ '000	₩'000	₩'000	₩'000
	Deferred tax assets /(liabilities) in relation to:				
	Property, plant & equipment	1,079,096	740,825	-	1,819,921
	Employee benefit	(22,423)	(120,870)	-	(143,293)
	Impairment of trade receivables	12,414	(92,910)	-	(80,496)
	Unrealised exchange loss	3,093	(102,083)	-	(98,990)
	Unutilised capital allowance	13,354	(13,354)	11,051	11,051
	Impairment on inventory		40,118		40,118
		1,085,534	451,725	11,051	1,548,310

14 Property, plant and equipment

COST:	LAND N'000	BUILDING N'000	MOTOR VEHICLES	OFFICE EQUIPMENT	PLANT & MACHINERY	FURNITURE & FITTINGS	CONSTRUCTION WIP	TOTAL
At 1 January 2020 Additions Disposals Transfer out	706,9	8,566,089 230,877 337,082	851,279 851,279 296,914 (219,355)	907,423	3,477,321 143,724 (798) 12,879	3,504	587,581 1,212,860 (349,961)	15,323,264 2,070,861 (220,153)
At 31 December 2020 Additions Disposals Reclassification Adjustment/Transfers	793,253 - (89,723) 79,556	9,134,048 - (202,627) (79,556) 38,403	928,838 231,813 (228,507) -	1,004,105 104,779 (198,624)	3,633,126 128,072 (516,669) -	230,122 10,089 (29,146) -	1,450,480 2,171,439 - - (571,013)	17,173,972 2,646,191 (1,265,295)
As at 31 December 2021	783,086	8,890,268	1,102,623	941,081	3,568,668	218,236	3,050,906	18,554,868
DEPRECIATION: At 1 January 2020 Charge for the year Transfer out Disposal		799,873 167,800	684,996 65,805 - (208,383)	649,772 168,332	1,061,133 251,811 (269)	130,606		3,326,380 668,434 - (208,652)
At 31 December 2020 Charge for the year Transfer out Disposal As at 31 December 2021		967,673 164,260 - (45,706) 1,086,227	542,418 136,738 - (215,579) 463,577	818,104 69,236 - (186,095) 701,245	1,312,675 269,245 - (303,537) 1,278,383	145,292 14,630 - (27,480) 132,442		3,786,162 654,109 (778,397) 3,661,874
CARRYING AMOUNT: At 31 December 2021 At 31 DECEMBER 2020	783,086	7,804,040	639,046	239,836	2,290,285	85,794	3,050,906	14,892,994

- 14.1 This represents reclassification from capital work in progress to plant and machinery.
- 14.2 This represents reclassification from property plant and equipment to right of use assets in line with IFRS 16.
- 14.3 Finance Lease - the carrying value of property, plant and equipment held under finance lease at 31 December 2021 was motor vehicles N100.59million, plant & machinery N385.67million (31 December 2020 motor vehicle N173.05million, plant & machinery N422.14million).
- The company's assets have been pledged as security for bank borrowings to the tune of the outstanding balance of 14.4 total borrowings outside the Company at the reporting date (See Note 24). The company is not allowed to pledge or sell these assets as security for other borrowings or sell them to another entity.

15 **Right of Use Assets**

COST:	MOTOR VEHICLES	PLANT & MACHINERY	TOTAL
	N'000	N'000	N'000
At 1 January 2020	370,529	476,928	847,457
Additions	-	-	-
Disposals	(4,289)		(4,289)
At 1 January 2021	366,240	476,928	843,168
Additions	-	-	-
Disposals	(6,437)	-	(6,437)
At 31 December 2021	359,804	476,928	836,732
ACCUMULATED DEPRECIATION:			
At 1 January 2020	125,956	18,319	144,275
Charge for the year	70,443	36,468	106,911
Disposal	(3,212)		(3,212)
At 1 January 2021	193,187	54,787	247,974
Charge for the year	69,382	36,468	105,850
Disposal	(3,363)	-	(3,363)
At 31 December 2021	259,206	91,255	350,461
CARRYING AMOUNT:			
At 31 December 2021	100,598	385,673	486,271
At 31 December 2020	173,053	422,141	595,194

The company leases motor vehicles and Plant & Machinery. The average lease term is 5 years. Approximately N268.47m of the leases for the company expired in the current financial year.

15.1	Amounts recognised in profit or loss	Dec-21	Dec-20
		₩'000	₩'000
	Depreciation expense on right of use assets	105,850	106,911
	Interest expenses on lease liabilities	38,531	85,326

There are no indications of impairment of right of use assets.

16.0.

. Investment Property	Dec-21 ₩'000	Dec-20 ₩'000
Cost		
At 1 January	48,376	48,376
At 31 December	48,376	48,376
Accumulated depreciation		
At I January	15,634	14,715
Charge for the year	919	919
At 31 December	16,553	15,634
Carrying amount	31,823	32,742
The only investment property held by Fidson Healthcare Plc is the premises use commenced in June 2010. The fair Value as at 31 December 2021 N31million (N	•	I
Rental income derived from investment property	3,167	6,000

The company has no restrictions on the realisability of its investment property and no contractual obligations to purchase, construct or develop investment property or for repairs, maintenance and enhancements.

17.	Intangible assets Product licenses	Dec-21 ₩'000	Dec-20 ₩'000
	Cost:		
	At 1 January	276,729	243,166
	Additions	38,550	33,563
	At 31 December	315,279	276,729
	Amortization		
	At 1 January	253,199	215,430
	Charge for the year	40,358	37,769
	At 31 December	293,557	253,199
	Carrying amount	21,722	23,530

The product licenses are intangible assets with finite life and are amortized in line with the provisions of IAS 38. The intangible assets are tested for impairment when there are indicators of impairment in line with the provisions of IAS 36, by comparing the recoverable amount with the carrying amount at the end of the reporting period. There were no indicators of impairment during the year.

18. Financial assets

The company's financial instruments are summarised by categories as follows:

	Dec-21	Dec-20
	₩'000	₩'000
Available-for-sale financial assets (18a)	5,030	4,960
Loans and receivables (18b)	14,027	12,871
Total financial instruments	19,057	17,831

		Dec-21 ₩'000	Dec-20 ₩'000
18a.	Available-for-sale financial assets		
	Quoted equity at fair value (Zenith Bank Plc)		
	At 1 January	4,960	3,720
	Gain/(Loss)	70	1,240
	At 31 December	5,030	4,960

The Company recognised a fair value gain of N70,000 (2020: N1,240,000) on available for sale quoted equity. The gain is recognised in other comprehensive income.

18b.	Loans and receivables	Dec-21 ₩'000	Dec-20 ₩'000
	Investment with Cardinal Stone Partners		
	At 1 January	11,190	10,172
	Additions		-
	Drawdown	-	-
	Interest accrued	1,114	1,018
	Sinking Fund	1,723	1,681
	At 31 December	14,027	12,871

CardinalStone Partners Limited is the portfolio management and custodial service provider for the Company.

19.	Other non-current financial asset	Dec-21 ₩'000	Dec-20 ₦'000
	ALM Trustees		
	At 1 January	171,673	441,337
	Additions	-	-
	Drawdown	-	(272,030)
	Accrued interest	1,489	2,366
	At 31 December	173,162	171,673

The amount which resides with ALM Trustee is an investment in a Perfection Reserve Account equal to 100% of the officially accessed cost of stamping and registration of the Company's Security structure.

		Dec-21	Dec-21
		₩'000	₩'000
20.	Inventories		
	Finished goods	2,984,379	2,385,032
	Goods-in-transit	5,095,948	2,558,967
	Raw and Packaging materials	2,830,290	1,746,349
	Work- in- progress	71,300	44,845
	Engineering spare parts	119,548	102,580
	Promotional and Other Consumable Materials	128,862	68,361
		11,230,327	6,906,134
	Total inventory Impaired (Note 20a)	(75,792)	(125,368)
		11,154,535	6,780,766

21.

20a.	Impairment on Inventories	Dec-21	Dec-20
		₩'000	₩'000
	At 1 January	(125,368)	(37,201)
	Addition	-	(88,167)
	Write off	49,576	-
	At 31 December	(75,792)	(125,368)

The Company did not pledge any inventory as collateral for loans. There was no inventory write down in the year under review.

. Trade and other receivables	Dec-21 ₩'000	Dec-20 ₩'000
Trade receivables (Note 21b)	2,430,857	2,447,263
Impairment Loss	(182,070)	(270,271)
	2,248,787	2,176,992
Other receivables (Note 21c)	731,080	554,280
	2,979,867	2,731,272

Other receivables relate to withholding tax, value added tax receivables and staff advances. These are not interest bearing and repayment is within 1 year.

Trade receivables meet the definition of financial asset and the carrying amount of the trade receivables approximates their fair value. Trade receivables are expected to be fully collected within 1 year.

The company measures the loss allowance for trade receivables at an amount equal to lifetime expected credit loss (ECL). The expected credit losses on trade receivables are estimated using a provision matrix by reference to past default experience of the debtor and an analysis of the debtor's current financial position adjusted for factors that are specific to the debtors' general economic conditions of the industry in which the debtor operate and an amendment of both the current as well as the forecast direction of conditions at the reporting date.

There has been no change in the estimation techniques or significant assumption made during the current reporting period.

The company writes off a trade receivable when there is information indicating that the debtor is in severe financial difficulty and there is no realistic prospect of recovery, e.g., when the debtor has been placed under liquidation or has entered bankruptcy proceedings, or when the bad receivables are over two years past due, whichever occurs earlier.

Trade receivables amounting to N335million were written off in the year.

SUMMARY AGED RECEIVABLES AS AT 31/12/2021

		I-30 Days	Days	Days	Days	Days	Days	360 Days	
	Estimated total gross carrying amount at default	210,017,753	661,688,804	25,358,327	8,135,479	1,985,595	3,439,799	32,264,564	942,890,321
	HISTORICAL LOSS RATE	0.34%	0.77%	1.48%	1.48%	2.92%	4.24%	11.74%	
DISTRIBUTORS	FORWARD LOOKING INFORMATION (INFLATION RATE)	0.03%	0.03%	0.03%	0.03%	0.03%	0.03%	0.03%	
	Expected credit loss (ECL) rate	0.37%	%08'0	1.51%	1.99%	2.95%	4.27%	11.77%	
	Lifetime Expected credit loss	781,550	5,261,146	382,331	162,004	58,567	146,733	3,796,893	10,589,224
	Estimated total gross carrying amount at default	132 243 030	559 212 580	213 546 442	90 321 464	149 557 232	59 740 272	145 290 550	1 349 911 570
ONCITITITION	HISTORIUS IN SULLENIA SILVINIA	1 00%	/ 10% / 10%	5 03%	7 28%	0 60%	17.08%	26.04%	5,5,5,5
	FORWARD LOOKING INFORMATION (INFLATION BATE)	0.24%	0.24%	0.24%	0.24%	0.24%	0.24%	0.24%	
	Expected credit loss (ECL) rate	1.03%	4.22%	2.96%	7.31%	9.63%	17.11%	26.07%	
	Lifetime Expected credit loss	1,358,538	23,622,463	12,718,969	6,601,623	14,408,901	10,220,059	37,871,595	106,802,148
	Estimated total gross carrying amount at default	12,066,910	75,845,525	10,515,110	3,282,935	2,450,151	1,837,983	18,414,919	124,413,533
REPS	HISTORICAL LOSS RATE	1.23%	16.61%	21.42%	27.03%	32.22%	41.70%	52.45%	
	FORWARD LOOKING INFORMATION (INFLATION RATE)	0.24%	0.24%	0.24%	0.24%	0.24%	0.24%	0.24%	
	Expected credit loss (ECL) rate	1.26%	16.64%	21.45%	27.06%	32.25%	41.73%	52.48%	
	Lifetime Expected credit loss	152,595	12,621,494	2,255,112	888,349	790,131	767,051	9,663,246	27,137,978
	A desired to the second of the								
	Lestinated total gloss carrying annount at delaunt	0 400	0 700/	0 400	0 400	0 400/	0 400	0 00 00	
	TISTORICAL FORM	04.40%	04.40%	04.40%	04.40%	04.40%	04.40%	32.20%	
GOVT BUS	FORWARD LOOKING INFORMATION (INFLATION RATE)	0.24%	0.24%	0.24%	0.24%	0.24%	0.24%	0.24%	
	Expected credit loss (ECL) rate	65.28%	65.28%	65.28%	65.28%	65.28%	65.28%	33.08%	
	Lifetime Expected credit loss	•	•		•		1		0
	Estimated total gross carrying amount at default	1	3,975,794.58	1	1	1	0	10,800,786	14,776,581
EXITED STAFF	Expected credit loss (ECL) rate	100%	100%	100%	100%	100%	100%	100%	
	Lifetime Expected credit loss	1	3,975,794.58	1	1		1	10,800,786.28	14,776,580.86
	Estimated total gross carrying amount at default	1	1	1	1	1	0	0	
DOUBTFUL DEBT	Expected credit loss (ECL) rate	100%	100%	100%	100%	100%	100%	100%	
	Lifetime Expected credit loss	1		1	1		1	1	1
	Total gross carrying amount at default	354.327.693	1.300.722.704	249,419,879	101,739,879	153.992.978	65.018.053	206.770.818	2.431.992.004
2021 SUMMARY	Impaired item from staff loan and Other Debtors							22,763,732,47	22,763,732,47
	Total lifetime expected credit loss	2,292,683	45,480,897	15,356,411	7,651,976	15,257,599	11,133,842	62,132,522	159,305,930
	CONTRACTOR OF THE CONTRACTOR O	352 035 010	10077001	004 000 400	0001000	1001	77.00	100 000	010 000 010

EXPECTED CREDIT LOSS AS AT 31/12/20

		1-30	31-60	61-90	91-120	121-240	240-360	Above	Balance
Estimated total gross carrying amount at default		90,679,710	606,582,470	157,672,620	19,973,064	26,824,376	8,502,424	88,643,019	998,877,683
HISTORIC	HISTORICAL LOSS RATE	0.07%	0.53%	1.24%	1.70%	2.64%	3.68%	8.58%	
FORWARD LOOKING INFORMATION (INFLATION RATE)	-ATION RATE)	0.72%	0.72%	0.72%	0.72%	0.72%	0.72%	0.72%	
Expected credit loss (ECL) rate		0.79%	1.25%	1.96%	2.42%	3.36%	4.40%	9.30%	
Lifetime Expected credit loss		714,681	7,599,169	3,094,883	483,836	902,517	374,128	8,242,862	21,412,076
Estimated total gross carrying amount at default	22	5,128,353	278,194,410	168,494,346	140,350,073	194,369,268	119,447,583	217,849,559	1,173,833,592
HISTORICAL LOSS RATE	OSS RATE	%96.0	4.16%	5.92%	7.28%	9.61%	16.96%	25.19%	
FORWARD LOOKING INFORMATION (INFLATION RATE)		0.72%	0.72%	0.72%	0.72%	0.72%	0.72%	0.72%	
Expected credit loss (ECL) rate	ECL) rate	1.68%	4.88%	6.64%	8.00%	10.33%	17.68%	25.91%	
Lifetime Expected credit loss		926,469	13,563,483	11,182,829	11,223,725	20,070,082	21,120,399	56,438,086	134,525,073
Estimated total gross carrying amount at default		8,410,707	79,705,922	15,573,625	7,484,631	4,892,344	5,560,399	29,795,065	151,422,693
HISTORICAL LOSS RATE		0.74%	18.09%	24.21%	30.55%	35.87%	45.31%	55.77%	
FORWARD LOOKING INFORMATION (INFLATION RATE)	RATE)	0.72%	0.72%	0.72%	0.72%	0.72%	0.72%	0.72%	
Expected credit loss (ECL) rate		1.46%	18.81%	24.93%	31.27%	36.59%	46.03%	56.49%	
Lifetime Expected credit loss		122,595	14,992,870	3,883,102	2,340,725	1,790,298	2,559,515	16,829,795	42,518,900
Estimated total gross carrying amount at default	efault	0	0	0	0	0	0	111,758,807	111,758,807
HISTORICAL LOSS RATE		32.20%	24.21%	30.55%	35.87%	45.31%	22.77%	20.00%	
FORWARD LOOKING INFORMATION (INFLATION RATE)		0.72%	0.72%	0.72%	0.72%	0.72%	0.72%	0.72%	
Expected credit loss (ECL) rate		18.81%	24.93%	31.27%	36.59%	46.03%	26.49%	50.72%	
Lifetime Expected credit loss	dit loss	<u> </u>	1	Ī	1	1	1	56,684,537	56,684,537
									17,685,099
Estimated total gross carrying amount at default	əfault	1	1	1	17,685,099	1	0	0	
Expected credit loss (ECL) rate	.) rate	100%	100%	100%	100%	100%	100%	100%	
Lifetime Expected credit loss	t loss			1	17,685,099	'	1	'	17,685,099
Total gross carrying amount at default		154 218 771	964 482 801	341 740 591	185 492 867	226 085 988	133 510 406	448 046 450	2 453 577 874
Intal gloss carrying allounit at		1,,,012,	304,406,00	1,140,00	100,454,001	220,000,000	0,000	410,010,100	1,10,110,004,7
Impaired item from staff loan and Other Debtors		1						(3,760,419)	(3,760,419)
Total lifetime expected credit loss		1,763,746)	(36,155,523)	(18,160,814)	(31,733,384)	(22,762,898)	(24,054,041)	(138,195,279)	272,825,685
Net Rec	Net Receivables 152,4	2,455,025	928,327,278	323,579,777	153,759,483	203,323,090	109,456,365	306,090,751	2,176,991,769

As at 31 December 2021, trade receivables of an initial value of ₩182million (2020: ₩272million) were impaired and provided for. See below for the movements in the provision for impairment of trade receivables.

		Individually impaired ' N 000	Total ³ N 000
	At 1 January 2021	272,825	272,825
	Addition	245,050	245,050
	Write off of trade receivables	(335,806)	(335,806)
	At 31 December 2021	182,069	182,069
	At 1 January 2020		
	Addition	522,666	522,666
	Write off of trade receivables	270,271	270,271
	Write off of WHT receivables	(384,266)	(384,266)
		(135,846)	(135,846)
	At 31 December 2020	272,825	272,825
21c.	Other receivables	Dec-21	Dec-20
		₩'000	₩'000
	Withholding tax receivables (WHT)	160,802	142,363
	Staff advances and other debtors	570,278 ————————————————————————————————————	411,917
		731,080	554,280
22.	Prepayments	Dec-21	Dec-20
		₩'000	₩'000
	Advance to suppliers	1,233,255	217,636
	Other prepayments	156,570	78,676
		1,389,825	296,312

This represents advances made to suppliers for the purchase of factory raw and packaging materials. Other prepayments include prepaid advert, prepaid insurance, and prepaid rent. Prepaid rent relates to rental paid for warehouses.

23.	Cash and cash equivalents	Dec-21	Dec-20
		₩'000	₩'000
	Bank balances	1,108,756	2,772,628
	Cash at hand	4,740	4,817
	Short-term deposits (including demand		
	and time deposits)	842,658	427,909
	Total cash and cash equivalents	1,956,154	3,205,354

Short-term deposits are made for varying years of between one day and three months, depending on the immediate cash requirements of the Company and weighted average interest rate is at 9.57%. For the purpose of cash flows, cash and cash equivalents consist of:

	Dec-21	Dec-20
	₩'000	₩'000
Bank overdraft	(259,662)	(232,229)
Cash and cash equivalents	1,956,154	3,205,354
	1,696,492	2,973,125

Bank overdraft represents the outstanding commitment on short-term borrowings for working capital management. The bank overdrafts are secured against mortgage debenture held by a trustee. The lenders are Access Bank, Guaranty Trust Bank, FCMB, Fidelity and FSDH. The interest on the overdraft ranges from 13-16%. Cash at banks in some classified account (e.g Call accounts, DSRA account and others) earn interest at floating rates based on daily bank deposit rates. Short-term deposits are made for varying periods of between one day and three months, depending on the immediate cash requirements of the Company, and earn interest at the respective short-term deposit rates.

24.	Interest Bearing Loans and borrowings	Dec-21 ₩'000	Dec-20 ₩'000
	(Non-current portion)		
	Bank of Industry ('BOI') (24f)	1,646,403	-
	First City Monument Bank - RSSF (24c)	61,947	382,168
	Bank of Industry ('BOI') 3 (Note 24b)	-	268,274
	Bank of Industry ('BOI') 4 (Note 24b)	632,032	597,465
	CBN DCRR/FCMB-working Capital (Note 24d)	-	316,494
	NEXIM/Fidelity-Capex (Note 24e)	950,240	1,155,125
	CBN DCRR/FCMB-Capex (Note 24d)	1,513,502	1,331,157
	NEXIM/Fidelity-working capital (24e)	1,406,605	
		6,210,729	4,050,683
	(Current portion)Bank of Industry ('BOI') (24f)	33,333	-
	First City Monument Bank - RSSF (24c)	333,333	456,127
	Bank of Industry ('BOI') 3 (Note 24b)	-	628,304
	Bank of Industry ('BOI') 4 (Note 24b)	166,667	292,383
	CBN DCRR/FCMB-working Capital (Note 24d)	484,835	137,894
	CBN DCRR/FCMB-Capex (Note 24d)	400,000	149,990
	CBN/DCRR/FCMB - CAPEX	178,304	-
	Short term borrowings (Note 2g)	603,647	4,971,570
		2,200,119	6,636,268
	Total	8,410,848	10,686,951
24a.	Reconciliation of interest bearing loans	10 600 050	6 200 005
	At 1 January	10,686,952	6,322,665
	Interest expense	1,183,768	1,249,193
	Additions Principal renormant	3,500,000	6,768,450
	Principal repayment	(5,776,105)	(2,404,163)
	Interest paid	(1,183,768)	(1,249,193)
		8,410,847	10,686,952

- The BOI loan is a N2billion loan granted in two tranches of N1bn each. The first N1bn granted at 10% for 84 months for capital expenditure while the other N1bn granted at 15% for 42 months to augments working capital. A fair value of the loan was obtained using estimated market rate of 18%. The difference between the loan rate and market rate accounted for a grant element of N221.2m. This was recognised as government grant and will be recognised in profit or loss over the duration of the loan. The loan was granted in 2019 with a moratorium of 1 year. The moratorium on principal repayment of BOI loan 3 and 4 has been extended by one year, this is to cushion the effect of the covid pandemic, 2% reduction in interest rate was also granted until March 31, 2021. The working capital loan has been paid off.
- 24c RSSF loan is a N1.5billion Central Bank of Nigeria (CBN) Real Sector Support Facility granted to Fidson Healthcare Plc at 9% for 60 months. A fair value of the loan was obtained using estimated market rate of 17%. The difference between the loan rate and market rate accounted for a grant element of N213m which has been recognised as government grant and will be recognised over the duration of the loan. The loan was granted in 2018 for the acquisition of Gas Generators and other pharmaceutical machinery for the factory. The interest on RSSF loan was reduced to 5% for a period of one year to cushion the effect of pandemic.

- FCMB loan is a N2.5billion Central Bank of Nigeria (CBN) Real Sector Support Facility-Differentiated Cash Reserve Requirement granted to Fidson Healthcare PLC for 84 months. The principal and interest shall be in twenty equal instalment and the interest shall be 9% per annum, however the CBN concessionary rate of 5% will apply till February 28, 2021.in addition the moratorium period for principal repayment has been extended further by another one year till 2022.
- 24e Nexim Loan is a N3billion Nigerian Export-Import bank loan under the direct leading scheme to Fidson healthcare PLC at the rate of 9% per annum.

The loan was disbursed in two equal instalments, N1.5billion for equipment finance and the other for working capital utilization. The first instalment was disbursed in December 2020 while the last instalment was disbursed in February 2021.

24f Short- term borrowings above are current and are expected to be settled within 12 months of the reporting date. The loan is from Guaranty Trust Bank, Access Bank and First City monument Bank with an Interest rate of 20%. The security on the borrowing is a tripartite legal mortgage over the property.

The carrying value of short-term borrowings approximates their fair value due to the short-term nature and the fact that there were no material movement in market rates since the inception the loans.

Breakdown of Note 24f	Dec-21	Dec-20
	₩'000	₩'000
GTB- Import Finance Facility	-	-
Access- Import Finance Facility	-	50,061
FCMB -Bankers' Acceptance	307,042	598,813
FSDH - Import Finance Facility	281,973	303,407
Fidelity - Import Finance Facility	-	389,779
Short Term Loans - Others	-	667,000
Wema LC Account	-	975,527
Union Bank LC Account	14,632	206,764
Zenith Bank LC	-	39,396
Coronation Bank LC	-	1,396,026
Fidelity Bank LC Account	-	81,610
Access Bank LC Account	<u> </u>	263,187
	603,647	4,971,570

25. Obligation under finance lease

25a.

The company has entered into commercial leases on certain motor vehicles. These leases have an average life of between three and five years with no renewal option included in the contracts. There are no restrictions placed upon the Company by entering into these leases.

Maturity analysis	Dec-21	Dec-20
	₩ '000	₩'000
Year 1	111,600	130,687
Year 2	62,216	120,674
Year 3		68,827
	173,816	320,188
	(22,876)	(59,747)
Less Unearned Interest	150,940	260,441
Analysed as		
Current	87,350	95,982
Noncurrent	63,590	164,459
	150,940	260,441

26.	Retirement benefit obligation	Dec-21	Dec-20
		₩,000	₩'000
	Net benefit expense (recognised in administrative expenses)		
	Interest cost on benefit obligation	20,011	36,838
	Net benefit expense	20,011	36,838
	Defined benefit liability	268,185	447,792

The actuarial valuation was carried out by Ernest & young FRC/2012/NAS/0000000738 Changes in the present value of the defined benefit obligation are as follows

Changes in the present value of the defined benefit obligation are as follows:

	Dec-21 \\ '000	Dec-20 ₦'000
Defined benefit liability at 1 January	272,143	278,533
Interest cost	20,011	36,838
Benefits paid	(3,958)	(6,390)
Re-measurement gain on obligation		
(Experience adjustment)	(20,011)	(36,838)
	268,185	272,143
Executive gratuity	-	175,649
	268,185	447,792

The valuation assumptions used in determining retirement benefit obligations for the plans are shown below:

Financial Assumptions		
(Long Term Average)	2021	2020
	%	%
Discount Rate (p.a)	13	7.50
Average Pay Increase (p.a)	N/A	N/A
Average Rate of Inflation (p.a)	13	8.0
Rate of future Interest Credit (p.a)	12	12.00

2021		Accrued Liability
Base		₩'000
Discount rate		268,185
Discount rate	+1%	268,185
Age rated up to 1 year	-1%	268,185
Mortality rate		268,185
Age rated down by 1 year		268,185
		268,185

		Accrued
2020		Liability
		₩'000
Base		272,144
Discount rate	+1%	272,144
Discount rate	-1%	272,144
Age rated up to 1 year		272,144
Mortality rate		272,144
Age rated down by 1 year		272,144

Demographic Assumptions Mortality in Service

(Sample Ages)		Number of deaths in the year out of 10,000 lives	
(Campio Agoo)	2021	2020	
25	7	7	
30	7	7	
35	9	9	
40	14	14	
45	26	26	
Withdrawal from Service			
(Age Band)			
	2021	2020	
	%	%	
Less than or equal to 30	7.5	7.5	
31 – 39	6.0	6.0	
40 - 44	5.0	5.0	
45 – 60	3.0	3.0	

The discount rate is determined on the Company's reporting date by reference to market yields on high quality Government bonds. The discount rate should reflect the duration of the liabilities of the benefit programme.

The company has a medium-term strategy of increasing salaries to reflect inflation, the actuaries prudently allowed for 1% margin for 2021.

The mortality base table used for the scheme is A67/70 Ultimate Tables, published jointly by the Institute and Faculty of actuaries in the United Kingdom.

The table below shows the maturity profile of defined benefit obligation:

	2021	2020
	₩ ′000	₩ ′000
Within the next 12 months		
(next annual reporting period)	15,582	10,664
Between 2 and 5 years	119,281	107,837
Between 5 and 10 years	362,684	242,563
Beyond 10 years	251,644	138,014
	749,191	499,078

The weighted average duration of the defined benefit plan obligation is 6.93 years. (7.49 years in 2021)

27.	Government grant	Dec-21 \(\frac{1}{2}\)'000	Dec-20 ₩'000
	At 1 January	1,182,477	367,875
	Additions	168,809	1,014,690
	Released to profit or loss	(333,871)	(200,088)
		1,017,415	1,182,477
	Current	356,651	244,229
	Non-current	660,764	938,248
		1,017,415	1,182,477

This represents the grant elements of the Central Bank of Nigeria intervention loans, after the loans were remeasured using the effective interest rate. The government grants have been recognised in the statement of financial position and are being amortised through the profit or loss on a systematic basis over the tenure of the loans.

28.	Deferred revenue	Dec-21 ₩'000	Dec-20 ₩'000
	At 1 January	7,917	11,084
	Addition	-	-
	Released to the profit or loss	(3,167)	(3,167)
	At 31 December	4,750	7,917
	Current	3,167	3,168
	Non-current	1,583	4,749
		4,750	7,917

This represents deferred rental income from an insignificant portion of the Company's building held to earn rentals.

29.	Trade and other payables	Dec-21	Dec-20
	Too de manables	₩'000	₩'000
	Trade payables	1,773,060	866,760
	Accruals	1,283,684	845,369
	Other payables (Note 29a)	1,390,386	465,439
		4,447,130	2,177,568
29a.	Other payables	4 000 004	000 570
	Other creditors	1,292,631	323,572
	Withholding tax (WHT)	66,133	105,265
	Payable to the Directors	6,022	20,369
	Pay as you earn (PAYE)	15,351	11,225
	Staff Cooperative	1,930	1,560
	NHF	584	458
	VAT Payable	234	522
	Staff Pension Fund	7,501	_
	Outstanding due General Managers	-	2,468
		1,390,386	465,439

Terms and conditions of the above financial liabilities:

- Trade payables are non-interest bearing and are normally settled on 60-day terms.
- Other creditors are non-interest bearing and have an average term of six months.

Trade payables, and other payables meet the definition of financial liability and their carrying amounts approximate fair value because the terms and conditions of payment is within 1 year for trade and other payables.

	Dec-21	Dec-20
	₩'000	₩'000
Distributors and sales representative	394,744	50,756
Deposit for Ecomed property	259,164	254,164
Deposit for FPL property	550,000	-
Deposit by Primus investment limited	-	18,652
Pioneer Director Retirement Liability	88,723	
	1,292,631	323,572

30.	Other Current Financial Liabilities	Dec-21	Dec-20
		₩'000	₩'000
	Commercial papers	2,150,000	
		2,150,000	

31. **Dividends**

On 22 July 2020, a dividend of N0.15k per share (total dividend N225million) was approved by shareholders to be paid to holders of fully paid ordinary shares in relation to 2019 financial year.

In respect of the current year, the Directors proposed a dividend of N0.20k per share. This dividend is subject to approval by shareholders at the Annual General Meeting and has not been included as a liability in these financial statements.

		Dec-21 ₩'000	Dec-20 N '000
	Dividends paid and proposed Paid during the year Balance unpaid	521,591 (521,591)	225,000 (225,000)
	Dividends on ordinary shares: Proposed dividend for 2021: N0.50k per share (2020: N0.25k per share)	1,043,180	521,891
31a.	Unclaimed dividend	Dec-21 ₦'000	Dec-20 ₦'000
	Unclaimed dividend	88,215	38,937

Unclaimed dividend relates to dividend paid in the prior year which was returned by the registrar as they remained unclaimed by the beneficiaries.

31b.	Reconciliation of unclaimed dividend	Dec-21 ₩'000	Dec-20 ₦'000
	At I January	38,937	38,937
	Additions	521,590	312,939
	Payment	(521,590)	(312,939)
	(Payment)/refund of nclaimed dividend	49,278	-
	At 31 December	88,215	38,937
32.	Share capital and reserves	Dec-21 ₦'000	Dec-20
	Authorised share capital		
	2,400,000,000 ordinary shares of 50k each	1,200,000	1,200,000
		Dec-21	Dec-20
	January and fully maids	₩'000	N '000
	Issued and fully paid: 2,086,360,250 ordinary shares of 50k each	1,043,180	1,043,180
		1,043,180	1,043,180

33.	Share premium	Dec-21	Dec-20
		₩'000	₩'000
	At 1 January 2021	4,933,932	4,933,932
	Addition in the year		
		4,933,932	4,933,932

Section 120.2 of Companies and Allied Matters Act requires that where a Company issue shares at premium (i.e. above the par value), the value of the premium should be transferred to share premium.

Share premium arises from shares issued at a price higher than the nominal value. The current balance was as a result of increase in share capital with a nominal value of 50k from 200,000,000 to 1,500,000,000 and 1,500,000,000 to 2,086,360,250 ordinary shares in November 2007 and April 2019 respectively.

34. Available for sale reserve

The reserve records fair value changes in available for sale financial asset.

	Dec-21	Dec-20
	₩'000	₩'000
At 1 January	515	(725)
Other Comprehensive gain /(loss) for the year, net	70	1,240
At 31 December	585	515

Gain or loss on equity available for sale financial asset is not taxable. Hence, no deferred tax was recognised for fair value gain or loss. This is to aid any user of the financial statement not familiar with Nigerian tax laws.

Guarantees and other financial commitments 35

Capital expenditure a.

The Company has proposed ₩3.03billion (N2.73 billion:2020) for capital expenditure for 2021financial year as

Contracted for: ₩1.88 billion (N367million:2020)

Not contracted for: ₩1.14 billion(N2.36billion:2020)

b **Financial commitments**

The directors are of the opinion that all known liabilities and commitments have been taken into account in the preparation of the financial statement under review. These liabilities are relevant in assessing the Company's financial position and performance.

Security of facilities C

The bank loans and overdrafts are secured principally by a legal mortgage over some of the Company's land and buildings, debenture on the Company's assets, lien on shipping documents of goods imported, personal guarantee of Dr. Fidelis A. Ayebae and joint and several guarantees of the Directors of Fidson Healthcare Plc. The mortgage debenture is on the land, building, plant and machinery of Fidson Healthcare Plc (including plant and machinery of the biotech factory located at Veepee Avenue, Otta Industrial Estate, Ogun State. The carrying amounts of the assets are N11.9billion at 31 December 2021. (2020: N11.9billion).

36 Contingent liabilities

There were judgements against the company in two suits with a total award of damages in the sum of N6million payable.

However, the liability has been settled and case closed.

37 **Related party transactions**

There was no related party transaction for the period under review.

37a.

	empensation of Key Management Personnel	Dec-21	Dec-20
		₩'000	₩'000
Sho	ort-term employee benefits	408,628	343,120
Pos	st-employment benefits	12,459	11,556
Tot	tal compensation paid to key management personnel	421,087	354,676
The	e amount disclosed in the note above are the amount recognised as	s an expense during the reporting	neriod relate
to k	key management personnel.		period relate
	,000,000 to N10,000,000	9	10
N1	, ,	9 8	
N1.	,000,000 to N10,000,000		10

Key management includes directors and members of senior management (Directors, GM, DGM, AGM, Principal Manager)

37b. Directors' emoluments

The remuneration paid to the Directors is as follows:

	Dec-21	Dec-20
	₩'000	₩'000
Executive compensation	175,666	106,058
Fees and sitting allowance	7,578	3,390
Total Directors' emoluments	183,244	109,448

Fees and other emoluments disclosed above include amount paid to the chairman.

	Dec-21	Dec-20
	N '000	₩'000
The chairman	5,000	5,000
Highest paid Director	57,000	50,000

Information relating to employees 38.

The number of employees in respect of emoluments within the following ranges were:

	Dec-21	Dec-20
	Numbers	Numbers
Less than 500,000	-	-
500,001 - 1,000,000	91	102
1,000,001- 1,500,000	108	76
1,500,001 -2,000,000	89	89
2,000,001 -2,500,000	62	57
2,500,001 -3,000,000	48	20
3,000,001 and above	80	61
	478	405

38.1 Staff

The average numbers of persons employed were as follows:

	Numbers	Numbers
Executive Mgt	17	13
Commercial and Marketing	170	144
Production	161	155
Operation	84	49
Finance and Admin	46	44
	478	405

40. Segment information

For management purposes, the performance of the business is assessed along product classes. Two of the Company's products have been identified as reportable segments for the purpose of IFRS 8. However, information for the product classes is only maintained at the revenue and cost of sales level. Financing and Income taxes are reported Company wide.

There is no single external customer whose transaction amount to 10% or more of the entity's revenues. Revenue for over-the-counter product accounts for 35% of total revenue, while Ethical product accounts for 65%. Revenue from Lagos region accounts for 42% of the total revenue. The Executive Management Committee monitors the operating results of the whole business for the purpose of making decisions about resource allocation and performance assessment.

The summary below shows the revenue and cost of sales information made available to the Executive management committee:

	Dec-21	Dec-20
Revenue:	₩'000	₩'000
Consumer Healthcare (Toll Manufacturing)	117,366	-
Ethical	20,109,605	10,672,684
Over-The-Counter	10,633,846	7,603,172
Total Revenue	30,860,817	18,275,856
Cost of Sales	72,499	_
Consumer Healthcare (Toll Manufacturing)	5,526,160	4,827,129
Ethical	7,879,782	3,354,446
Over The Counter (OTC)	569,922	499,496
Depreciation of factory PPE (Note 15)	549,226	317,563
	•	•
EnergyPersonnel Cost	625,483	418,157
Other Factory Overheads	534,710	277,725
Total cost of sales	15,757,782	9,694,516

None of the major customers of the Company account for up to 10% of total revenue.

Geographical Information

Currently the company's operation is domiciled in Nigeria

40.2 **Information about Major customers**

Included in Revenue are revenues of approximately N1.45billion (2019: N1.33billion) which arose from sales to the company's largest customer. In addition, three other customers contributed more than 10% to the company's revenue altogether amounting to N3.56billion (2020: N2.58billion)

Financial instruments risk management objectives and policies

The company deploys a number of financial instruments (financial assets and financial liabilities) in carrying out its activities. The key financial liabilities, of the Company comprise bank borrowings, trade payables and finance leases which are deployed purposely to finance the Company's operations and to provide liquidity to support the Company's operations.

The financial assets of the Company include availablefor-sale investments, loans and receivables, trade receivables, and cash and short-term deposits also necessarily required for the operations of the Company.

The principal risks that Fidson Healthcare Plc is exposed to as a result of holding the above financial instruments include market risk, credit risk and liquidity risk. The senior management of the Company oversees the management of these risks through the establishment of adequate risk management framework with appropriate approval process, internal control and authority limits. Thus, the Company's financial risk-taking activities are governed by appropriate policies and procedures and that financial risks are identified, measured and managed in accordance with those policies. The Board of Directors which is responsible for the overall risk management of the Company reviews and agrees on policies for managing each of these risks inherent in its involvement in financial instruments and operations are as summarised below.

Market risk

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. Market prices comprise four types of risk: interest rate risk, currency risk, commodity price risk and other price risk, such as equity price risk. Financial instruments affected by market risk include loans and borrowings, trade payables, available-for-sale investments, finance lease obligations, cash and cash equivalents, bank overdraft, finance lease obligation and loans and receivables.

Currency risk

Management has set up a policy requiring the Company to manage their foreign exchange risk against their functional currency. The company is required to manage its entire foreign exchange risk exposure with the Company finance. To manage their foreign exchange risk arising from future commercial transactions and recognised assets and liabilities, the Company ensures that significant transactions are contracted in the country's functional currency. Foreign exchange risk arises when future commercial transactions or recognised assets or liabilities are denominated in a currency that is not the Company's functional currency.

Foreign currency sensitivity

The following tables demonstrate the sensitivity to a reasonably possible change in USD exchange rates, with all other variables held constant. The impact on the Company's profit before tax is due to changes in the fair value of monetary assets and liabilities.

Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The company does not carry debt at fair value neither does it have any floating rate exposure.

Equity price risk

This is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Fidson Healthcare Plc has a price risk in relation to its available for sale investments. This is because the investments are traded in an active market and are subject to price fluctuation. The company manages the equity price risk by placing limits on individual an. Reports on the equity portfolio are submitted to the senior management on a regular basis. The Board of Directors reviews and approves all equity investment decisions.

At the reporting date, the exposure to listed equity securities at fair value was N5,030,000 (2020: N4.960.000), An increase of 33% on the Nigerian Stock Exchange could have an impact of approximately N70,000 (2020: N1,230,000) on the income or equity attributable to the Company, depending on whether or not the decline is significant or prolonged. An increase of 1.41% in the value of the listed securities would only impact equity but would not have an effect on the profit or loss.

Credit risk

Credit risk is the risk that counterparty will not meet its obligations under a financial instrument or customer contract, leading to a financial loss. The sources of the Company's credit risk include trade receivables. receivable from related parties and deposits with banks and financial institutions. See Note 22a for analysis of the age of financial assets that are past due as at the end of the reporting year but not impaired the credit risk of the Company is unsecured The maximum exposure to credit risk for the components of the statement of financial position at 31 December 2020 is the carrying amounts as shown in Note 22a. Refer to Note 25 for the maximum risk of Banks and financial institutions.

Financial instruments and cash deposits

Credit risk from balances with banks and financial institutions as well as deposit with ALM Trustees is managed by the Company's treasury department in accordance with the Company's policy. The company limits its exposure for default by keeping cash with banks with good solvency margin. Maximum exposure to credit risk at the reporting date is the carrying value of the financial asset disclosed in Note 24. Investments of surplus funds are made only with approved counterparties and within credit limits assigned to each counter party. Counterparty credit limits are reviewed by the Company's Board of Directors on an annual basis, and may be updated throughout the year subject to approval of the Company's Finance Committee. The limits are set to minimize the concentration of risks and therefore mitigate financial loss through a counter party's potential failure to make payment.

Customer credit risk is managed by credit managers and management as a whole subject to the Company's established policy, procedures and control relating to customer credit risk management. Credit quality of the customer is assessed based on an extensive credit rating scorecard and individual credit limits are defined in accordance with this assessment.

Staff advance are also secured by employee salaries and deductions are made at source. Receivable from related party is managed by the management subject to the Company's established policy, procedures and control relating to credit risk management.

Outstanding customer receivables are regularly monitored and any deliveries to major customers are generally covered by valid customer order. Customer backgrounds are studied to avoid concentration risk. The company evaluates the concentration of risk with respect to trade receivables as low.

Balances with banks and financial institutions Credit risk from balances with banks and financial institutions is managed by the Managing Director in accordance with the Company's policy. Investments of surplus funds are made only with approved counterparties and within credit limits assigned to each counterparty. The policies are set and reviewed by the Board annually.

Liquidity risk

Liquidity risk is the risk that the Company will be unable to pay its obligations when they fall due. The company monitors its risk to a shortage of funds using a recurring liquidity planning and continuous budget tool. The company's objective is to maintain a balance between continuity of funding and flexibility through the use of bank overdrafts and bank loans. The Board of Directors defines the Company's liquidity policy annually.

	Contractual Undiscounted cash flows **2000	On demand N '000	Less than 3 months	3 to 12 months ₩'000	1 to 5 years ₩'000	Carrying value N '000
At 31 December 2021						
Interest bearing loans &						
borrowing (non-current)	6,398,489				6,398,489	6,398,489
Trade payables	1,773,060	1,773,060				-
Bank overdraft	259,662		259,662			259,662
Other financial liabilities						
Interest bearing loans and						
borrowing (current)	2,012,359			2,012,359		2,012,359
Finance lease	173,816			87,350	63,590	150,939
	10,617,386	1,773,060	259,662	2,099,709	6,462,079	8,821,449

	Contractual Undiscounted cash flows **Y000	On demand ₩'000	Less than 3 months	3 to 12 months ₩'000	1 to 5 years ₩'000	Carrying value N '000
At 31 December 2020						
Interest bearing loans &						
borrowing (non-current)	4,050,683				4,050,683	4,050,683
Trade payables	866,761	866,761				866,761
Bank overdraft	232,229		232,229			232,229
Other financial liabilities						
Interest bearing loans and						
borrowing (current)	6,636,268			6,636,268		6,636,269
Finance lease	320,188			95,982	224,206	320,188
	12,106,129	866,761	232,229	6,732,250	4,274,889	12,106,130

Fair values

Set out below is a comparison by class of the carrying amounts and fair values of the Company's financial instruments that are carried in the financial statements.

	Carryin	g values	ues Fair value	
	31-Dec-21 31-Dec-21 N'000 N'000		31-Dec-21 N'000	31-Dec-20 N'000
Financial assets				
Loans and other receivables	14,027	12,871	14,027	12,871
Trade receivables	2,248,787	2,176,992	2,248,787	2,176,992
Cash and bank	1,224,516	303,919	1,224,516	303,919
Available for sale	5,030	4,960	5,030	4,960
Other non-current financial asset	173,162	171,673	173,162	171,673
Total	3,665,522	2,670,415	3,665,522	2,670,415
Financial liabilities				
Interest-bearing loans and borrowings	6,398,489	2,918,518	2,918,518	2,695,083
Short-term borrowing	2,012,358	1,703,745	2,012,358	1,703,745
Bank Overdraft	259,662	546,604	259,662	546,604
Finance Lease	150,940	528,916	173,816	696,241
Trade and other payables	4,447,132	1,399,045	4,447,132	1,399,045
Total	13,268,581	7,096,828	9,811,486	7,040,718

41b Determination of fair value and fair value hierarchy

As at 31 December 2021 the Company held some financial instruments carried at fair value on the statement of financial position. The company uses the following hierarchy for determining and disclosing the fair value of nonfinancial assets by valuation technique:

Level 1: quote prices in active markets for identical assets or liabilities

Level2: other techniques for which all inputs which have a significant effect on the recorded fair value are observable, either directly or indirectly.

Level 3: techniques which use inputs that have a significant effect on the recorded fair value that are not based on observable market data.

The company has investment in listed equity securities. The fair value of the quoted equity shares is determined by reference to published price quotations in an active market.

Valuation Date of	Level 1	Level2	Level3
Assets measured at fair value:	₩'000	₩'000	₩'000
Available-for-sale financial assets: (Note 18)			
31-Dec-21	5,030		
31-Dec-20	4,960		
Assets for which fair values have been disclosed:			
Investment property(Note16)			
31-Dec-21			329,100
31-Dec-20			329,100
Interest bearing loans and borrowings - Noncurrent (Note 41a)			
31-Dec-21		6,398,489	
31-Dec-20		4,050,683	
Interest bearing loans-current (Note 41a)			
31-Dec-21		2,012,358	
31-Dec-20		6,636,269	
Finance Lease (Note 25)			
31-Dec-21		150,940	
31-Dec-20		260,441	

There have been no transfers between Level 1 and Level 2 during the period Interest bearing loan and borrowings are evaluated by the Company based on parameters such as interest rates that reflects market risk characteristics at the measurement date.

The fair value of the loans and borrowing are determined based on DCF method using discount rate that reflects the issuer's borrowing rate as at the end of the reporting period.

42 Capital management

Capital includes issued share capital, share premium, retained earnings and other reserves in the statement of financial position. The primary objective of the Company's capital management is to ensure that it maintains healthy capital ratios in order to support its business and maximise shareholder value.

The company manages its capital structure and makes adjustments to it in light of changes in economic conditions. To maintain or adjust the capital structure, the Company may adjust the dividend payment to shareholders, return capital to shareholders or issue new shares.

No changes were made in the objectives, policies or processes for managing capital during the year ended 31 December 2021 and year ended 31 December 2020.

The company monitors capital using a gearing ratio which is net debt divided by total capital plus net debt. The company's policy is to keep the gearing ratio between 45% and 60%. The company includes within net debt interest bearing loans and borrowings, trade and other payables, and cash and short-term deposits.

	Dec-21 ₩'000	Dec-20 N'000
Interest bearing loans and borrowings (Note 24)	8,410,847	10,686,951
Trade and other payables (Note 29)	4,447,132	2,177,568
Overdraft (Note 24)	259,662	232,229
Less: Cash and bank balances	(1,956,154)	(3,205,354)
Net debt	11,161,487	9,891,394
Capital - Equity	13,751,835	10,539,435
Capital and net debt	24,913,322	20,430,829
Gearing Ratio	45%	48%

43.0 Earnings per share

Basic earnings per share are calculated by dividing the net profit for the year attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding at the reporting date. The following reflects the income and share data used in the basic earnings per share computations:

Basic	Dec-21 ₩'000	Dec-20 ₩'000
Net profit attributable to ordinary shareholders Weighted average number of ordinary shares	4,243,148 2,086,350	1,205,039 2,086,350
Basic / (Loss) earnings per ordinary share	148k	58k

There was no dilutive effect of ordinary shares during the reporting and the comparative years.

44.0 **Events after the reporting period**

There are no events or transactions that has occurred since the reporting date which would have a material effect on these financial statements, or which would need to be disclosed in the financial statements.

VALUE ADDED STATEMENT

	2021 ₦'000	%	2020 N '000	%
Revenue	30,860,817		18,275,856	
Other operating income	596,552		349,745	
Finance income	77,718		9,240	
Bought in goods and services				
- Imported	(11,713,927)		(7,587,675)	
- Local	(10,518,292)		(5,176,787)	
Value added	9,302,868		5,870,379	
Applied as follows:				
To employees:	0.504.000	00	1 0 10 0 10	00
Salaries and other benefits	2,561,690	28	1,949,616	32
To Government:				
Income tax	851,747	9	116,038	2
To pay providers of capital:				
Bank interest	1,222,299	13	1,333,927	23
To provide for replacement of assets				
and expansion of business:				
- Depreciation and amortization	801,235	8	814,034	14
- Deferred taxation	(377,251)	(4)	451,725	8
Retained profit/(loss)	4,243,148	46	1,205,039	21
	9,302,868	100	5,870,379	100

The value added represents the wealth which the Company has been able to create by its own and its employees' efforts. This statement shows the allocation of that wealth to employees, providers of finance, government and that retained for the future creation of more wealth.

FIVE-YEAR FINANCIAL SUMMARY

Non-current assets
Right of use Assets 486,271 595,194 703,182 - Investment property 31,823 32,742 33,586 34,504 35,34 Intangible assets 21,722 23,530 27,736 54,475 60,18 Loans and other receivables 14,027 12,871 10,172 50,038 47,80 Available for sale 5,030 4,960 3,720 4,610 5,12 Investment in associate 0ther non-current financial assets 173,162 171,673 441,337 393,209 294,42 Net current (liabilities)/assets 6,508,720 3,464,889 1,030,463 (2,960,403) (2,073,018 Non-current liabilities Interest bearing loans and borrowings— (6,210,729) (4,050,683) (2,695,082) (1,124,287) (1,246,254) Lease liabilities (63,590) (164,459) (312,409) (213,180) (592,411) Staff retirement benefits (268,185) (447,792) (278,533) (300,957) (309,831) Government grant (660,764) (938,248) </th
Investment property 31,823 32,742 33,586 34,504 35,346 Intangible assets 21,722 23,530 27,736 54,475 60,186 50,308 47,807 12,871 10,172 50,038 47,807 12,871 10,172 50,038 47,807 12,871 10,172 50,038 47,807 12,871 10,172 50,038 47,807 12,871 10,172 50,038 47,807 12,871 10,172 50,038 47,807 12,871 10,172 50,038 47,807 12,871 10,172 50,038 47,807 12,871 10,172 50,038 47,807 12,871 10,172 50,038 47,807 12,871 10,172 50,038 47,807 12,871 10,172 10,1
Intangible assets 21,722 23,530 27,736 54,475 60,18 Loans and other receivables 14,027 12,871 10,172 50,038 47,80 Available for sale 5,030 4,960 3,720 4,610 5,12 Investment in associate Other non-current financial assets 173,162 171,673 441,337 393,209 294,42 Net current (liabilities)/assets 6,508,720 3,464,889 1,030,463 (2,960,403) (2,073,018) 22,133,749 17,693,669 14,247,080 9,947,439 10,733,08 Non-current liabilities Interest bearing loans and borrowings— (6,210,729) (4,050,683) (2,695,082) (1,124,287) (1,246,254,124,124,124,124,124,124,124,124,124,12
Loans and other receivables 14,027 12,871 10,172 50,038 47,800 Available for sale 5,030 4,960 3,720 4,610 5,120 Investment in associate Other non-current financial assets 173,162 171,673 441,337 393,209 294,420 Net current (liabilities)/assets 6,508,720 3,464,889 1,030,463 (2,960,403) (2,073,018 10,000)
Available for sale 5,030 4,960 3,720 4,610 5,12 Investment in associate Other non-current financial assets 173,162 171,673 441,337 393,209 294,42 Net current (liabilities)/assets 6,508,720 3,464,889 1,030,463 (2,960,403) (2,073,015) Phon-current liabilities Interest bearing loans and borrowings— (6,210,729) (4,050,683) (2,695,082) (1,124,287) (1,246,254) (2,241,242) (2,241
Investment in associate Other non-current financial assets 173,162 171,673 441,337 393,209 294,42
Other non-current financial assets 173,162 171,673 441,337 393,209 294,42 Net current (liabilities)/assets 6,508,720 3,464,889 1,030,463 (2,960,403) (2,073,015) Non-current liabilities Interest bearing loans and borrowings— (6,210,729) (4,050,683) (2,695,082) (1,124,287) (1,246,254) Lease liabilities (63,590) (164,459) (312,409) (213,180) (592,41) Staff retirement benefits (268,185) (447,792) (278,533) (300,957) (309,83) Government grant (660,764) (938,248) (247,299) (156,068) (143,124) Deferred revenue (1,583) (4,751) (7,916) - (1,000)
Net current (liabilities)/assets 6,508,720 3,464,889 1,030,463 (2,960,403) (2,073,018) Non-current liabilities Interest bearing loans and borrowings— (6,210,729) (4,050,683) (2,695,082) (1,124,287) (1,246,254) Lease liabilities (63,590) (164,459) (312,409) (213,180) (592,417) Staff retirement benefits (268,185) (447,792) (278,533) (300,957) (309,837) Government grant (660,764) (938,248) (247,299) (156,068) (143,124) Deferred revenue (1,583) (4,751) (7,916) - (1,000)
Non-current liabilities (6,210,729) (4,050,683) (2,695,082) (1,124,287) (1,246,254) Lease liabilities (63,590) (164,459) (312,409) (213,180) (592,417) Staff retirement benefits (268,185) (447,792) (278,533) (300,957) (309,837) Government grant (660,764) (938,248) (247,299) (156,068) (143,124) Deferred revenue (1,583) (4,751) (7,916) - (1,000)
Non-current liabilities Interest bearing loans and borrowings— (6,210,729) (4,050,683) (2,695,082) (1,124,287) (1,246,254) Lease liabilities (63,590) (164,459) (312,409) (213,180) (592,41) Staff retirement benefits (268,185) (447,792) (278,533) (300,957) (309,833) Government grant (660,764) (938,248) (247,299) (156,068) (143,124) Deferred revenue (1,583) (4,751) (7,916) - (1,000)
Interest bearing loans and borrowings— (6,210,729) (4,050,683) (2,695,082) (1,124,287) (1,246,254) Lease liabilities (63,590) (164,459) (312,409) (213,180) (592,410) Staff retirement benefits (268,185) (447,792) (278,533) (300,957) (309,830) Government grant (660,764) (938,248) (247,299) (156,068) (143,124) Deferred revenue (1,583) (4,751) (7,916) - (1,000)
Lease liabilities (63,590) (164,459) (312,409) (213,180) (592,417) Staff retirement benefits (268,185) (447,792) (278,533) (300,957) (309,837) Government grant (660,764) (938,248) (247,299) (156,068) (143,124) Deferred revenue (1,583) (4,751) (7,916) - (1,000)
Lease liabilities (63,590) (164,459) (312,409) (213,180) (592,417) Staff retirement benefits (268,185) (447,792) (278,533) (300,957) (309,837) Government grant (660,764) (938,248) (247,299) (156,068) (143,124) Deferred revenue (1,583) (4,751) (7,916) - (1,000)
Staff retirement benefits (268,185) (447,792) (278,533) (300,957) (309,833) Government grant (660,764) (938,248) (247,299) (156,068) (143,124) Deferred revenue (1,583) (4,751) (7,916) - (1,000)
Deferred revenue (1,583) (4,751) (7,916) - (1,000
Deferred taxation (1,177,063) (1,548,311) (1,085,533) (999,166) (817,546)
13,751,835 10,539,425 9,620,308 7,153,781 7,622,92
Financed by:
Share capital 1,043,180 1,043,180 750,000 750,000
Share Premium 4,933,932 4,933,932 2,973,043 2,973,04
Retained earnings 7,774,138 4,561,808 3,643,921 3,430,573 3,899,19
Available for sale reserve
13,751,835 10,539,435 9,620,308 7,153,781 7,622,92
Revenue 30,860,817 18,275,856 14,062,015 16,229,903 14,057,39
Profit before taxation
Profit / (Loss) for the year 4,717,644 1,772,211 575,666 160,867 1,578,54
Dividend 3,719,913 1,205,039 407,188 (97,447) 1,060,78
1,043,180521,591312,939225,000300,00
Per Share Data
Earnings per share (kobo) 178 58 20 (6) 7
Dividend per share (kobo) 50 25 15 15 2
Net assets per share (kobo)

HISTORY OF THE COMPANY'S SHARE CAPITAL

1.	March 13, 1995	The Company was incorporated with an authorized share capital of =N=1,000,000.00 (one million naira) divided into 1,000,000 ordinary shares of =N=1.00 each.
2.	June 22, 1999	The share capital of the Company was by an ordinary resolution increased from $=N=1,000,000.00$ (one million naira) to $=N=21,000,000.00$ (twenty-one million naira) through the creation of $20,000,000$ ordinary shares of $=N=1.00$ each.
3.	July 6, 2001	The share capital of the Company was by an ordinary resolution further increased from $=N=21,000,000.00$ (twenty-one million naira) to $=N=71,000,000.00$ (seventy-one million naira) through the creation of $50,000,000$ ordinary shares of $=N=1.00$ each.
4.	January 5, 2004	The share capital of the Company was by an ordinary resolution increased from $=N=71,000,000.00$ (seventy-one million naira) to $=N=100,000,000.00$ (one hundred million naira) through the creation of 29,000,000 ordinary shares of $=N=1.00$ each.
5.	November 8, 2007	By a special resolution, the Company subdivided the nominal value of its shares from =N=1.00 (one naira) each to 50k (fifty) kobo.
6.	November 8, 2007	The share capital of the Company was by an ordinary resolution increased from $=N=100,000,000$ (one hundred million naira) to $=N=750,000,000$ (seven hundred and fifty million naira) through the creation of 1,300,000,000 ordinary shares of 50 kobo each.
7.	August 25, 2017	The share capital was increased from =N=750,000,000 to =N=1,200,000,000 by the creation of additional 900,000,000 ordinary shares.

PK	OXY FORM	Resolution	For	Against	Abstain
At the twenty-third Annual General Meeting of Fidson Healthcare Plc holding at the Conference Centre, 2nd Floor, Fidson Towers, 268 Ikorodu Road, Obanikoro Lagos, at 10am on the 28th of July, 2022. I/We		1. To declare a dividend of 50 kobo per 50 kobo ordinary shares amounting to a total of N1,043,180,125 (one billion and forty-three million, one hundred and eighty thousand, one hundred and twenty-five naira, only).			
		2. To re-elect Mr. Olusegun Adebanji who is aged over 70 years as a Director pursuant to Sections 261 and 282 of the Companies and Allied Matters Act, 2020, special notice being hereby given and to re-elect other Directors who are due for re-election.			
1. 2.	hereby appoint Mr. Segun Adebanji Dr. Fidelis Ayebae	3. To authorize the Directors to fix the remuneration of the Auditors.			
3. 4.	Chief Matthew Akinlade, FCA Alhaji Abdulkabir Babatunde Sarumi	4. To disclose the remuneration of the Managers of the Company.			
5. 6.	Mr. Solomon S. Akinsanya Sir Sunny Nwosu	5. To elect members of the Audit Committee in accordance with Section 404(3) of the Companies and Allied Matters Act, 2020.			
5. Mr. Solomon S. Akinsanya		 6. To consider and if thought fit to pass the following as an ordinary resolution: (I) ISSUANCE OF BONUS SHARES "That in line with the recommendation of the Board of Directors and to comply with the provisions of Section 124 of the Companies and Allied Matters Act 2020 and Regulation 13 of the Companies Regulations 2021 with respect to the company's unallotted shares, a bonus issue of one new ordinary share of 50 kobo for every ten ordinary shares held as at the close of business on the 8th of July 2022, and totaling 208,636,025 ordinary shares be and are hereby issued to rank pari-pasu in all respects with the existing ordinary shares of the company. (ii) 'That, in furtherance of the above and pursuant to Section 430(5) of the Companies and Allied Matters Act, 2020, the sum of N104,318,012.50 (one hundred and four million, three hundred and eighteen thousand and twelve naira, fifty kobo) out of the total balance of N4,933,932,000 (four billion, nine hundred and thirty-three million, nine hundred and thirty-two thousand naira) only standing to the credit of share premium account be and it is hereby applied for the bonus issue.' 			
Note A member of the company entitled to attend and vote at the Annual General meeting is entitled to appoint a proxy to attend, speak and vote instead of that member. A proxy need not be a member of the company. Registered holders of the certificated		 (iii) "That the Directors be and are hereby authorized to allot any outstanding amount of shares after the bonus issue whether by way of Employee Shares schemes or in any manner as they may deem fit for consideration that shall be fixed by them' (iv) "That the Directors be and are hereby authorized to do all things necessary to give effect to the allotments with the 			
Fids	on Healthcare Plc's shares and holders of dematerialised	relevant Regulators by way of registration and/or listing.'			
	on Healthcare Plc's shares in their own name who are	8. To fix the remuneration of Directors.			
	pole to attend the meeting and who wish to be represented at meeting must complete and return this form of proxy. The	9. To consider and if thought fit, to pass the following as an ordinary resolution: "That, pursuant to Rule 20.8 of the			

DETACH FROM HERE

terms be and is hereby renewed."

rulebook of Nigerian Exchange Limited, 2015: Issuers Rule,

the general mandate given to the Company to enter into

recurrent transactions with related parties for the Company's

day-to-day operations, including amongst others the procurement of goods and services, on normal commercial

DE MONTHERE
Before posting the above card, please tear off this portion and retain it.
Serial Number:
Signature of Proxy:

form must be received by the Registrars, Meristem Registrars

and Probate Services Limited, 213, Herbert Macaulay Way,

Ebute-Meta, Lagos or by the Company Secretary at 268,

Ikorodu Road, Obanikoro, Lagos not later than 48 hours before

the commencement of the meeting.

The Registrars, Meristem Registrars Limited, 213, Herbert Macaulay Way, Adekunle, Yaba, Lagos.



MANDATE FOR E-DIVIDEND PAYMENT

It is our pleasure to inform you that you can henceforth, collect your dividend through DIRECT CREDIT into your Bank Account. Consequently, we hereby request you to provide the following information to enable us to direct payment of your dividend (when declared) into your bank account.

Item																								
(1)	FIDSON SHARES								Da	ite (D	D/M	M/Y	VVV)										
				ı													[
													Chara	الما ما			Num	bon (i	£ Irmo:)				
													Share	HOIGE	Acc	Ount	Nulli		KIIO	WII)				
(2)	Surname/	Comp	onri'a	Nom	2																			
(2)	Surname/	T	any s	Nam	е Г																	$\overline{}$	$\overline{}$	
(2.1)	Other Na	me (fo	r Indi	vidua	l Share	ehol	der)																	
(2.2)	Present P	oster A	Addres	ss																				
					П																			
(2.3)	City						!									<u> </u>								
(2.3)		Т		Г	П		Г]									Г			Г		П		
				<u> </u>				J									<u> </u>					<u> </u>	<u> </u>	
(2.4)	Email Ad	dress																						
(2.5)	Mobile (0	GSM) I	Phone	Nun	nber																			
]													
(3)	Bank Nar	ne.									,													
(3)		T			П																			
				<u> </u>	ш						_													
(3.1)	Branch A	ddress										1				Ι	_	ı			1	т —	_	1
																							$ldsymbol{ldsymbol{ldsymbol{ldsymbol{L}}}$	
(3.2)	Bank Acc	ount N	Numbe	er																				
(3.3)	Bank Sor	t Code	;							•	•													
, ,]													
				<u> </u>					<u> </u>		J													
	Please f													ends	to v	hich	ı I/W	e be	com	e en	title	d for	the	item
	detailed	in 1 a	bove	to th	ne brai	nch	of th	e baı	ık de	etaile	ed in	item	3.1.											
							٦ [] [
(4)																		Cool/Inc	····· o moti o	a Numb	on (Com	orate Sha	onah alda	m)
	Share	holder's	Signatu	ire or T	humprint	t	Shareholder's Signature or Thumprint									Ompany	Seal/Ille	прогаси	ni Nullio	Jer (Corp	I I	lienoidei		
						_									_									
							ALITHODISED SIGNATURE AND STAMB OF BANIZERS																	
	AUTHORISED SI									GNATURE AND STAMP OF BANKERS														

The branch stamp and signature of the authorized signatory of your bank is required to confirm that the signature(s) in box 4 is that of shareholder(s) or an authorized signatory, before returning to the registrars.

The Registrars, Meristem Registrars Limited, 213, Herbert Macaulay Way, Adekunle, Yaba, Lagos.

UNCLAIMED DIVIDEND LISTS

"VI" ACCOUNT AXHOLME NOMINEES AAGABO TERHEMEN JUSTINE AARE TAOFEEK AARON BABATUNDE ANTHONY AARON-OBI ALOYSIUS CHIJIOKE AASA KOLA ABACHA FATIMA GAMBO ABANIWONDA OLUFEMI S. ABAYJONG LINKS NIG LTD ABAYOMI ADESEGUN ABBA FALMATA KAZA ABDUL AKEEM OLASUKANMI ABDUL GARBA ABDUL HAMEED KHALILAT OLUWAKEMI ABDUL KWANGILA USMAN ABDUL LATEEF ADESILE ABDULAMID ABDULWASIU ABDULAZIZ ABDULAHI ABDULAZ**I**Z MURTALA ABDULAZIZ SAFINA GAFASA ABDUL-GANIYU MUIDEEN ATILOLA ABDULKADIR BELLO AHMED ABDULKADIB SHEHU E ABDULLAHI ABDUR RAHMAN ABDULLAHI AKANJI AHMED TIJANI ABDULLAHI ALIYU BARDE ABDULLAHI AUWALU ABDULLAHI MUHAMMAD ABDULLAHI MUHIBBA ABDULLAHI MUSA HALIMA ABDULLAHI SAFINATU ABDULLAHI SAUDAT NURADDEEN A ABDULLAHI TAMBARI KABIRU A.T. ABDULLAHI ZAINAB ABDULQUADRI SANNI IDOWU ABDULRAHMAN ABDULWASIU ALARAPE ABDULRAHMAN HUSSENI ABDULRAHMAN LUKMAN TAIYE ABDULRAHMAN MUHAMMAD JIDDA ABDULRASHEED BASHIR ABDULRAZAQ ABDULMJEED ADIGUN ABDULSALAAM ABDULFATTAH ABDULSALAM ADETOKUNBOH ABDULWAHAB MUBAARAQ OLOLADE ABDUL-WASIU RIDWANALAHI ABE ADUNOLA WURAOLA ABE MIKE ABU ABE OLUWASEYI EMMANUEL ABE OMOLAYO JEREMIAH ABIA JOY OKON ABIAKUM MACBETH A ABIARA OJO ABIARA SEGUN JAMES ABIDOYE MAJEED TUNJI ABIDOYE OLUFEMI EBENEZER ABIDOYE TAOFIK OWOLABI ABIDOYE YEMI MUI KAH ABIJO BALIQEES ADESOLA ABIMBOLA ADARAMOLA ABIMBOLA OLAKUNLE KASIM ABIMBOLA SAMSON OLUSEGUN ABIODUN JOHN ABIODUN KAMILDEEN GBOLAHAN ABIODUN KAYODE TUNDE ABIOLA OLADIPO FOLORUNSO ABIOLA OLAYINKA STEPHEN ABIOLA OLUMAYOWA ABEL ABIOLA TAJUDEEN OYETUNJI ABIONA ABIODUN ABIRU ADETOKUNBO ABIRU HABEEB ADEWALE (HON. JUSTICE) ABIRU HABEEB ADEWALE OLUMUYIWA ABOBARIN ABIGEAL OMOWUMI ABOBARIN ADERONKE RISKAT ABOBARIN KAYODE KEHINDE ABOBARIN PAUL OLUWASEGUN ABOBARIN SAMSON BABATUNDE ABODE LUCKY OZEMOYA ABODERIN NATHANIEL OLATUNJI ABODERIN OLAJUMOKE ABODUNRIN BOSEDE MARY ABOH JOHN ABOH OCHE

ABOH ONAZI

ABOLANI OYINKANSOLA

ABOLARINWA KAYODE ABOLARINWA OLUKAYODE ISAAC ABOLO CHUX UKADIKE ABOLOMA CHUKWUNWEIKE JUDE ABOLUWOYE AKINWANDE EBENEZER ABORISADE SILAS OLADELE ABRAHAM KEHINDE P ABRAHAM SUSAN SIMISOLUWA ABRAHAM TAIWO P ABRAHAM-ALOWONLE JOSHUA OLURUNTOSIN ABU EMMANUEL ELEOJO ABU PRAISE STEPEHN ABUBAKAR AISHA ALHAJI ABUBAKAR GARBA BAIDU ABUBAKAR HINDATU ABUBAKAR INGAWA BELLO ABUBAKAR MOHAMMED ABUBAKAR MUHAMMAD SAMINU ABUBAKAR NASIRU RAHINA ABUBAKAR RACHEL ABUBAKAR SADIO MARYAM ABUBAKAR SALIU ABU-MOMOH JOY FATIMA ACHARA MAGDALEN NWANUA ACHAREKE BENSON C. ACHEBE CHRISTOPHER OKEY ADABAWA INVESTMENT LIMITED ADACHIE TOCHUKWU ADAGUN TITILOPE OLAWUNMI ADAGUNODO ANDREW AKANMU ADAJA FELIX OLADUNJOYE ADAKI ELIZABETH .N. ADAMOLEKUN OLUSESAN BOLARINWA ADAMOLEKUN OLUSESAN BOLARINWA ADAMS-IDAKWO SAMUEL OJONUGWA ADAMU ABDULLAHI MAIKASUWA ADAMU ABUBAKAR YOBE ADAMU AHMED ADAMU DIMIE ADAMU MARYAM YOBE ADAMU MOHAMMED BASHIR YOBE ADAMU MOHAMMED KABIR YOBE ADAMU MOHAMMED NURA ADAMU RABI TALATU ADAMU SAHAR AHMAD ADAMU SAIDU SHABBAL ADEAGBO ADESOPE ADEYEMI ADEAGBO AYOTUNDE ADEAGBO FOLUSO OMOTADE ADEAGBO IDOWU ADELOWO ADEAGBO OLUWADEMILADE ADESIMISOLA ADEAGBO RUFUS ADEWALE AKANNI ADEBAKIN KEHINDE HASSAN ADEBANBO TUNDE ADEBANJO ADEYINKA AHMED ADEBAYO A. ABIGAIL ADEBAYO ABIMBOLA HENRY ADEBAYO ABOSEDE JOSEPHINE ADEBAYO ADEMOLA OLUWASEYE ADERAYO ADERONKE OLUBUNMI ADEBAYO ADEWALE ADEKUNLE ADEBAYO ADEYEMI-ELIZABETH ADEBAYO ADEYEMO ADEBAYO ARIYIBI ADEBAYO BISOLA ADEBAYO BUNMI ADUNOLA ADEBAYO JOSHUA AJEWOLE ADEBAYO LATEEFAT OLAIDE ADEBAYO OLABODE TUNDE ADEBAYO OLADIMEJI TAHIR ADEBAYO OLUFEMI ADEDAMOLA ADEBAYO OLUFUNMILAYO MODOKPE ADEBAYO OLUSESAN STEPHEN ADEBAYO OLUWAFEMI ABAYOMI ADEBAYO OYETOLA ADEBAYO RICHARD ADEMOLA ADEBAYO TOMIWA OLUWANIYI ADEBAYO VICTOR ADEDAMOLA ADEBERO JULIUS OYEWOLE ADEBESO MUINAT OLUWATOYIN ADEBISI ADENIYI ARAUNSI ADEBISI RUFUS ADEMOLA ADEBIYI ADEBOWALE JEREMIAH

ADEBIYI ADETUNJI EMMANUEL

ADEBIYI ALADE ADEGBOYEGA

ADEBIYI PATIENCE ADEOLA OLUKEMI(CHIEF) ADEBIYI SAMUEL ADEYEMI ADEBIYI TAJUDEEN ADEBIYI ADEBO MARK IRIVEMI ADEBOGUN MUDASHIRU ADETOLA ADEBOLA ADENIYI ADEBOLA FUN CENTRE ADEBOLA OMOLE ADEBOMI FOLUKE IBIDUN ADEBOWALE ADEOLA DAVID ADEBOWALE ADEWALE ADEBOWALE ADEYANJU ADEBOWALE ISLAMIAH IDOWU ADEBOWALE MUTIU OWOLABI ADEBOWALE OLUWADARE OLUSEGUN ADEBOWALE OWOLABI M ADEBUSOYE FUNMILOLA ABIMBOLA ADEBUSOYE ROTIMI ADEDAPO OLUSEGUN MICHAEL ADEDEJI ADEFOWOPE GBENGA ADEDEJI BABATUNDE ADEDEJI BUSURA ADEDEJI FELICIA OMOTOLA ADEDEJI NOSIRU ADIGUN ADEDEJI OLAIDE ADEDEJI TIAMIYU ADEDEJI WALE ADELEKE ADEDIGBA OLABISI ADEDINSEWO ADEFEMI FEYISAYO ADEDIRAN OLAKULEYIN MIRACLE ADEDIRAN OLAMBO FAITH ADEDIRAN PHILIPS AYOBAMI ADEDO AKANBI ADEDOKUN ABDULSALAM ADEDOKUN ADEBAYO ADEKUNLE ADEDOKUN ADEBAYO ADEKUNLE (2) ADEDOKUN FIRDAUS ADEOLA ADEDOKUN OLUREMI ATILADE ADEDOYIN ANIKE ADEDOYIN NURENI ADEYINKA ADEDOYIN SOLAJA ADEDUNMOLA ADEWOLE DANIEL ADEEKO ADEBAJO SAMSON ADEEKO TAIWO ADESANMI ADEFARAKAN JANET OLUFUNMILAYO ADEFEHINTI OLUWAFEMI ABIODUN ADEFIDIPE EMMANUEL ITUNU ADEFUYE ADEOLA PIUS ADEGBAYI MONSURAT BOLAJI ADEGBESAN ADEGBOYEGA ADEKUNLE ADEGBEYE OLUSEGUN ORITSEMA ADEGBINDIN AISHA ABIKE ADEGBITE ADEYINKA JOHN ADEGBITE AMINAT OMOLABAKE ADEGBITE OLA EMMANUEL ADEGBITE ZULAIKHA OMOWUNMI ADEGBOYE ABIMBOLA OPEYEMI ADEGBOYE EMMANUEL AYODEJI ADEGROYEGA MOSES ADEMOLA ADEGRUSI ADEMOLA ADEGBUSI ANTHONY ADEGBUYI YINKA ADEGOKE ADEBISI ADEGOKE ADELANI JOHN ADEGOKE ADERONKE N ADEGOKE FOLARANMI ADETUNJI ADEGOKE OLUWAGBEMIGA ADEGOKE OLUWATOYIN REMILEKUN ADEGOKE SAMUEL OMOLOLU ADEGOROYE MONISADE OLUKEMI ADEGOROYE OLUKEMI MONISADE ADEGUN FUNMILOLA AYODELE ADEGUNWA ABDULRAHMAN OMOLOLA ADEGUNWA KAREEMA ADEGUNWA MONSURAH ADEGWE OSAS PATIENCE ADEIGBO ADEBISI ADEISA AFOLABI ABIMBOLA ADEJARE QUADRI ADEKUNLE ADEJOBI LYDIA ADEYANJU ADEJORIN ADEYINKA OJUOLAPE ADEJUMO ADEKANMI ADEJUMO LASISI AKANMU ADEJUMO MUINAT OLUWATOYIN ADEJUMO RUFUS OLU

ADEJUNMOBI ADENIKE ASABI ADEKANBI SEMOLA CHRISTIANIAH ADEKANYE ADEYINKA OLAJIDE ADEKANYE MUDASHIR ADENRELE ADEKITAN SUNDAY OLUFEMI ADEKOLA ABEL ADELEKE ADEKOLA AHMAD ADEKUNLE ADEKOLA AMODE SIJUADE ADEKOYA AYO ABIODUN ADEKOYA BOSUN ADEKOYA MICHAEL OLAYINKA ADEKOYA SULAIMON ADEDOYIN ADEKOYA-COLE TEMITOPE THOMAS ADEKUNLE ADESINA TAIWO ADEKUNLE ALAMU SODIQ ADEKUNLE OLADIMEJI OJO ADEKUNLE OLUBAYO ADEKUNLE SAHEED OMOTAYO ADELABU SUWEBAT A. ADELAJA TAIWO SHAKIRAT ADELAKUN BABATUNDE ADELAKUN MICHAEL ADEGOKE ADELAKUN OLAWUNMI ADELAKUN YINKA OLUTOMI ADELEKE ADEKUNLE IZUDEEN ADELEKE ADEMOLA OLUFEMI ADELEKE ADEPEJU ADELEKE BALIKISU ARINLADE ADELEKE GIDEON ABIOLA ADELEKE ISAAC A. ADELEKE NIKE ADELEKE OLOLADE SHAKIRAT ADELEKE THOMAS ADEREMI ADELERE ADEROJU ADELEYE OLANLREWAJU SAMUEL ADELEYE OLUGBENGA BANKOLE ADELEYE SAFIAT ADELEYE TOSIN MICHAEL ADELODUN BLESSING ADELOPO ABDULRAMON ABIODUN ADELOYE ADEBAYO ADELUGBA ADEREMI DAVID ADELUMOLA OYINDA ADEMEHIN YETUNDE OMOLARA ADEMILOYE SAMSON ADEOLA ADEMOLA KAFILA ABIODUN ADEMOSU AYODEJI ADEBAYO ADEMOSU SOLOMON TANIMOWO ADEMOYEGUN RUFUS OLANREWAJU ADEMULEYA STEPHEN ADEYEMI ADEMUYIWA OLUEGUN ADENAIYA BABALOFUNWA BABASEYITIMOFE ADENAIYA OLUMIDE OPEOLUWA ADENIJI ABBAS AYOADE ADENIJI ADEGBOLA OYEDOTUN ADENIJI HAMED BAMIDELE ADENIJI JESSE ADEBAYO ADENIJI MOJOYINOLUWA JONATHAN ADENIJI NINIOLUWA ADENIJI OLAWORE ADENIJI SEMILORE JOAN ADENIJI SIJU ADENIKA MOYINOLUWA PRECIOUS ADENIPEKUN TIMILEHIN ADEBUSOLA ADENIYI ADEFUNKE ADEIYUN ADENIYI BISOLA AMINA ADENIYI NAJIMUDEEN ADENIYI OLUWADARE SAMUEL ADENIYI SUNDAY ABRAHAM ADENLE AZEEZ TAIWO ADENMOSUN ADEWUYI ADESOLA ADENRELE SHERIFAT ADEBOLA ADENUBI ROTIMI ADENUGA ADEBOWALE ADESEGUN ADENUGA REMI MICHAEL ADEOYE ADENUGA WASIU ADENUGBA SAMSON ABIMBOLA ADEOGUN EMMANUEL OLATAYO ADEOLA ADEDIRAN ADEOLA ELIZABETH ADEOLA LATEEF ADEOLA OLAWUMI MARY ADEOLA VICTORIA BOLATITO ADEOSIN OLUWATOSIN SHOLA

ADEOSUN ADEBOWALE OLAİTAN

ADEOSUN OLAJUMOKE SOLABOMI

ADEOSUN OLUWATOBA SAMUEL ADEOSUN OLUWATOFUNMI ADEOSUN OLUWATOSIN ADEOSUN TEMITOPE ADEOSUN TEMITOPE TEMILOLA ADEOTI ADEMOLA ADEOYE ELIJAH AJIBOYE ADEOYE ESTHER OMOWUMI ADEOYE SOLOMON ABIOLA ADEOYE SOLOMON OLUSEGUN ADEOYE TITILOLA IDOWU ADEPEKO ABAYOMI ADEPITAN ANIKE YEMISI ADEPOJU GEORGE ADEWUSI ADEPOJU MOJISOLA AJOKE ADEPOJU SAMUEL OLUSEGUN VICTORIA ADEPOJU SULAIMON BOLAJI ADEPOJU TAOFIK OMOSALEWA A. ADEREMI ADETOKUNBO OLUKAYODE ADEREMI RUKAYAT ADENIKE ADERIBIGBE ADEGOKE ADERIBIGBE CHRISTIANAH OUWASHOLAPE ADERIBIGBE OLUSEGUN ADERIBIGBE SEGUN ABIDEMI ADERIBIGBE WALE TAYO ADEROHUNMU ADEOLA RAFIU ADEROUNMU SULEIMAN ADESANMI ADEEKO KEHINDE ADESANMI SAMUEL ADEKUNLE ADESANYA ADEBAYO MAYOWA ADESANYA DANIEL TAIWO ADESANYA DAVID KEHINDE ADESANYA INIOLUWA ELIZABETH ADESANYA MOIBI FOLARIN ADESANYA OLAJUMOKE ELIZABETH ADESANYA OLUKAYODE PATRICK ADESANYA OLUSEGUN ROTIMI ADESANYA OWOLABI ADEDAPO ADESANYA RACHAEL ADESANYA SAMSON ABIODUN ADESANYA SUNDAY ADETOLA ADESEGHA HENRY OLABODE ADESEYE ABIGAIL BIMPE ADESHINA TAJUDEEN ADEGOKE ADESHINA THERESA OLUSHOLA ADESINA ADESEGUN ADESINA ELIZABETH MOJISOLA ADESINA JOHNSON GBADEBO ADESINA MOSES OREOLUWA ADESINA OLUSEGUN OLANREWAJU ADESINA OLUWADARE BABATUNDE ADESINA RASHIDAT OLUWATOYIN ADESINA TOLUWASE OLAOLU ADESIYAN AMOS OLUFEMI ADESOGA MOJISAYO OLUSOLABOMI O.

ADESOGAN SAMUEL ADEDAYO ADESOLA ALICE OMOBOADE ADESOLA KUNLE FELIX ADESOLA SELIMOT NIYIOLA ADESOLA VICTORIA OLUWATOYIN ADESUGBA LANA GABBY ADESUYI OLUMUYIWA MICHAEL ADETAYO ADETUTU ADETAYO AKIM AKANBI ADETAYO CHRIS ADETAYO JOSEPH AJIBADE ADETAYO OLUWASEYI ADETAYO REBECCA ANUOLUWAPO ADETAYO VICTOR SEMAKO ADETAYO YEMISI ADETOLA MORIYIKE A. ADETOLU ADEBOLA OLUWAGBOTEMI ADETOLU OLUFUNKE ADETONA OLUKAYODE ADEMOLA ADETORO ABDUL GANIYU YUSUF ADETORO OMOTAYO ADETORO OYEYEMI ADEDIRAN ADETUNJI ADEGBOYEGA .A. ADETUNJI JAMES SEGUN ADETUNJI REBECCA OLUFUNKE ADEUSI ILUYOMADE STEPHEN ADEUYI SMART GBENGA ADEWALE ABIODUN OKERONBI ADEWALE ADEBISI ADEWALE ADELEYE OLUSHOLA ADEWALE ADEREMI

ADEWALE FARUQ AKOREDE

ADEWALE OLUDAISI ADEWALE OLUSOGA STELLA TAIWO ADEWALE SAMSUDEEN ADEKUNLE ADEWALE YUSUF BABATUNDE ADEWOLE ADESUA OMOLEGHO ADEWOLE ISAAKI TRENCHARD ADEWOLE OLUBUSOLA ADEWUMI ADESINA DEMILADE ADEWUMI DAVID ADEBOWALE ADEWUMI FESTUS AYOOLA ADEWUMI KOLA JAMES ADEWUMI TAOFIK ABDUL ADEWUSI ADEOLA OLADELE ADEWUYI CLEMENT ADEDAYO ADEWUYI ESTHER OLUWATOYIN ADEWUYI PHILLIPS ADEMOLA ADEYANJU ADEWALE ADEYEKUN KAYODE VICTOR ADEYEMI ABAYOMI ADEYEMI ADEFUNKE ABIOLA ADEYEMI ADEKUNLE AYOMIDE ADEYEMI ADEYEMO ADEYEMI AFEEZ OLALEKAN ADEYEMI AKEEM ADEBIYI ADEYEMI AKINLENBOLA ADESINA ADEYEMI BABAYEMI OLUWATOYIN ADEYEMI COMFORT TEMITOPE ADEYEMI FUNSHO ADEDIRAN ADEYEMI GANIAT OMOWUNMI ADEYEMI KAYODE BAMIDELE ADEYEMI MAYOWA ISRAEL ADEYEMI MOFOLUWASO ADEYEMI OLORUNTOBA ADEYEMI OLUKAYODE AKANBI ADEYEMI OMOLARA OLUWAKEMI ADEYEMI OPEYEMI AYUB ADEYEMI STANLEY ADEYEMO ADEKUNLE ADEYEMO OLAWALE MOSES ADEYEMO SOLARIN ADEYEYE FRIDAY ABRAHAM ADEYEYE SUNDAY ADEYIGA SAMSON OLUSEGUN ADEYINKA AMOS ADEDIWURA ADEYINKA MOYOSOREOLUWA OLUWAFIKUNMI ADEYINKA OLUSOLA OLUTOYIN ADEYINKA OLUWASEUN OLUWADARA ADEYINKA OLUWATOBI OREOLUWA ADEYINKA PAUL ADEWUMI ADEYINKA-OJO NAKRIS CHRISTABEL ADH NOMINEES ABIMBOLA AJOMALE ADH NOMINEES ADEWALE & ESTHER (MR. & MRS.) ADH NOMINEES OLIYIDE SHERIFAT **FEHINTOLA** ADIEFE OLISEMEKA JUDE ADIELE NDUBUISI JUDE ADIGUN ELIZABETH OLUDAYO ADIGUN JOSEPH OLUGBENGA ADIGUN LUKMAN ABIOLA ADIGUN MURPHY AKANNI ADIGUN TEJUMOLA ADIGUN TEMITAYO AJIBOLA ADIGWE ANTHONY IFEANYI ADIGWE EMMANUEL IKECHUKWU ADIMOHA OLIVER UZOZIE ADIMORA NNANYELU L ADIO ABDULHAKEEM ADIO GORIOLA KEHINDE ADIO GORIOLA MOHAMMED ADIO ISRAEL KEHINDE ADIO OLAYIWOLA GBEMISOLA ADIO TAOFEEK OLALEKAN ADISA GANIYU DAMILARE ADISA WALE JOHNSON ADMOS MULTI BUSINESS LIMITED ADODO BABATUNDE OHIS ADONAI STOCKBROKERS LIMITED ADU AYODELE ADU OLUGBENGA JOSEPH ADU OLUWASEYE TEMITAYO

ADUAKA PASCHAL NDUBUISI

ADUBI OMOLOLA GRACE

ADUNMO KEHINDE MOSES

AFERE MERCY OLUSOLA

ADUROJA ABIMBOLA & BOSEDE

ADUKU ADAJI SALIHU

ADUKU SALIHU ADAJI

AFEKHUME DANIEL

AFIKODE ADEKUNLE AFOLABI ABIODUN TUNDE AFOLABI AMOS ADEJUNMO AFOLABI BUSUYI LAWRENCE AFOLABI GBENGA AFOLABI MICHEAL OLUSHOLA AFOLABI OLOLADE ESTHER AFOLABI OLUFUNMILAYO AFOLABI OLUMUYIWA AFOLABI AFOLABI OLUWASEUN ESTHER AFOLABI OMOTAYO OLUWAROTIMI AFOLABI RAPHAEL ADELEKE AFOLABI SUNDAY AFOLAOGUN ROTIMI AFOLAYAN ABEY DANIEL AFOLAYAN KAYODE MOSES AFOLAYAN MICHAEL AFOLAYAN SAMUEL OLAJĪDE AFONJA AYOOLA TAIWO AFONJA TAIWO AYOOLA AFUGA ARIONINI (MRS) AFUWAI MUSA AYOCK AGADA DANS SUNDAY AGADA IJEOMA DORATHY AGADA SAMSON OJIMA AGAGU OYINDAMOLA OLUBANKE AGANGA OLUYEMISI AGANS-OLIHA OHIMA AGAPE AGULONYE AGARO OGHENENYERHOVWO AGAZIE ONYEKACHI CYNTHIA AGBA IFEOMA ELIZABETH AGBADI ABDUL AGBAGA DENNIS EJAKPOVWERE & **OMOKUNLE** AGBAGA ODAFE OGHENEDIAKEVWE AGBAIM EMMANUEL AJULUCHUKWU AGBAJE BECKY OLUWAYEMIS AGBAJE MOJISOLA ADEBOLA AGBAJE OBAFEMI ORIYOMI AGBAKA NGOZI AUGUSTINA AGBANA GBENGA AGBANIGO YETUNDE MARY AGBAOSI TOLULOPE OLUWAFEMI AGBARA COMFORT EZINNA AGBARUDE PHILIP OGE AGBAVWE CHARLES EDEKI AGBE OLUSANYA IMAFIDON AGBEDE GABRIEL KEHINDE AGBEDE OLAITAN ALFRED AGBEFEYITIMI MICHAEL OLUMUYIWA AGBEYANGI IRANLOWO JUBILEE AGBIBOA BENEDICTA AGBO CHRISTOPHER ENENCHE AGBOLA OYENİYI JOSHUA AGBONBA EBOSE PEACE AGBOOLA EXCELLENCE ADEKUNLE AGBOOLA FEMI AJANI AGBOOLA HENRY AGBOOLA OMOTAYO OLUGBENGA AGBOOLA WASIU KOLAWOLE AGBOYINU DANIEL AGELESS RESOURCES AGEMO RAZAK TITILOYE AGENMONMEN AGATHA AGENMONMEN CHERLY AGHARESE COLLINS OMOSIGHO AGHUNO GABRIEL O. AGIAKE JOHN AGIAKE AGIOPU PAUL AGBEUNIMSHUYE AGOMO CHIOMA KANU AGORSON OTUCHICHORO CHINEDU AGU BUCKLY EMENİKE AGU GODWIN OKECHUKWU AGU HELEN IJEOMA AGU IFEYINWA EUNICE AGU MAXWELL NNABIKE AGUBOSIM AMOBI BETHRAND AGUDAH JOHN AGUNBIADE FESTUS ADELOYE AGUNBIADE RASHEED OLATUNJI AGUNBIADE SAMUEL OLUROTIMI AGUOCHA MARTIN CHUKWUKAODINAKA AGUPUSI ANTHONY UCHENNA AGWU AMECHI OGBONNAYA AGWU EKWE AGWU AGWUENU FELIX AGWUNCHA AMAECHI ANTHONY AGWUNOBI SAMUEL AHAMEFULE NICHOLAS UGOCHUKWU

AHANEKU EMMANUEL UGOCHUKWU AHMAD ADAM AHMAD SANI TUKUR AHMED IBRAHIM BABA AHMED ODION ALIAT SOUGHIE AHMED RUKAYYA MOHD AHMED SALMA ADAMU AHMED ZUBAIR AHTSEMA VENTURES LTD AHUCHAOGU BENJAMIN CHIJIOKE AIBOGHOMHEN JOSEPH ISEMHENBITA AIBU IBRAHIM AIDEYAN OSATO ANSELM AIGBODION AIGBOKHAN EMONYON AIGBOGUN KATHERINE WAGHANUWA AIGBOTSUA AUGUSTINE AMHAGBO AIGORO MODUPE ADUKE AIGORO TAJUDEED KEHINDE AIICO EQUITY TRADING A/C AIKAHUNUELE OTIBHOR AIKHOMU ANITA OTIBHOR AIKHOMU WILLIAMS EHIZOGIE AIKHOMU WILSON OMOGBALE AILERU SALIMOTU AMOPE AINA ADEDEJI OLANREWAJU AINA OLADIPO ABIOSE AIPOH LAWRENTTA OTHE AISUEBEOGUN JORDAN (SNR) AIYEDOGBON OLADIPO OLAOLU AIYEETAN ABDULGANIYU OLUMIDE AIYEGBUSI AYOMIDE AMANDA AIYEGBUSI ENIOLA DEBORAH AIYEGBUSI OLUSEGUN AIYEKU JOHN EBUNOLA AIYESA OLUBUSAYO OLUFUNMILOLA AIYESA OLUMIDE ARIYO AJA AUGUSTINA AJADI FATAI DAVID ISREAL AJADI SULAIMON AYODELE AJAGBE FATAI AJAGUNNA OLUBUNMI AYODEJI AJAKA ANUOLUWAPO GEORGE AJALA ADELOLA AJALA ESTHER NIHINLOLA AJALA FATAI OLATUNJI AJALA ISAAC OYEKANMI AJALA KUDIRAT ABEBI OLABISI AJALA OLUGBENGA ABIODUN AJALA OPEYEMI AYOWUMI AJALA SILIFAT TOYIN AJALA TIMOTHY AYANBAMIJI AJAMAJEBI RICHARD OLADIMEJI AJANI ADEKUNLE YUSUF AJANI BILIKISU MORENIKE AJANI TAIWO SAIDAT AJAO ADEFUNSHO ADEYI AJAO MOSUDI AYINDE AJAPE BABATUNDE AJAPURUMBA JOEL IFEANYICHUKWU AJAYI ADEDIRAN GABRIEL AJAYI BARNICE OMOLOLA AJAYI BOLARINWA AJAYI EMMANUEL OLUMIDE AJAYI ESTHER AHUOIZA AJAYI FEYIKEMI AJAYI İBİRONKE ADETOLU AJAYI NICHOLAS OPEOLUWA AJAYI OLAKUNLE O. AJAYI OLAROTIMI ADEREMI AJAYI OLUFEMI IDOWU AJAYI OLUKUNLE OLANIYI AJAYI OLUWAFEMI MOSES AJAYI OLUWOLE WILSON AJAYI RAMOTA TOWOBOLA AJAYI SAMUEL ADEMOLA AJENIFUJA OLAJIDE ABDULRASHEED AJENIFUJA OLAKUN YUSUF AJETUNMOBI RASHIDAT .F AJI ISUWA SUI FIMAN AJIBADE AUGUSTINE SUNDAY AJIBADE AZIZAT ADEBOLA AJIBADE BABATUNDE AYODEJI AJIBADE NOIMOTU OMOTOLA AJIBADE OLOLADE ADEDAYO AJIBIKE ADEGUNWA AJIBIKE DANIEL FEMI AJIBOLA &ALABA JOLAOSHO, REV.& PROF (MRS

AJIBOLA FUNKE

AJIBOLA MUSIBAU OLAOSEBIKAN

AJIBOLA RASHIDI OLADEJO AJIBOLA SEGUN AJIBOYE AYOBAMMY DAMILOLA AJIBOYE EMMANUEL TEMITOPE AJIBOYE MICHAEL ADEBAYO AJIBOYE OLUWASEYI EMMANUEL AJIGA OLAJIDE FREDERICK AJIKOBI ABDUL ALIYU AJIKOBI ANTHONY AJILA SALISU OLAYEMI AJISEFINNI TAJUDEEN AJOKU OBINNA CHIBUNDU AJONYE JOHN OYINU AJUGWO PRINCE NHYGINUS AJULO OJEAWE OLUWAFEMI AJULO OLUWASEGUN AJUTA MICRO FINANCE BANK AJUWAPE ADEBOWALE TITILAYO P. (DR.) AKADIRI HARUNA SHENI AKALI GODWIN MONDAY AKAMADU OKENWA AKAMADU PRINCE OKENWA AKANBI ADENIRAN AKANBI RAFIU ADISA AKANDE ADETUNJI AKANDE CELILIA NUNAWON AKANDE ENIOLA AKANDE FIYINFOLUWA OLUWATOMINI AKANDE ITEOLUWAKINSHI OLUWASEUN AKANDE JOEL OLUSOLA AKANDE OLUWANIFEMI OLUBUKOLA AKANDE PRISCA MONISOLA AKANDE SEWEDO JULIET AKANDE SOLOMON SUNDAY AKANDE TITILAYO BAMIKALE AKANEGBU EUGENE NWAKANZE AKANJI ABDULSALAM AKOREDE AKANJI JOSEPH FEMI AKANMU ADE ENTERPRISES AKANMU ISAAC OLUBAYO AKANMU OLABISI AKANNI AUSTIN AKANNI AYODELE ELIZABETH AKANNI OLADEHINDE I. AKEJU JIDE CHARLES AKEREDOLU ISHOLA AKEWUSHOLA AISHAT OYIDAMOLA O AKHIGBEMIDU STEVENS ILUOBE AKHILE OSEZUA STANLEY AKI AKERAINO INNOCENT UZEZI AKIN MARINHO AKIN-AKINBULUMO ABIMBOLA & FOLASADE AKIN-AKINTUNDE AKINWUNMI ADEBOWALE AKINBAMI GBOLAHAN OLUWOLE AKINBISOSE FRANCIS AKINBIYI FESTUS OLADIMEJI AKINBO ELIZABETH OLATAYO AKINBO OLAYIWOLA ADIO AKINBOBOLA GBENGA AKINBOBOYE OLUSHOLA ABIMBOLA AKINBODEWA OLUWATOYIN OLABISI AKINBOLA AKINLOLU ADERINOLA AKINBOLA GABRIAL EMIOLA & BUKOLA RUTH AKINBOYO FOLUKE TUMININU AKINBOYO FUNMILOLA AKINBOYO IBUKUNOLUWA CHRISTINE AKINBOYO IFEOLUWADOTUN PETER AKINDE ELIZABETH OLUWATOSIN AKINDELE ADETOKUNBO AKINDOYOGBE ISAIAH OLUWAGBEMIGA AKINFENWA FUNMI OMORINOLA AKINFENWA OLUBUNMI TOLULOPE AKINGBADE AKINDELE ADELEYE AKINGBADE G. ADENIKE AKINGBESOTE TAIYE SETO AKINIYI SUNDAY SHOLA AKINLABI AKINPELU AKINLADE MOJISOLA BISOLA AKINLADE MORAKINYO ADEKANMI AKINLADE RASHEED OLASENI AKINLOLU AKINDURO AKINLOYE WAHEED OLUWADAMILARE AKINLUYI KIKELOMO CHRISTY AKINLUYI TOYOLE AKINMADE RONKE OMOTOLA AKINMOLA BANKOLE AKINNIBOSUN IBIKUNLE OLUDAMILOLA

AKINOLA AKINLABI AKINOLA CLEMENT ADEBANJI AKINOLA SIMEON AYODEJI AKINOLA TITI OLUBUKOLA AKINRINADE AKINJIDE AKINRULIE SAMSON OLADOTUN AKINSANYA AKINWUNMI FEMI AKINSANYA FOLASHADE OMOLAYO AKINSANYA OLUWASEYI AKINSANYA TAIWO OMOBOLA AKINSOJI OLATUNBOSUN SEUN AKINSOLA OLUWATOSIN SARAH AKINSOWON CHRISTIANA TOLULOPE AKINTEBI KIKELOMO OKETOLA AKINTILO ADEGBOYEGA LATEEF AKINTOKUN AYODEJI & OMOLOLA AKINTOLA AKINSOJI AKINTUNDE AKINTOLA DARE AKINTOMIDE AFOLARIN ABIODUN AKINTOYE VICTORIA OMOLEWA AKINTUNDE BOLANLE ONIKEPO AKINTUNDE FORTUNE OLUWADARASIMI AKINTUNDE ISMAIL TITILOPE AKINTUNDE MOHAMMED SABITU AKINTUNDE SEUN AKINWALE ADEMOLA AKINWALE ADEMOLA AKINLOLU AKINWALE ALABI AKINWALE LAWRENCE OLUSEGUN AKINWALE TAIWO OLUTOYIN AKINWANDE ABAYOMI AKINWANDE BAWO AKINWUMI EMMANNUEL IBITUASE AKINWUMI FESTUS BAMIDELE AKINWUMI MARY ADEYINKA AKINWUNMI BOLANLE TAIBAT AKINYEMI AKANNI & FOLASHADE AKINYEMI HASSAN TAIWO AKINYEMI JOSUA OJO OLUWAFEMI AKINYEMI JUSTINA ADA AKINYEMI MUJEEB OLALEKAN AKINYEMI NIYI AKINYEMI OLANREWAJU AKINYEMI OMOBOLANLE OLANREWAJU AKINYEMI SAMUEL REMI AKINYERA OLUWASANMI AKINTOYINBO AKINYINKA AKINWALE AKITOYE ADESEGUN AKOBE BABATUNDE RAPHAEL AKOGWU PRISCILLA AMINATU AKOH FRIDAY NEHEMIAH AKOMOLAFE OMOBOLA (MRS) AKO-NAI KWASHIE AJIBADE AKOR OCHANYA ROSELINE AKOREDE MOROUNMUBO AKOREDE SEMIU ALANI AKPA MARTHA AKPAN ENOH EKONG AKPAN FELIX UDO AKPAN JULIET ENO AKPAN LINUS AKPAN AKPAN MICHAEL EFFIONG AKPAN RAYMOND A AKPAN SMART E AKPAN SMART EMMANUEL AKPAN UDUAK MARIAN AKPAN VERONICA ISIDORE AKPEDE OGHENETEGA OLUWATOYIN AKPENE GODWIN AKPI EBIZIMOH C AKPOM WILLIAN UCHENNA PAUL C. AKPOVWA ESOSURAKPOR AKPOYIBO MARIAN IGHO AKPOYIBO SIDIKAT AKUBUE IMMACULATA CHINWE AKUBUO ANTHONY UCHE AKUCHI PROPERTIES AND INVESTMENTS LTD AKUDO CHINWE TENIOLA AKUNYILI DOROTHY AKUNYILI PATRICK OKEKE AKUNYILI TOCHUKWU OBIAJULU AKURIENNE LOURETTA OBIAGELI AKWIWU- NWADIKE FLORA AKWIWU- NWADIKE OBIAKU AKWUOBI, CHINEDU ALABI ABIVAH MORAYOLUWA ALABI ADE-LAYO JOSEPH

ALABI DAMILARE

ALABI GBADEBO TUNDE

ALABI LANRE & FUNMI ALABI OLUFEMI ANTHONY ALABI OLUSHOLA ALABI OLUWOLE YEKEEN ALABI SAMUEL AYODELE ALADE FOLORUNSHO ALADE JOHNSON IDOWU ALADE SAHEED ALADE YEKEEN OLUWOLE ALADEJUYIGBE OLUFUNKE ADEBOLA ALADETIMI AYOOLUWA ELIZABETH ALADJA BLESSING ALAGOA BLESSING MIEBI ALAJULONYE EZEKIEL IFEANYICHUKWU ALAJULONYE IFEANYI EZEKIEL C ALAKA SHEDRACH OKO ALAKIRI ENOCH THOMPSON ALAMU EYITAYO ALAO AL-HARITH OBAGBANI OPEYEMI ALAO EZEKIEL OYENIYI ALAO SIKIRU ADETONA ALAO-AKINYEMI TAJUDEEN ENIOLA ALAPOTIOWO TAOFEEK ABIOLA ALARABA MUSA ALASA BAWA ALASAN IBRAHIM MUHAMMAD ALASONYE JOACHIN ALATISHE IDOWU NAFISAT ALAUSA WALEEM BABATUNDE ALAWODE FOLORUNSHO OLAYIWOLA ALAWODE JAMES SUNDAY ALAYAKI IDOWU MOSIDAT ALAYO ADEWALE MUKAILA ALAYO LATIFAT SOLAPE ALAYO MUINAT ADEDAYO ALBERT VICTORIA ALEBIOSU ABISOLA ALEBIOSU ADEPEJU ALEBIOSU BUSURA ALEBIOSU FUNMILAYO ALEBIOSU HAIRAT ALEBIOSU MONSURAH ALEBIOSU STEPHEN ADEBISI ALEGE TITILAYO FLORENCE ALENOGHENA RAYMOND ALERE OLUWAFEMI OLAKUNLE ALFADARAI NANA HAUWA HABIBU ALFRED PETTERSON LIMITED ALHASSAN AYANNIYI BAKO AL-HAYAT RELIEF FOUNDATION ALI ALIYU DANEJI ALI DEBORAH JOLAS ALI DOUGLAS ALI JOSEPH ANEJODO ALIBO MARTINA CHINATU ALIGWE EMEKA ALIMI AYOOLA JOHN ALIU ADIZETU BOSEDE ALIU MOMOH JIMOH ALIU SAMUEL MOSES ALIYU ABDULWAHHAB HARUNA ALIYU AUWALU ALIYU DAHIRU FAHD ALIYU FATIMA YOLA ALIYU IBRAHIM DAMINA ALIYU MOHAMMED MARYAM ALIYU MUHAMMAD LAWAL ALIYU MUHAMMAD SANUSI ALIYU OLAJTAN ALIYU SHUAIBU AISHATU ALIYU YUSUF BAGEL ALIYU YUSUF SALHU ALLEN OLUMIDE AKINWUNMI ALLI BOLANLE HALIM A ALLI OLALEKAN ALLI RAUFU AMAO ALLI SHAIBU ALLI ADFJOKE ALLI-BALOGUN ABAYOMI ALLI-BALOGUN L. ABAYOMI ALLISON FATAI ADEKUNLE ALLOH EMMANUEL OLUTOLA (MR & MRS) ALO AJANI LATIFAT TITIOLA ALOBA OLUFEYIFUNMI ABIMBOLA ALOHAN HARRY IGBINEDION ALONGE ADEBAYO SAMUEL ALONGE ANDREW ANDERSON ALONGE AYODELE

ALONGE GBENGA BABATUNDE ALONGE ISAAC OMEIZA ALONGE JACOB FUNMILAYO ALONGE OMOTOSHO PETER ALOZIE ANTHONY JAMES UZOMA ALPHA NET NIG LTD CONCEPT LIMITED ALUGEH ABIGAIL ALUGEH JOY ALUGEH OJEAGA MICHAEL ALUGEH OJEAGA MONDAY ALUKO BAMIDELE JAMES ALUKO OYEBUKOLA ABOSEDE ALUOLA EMMANUEL E. AMABEOKU EDITH AMACHI CHINEDUM AMADI IMOBISA SARAH AMADI MATTHEW OGBONNA AMADIGWE EBERE A. F. AMAECHI IHEANYI GODFERY AMAEFULE JUDE OGBONNAH AMAEFULE M CHIDI AMAEFULE OKWUCHUKWU CHRISTIAN AMAFONYE WILFRED AMALA KENNETH CHIGOZIE AMANDO PAUL AMAOMA UWAOMA CHINWENDU AMASA OBA AMASIORAH BENETH AMBALI YEKINI AMEDU UGBEDE SAMUEL AMHIEGBERHETA EBOSE AMIDU AHMED ISOLA AMINU BAKARI AMINU GAZZALI ABDULSALAM AMINU HARUNA ABDULLAHI AMINU MOHAMMED-AMINU MOHAMMED NANIYA AMINU MUKHTAR ISAH AMINU RASHEED OLASUNKANMI AMINU STEPHEN FRIDAY AMINU SULE AMODU OYEBOLA CHRISTINA AMOIHU OMONZELE MONICA AMOLE ADEWOLE AMOLE HABEEBLAI OLAWALE AMOLE SALAM, SABUR, SAMAD AMOLO PETER OKECHUKWU AMOO IBRAHIM OPEYEMI AMOO ISIAKA GBADEGESHIN AMOO OLANREWAJU FATAI AMOO OLUSOLA KAZEEM AMOS EMMANUEL AMOSEOLA ADEOLA AMPITAN JULIUS OLUGBENGA AMPİTAN OLUWATOYIN KEMI AMUDA FUNKE IYABO AMUSA FATIMO OLABIYI AMUSA-OSENI AARON ADEKUNLE AMYN INVESTMENTS LTD-TRADED-STOCK ANAEDO FRANK ARINZE ANAENUGWU EMMANUEL IKANAYOCHUKWU ANAFI ABDULWAHAB OLUWATOYIN ANAGBOGU MICHAEL MATTHEW ANAM CHINYERE DORATHY ANDAGAT INTERNATIONAL LIMITED ANDE BABABUSOLA ABAYOMI ANDE BABAUSOLA ABAYOMI ANDEM ANDEM NYONG ANDREW ANIEFIOK DAVID ANDREW OWOYE ANDZENGE KARMEL ANEFU EDEN INALEGWU ANEGBE AYODELE ANEKE OBIAGELI EUGENIA ANEKWE IFY STEPHEN ANENE NWANKWO ANETEKHAI RICHARD SIMEON ANGA KENNETH ANI CHRISTIAN OZOEMENA ANIA ALPHONSUS IWEANYA ANIEGBOKA OGECHUKWU PETER ANIEKWE ANULIKA ALEXIS ANIEKWE EUGENE OKWUCHUKWU ANIEROBI UKAMAKA GLORIA ANIETO OLUWATOSIN CHINENYE ANIFOWOSE ADEWUNMI AINA ANIFOWOSE SAMSON OLAYEMI ANIGBO GIDEON EKENE ANIKWE OBINNA NNABUIFE

ANIMASHAUN ELIZABETH JAIYEOLA ANIMASHAUN MICKY OLANREWAJU ANIMASHAUN TAOFEEK AKANNI ANIYELOYE ADEFEMI ADESOLA ANJORIN AANUOLUWAPO OLUWASEMILOGO ANJORIN TOPE PETER ANJORIN-OHU OLUWAKEMI ANNOMUOGHARAN E. ARITETSOMA ANOCHIE PETROLINA NZUBECHI ANOGIE REMAIGBE FRANCES ANOJE ONYINYE JOSEPH ANONYAI EMEKA AUGUSTINE ANOWAI SOMTO ELOKA ANOZIA CAROLINE EFURU ANTHONY ARTHUR ANTHONY EBERE MERCYMERIT ANTHONY ONOCHIE ANUCHI ANTHONY VICTORIA ANTIA VICTORIA INYANG ANUCHUE RICHARD CHIMA ANUDE JONAH ANUJULU IFECHUKWU JOSEPH ANUKU WALTER ANUMBOR EMMANUEL ANUMBOR EMMANUEL IFECHUKWUDE ANUNWA CHUKWUEMEKA CHIEDOCHIE ANUNWA IFEYINWA CHIDINMA ANUPUO EMMANUEL ANUSIONWU OKEY JIMMY ANWANANE BASSEY BASSEY ANWUTA BENJAMIN IFEANYI ANYA EUGENE UCHECHUKWU ANYA EUGENE UCHECHUKWU ANYADIBE EKWUEME MICHAEL ANYAENEH ETHELBERT CHIGOZIE ANYAKWO FRANCIS OKECHUKWU ANYALEWECHI DENIS OHAERI MR ANYANWU ANTHONY UCHE ANYANWU CHIBUIKE T ANYANWU CHINEDU JOHN ANYANWU IFEANYI CHIDIKE ANYANWU JOSEPH OKECHUKWU ANYANWU KOSI ANYANWU MARCEL KEMJIKA ANYASI AZUKA SOLOMON ANYIAM VITALIS EKWEM ANYIAM-OSIGWE EMMANUEL CHUKWUKA ANYIWO ONYEDIKACHUKWU OLAEDO AONDOAKAA YEMISI CHRISTIANAH APAMPA LOLA APEDZAN JONATHAN IGBADUL APEH BABA JOSEPH APEL ASSET LTD - NOMINEES APEMIYE JOHNSON JETEMOH APENA ABOLORE MODINAT APENA AYOMIDE KAOSARA APENA YUSUF GBOLAHAN APOR SAMUEL EGAROGHENE ARACHIE GODWIN ARAKA LYNA OBONUMETEHA ARAUSI AJOMOVUAI JOE ARCHIBONG MAGDALENE AREGBE ANIKE MODINAT AREMU ABIODUN AYINDE AREMU ISAAC OLAWALE AREMU MATHEW ARAMIDE AREMU SAMUEL ADEJARE AREMU TUNJI JOSHUA AREMU-IGBALAJOBI ISAAC OLAWALE AREOLA SAMUEL OLAOLUWA AREWAH MARTIN ARIAN CAPITAL MANAGEMENT LTD ARIKAWE ABOSEDE ROSELINE ARIKEWUYO OLASUBOMI EXCEL ARIKEWUYO RASHEED ATANDA ARISE OLAJIDE ARIYO OYINDAMOLA A ARIYO TOLUWALOPE EMMANUEL ARIZ AINA ELIZABETH AROGUNDADE FESTUS OLUFEMI AROH CHINASA BLESSING AROH CHUKWUDI BENJAMIN AROH SANTHUS CHUKWUDI AROLEOWO GANIAT ABIODUN AROMAYE BUNMI TITILOLA AROTIBA AYODELE RICHARD

AROWOBUSOYE TAIWO PAUL

AROWOGBADAMU ABDUL-GAFAR ADESOLA AROWORADE SAHEED OLUFEMI ARUA GODWIN MATHEW ARUBUOLA OLUFISAYO EBENEZER ARUM IRENE ONUABUCHI ARUNA GANIYAT ARUNA QUADRI AKINADE ASAJU RASAQ KUNLE ASANGANSI EFFIONG OKWONG ASAOKU JANE ASAOLU IBIYEMI FUNMILAYO ASARE BERNARD ASEIN EVAGHOMO MERCY ASHADE BENJAMIN KOLAWOLE ASHAN ROTIMI SONAYON ASHAOLU SUNDAY GBENGA ASHAYE ABOSEDE ARIYIKE ASHI KENTUA ASHINDOITIANG JOHN ADI ASHIOFU ANTHONY IKE ASHIRU IBRAHIM ABIODUN ASHIRU JARINAT ABIOLA ASHLEY OSUZOKA JOSEPH ASI CHIDINMA JUMBO ASIEGBU ROSELINE N. ASINOBI NNADOZIE IKENNA ASINWO SYLVESTER ADEREMI ASIRU AYORINDE ASIWAJU AYORINDE OMONIYI ASIYANBI OLALEKAN JOHNSON ASOGWA CHINWEIKE C ASOH NKECHI JANE ASUNMO GANI AYODEJI ASUQUO IFIOK ETIM ASUQUO L. (ESTATE OF) ASURU BRIGHT OBINDAH ATAKE MAIWADA BALA ATALOR LUKE EHIS ATANDA JOLAOLUWA ATANDA OLUREMI ADEMOLA ATE GIDEON ATIM ATELE UFUOMA ATELISIKA NKOLIKA KIRI ATEWOJAYE MICHEAL OLUGBENGA ATIATOBE ANTHONY ADAUMBE ATILOK ENTERPRISES ATILOLA OLAYINKA ATIYE FRANCIS DENNIS ATOJOKO SALIF ATTAH EBO ATTAH ENEYE DANIEL ATTAH JAMES EDIBO ATTE AYODEJI OLUWASEYI ATTIH EDEM EDET ATTIH TITILAYO OLUWAWEMIMO ATUBE KEMEDI CHUKWUNWEIKE ATUEYI CHARLES IFEANYI ATUEYI CHIKELUBA DONATUS AUDU ANDREW AUDU ANSLEM OTOBO AUDU ATIKU AUDU JONATHAN AUDU JOSEPH AUDU ODUFA GLORIA AUDU RABI ADA AUGUSTINE AKHIE AVOSE MAUTON AVOSEH KEHINDE EDUN AVWADJUYO FAUSTINA ADAKU AWOBADE OLUWAKOREDE DAVID AWOBAMISE JOSEPH AKINBANJI FOI ORUNSO AWOBIMPE KAYODE CAMALDEEN K AWOBUSUYI MARGRET FUNMILAYO AWODEIN OLUBUKANYO BIODUN AWODIYA OMOLOLA OLUBUNMI AWOFESO AWOLEKE AUGUSTINE AWOJINBIN BICHARD OLATUNJI AWOJOODU ELIZABETH BUSOLA AWOLANA OMOLARA OLAWUNMI AWOLEYE OLAKUNLE STEPHEN AWOLOWO AJIBOLA OLADELE AWOLOWO AYODEJI ADEDOYIN AWOLOWO OLUWATOSIN OMOLADE AWOLUMATE ADEJUMOKE AWOLUSI OLUMIDE AWOLUSI RUFUS ABIODUN AWONUGA ABIOLA OLAWUNMI

AWOPETU OLUWAGBENGA

OLATUNBOSUN AWORINDE MARY ADEOLA AWORINDE TEMITOPE TAIWO AWOSIKA OLUWATOYIN BILIKIS AWOTAYO OLAYEMI AWOTOLA ADEWALE AWOTUNDE OLUWAFEMI ATANDA AWOYALE OLUFUNMI ADEBOLA AWOYINFA VICTOR AYOBAMI (MASTER) AWOYINFA VINCENT AYODEJI AYAK JOY NENKA AYANBIOLA EDWARD OLUSEGUN AYANBULE OLUSEGUN AYANFALU TİTİLOPE OLUBUKUNOLA AYANLEYE IBRAHIM AYANKUNLE AYEBOGUN HENRY OLAKUNLE AYEDUN FUNMILAYO ABIODUN AYEH AJANIGO VICTORIA AYELARI OLUSOJI SEBASTINE AYEMENREAKAHOMEN DAVID AIBHUEDAFE AYEMHERE BLESSING OBEHI AYENI ABIODUN AYENI ABIODUN SEGUN AYENI ADUKE ALICE AYENI EMMANUEL OLUWADUNSIN AYENI OLORUNGBON DAVID AYENI OLUSOJI SAMUEL AYENI OLUWAFEMI SAMUEL AYENI OLUWAFEMI TAIWO AYENI SANMI OLUWAFEMI AYENI-AKEKE MOROHUNKE BUKOLA AYILARA SEGUN J AYINDE BUKOLA AYINDE OLATIMBO AYINDE OLUFEMI AYO DURODOLA AYO FIYINFOLUWA AYO FOPEFOLUWA AYOADE HAMMED ADEKOLA AYOADE JOSHUA ADEYINKA AYODEJI KOLAWOLE AYODEJI OLUWATOSIN CHARLES AYODELE AYOOLA YEKEEN AYODELE BEATRICE FUNMILAYO AYODELE OMOWUNMI OLUTOKUNBO AYODELE SAMUEL JUDE AYOGU TITUS IKECHUKWU AYOKUNLE OKUSANYA AYOKUNLE OMONIJO AYOOLA OLULANU ADEBISI AYORINDE SAKA OLALERE AYUBA KADIRI YEMI AYUBA PETER SHUWA AYUBA REBECCA AYUBA RONKE AYUBA TANKO SOLOMON AZEEZ ABDUL-MALIK OLANREWAJU AZEEZ ABOLANLE AYINKE AZEEZ AMIDU BABATUNDE AZEEZ JIMOH OGUNBANWO AZEEZ RAZAQ AZER OBADIAH AZERE AZIENGBE EUNICE A AZORT NIGERIA LIMITED AZUBIKE UGOCHUKWU CHRIS AZUEGWU IFEOMA QUEENETH AZUH PRINCE PETER AZUNNAYA HENRY I. AZURUNWA LAWRENCE ENYINNAYA BABA USMAN IBRAHIM BABAJI SHARIF ABDULLAHI BABALOLA ABIODUN OLAWOYIN MICHAEL BABALOLA MATTHEW ADISA BABALOLA MUKAILA OLANREWAJU BABALOLA OLUYEMI AKINTOYE BABALOLA OMOLOLA FOLAKEMI BARALOLA OPFOLUWA AYOMIDE BABALOLA TUNDE OLANREWAJU BABARINDE OLUSHOLA ALADE BABATUNDE ABRAHAM OLAYIWOLA BABATUNDE ASAFA IYANDA BABATUNDE FATAI AYODELE BABATUNDE FELIX ADEKUNLE BABATUNDE OLADAPO BABATUNDE OLALEKAN BABAYOMI BUKOLA

BACCIJI ZAINAB UMAR

BADEJO OLATUNDE

BADEJO OLAWUNMI FOLASHADE BADIRU IYABO REKIYAT YAKUB BADMOS ABDUL-RAHMAN BADMUS ABDULRAHMON ABIODUN BADMUS MUDASHIRU OLATOKE BADMUS TUNDE BADOM DUGDALE KPOOBARI BADRU MUTIU AYOTUNDE BAJOMO IYANU OREOLUWA BAJOMO MOROLAIFEOLUWA JASON BAJOMO OLUWATAMILORE TIFFANY OLAMIDE BAJULAIYE OLUROTIMI ISHOLA BAKARE ABIMBOLA RASHEED BAKARE AFUSAT BAKARE FALILAT BAKARE JOSHUA ADEOLU BAKARE OLABODE BAKARE SHERIFAT BAKARE SULKIFLI ADEOLU BAKARE YETUNDE LATEEFAT BAKRE ISMAIL OMOTOLA BALA ISHAYA KYEK'S BALAMI DAVID HALIDU BALAN WADA ABDULBAS BALAN WADA AMARA'U BALAN WADA UMMUHANI BALARABE YUSUF BALOGUN ABDURRAZAQ BALOGUN ABIDEEN OTOLORIN **BALOGUN ADEWALE TAIWO BALOGUN ADISA** BALOGUN AFOLUKE FATIMAT BALOGUN AISHA KEHINDE **BALOGUN BOLANLE** BALOGUN BOLANLE ABIDEMI BALOGUN ISHOLA JELILI BALOGUN KAMAL OLAKUNLE BALOGUN MOBOLAJI BALOGUN MORUFU ADEBIYI BALOGUN MUEEZAH TAIYE BALOGUN MUHAMMED OREOLUWA BALOGUN MUKAILA AYINLA BALOGUN OLALEKAN BALOGUN OLUWAKEMI YETUNDE BALOGUN OLUWATOYIN BALOGUN PATRICK OLUFEMI BALOGUN RAFAT OMOWUMI BALOGUN RAFIU ADEGBOYEGA BALOGUN SARATA IYABO BALOGUN SIKIRU BOLARINWA BALOGUN WASIU AYOBAMI BAMALLI BATURE BAMGBADE OLUGBENGA BAMGBOSE ADERINOLA ELIZABETH BAMGBOSE FOLASADE ABOSEDE BAMGBOSE JULIUS BAMGBOSE STEPHEN ISHOLA BAMGBOYE VERONICA OLAITAN BAMIDELE ADEBUNMI SALIMOT BAMIDELE AGBOOLA ISAAC BAMIDELE OLUWATOYIN ONABODE BAMIGBAYE OLUDOTUN EMMANUEL BAMIGBOLA PIUS AKINLOLU BAMIGBOYE JAMIU AKINWUNMI BAMISILE ABIOLA O BAMMEKE OLABISI A. BANJO YETUNDE OLAMIDE BANKOLE ADEBUSOLA BANKOLE DEBORAH REGINA BANKOLE JOSEPH OLUMAYOWA BANKOLE OLUFUNMILAYO ADENIKE BANKOLE OLUYEMI STEPHEN BANKOLE REGINA DEBORAH BANTAM AISHA BAPTIST STUDENTS FELLOWSHIP UNILORIN BARUWA OLAYIWOLA ABDKABIR BASHIR AKEEM BASHIR HUSSAINA BASHIR MUHAMMAD FATI TALATU BASHIR NURA BASHIR OLUWAYEMISI OMOBOLANLE BASHIRU ALIU OLUWAGBEMIGA BASHIRU RASAK MATTHEW BASIRU LAWAN BASSEY EFIONG OTONG BASSEY ETIM NYONE BASSEY JOHN BASSEY NKOYO ETIM

BASSI ALI JIRAMA

BATULA ALHAJI BOONYAMIN ADISA BAWA GAIYA ISAH BAWA ZISHIM BAYAGBONA DAVID EGHOSA BAYAGBONA SUSAN OSARUGUE **EKOIGIAWUE** BAYODE SAMUEL OLUWAFEMI OLUFUNSO BAZUAYE EMMANUEL OSARO BECK BIODUN SHOLA BECKLEY FIKEHANMI EMMANUELA BEKEE UCHE RONALD BEKUNMI AKINSOLU BELGORE YAKUBU 2 BELLISIMO INV. & FIN. COY LTD BELLO ABDULAZEEZ OLALEKAN BELLO ABIOLA HANNAH BELLO ADISA SULE BELLO AHMAD ABDULMALIK BELLO AJIBOLA AHMED BELLO AKEEM OLASUNKANMI BELLO ALIYU KAKARA BELLO BUKUNOLA BELLO FARUK BELLO GANIYU O BELLO JEROME K. (REVD) BELLO KOKO MOHAMMED BELLO KOLAWOLE NURENI BELLO OLAMIDE ESTHER BELLO OLUWABUKOLA ADERAYO BELLO SURAJUDEEN BELLO WASIU BABATUNDE BENJAMIN SHEDRACH ONOGU BENSON OLALERE OLOYEDE BENSON-GAGAR DORA BESTMAN ASIKI BEWAJI AFOLABI BEYIOKU KEHINDE BEZAI SERVICES BFCL INVESTMENT A/C BGL/LONG JOHN IFURO-IYALLA BHADMUS ADEREMI KAMAR BIALA ADEMOLA ABAYOMI BIALA EMMANUEL OKANOLA BIBLE SOCIETY OF NIGERIA BIN LI BINUYO BIODUN A. BINUYO JOSEPH KEHINDE BIOSE NDUBUEZE DONATUS BIRMA SULAIMAN BISAYO DORCAS ENIOLA BISHI HAKEEM BABATUNDE BISIRIYU KEHINDE HASSAN BISIRIYU RAHAMAT OLAITAN BITRUS JAPHETH ZUGHUMTU BITRUS PUNARIMAM BLAZERS INVESTMENT LTD-A/C 2 BLESSED JOSIAH IKECHUKWU BLUE SEAL ENTERPRISES BOB SUNDAY OGBOBU BODE ADEOLU GLOBAL ASSOCIATES BODUNRIN ABIODUN BOLAJI SAHEED OWOLABI BOLARINWA LUKMON BOOSTEF NETWORK INVESTMENT LIMITED BOQAZ TECHNOLOGIES LIMITED BORISHADE OLUBUNMI IRETI BORODO ISA HAUWA BORONLE TIMOTHY OLUWAGBENGA BOSAH JOSEPH ISAIAH ESTATE OF BOSSEY FRANCIS EGBHATSE **BOYEJO MARGARET** BOYEJO OMOLARA BRADFORD & BINGLEY BRADFORD & BINGLEY INVEST LTD BRADFORD BINGLEY INVESTMENT LTD BRAIDE VIRGINIA SOBERENGE BRAIMAH JEMINAT BRAIMOH JANET BRIGGS ALATE SENIBO BRIGGS TEINBO NODI BROWN FLORENCE NKIRU BUBAGHA FAVOL TIMIKEY BULUS IKO ISHAKU BUORO EDWARD ORILOYE BUSARI BASIRU OKUNADE BUSARI BOLAJI HABIB BUSURA ADEDEJI

BUSUYI SOGO JIDE

BUSY BEES SOCIETY.ST. PAUL'S ISAGATEDO C.I.T.I INTERNATIONAL ON-LINE LTD CAC(OKE-IGBALA)IKOSI- WORKERS INV FUND CACTUS GLOBAL RESOURCES CAKES N CAKES NIGERIA LIMITED CALYX/MENSAH CHARLES OLALEKAN CANDY FLOSS LIMITED CAPITAL SHAREHOLODERS ASSOCIATION CAPTAIN DOWENUA CARDINALSTONE ACCOUNT CPM CARDINALSTONE SECURITIES LIMITED CARDINALSTONE SECURITIES LTD/CLIENTS CARING CHEMISTRY LTD CARING JOSEPH CARING OLUKAYODE CASHDEAL VENTURES CHAMPION INVESTMENT CLUB CHAN DIOH PAUL CHECHEI JESSE CHIBOGWU MICHAEL AMEDU CHIBUEZE PATRICK IKECHUKWU CHIDOZIE BLESSING CHINENYE CHIEDU ANTHONY CHIEDU MONICA UMEJEI CHIEGE IROABUCHI GODSWILL CHIEJINA AUGUSTINE CHINENYE CHIGBU OSCAR OGECHI CHIGBUNDU ONYEKACHI ROMANUS CHIJI KINGSLEY ONUEKWUOTU CHIJIOKE CHIOLI PASCAL CHIKADIBIA JUDE OKWUDILI CHIKELUBA AGWUNA THOMAS CHIKELUBA CONCILIA NCHEDO CHILE NOAH DANIEL CHIMA CHUKWU CHIMA OBINNA STANLEY CHIMA PAULINUS AGU CHIME CHIAMAKA ANITA CHIME NKEMAKONAM BENSON CHIMERE KANENE ARNIE CHINAKWE ALAIN NWABUGO CHIOMA NKESI GIFT CHIOMA OMELE PEACEPROFOUND CHIORLU WORDI CHIROMA AHMED BARROS CHITURU P. OWHONDA WOPARA CHIWETALU SYLVESTER OSITA CHRIST CRUSADE FOUNDATION CHRISTOPHER PELUMI CHRISTOPHER U. LUCKY CHUDE IFEANYI AFAM CHUKWU ADAORA NNENNA CHUKWU CHIDIEBERE MICHAEL CHUKWU CHRIS OBINNA CHUKWU EMMANUEL ONYEBUCHI CHUKWU INNOCENT IKECHUKWU CHUKWU JOSIAH CHUKWU NWAKAEGO CHRISTANA CHUKWUBUIKEM AZUKA DANIEL CHUKWUDEBELU MAYOR MAXIMUS CHIDOZIE CHUKWUDI NGOZI CECILIA CHUKWUDI OGOCHUKWU BIBIAN CHUKWUDI PASCHAL ONYEBUCHI CHUKWUDOLUE ANN NGOZI CHUKWUDOLUE OKEY CHINENDU CHUKWUEBUKA PROMISE UGOCHUKWU CHUKWUEDO EMEKA ROBERT CHUKWUEGBO STEPHEN A CHUKWUEMEKA CHIBUZOR EMMANUEL CHUKWUJINDU OBIAJULU CHUKWUNWIKE CHUKWUMA CHARLES CHIECHEZONA CHUKWUMA CHUKWUKA NDIDI CHUKWUMA CLETUS UCHENNA CHUKWUMA DANIEL IFEANYI CHUKWUMA NNABUIHE GODFREY CHUKWUMA VERONICA CHUKWUWETALU OBIANUJU CHUTA CHINJINDU ROSALINDA CHUZ NOMINEES LTD CITIGATE MICROFINANCE BANK NIG LTD CLARKE EKWEOSINOMO DICY CLEMENT JOSIAH ONYEBUCHI COLE BOLAJI

COLE OLAKUNLE IBIYINLA

COLLINS KENNEDY CHIGOZIE COLLINS VANESSA KELECHI ADAEZE COLUMBA ITORO PIUS COLVIA ENTERPRISES CONSTRUCTION PLANT & EQUIP INT'L CONSTRUCTION PLANT & EQUIPMENT INT'L CORLIS JANE BOSE CRAIG OLAYINKA OLUWASEUN CRANE SECURITIES LIMITED CYRIL OKECHUKWU JOHN CYVA CLINICS LTD. DA SILVA FOLARIN DABAWA RAHILA PHILEMON DABO AMINU YUSUF DABO MURTALA MOHAMMED DABO RABIU MURTALA DACHALSON MOSES GIDEON DADA AYO DADA AYODELE & INONGE DADA GRACE ODUNOLA DADA JAMES AJAYI DADA KELVIN O DADA OLADELE MICHAEL DADA OLAKUNLE SUNDAY DADA OLAMIDE DORCAS DADA OLUWASEGUN IBITOLA DAFE IFEOMA IFEANYI DAFIEWHARE STELLA ETARERI DAGOGO-JACK SAMUEL EREKOSIMA DAHIRU HARUNA SOJI DAHORO YOHANA CHOJI DAHUNSI ABRAHAM BABATUNDE DAJAH VINCENT A. DAKO ABEJE JOSHUA DAKO RALIAT JUMAT DALLAM SUNDAY LOHKAT DAMINABO JOSHUA IMIEBARA FRANK DAN NAYABA INVESTMENT NIGERIA LTD DANAZUMI SOLOMON SAM DANBABA LEUNARTH JOSHUA DANBAPPA BELLO ALHAJI DANBAUCHI ALEX ADESON DANIEL CHIDERA IFEANYI OKORIE DANIEL TIOLUWANIMI JOHN DANIYAN FUNMILAYO CHRISTIANA DANIYAN MAUREEN IDOWU DANIYAN TENNY MANKINI DANJUMA JOHN DANKETA TIJJANI SANI DANLAMI MADOH MAKAMA DANSAK INTERGRATED NIG LTD DANSU IYABO MAUSI DAPO ENIOLA-MARTINS DAPO ROTIMI DARA ABIDEMI OWADAPO DARAMOLA OLUFEMI AROMOLARAN DARAMOLA OLUWADEMILADEOGO O. DARANIJO AYODEJI EKUNDAYO DARAS CHINWE EUCHARIA DARKHORSE VENTURE DASPAN LAIATU DASUKI ABOU IBRAHIM DAUDA ILIYASU UMAR DAUDA RASAQ DAUDU TAOFIKI BAMIDELE DAVID KAYUS DAVID UDOH DAVID YAKUBU LAI DAVIES ADEWUYI ADEDAPO DAVIES ADEYINKA SAMUEL DAVOU NUHU ZANG DAWAM JOSEPHAT DAKYEN DAWODU BOLARINWA DADA DAWODU OMOLARA ADIAT DAWODU SHUAIB ADEBOWALE DAWUD IDRIS DAYYABU UMAR KURFI DBSPS LIMITED DEBUA TARRY AYI DELANO KEHINDE ADEBAYO DELE-GIWA OLUFUNMILAYO ABIMBOLA DEMEHIN DAVIS OLAWALE DEMEHIN FESTUS ORIMISAN DEMI-SHOBAKIN TAIWO DEPENDABLE SECURITIES LTD DEROX INVESTMENT LTD DERU DAN ADEBOLA

DESIGN UNION CONSULTING LTD.

COLLINS JULIE NNENNA

DEYINI NZALU DIALA SUNNY IFEANYI DIARA JOHNSON CHIJINDU DR DIEUDONNE AJAH DIGITAL REALM LTD DIKE DANIEL OMENIHU SUNDAY DILINYE OKECHUKWU THEOPHILUS DILINYE PHINA NWADINMA DIM REUBEN CHUKWUDI DINA YETUNDE OLUBUKUNOLA DIOKPARA IJEOMA RHODA DIPEOLU MORENIKE ATINUKE DISU LIADI KOLADE DISU MOSHOOD KAYODE DODE ONITSHA PRESLEY DODUBOGUN OLUSEGUN ADEDEJI DOGHUDJE KENNETH DOGO GIDEON BABANGIDA DOGONYARO HAUWA DOHERTY ODUNAYO OMONIYI DOME CAPITAL RESOURCES INVESTMT LTD DOMINION CAPITAL LIMITED DONFAH HIGHLIFE GODWIN DONOKOROMO OGHENEKEVWE .W DOORSTEP AGENCY & LIASON SERV DOSUMU LATEEF DOSUMU OLUWABUSOLA BOLANLE DOSUMU SUNDAY OLUMIDE DOSUNMU ADEROPO OLATUNBOSUN DOSUNMU MARY ADETOKUNBOH DOSUNMU-PEREIRA FADEKEMI TITILAYO DOTTIE JOHN OFEORITSE DOUGLAS EMMANUEL S.O. DRESSMAN SUNDAY ANUME DUKE RICHARD DUNN LOREN MERRIFIELD SECURITIES LIMITED - MM TRADING DUNTOYE MOYOSORE BEATRICE DUNU RICHARD IGWEBUIKE DUNYA YAHI DURO-DOLA AREMU-DAUDA DURODOLUWA TAIWO GILBERT DUROJAIYE ANTHONIA OLAIDE DUROSINMI TITUS AKANBI DUROWAIYE ADEWUNMI AFUSAT DURU IKECHUKWU ABIANURU DURU PATRICK EBERECHUKWU DURU-IGBONEKWU CHIDI LIVINUS AKUBUEZE DURUIKE ALEX AMAECHI DURUIKE JANE IJEOMA DUYILE FOLORUNSO FRANCIS E. W. CHIROMA MR & MRS EASTERBROOK SHEHU AMADU TIJIANI EBBIS ELUWAH OBIANYI EBEH CHRISTIAN UCHECHUKWU EBELE JINGO ONYEANUSI EBELEBE PAUL ETISOBI EBEM OBIAGERI VICTORIA EBENEZER AFRICAN CHURCH ENDW. FUND EBERE NWANGANGA EBHOMIELEN THECLA IZEHI EBHONU RUTH-FIRMINUS EBHOTEMEN LARRY OSARO EBIEFIE ANTE OKON EBINE FESTUS OLORUNWA EBITE EVELYN NKECHI EBIUWE EMIOMODONO EBO NKEMAKONAM VERONICA EBOH FIDELIS EBOH NDUBISI INNOCENT EBOKA HENRY EKENE EBORAH CHUKA OLISE ECHEKA KENNEDY CHIBUEZE ECHENG ENYA EWORO ECOBANK NIG.PLC/SMADAC SEC.LTD-TRADING ECOBANK NIGERIA PLC/DMC MGT-TRADING ECOMARK INVESTMENTS LTD EDAFERIERHI OBORHE ABEL EDE EMMANUEL CHIKWENDU EDE PETER EDEKHOR PIUS A. EDEKOBI PATRICK BOSAH EDEM MICHAEL ETIM EDEMIRUKEWA IRENE TEKELE EDEMODE OKHATE JOHN EDEOKO CHIKODI EDET OKON GODWIN EDET UDOFIA SAMUEL

EDET UKO JOHN EDIALE ISI PATIENCE EDIJALA ANITA TOBORE EDIM DENNIS PATRICK EDJEBA MARY OLUYOMI EDOGI, BASSEY EDOSOMWAN OSAIGBOVO PETER EDUN DAVID OLAWALE EDUN OLUSEGUN ABIODUN EDUVIERE DAVID OBA EDWARD TITOBILOLUWA OLAMIKUN EDWIN VICTOR EFEMENA EFE MILLER **EFEGI GESIKEME** EFFAH PATRICK EFFAH EFFIONG AUGUSTINE B EFFIONG EDEM ESSIEN EFFIONG ENO EDET EFFIONG VINALINE BASSEY EFIOM EFFIONG OKON EFOLI ESUKU ONEN EFRAIN INVESTMENT LIMITED EFUWAPE FOLASADE EYITAYO EGAGIFO OBERHIRI WILLIAM EGAMANA SAMUEL AGAINA EGBAGO OKWUDILI MIKE EGBEH ROBERT EGBEKUNLE OLUKAYODE AKANJI EGBENI PATRICIA OBIAJULU EGBENIYOKO SAMUEL EGBEYEMI OLUWADARAFUNMI EGBO AMAECHI EGBOGAH EMMANUEL ONU EGBONG NKORO SIMON EGBOWOROMO BENJAMIN EYITOKUNBO EGBU LIVINUS EGBUCH CYRIL CHUKWUEBUKA EGBUCHE ROWLAND OBIORA EGBUKA ISIDORE CHIJIOKE EGBUNU WILLIAMS EGBUONU CHINWE EGBUONU CHUKWUDI EGBUONU ROSEMARY CHINAZOM EGBUONU TOBENNA EGEKENZE PATRICK IKECHI EGEMONU MAUREEN OLACHI EGESI CHIGOZIE EGIGA ESTHER NKO EGONU OBINNA JUDE EGONU UGOCHUKWU CHIDERA EGU CHUKWUEMEKA EMMANUEL EGUANDO MOLA EGUGBO CHRISTOPHER CHUKWUNEDUM EGWAHOR JONATHAN NWUZU EGWUATU VICTOR OFILI EGWUEKWE NDUBISI MARTINS EGWUH ODOKUM EMMANUEL EGWUONWU CHIBUZO ANAYOCHUKWU EHIAGWINA ABHULIME EHICHIOYA ILOBEKEME F EHIGIATO EMWANTA O & JOSEPHINE EHIMARE PIUS EKHOMU EHIMHEN VICTOR IGHEDOSA EHINMOWO OLUSEGUN AFOLABI EHONWA ELIZABETH EIDANGBE JONATHAN IKHODALO EIGBOKHAN BRIDGET EHINETA EITOKPEMHOLEN AUGUSTINE EJEH BENEDICT EJEMA ORAZIMENU ROSEMARY EJI THERESA EJIKA CHARLES EMEKA EJIKE CHINENYE SUNDAY EJIKE COLLINS ONYEZE EJIKE HENRY UCHENNA EJÍKE UGWU EJIKEME IFEANYICHUKWU EMMANUEL FJIM FRANCIS OBUM EJIMUDA UZOAMAKA ADAOBI EJIOFOBILI VINCENT CHIMUANYA EJIOFOR FLOVIUS CHIAGOZIE

EJIOFOR JONATHAN

EJIOGU FRANCIS CHIBUIKE

EJIWALE PAUL OLUSEGUN

EKAKITIE OVOKE WILSON

EKANEM ITA GEORGE

EKAMA RICHARD OGHENEOVO-

EKECHI EMMANUEL CHUKWUDI

EKANEM IMAOBONG OWOIDIGHEABASI

EKEGHE OGBONNAYA NDUKA EKEGHE OGBONNAYA NDUKA AND **EUNICE O EKEH ANTHONY** EKEH CAROLINE UCHENDU EKEH CONSTANCE OGECHI EKEKEZIE GODSWILL CHUCKS EKELEDO CHINONYE JONATHAN EKENYEM EMMANUEL & CHINONYE EKEREOKOSU DAVID PETER EKHAIFO DANIEL OLUSEGUN EKHAIFO FREDRICK **EKOME LOUIS** EKONG BONIFACE B EKPENISI SAMUEL NDUBUISI SNR EKPENYONG MARCELLINA EZIOBI EKPO EDIMA BEN EKPO MFON JOY EKUNDAYO OLUFEMI EKWEBALAM UCHENNA EKWEGH UGOCHUKWU JOSEPH EKWEN FRANK OBINNA EKWEREMADU C MERCY EKWESIRIKE PATRICK EKWURUKE CHUKWUECHEFULAM VICTOR ELEAH GODWIN ELEAZU KELECHI CYNTHIA ELEBUTE SIDIKAT KEMISOLA ELEJA OLUFUNMILAYO DEBORAH ELEOJO BEN ANDREW ELESIN OLANREWAJU GANIY ELIJAH DORAH ELIJAH OFFONIME ELIMHINMIA ORUKPE ARTHUR ELLA ADAMS ELMIRAGE INVESTMENT LTD ELNICK ENG CONSTRUCTION LTD ELUDOYIN AKINOLA ELUWA CHINEDU **EMAJEMITE IGHO JEFFREY** EMAVWOYAN OMAMUYOVWIN ANDREW EME UCHECHUKWU EMEFIELE NATHSON SATURDAY EMEFIENE GERALD CHIBUOGWU EMEJEAMARA CHIDIEBERE EMEJULU ARINZE CHIMA ELIAS EMELE UCHE ESOWE EMENIKE OZIOMA EMEREUWAONU ERIC EJIMADUEKWU EMERIBE PATRICK UCHENNA EMERUEM CHINEDU SAMUEL **EMETENJOR ANTHONY** EMMANUEL AKANIMOH NELSON EMMANUEL EBUK JACKSON EMMANUEL ONUKAK EMMANUEL OYINLOLA SOREMEKUN EMMANUEL QUEEN ESEGGENE EMOKPAE AIGBUHUMWUEZE **IBUKUNOLUWA** EMOKPAE OMOSEFE OLUWATOSIN EMOKPAE OSASENAGA OMOROGIEVA EMONO CHRISTOPHER AZUKA .J. EMORDI OPUTA MARTINS EMUANYAKA EZENWA HENRY EMUOBO OGHENEKARO ENAHORO MICHEAL ENAKHIFO VICTOR ENAMU TIMI ENANG ETIM PETER ENANG ENEANYA HENRY IZUCHUKWU ENEBE JOHN CHUKWUKA **ENEBE SALMON ENEBE** ENEBONG EMMANUEL AKAROM ENEDA OBIAGELI EUNICE ENEMUOCHUKWU JUDE ONYEAKUSIOBI ENENCHE FELICIA KOKOLO ENIAYEWU DORCAS FOLASHADE ENIFENI IBIDUN I ATIFAT ENIKANOSELU MODUPE ABOSEDE ENISUOH SUNNY EBIPUAKEBENA ENOGHAMA MAGDALENE ENTERPRISE INVESTMENT MANAGEMENT II

ENTERPRISE STOCKBROKERS PLC

ENUONYE NELSON CHUKWUEMEKA

ENUECHUSUE EMMANUELLA

ENYINNAYA CHRISTIAN C.

ENUANI NGOZI NELLY

OBIERUMANI

ENYINNAYA MERCY EBERE ENYINWA PATIENCE CHIZARAM EREBA DUMBOR SARNA ERETAN OLUWOLE RICHMOND EREWARI NENGI BRIGHT TARIBIO ERHABOR LAWRENCE EDOSA ERHABOR OGHOGHO ERINJOGUNOLA RASHEED LOQMAN ERINLE FLORENCE FUNMI ERINLE OMOBAYOWA TEMITOPE ERIOMOLA ADEYANJU ERO JANE ERO OMORUYI GEORGE ESAN ABIODUN MAYOWE ESAN ADEGBENGA OLUWAFEMI ESAN JOSEPH OLUSOLA ESEMUJE CECILIA ESENE OMONUA OKOEDO ESENE OMOZOKPIA ANDREW ESIERE AKANINYENE ETIM ESIMAJE JOLOMI ESONWANNE CALISTER KELECHI ESSELL ANTHONY CHINWUBA ESSIEN EMMANUEL OKON ESSU ENUAGUNE PAUL ESTATE BAPTIST CHURCH ABESAN ESTATE OF AHIMIE PATRICK OHIWERE ESTATE OF LATE NWANYANWU EMMANUEL MADUWUEZE ETADERHI EMMANUEL ETHAGBE JOHN O. ETIKO SHITTU (FAMILY) ETONYE OYINTONYEFIE ETTA HENRY ELLA ETU EDET OKON ETU NKOYO OKON ETUK CHIOMA ETUK INYANG E N ETUK UNYIME SUNDAY ETUKUDOH OKON ETUWEH CLINTON ETUWEH EVA AKHERE HENRIETTA EVBOSOMON IYOBOSA EVBUOWAN JIMMY OMOREGIE EVWIEPAMARE G. JOHN EWAJANE LOLA KAYODE EWEBIYI ABDULLAHI GBOLAYO EWELAKU GODSON CHY EWELIKE HANNAH CHIMEZIE EWEWIE ANDREW EBEHIGHA EWHERIDO ANTHONY OVAYERO EWODAGE DANIA AYOBAMI EWOH OKWUKWE FAITH EYEBIOKIN ISAAC OLUWADARE EYI-OGUNGBAMILA MOROHUNKE BUKOLA EYO DANIEL FELIX EYO OKON ASUKWO EYOH OKON EDET EZE CHARLES EJIKE EZE ERNEST CHIDIEBERE EZE FLORENCE NKECHINYERE EZE JERRY NKEM EZE KENNETH AZUBUIKE EZE LIVINUS OKECHUKWU EZE LIZZY EZE NWOGBU EZE PAUL CHUKWUEMEKA EZE UGONWA ANISTINA EZE VINCENT EZEAGUBA CHRISTIAN OKEY EZEAMUZIE IFEAMALUME CHARLES EZEANI SAMUEL N. EZEANYA GODWIN EZE EZECHIDIEBUBE CHINONSO CORNELIUS EZEH MICHAEL EZEH OBIAGELI MERCY EZEIGBOKWE IFEOMA LUCY EZEIGWE BONIFACE OKWUERIKA EZEIGWE EMMANUEL EZEIGWE MELETUS CHINWE EZEJA CHRISTIANA A. EZEJA IGNATIUS ODO EZEKAFOR EUCHARIA NKEM EZEKIEL ESTHER TEMILOLA EZEKOMA UGOO FRANCIS

EZEKWEM MARCEL ONYEMACHUKWU

EZEM KEVIN CHUKWUEMEKA

EZEMA JOSEPH EMEKA

EZEMBA CHINWENDU A. J.

EZEMEGBU ANASTESIA NWABUONU EZEMEGBU LIVINUS EZEMEZUE FELIX CHEKWUBECHUKWU EZEMONYE LAWRENCE EZENAGU CHARLES EMEKA EZENAGU CHIJIOKE VALENTINE E. EZENDIOKWERE BENJAMIN EZENNABUENYI AMARACHUKWU IJEOMA EZENWA CHINEMEREM TESTIMONY EZENWA EMMANUEL CHUKWUZUBELU EZENWA FRED CHUKWUNOLU EZENWA VIVIAN CHIZUBE EZENWANNE EMMANUEL OKECHUKWU EZENWATA PHILOMENA MARIAN EZENYIRIOHA STANLEY JULIUS EZEOBI BENIGRUS CHINONSO EZEOMA IKECHI TAMUNOTONYESIA EZEORJI OGECHUKWU EZINWANNE EZEUDU ONYEKWELU CYRIACUS EZEUGO IKECHI EBENEZER EZEUGO NDUBUISI EZEUGO PRINCE I O NWAEZEUGO EZEUGWU EBUBECHUKWU EDWARD EZEUKWU TOCHUKWU MICHAEL EZEWUIKE UCHECHUKWU GODSWILL EZIAMAKA JOHN EJIKEME EZIKE DESMOND CHIMA JNR EZIKE JONATHAN CHINYERE EZIKE RICHARD EZIKE SIMON EZINWANYI DAMASUS-UMEH EZOMO OGIE EZUGWU CHINELO EZUGWU SYLVESTER O EZURUM NWAMAKA ROSEMARY F & FIT SERVICES F&C SECURITIES-DEPOSIT A/C FABEKU KOLAWOLE OLALEKAN FABIYI TIMOTHY FALODUN FABODE ABIODUN OLUFEMI FABOYEDE OMOLARA ABIOLA FABUNMI AKINWALE ADEBIYI - 2 FABUNMI JOSEPH IRETI FABUNMI THOMAS OLADEJI FADAHUNSI OLUFEMI ADEDOYIN FADEYI NURUDEEN TUNDE FADHILAH BOLUTIFE AYINKE ALIMI FADIORA ISAAC FADIPE ADEBIMPE OLAYINKA FADIPE JIMOH OLUKAYODE FADIPE MOTUNRAYO FADOJU ADEOLA OLUWASEUN FADONUGBO MARY ABOSEDE FADUMILA KEHINDE STEPHEN FADUYILE GRACE OLABODE FAFIOLU ANTHONIA OLUWASEUN FAFOLAHAN EZEKIEL ADEKUNLE FAFUNWA ADENIYI FAGBAYI ELIKEHAN BOLAWOLE FAGBEMI ITUNU HANNAH FAGBEMI MARY ABOSEDE FAGBEMI OLAYEMI OLUFUNMILOLA FAGBEMI OLAYINKA OLAWANLE FAGBEMI VICTORIA OLUWATOBILOBA FAGBEMIDE ADESOLA FAGBEMIDE ADESOLA ALABA FAGBULU ADEYINKA OLUFUNMILAYO FAIR PRICE VENTURES LTD. FAJANA TEMITAYO SUZAN FAKAN OLATUNBOSUN BABATUNDE FAKAYODE OLAWALE VICTOR FAKIYESI AYOKANMI OLUWASEUN FAKOLUJO OLAKUNLE KAYODE FAKOREDE ADENIKE MONISOLA FAKOREDE OLADIPO FAKOREDE TITILAYOMI SAKIRAT FALABI ESTHER FALABI IDOWU FALABI KEHINDE FALABI OLAYIOYE FALABI OMOLOLA FALABI OMOTUNDE FALABI SAMUEL FALADE IBUKUN OLUWASEUN FALADE OLUSEGUN LUKMAN FALCON SECURITIES LTD. TRADING A/C FALEGAN KOFOWOROLA OLUFUNMILAYO FALEYE OLAJIDE OLASUNKANMI FALLE NANBOL PAUL FALOLA HEZEKIAH OLUBUSAYO

FALORE OLASUPO FALORE OLUWASIJIBOMI AYOMIDOTUN FALORE OLUWASIKEMI AYONITEMI FALORE TEMITAYO FAMAKINWA FESTUS OLATUNBOSUN FAMAKINWA GLADSTONE OLUMUYIWA FAMILUSI JONATHAN AKINYEMI FAMODIMU ALFRED OLUSEGUN FAMOROTI ADERONKE FAMOROTI OMOTAYO OMOLE FAMOTI AYOMIDE DAVID FAMOUS AKEEM FAMUTIMI FEYISOLA OLAMIDE FANAMA PETER AREDE FANIYI ESTHER ADEWEMI FANIYI OLUWAGBENGA AMOS FAPOHUNDA KAYODE JAMES FAPOHUNDA OLAİTAN FAPOHUNDA TEMITOPE FARAMADE OYENIYI FARAMAYE FELIX OLATUNJI FARAMAYE OLATUNJI FELIX FARAWE ROTIMI OLUSEGUN FARAYOLA DANIEL OLADAPO FARI MUSTAPHA UMAR FARRI AJAGBE GBOLAHAN FASANYA ADESOJI FASASI OLUSOLA ABDULWAHEED FASEDEMI TITILAYO FASEEMO OLADIPO GABRIEL FASEGHA VINCENT OLASEINDE FASHAKIN OPEOLUWA ADEMOLA FASHEDEMI OLUSHOLA FASHEDEMI TITILAYO TOSIN FASHINA DAVID FASHINA ENIOLA ELIZABETH FASHINA OLUWABUSOLAMI PEACE FASHINA RILWAN ADEBOLA FASIKU ADEWUNMI AJIBADE FASIKU OLAYINKA FASOTO GRACE BUKOLA FASTRACK INTERNATIONAL SCHOOL FASUSI OLADAPO FATADE HABIBAT FATBOL SUPERIOR PRINTERS FATE ABUBAKAR ALIYU FATILE OLUBUNMI E. FATIMAH ADEGUNWA FATOBI FUNSO FATOGUN OLUBANJI THOMAS FATOLA JOSEPH OLUFUNMILADE FATOYE OLUSEGUN JOHN FATUBARO TEMITOPE KOREDE FATUNBI KEHINDE AYODEJI FATUROTI FOLAKE BOLAJI FAYANKINNU AKINYEMI OMOTOLA FAYOADE BABATUNDE FAYOMI JOHN OLUKAYODE FBC TRUST & SECURITIES LTD-DEPOSIT FBN CAPITAL NOM-KURA MOHAMMED FCL ASSETS MANAGEMENT LTD -FEABS VENTURES FEHINTOLA DAUD OLUSHOLA FEHINTOLA SIMEON AKINADE FELIX PRAISE EBIRERI FERRANO & ASSOCIATES FIDELIS EGUREFA FINANCIAL DERIVATIVES CO LTD FINMAL FINANCE COMPANY LIMITED FIRIMA BARI-MM-ME EMMANUEL FIRST ATLANTIC SEC. LTD-DEPOSIT A/C FITIS VENTURES LIMITED FOLAJU OLUYEMISI OLUDOYIN FOLAMI HAKEEM FOLAMI ISMAIL ADEBOWALE FOLARIN OLADIPO FOLARIN SEGUN TOPE FOLORUNSO ALADE FOLORUNSO OLUBUNMI SADE FORTE ASSET MGT LTD-TRADED-STOCK-FORTRESS CAPITAL LIMITED FOTOTEK INDUSTRIES LIMITED FOWORA EMMANUEL OLUFEMI FOWORA INIOLUWA ANNA FOYDEX VENTURES FRANK AJANAKU SEGUN PETER

FRED EHI UGHULU & COMPANY

FRED-HORSFALL TONYE AWOALA JANE

FREEDOM INVESTMENT CLUB FREEMAN HENRY BIRCH FUND MANAGEMENT SECURITIES FUSL NOMINEE AC FRANCIS OGBAJIOGU FUTURE- CARE INVESTMENT CLUB FUTURE TRUST SECURITIES GABRIEL SUNDAY MATTHEW GALLAGHER TRUST LTD GAM-IKON OTO-OBONG OLUMUYIWA GANA GIREI USMAN GANIYU FUNMILOLA GARBA ABDULAZIZ GAFASA GARBA AZEEZ YINKA GARBA BITRUS AMUCCAN GARBA GWAMKAT MARY GARBA HALIMAT YETUNDE GARBA JUMMAI GARBA MUHAMMED GHALI GARBA VERALUCIA ERIS TER GARUBA HALIMA LADIDI GBADEBO BOLAJI SIMEON GBADEBO OPADIYA GBADEBO TEMITOPE GBADEBO-SMITH FOLARIN GBADEGESIN OLUGBENGA MURITALA GBADEGESIN SUNDAY AJIBOLA GBADERO MICHAEL KAYODE GBADEYAN SUNDAY ALABI GBEM TER-ER FESTUS GBEYIDE EMMANUEL OLUWOLE GBOROGEN EDWARD GODDEY GEORGE FAITH EKELIKHOTSE GEORGE KUKOYA GEORGE OLUMUYIWA GEORGE TEMITAYO GIDADO MOHAMMED GIDIGBIH OLUYEMISI MONSURAT GILENYA JOEL ANDREW GIWA IDRIS GIWA MOTUNRAYO BILKIS GIWA OLAYINKA GLOBAL ASSET MGT. LTD-TRADED-STOCK-A/C GLOBAL FIELD INVESTMENT SERVICES LTD GLOBAL TOWER LIMITED GLOBAL UNIFORM PLACE VENT & INVEST LTD GLORIOUS HAVEN LTD GOLDEN LINKS VENTURES GOLDEN SECURITIES-DEPOSIT A/C GOMWALK CELESTINE W. G GONI BUKAR GOSPEL TEXTS INTL GOVINDAN RATHEESH GOYIT DAVID LUKA GOZAMS NIGERIA LIMITED GRACETRUST NIGERIA LIMITED GREENFIELD CAPITAL LIMITED GREENFIELD CAPITAL LTD GREENLIFE PHARMACEUTICALS LIMITED GUA LILIAN LOANIABARI **GURUMLAT FRANCIS** GUSIORA ADAEZE ANGELA GWAKZING ZINGBUT GIDEON GWAMNA IDRIS ISHAQ AADIL GWAMNA ISHAQ ISHAQ GWON GARBA MARCUS GYANG GREGORY D GYANG PAULINA HAASTRUP OLUGBENGA ADEDAYO HABIBU ALFADARAI FATIMA HABIBU ALFADARAI MUBARAK MUHAMMED HABIBU ALFADARAI SALIM MUHAMMED HABILA KALLAH HABIZHI MOHAMMED BITRUS HAM TEM NIG LTD HAMBEH SAMUEL TERHEMEN HAMDANA SAYUDI MOHD HAMELBERG MARIE MONIQUE HAMILTON RACHAEL OLUFUNKE HAMIS BALA MUSA HAMISU KABIR KURA HAMMAD RIDHWAAN ISHOLA

HAMMAN-OBELS RUKEVBE TEJIRI

HAMMED ABUBAKARE ABOLAKALE

HAMMED ABIDEEN ABIOLA

HAMZA YAHAYA HANNATU

HAMZAT NURUDEEN OLATUNJI HARRISON DAVID OGHENEKEVWE HARRISON PATIENCE ELEDU HART ADONYE FRED HARUNA BALA HARUNA BUKARI AHMAD HARUNA NURA HARUNA SHUAIBU HASHIRU AMINU HASSAN ADAMU WASE HASSAN ADERONKE OLUBISI HASSAN ADESOLA BOLANLE HASSAN AGNES MODUPE HASSAN AHMED HASSAN ALIU I. HASSAN BASIRAT IYABODE HASSAN İBRAHİM SALEH HASSAN KAYODE RAHEEM HASSAN MOMONUHU IBITOYE HASSAN SIKIRAT TEMITOPE HEDGE SECURITIES & INV. CO LTD HELEN UMOSEN OLIH HENSHAW EFFIONG ETIM HEPHZIBAH DOTUN JOSEPH HOLLAND KIERON JAMES PATRICK HOLY CROSS CATHEDRAL LAGOS HOTORO YAHAYA YAKUBU HOUNSINOU ALFRED OLUSEGUN HUBLINK ENT. NIGERIA LIMITED HUNDUGA AMOS KAZUGA HUNGA MOSES YEMARO HUNPATIN DANIEL BONA HUNPONU-WUSU JAMES JACOB HUSSAINI SAULAWA MUHAMMAD HUSSEIN MARIAM I.O.D. VENTURES LTD IBARE-AKINSAN BABATUNDE SODIPO IBE GODWIN EMEKA IBE IFEOMA GLORIA IBE JUDE IFEANYI IBE LEO IBE SUZAN IBEAWUCHI EMMANUEL CHUKWUEBUKA IBEGBULEM CHUKWUKA ONOCHIE IBEJIH CHRISTIAN OGUMKA IBEKWE MARTINS CHIDI IBEKWE STANLEY UGOCHUKWU IBEMENA CHARLES UCHECHUKWU IBEZIM DORIS CHIBUZOR IBEZIM JOY NNENNA IBEZIMAKO BATHLOMEW IBEZIMAKO CHINAZA IBEZIMAKO FRANCISCA IBEZIMAKO IFEOMA MARVELOUS IBEZIMAKO MIRACLE IBIANG IGWE IKONA IBITOYE ABDUL-LATEEF IBITOYE OYEWALE IBOBO IKEM DONATUS IBOI GODWIN EGBUNU IBOK BENNETH MBOSEOWO J IBOK EDET ISONGUYO IBRAHEEM MOSES GBOLAHAN IBRAHIM ABDULMUMINI IBRAHIM ACHETU ANITA IBRAHIM DANJUMA IBRAHIM DANTATA BILKISU IBRAHIM DAYYABU SABIU **IBRAHIM HABIB ADEYINKA** IBRAHIM HAMZA. IBRAHIM IMAM BABAGANA IBRAHIM ISSA LEKAN IBRAHIM JALO ADAMU IBRAHIM KAMARUDEEN OLATUNJI IBRAHIM KAZEEM KAYODE IBRAHIM MARY IBRAHIM MORILAT OLAYINKA IBRAHIM MUHAMMAD BASHIR IBRAHIM MUHAMMAD MUSTAPHA IBRAHIM MUKTAR GARBA IBRAHIM MURITALA IYANDA IBRAHIM OLADIPO OYEBOLA IBRAHIM OLAIDE HAFISAT

IBRAHIM RUKAYYA-

IBRAHIM SARAFA AYOBAMI

IBRAHIM TAJUDEEN AFOLABI

IBRAHIM TEMITOPE AMINAT

IBUBELEYE HEPHZIBAH DIEPRIYE

IBUZUGBE DAVID BEATRICE IMA (ESTATE

IJIMAKIN OLA EBOH

HAMZAT ISIHAQ OLANREWAJU

IDADIS VENTURES IDEHEN CHRISTOPHER OSAGHOBO IDEHEN ELIZABETH ANAMELECHIM IDEHEN EMMANUEL CHIKA IDEHEN GOODLUCK EWERE IDENA JOSEH IDIAGHE MARTINS IDIAKA AJIBOYE CHRIS IDJAGBORO SEGUN ANTHONY IDOKO ANTHONY SULE IDOKO CECILIA ADA IDOWU ABRAHAM ABIODUN AYODEJI IDOWU OLABODE DANIEL IDOWU OLUFADE IDOWU OLUMIDE OLALEKAN IDOWU OLUSOLA ADEBOYE IDOWU OLUWATOYIN ADENIKE IDOWU SEGUN OLUKEYEDE IDRIS NAFISATU IDRIS OLAJIDE IDRIS SAIDU NDAKO IDRIS UMAR FARUQ IDU OMOWUNMI PATIENCE IDUNGAFA JOHN MICHAEL IFALOLA IBUKUN IFEAJIKA NONYELUM KEHINDE IFEAKACHUKWU ELOCHUKWU AFAMEFUNA IFEDAYO KAYODE IFEKOYA JULIUS OLUFEMI IFELAGBA OROGUN (UNITY) IB NUT CICS IFEME CHINENYE OGECHI IFEZULIKE DAVID CHIDOLUE IFIDON GBENGA O A IGBAFE JOHN IGBALAJOBI JOHNSON OLADIRAN IGBASANMI BUKOLA AKINRINBIDO IGBASANMI JOHN OLATOMIDE IGBEARE SOLOMON OSAYABANWEN IGBEDA OLUGBENGA KOLAWOLE IGBINEDION NOSAZENE IGBINIDU BLESSED BELLO IGBO EZENWA BETHEL IGBOANUGO BONAVENTURE IKECHUKWU IGBOANUGO BONAVENTURE UGOCHUKWU IGBOANUGO ROSE NGOZI IGBOKWE CHIJIOKE CHUKWUEMEKA IGBONGI OCHE OCHE IGBRE ONORAKPOR JOHNBULLEY IGBRUDE ESTHER TSANG IGE JIDE (PROF.) IGE SAMUEL SUNDAY IGE SAMUEL TEMITOPE IGEKIE DANIEL OSHIOLENE IGHERE OVIPHAUVIEKE GODWIN IGHIWIYISI JULIUS OSAS IGHOJOVBE W. OGHENEKARO IGHORODJE BELIEVE IGHOVOJAH URINRIN IGIBAH STANLEY IGIEHON NELSON IGIM IYKE IGIWA FRIDAY IYENDEBAMHAN IGONI GIDEON OYEKUODI IGWE AYODEJI IGWE AYODEJI IGWE HENRY CHINEZEREM IGWE HEZEKIAH OKEREKE IGWE NWACHUKWU (MR) IGWE WOBO PROMISE IGWEGBU ELIAS CHIABOEZI IGWEH NDAH IGWEMMADU FELICIA UZONWANNE IGWOBA UWALELE SOLOMON IHEANACHO UCHE IHEANYICHUKWU HENRY ONUOHA IHEBIGHI GABRIEL SUNDAY IHEJIAKO BERNICE OWUTUBOPIRI IHEJIRIKA OBINNA CHIGOZIE IHEZIE CALISTA CHILEZIE IHWIGHU EMMANUEL OCHUKO IJADUNOLA KAMORU RAHEEM JAGBONE EUNICE ESEOHE IJAOLA ADELOKOJI OKEJINMI IJEI TOBECHUKWU ESTHER IJIMAKIN OLA

IJIMAKIN OLA EBOH IJOGUN AYODEJI IJOLO EDIRI OJIYOVWI IKE IFEYINWA MBATAKU IKEAGWU CYRIL IFEANCHUKWU IKEAGWUONWU ADAEZE C.AZUBUIKE IKECHUKWU CHIEDOZIE M. IKECHUKWU EVANS IKECHUKWU PASCAL SOLOMON IKEDIALA KINGSLEY IKEH FRANCIS IKEHI INTERGRATED VENTURES IKEM FERDINAND CHINENYE IKEMEFUNA AMAECHI MACKSON IKEMEFUNA UYI MARVIN IKEORA UCHE CALLISTUS IKEORAH CHIKE IKHIZAMA BOSEDE OMOKHUPON IKIAKHELE PATRICK EHIMEN IKORO CHIMA IKPA ROSEMARY NNENNA IKPE ETO INNOCENT IKPE NSIKAN UDO IKPEAZU AKUDO EZINNE IKPEH THERESA IKPETESHI EMMANUEL UCHECHUKWU IKPOKI KUENI ANDREW IJOMA IKPOKI MUZENI IVANA KONYEREM IKPOLO RITCHEY CHINEDU IKULOBURU DANIEL AJINDE IKUMAPAYI OLUMIDE JOHNSON IKUSORO ALABA IKWUEGBU FOLASHADE OLUBUNMI IKWUNADO GODSAVEUS MADU ILAKA MARIAM OYENIHUN ILECHUKWU ALEX CHUKWUDI ILECHUKWU BASIL OBUNIKE ILECHUKWU DONALD CHIGOZIE ILENBILUAN LYDIA SEUN ILIYA ESTHER ILIYA YUSUF UNGOGO ILLAH GEORGE ONU ILO VINCENT NBUDICHE ILOANUGO KENECHUKWU VALENTINE ILOBINSO PETER NDIULOKWE ILOBU COMMUNITY BANK LTD ILOESOGBUNA ESTHER ILOEZUMA BENEDETTE CHIKA ILORI IDOWU ADEPEJU ILORI OLAYINKA EMMANUEL ILU SULAIMAN ILUFOYE MUDASIRU ILUYEMI OLUFUNKE IMADOJEMU SEWANU DUPE IMAGELINKS ROYAL PROPERTIES LTD IMHANGUEZEJIE JOHN EHIS IMOISILI TONY IMOLEOLU ADESOLA FLORENCE IMOLEOLU OLUSOLA IMORU ISAU IMOSEMI OMOLE EKEIREME INEH - MIC AUTO COMPANY LTD INKO-TARIAH EMMANUEL A. BEKINBO INNOCENT JOHN IKECHUKWU INTERGRAPHICS (NIGERIA) COMPANY INTERNATIONAL HEALTH MGT CONSULTANTS INUWA B.K MUHAMMADU INVESTCORP & SECURITIES LTD INVESTDATA CONSULTING LIMITED INVESTMENT CENTRE LIMITED INVESTMENT STRATEGIES LTD INVESTORS PORTFOLIO SERVICES LIMITED INYANG UNYIME-ABASI MFON INYANGUDOH EFFIONG EFFIONG INYANGUDOH ISONG ITAUMA I-ONE E-PORTFOLIO AC - 201 IOBI IAM AVADOO VICTORIA IORLIAM TERKUMA DANIEL IOU INVESTMENT ADVISERS LTD IPEAIYEDA OYEDELE IPEAIYEDA OYEWALE IREGBENU PAUL CHINENYE IRENE ROLAND OLUMESE IREROA ELILE AYO IRHUEBOR DAVID IRIBIRI OMAFUME MEWHORORENE

IROBI CHIKAODINAKA ANENE ADLINE

IROENYENWA PRTER OKORIE

IRUH SYLVESTER KANYINELUWA IRUKWU CHIDINMA ROSELINE IRUNE BEATRICE ISA ABDUL HAMEED ISA ABDULLAHI ISA ALI ISA MAIRO TALATU ISA SAIDI ISAGBA EDNA NKEONYEASUA ISAH MEDINAT SALIHU ISAH YEWALE ISAIAH EMEKA PHILIP ISAIAH PRINCE JOSHUA ISAIAH ROSELINE NGOZI ISAMOTU BUKOLA ADEOLA ISHAKU MUSA FATIMA ISHOLA ADEKOLA ISHOLA ASIATA JUMOKE ISHOLA MOBOLAJI KAZEEM ISHOLA MOSOPEFOLUWA I. T. ISIADE OLUSOLA OLUMIDE ISIAKA AZEEZ OLAMILEKAN ISIJOLA AYOKA OLUWARANTI ISIJOLA CAROLINE KEHINDE ISIOMA UFERE ISIOYE NOJEEM OYELERE ISIYA-GAYA ZAINAB ISMAIL DALHAT AHMED ISMAIL RUKAYYA MUHAMMAD ISMAILA HAFIS AJAYI ISONG PETER SUNDAY ISSA ABDUL LATEEF ISSA ABIODUN AHMED ISSA NIMOTA BOLANLE ISUKURU SAMSON AKPOWHOFADAYE ISUNUOYA IRASE ANTHONY ISUO ATTE IBOK ISYAKU NAFIU ITA MICHEAL ITA OKPO OKOKON ITAH CECILIA MISSION ITAKPE FATIMETU ITUEN ANTHONY IVEEC INVESTMENTS LIMITED IWEANYA AMECHI VICTOR IWEANYA CHIKA VERONICA IWEGBU JULIANA EKENE IWENEKHAI ETSEOGHENA SOPHIE IWUCHUKWU NKEMDIRIM EZINWANNE IWUCHUKWU PATRICIA IWUH IFEANYICHUKWU FIDELIS IWUOHA CHIDINMA BLESSING IWUOHA CHUKWUMA UZOMA IYAGBA STELLA ABIYE IYAJI FAITH DEBORAH UNEKWUOJO IYAJI MONDAY AUDU IYAJI SAMUEL VICTOR OJONUGWA IYAMU DAVIESON OGIEOZEE IYANDA DEBO PHILIP IYANIWURA ADEBISI L. IYANIWURA MUJIDAT AJIKE IYAOMOLERE SUNDAY ADENIYI IYASELE IKE IYEIMO ILAMINA IYEIMOH SOBA IYIEGBU IKENNA IYIOLA FATAI BABATINDE IYOHA EHIWENUMA REBECCA IZORE NOSAKHARE LUGARD IZU ABIMBOLA IZUAFA OVIAWE ABIGAIL JABAR RASEED JABIR ABDULLAHI JACKSON CHRISTIAN ANTHONY JACKSON DASO ADOLPHUS JAGUN OLUWATOYIN OLAJUMOKE JAGUSA JEREMIAH TARWANGER JAIYEOLA KAYODE TIMOTHY JAIYEOLA BAZAK ADELEKE JAJA MICHAEL MORDICAI OKO JAMES CHRISTIANA AKULA JAMES E BASSEY JAMES GLORY MFON JAMES KOKOETTE SAMUEL PETER JAMES KOLADE SEMASA JAMES S JOSEPH JAPHET VICTOR BENSON JAWANDO OLUWAKEMI JAYEOBA MICHEAL OLUDARE

JAYEOLA SHEGUN ADETOLA

JEGEDE ADEBAYO VINCENT KAMIYOLE FAVOUR OJOCHOGWU JEGEDE MICHAEL KAMLA ARAB ABRAM JEGEDE OPEMIPO OPEOLUWA KAMSHIRE MOSES PHILIP JEHU PHILIP KAMSON OLAYINKA OLUSOGA JEJE SUNDAY TEMIDAYO KANCHOK SOLOMON ELISHA JEMENI CHUKWUEBUKA M. & CHIDINMA KANJIGA PROPERTIES VENTURES KANKAROFI MUHAMMAD KASIM JEMENI MMACHI JEMIBEWON ABAYOMI OLUWASEYI KANKU AYUBA JEMILUGBA JULIUS SUNDAY KANU GODWIN CHIEMERIA JERRIPATSONS INTEGRATED CO KANU IVAN SUNNY KARAYE FATIMA L.SUNUSI LIMITED JETAWO ABIMBOLA KAREEM WASIU OPEYEMI JIBOWO EBENEZER OLUSOJI KASALI ABAYOMI MATTHEW JIBOWU YISA KASIM ABIMBOLA - TRADING AC JIBRIN SANI GAWUNA KASIM AISHA JIBRIN USMAN KANFANI KASIM JOSHUA TIWATAYO JIDEKENE UDODIRIM CHIKODIRI KASIM JOTHAM TIWATOPE KASIM OLUWATOBILOBA JIDEONWO CHARLES FRANCIS JIFANI LIMITED KASIM ZARA JIMA NIG. ENTERPRISES KASIMU BILKISU GARBA JIM-AJASA AZEEZ (ALHAJI) KATO YAKUSSAK JIMLAWRIC INDUSTRIES LTD KATOR MARY OMATI JIMOB POWER COMPUTERS KAYBEE INTERBIZ NIG. LTD JIMOH ABEBI SOFFIAT KAYODE GBENGA MICHEAL JIMOH ADUNNI RASHIDAT KAYODE OLUBAYO JIMOH AKEEM OLUFEMI KAYODE OLUWADAMILOLA JIMOH FAIDAT ABIODUN KAYODEBOLAJI FLORENCE JIMOH JAMIU KAZAH JANE ALICE JIMOH LATEEF KAZEEEM ADEWALE NURUDEEN JIMOH MUSE AYINDE KAZEEM BINTU ADUNNI JIMOH ROTIMI MONSURU KAZEEM TAWAKALITU ABOLANLE JIMOH VERO KAZEEM-ABIMBOLA SHERIFAT OLANREWAJU JINADU BARAKAT ABIKE OPEYEMI KEHINDE ABAYOMI JINADU FOLASHADE MARY KEHINDE IBIRONKE MUINAT JINADU LAMIDI OLANIRAN KEHINDE OLATUNJI SUNDAY JINADU RAPHAEL AYOOLA JINADU WAFEEQ AJIBARE O. KELANI YUSUF OLUGBEMI KEMELAGHA FRANCES JIRIKO RUTH KEFAS KEMELE EDWARD JITUBOH DONALD KEMMENI SYLVESTER MONDAY OSANEBI JOHN ANIEKAN ASUQUO KENE-OKAFOR CHINENYE JOHN EMMANUEL DANJUMA KESANDU-UCHENYI ONYENWE IFEUDE JOHN HARCOURT KESHINRO RASHEED JOHN JOCHEBED ODUNAYO KIAMA KEUWE ROSEMARY KIKSENENSO DANIEL BENJAMIN JOHN OBI NNAJIOFOR JOHN OLUWAROTIMI (WEB PORTAL) KILANKO YINKA ELIJAH JOHNSON EMMANUEL ABAYOMI KINGDOM PILLAR INVESTORS JOHNSON LAURA NKECHI KINGS CAPITAL LIMITED JOHNSON OLADIPUPO EMMANUEL KINGSLEY-ODIA OSARENKHOE AGATHA JOHNSON SAMUEL PETER KINGSPRIDE SECURITIES LTD JOKODOLA MATTHEW OLALERE KIRKWOOD OLAJUMOKE ABIODUN JOMBO AFOLABI KOBOMA MULTI-PURPOSE COOP SOC JOSEPH ABIGAIL AKPUO KOFI BENNI JOHNSON (PROF) JOSEPH IBIRONKE ELIZABETH KOFO MAJEKODUNMI JOSEPH OLIKAYODE KOJAK INV LD KOKO CHRISTOPHER OKITOH JOSEPH OLUYEMISI ADETOKUNBO KOLA OLOJA KOLAWOLE ASIMIYU FOLARIN JOSEPH ROTIMI JOSEPH SIMEON OYEPATA DARE KOLAWOLE BOLANLE OMOLARA JOSHUA BULUS KWAGHE KOLAWOLE INVESTMENTS LIMITED JOYCE OLOHITARE OGEDEGBE KOLAWOLE OLAMIDE BUNMI JROCK INVESTMENT LTD KOLAWOLE SAMUEL OLADAPO JUBRIL ADELEKE KAZEEM KOLEY SANJAY JUBRIL AMINU BABATUNDE KOLO MAMUD HABIBA JULIEN NGOZI OZOEMENA KOLO NASIRU MOHAMMED JUMUDJAYEN RUTH & LUCKY KOMOLAFE JULIANA TOYIN JUNAID SIKIRU AREMU KASHIMAWO KOMOLAFE OLUWABUKOLA K.C. EZEM JUDITH & YADERA KONKWO DEDE ELEMEUWA JOE KADAFUR ALI BULAMA KONYEFA YERINDIDEKE KADIRI ABAYOMI SHEWU KORIE IJEOMA SHANDY KADIRI ABDULAZEEZ ADEOYE KOSISOCHUKWU MITCHEL ANYANWU KADIRI ANDREW KOSOKO ABDULLAHI JUBRIL KADIRI ASEKHAMHE ANDREW KOTIKU ROTIMI S. KADIRI FATIMAH ADEOLA OPEYEMI KUDAISI AFOLABI IBRAHIM KADIRI HAFEEZAH YETUNDE ABIOLA KUDAISI MOJISOLA HABEBAT KADIRI IDRIS ABIODUN OLUWATOSIN KUKOYI SIMISOLA KUKOYI TEMITOPE EMMANUEL KADIRI JOSEPH KUDI KUKU BALOGUN SIKIRU OLAJIDE KADIRI LOOKMAN AMOO KADIRI NIMOTULLAH ENIOLA KUKU GBADE SIKIRU KADIRI OLALEKAN JOHN KUMAPAYI O OLUWATOMISIN KADIRI WASIU OLAWALE KUMAPAYI OLUWAFIKAYOMI KADRI ONOISEDEBA ANGELA KUMAPAYI OLUWATITOFUNMI KADSULATE VENTURES KUMOEI LIMITED KAKA OLUFUNKE MARILIAT KUMOYE JULIUS SUNMADE TEMITOPE KALANGO INATIMI KURTONG ISITIFANUS IBRAHIM KALEJAYE SAMUEL ABIODUN KURUNMI TENIOLA KALESANWO FELIX OSILOLA KUTEYI IYABO LINDA ADETOKUNBO(DR) KUYE OLAMIDE KALU BLESSING BEAUTY KUYORO DANIEL AYODEJI KALU JUSTICE KWAJI DANIEL KALU NKEMDIRIM KWARU SALEH ADAMU

KWASARI ANDREW ROBERTS KWASAU ABDUSSAMAD SHEHU KWASHAL ZUBAIRU AYALA KWT LTD KYALO ANTONY KYAUTA YEPWI EMMANUEL LABARAN AMINU SULE LABARAN VICTORIA JAMANA LADAPO OLAJIDE LADEJOBI FOLUSO ADETOKUNBO LADIGBOLU ORIYOMI OLOUNWA LADIPO KOLAWOLE LADIPO LAYIWOLA LADIPO MOYOSIOREOLUWA GLORIA LADIPO OLATEMIDE MAYOWA LADIPO OLATUNDE AKINOLA LAGOS STATE BAPTIST CONFERENCE LALEYE TOLUWALASE ANTONY LAMIDI ADEBAYO AKIM LAMINA SIKIRU TAIWO LAMPSFORT NIGERIA PLC LANDMARK CAPITAL MANAGERS LTD LAR URIAH ALEXANDER LARAIYETAN H.O. LARAIYETAN OLUSEGUN HENRY LASISI WASIU LASOJU ABIKE MARY LASOJU AGNES MODUPE LASOJU OLAKUNLE OLADIPO LATEEF TAJUDEEN OWOADUNNI LAWAL ABISOLA RUKAYAT LAWAL ADEKUNLE ABEEB LAWAL ADEYEMI EMMANUL LAWAL AHMED LAWAL AZEEZ OLANREWAJU LAWAL AZEEZ OLANREWAJU LAWAL BOSE ADENIKE LAWAL IDRIS TANKO LAWAL IFEOLUWAKITAN ANUOLUWAPO LAWAL KABIR LAWAL KAZEEM ABUBAKRE LAWAL KAZEEM OLALEKAN LAWAL MORENIKEJI KAFAYAT LAWAL OLASUNKANMI FIRDAOS LAWAL OLUWASEMILORE ARIYIKE LAWAL RAMON TAIWO LAWAL RASHEED GBENGA LAWAL RASHEEDAT ADESHOLA LAWAL RISQNAT ABIMBOLA LAWAL SAHEED LAWAN HADIZA LAWANSON HAOLAT ROMOKE LAWANSON IBIYEMI KOLAWOLE LAWRENCE MARY LAWRENCE TEMITAYO BEATRICE LAYENI ADERIBIGBE IDOWU LEIGH KAYODE TUNMININU LENKA PHILIP MUSA LERAMO RICHARD AJAYI LEWIS RICHARD LIN JIANG LISA TAJUDEEN AKANJI OLA LMB STOCKBROKERS LIMITED LOKO IYANUOLUWA EMMANUEL LOKO OLUWATUNMISE TITILOLA ESTHER LONGREACH GLOBAL RESOURCES LIMITED LORI DAVID THANK GOD LOTTOJ GLOBAL INVESTMENTS LTD LSB INVESTMENT CLUB LUGARD INSURANCE BROKERS M A ONIGBINDE & SONS LTD M. A. ONIGBINDE & SONS LIMITED M.O.OGUNSOLA & SONS LIMITED MA'AJI ABUBAKAR MUHAMMAD MAAJI MOHAMMED MABADEJE EMMANUEL OLUBUNMI MABO OLUGBENGA OLUSANU MACAULAY SUNDAY NWACHUKWU(PASTOR0 MACT SECURITIES LTD - DEP A/C MADAWAKI SHAFIU KATSINA MADU CHIOMA SARAH MADU EDWIN EKENE MADU OBINNA KINGSLEY MADUABUM CHUKA/RAMCE MADUAFOR CHUKWUBUOKEM

THEOPHILUS

MADUBUKO ELISHA IHEME

MADUBUKO ONWUEMELIE BRENDAN MADUFORO GOLDEN C MADUFORO GOLDEN C. MADUKA STELLA MARIS MADUMERE GANDY NWABUEZE MADUWUBA EMEKA MAFULU OLIVER MAGAJI AHMED DOGON DAWA MAGAJI IFRAIMU ILIYA MAGBOH MAUREEN NKIRUKA MAGU BUKAR MAGU MAILUMO ABUBAKAR MUDI MAINA AISHA BUKAR MAINA HASSAN A MAIWADA SA'ADU MAJABE AHMED SANDA MAJEKODUNMI ADESEYE JACOB MAJEKODUNMI DAPO MAJEKODUNMI OLAWUNMI MAJOLAGBE OLABOWALE HENRY MAJORO OMOLAJA MAKINDE SAKIRU MALGWI HARUNA MOHAMMED MALOMO GABRIEL OLUSHOLA MAMMAN REGINA WAJEH MANBOL SUPA MANGGEI GABRIEL GLADYS MANI MORGAN MUSA MANSON BABATUNDE KABIR MARAIYESA GBENGA ADEMOLA MARCUS LUKAS MARS RESEARCH MARTINS BABATUNDE OLADIPO (JUSTICE) MARTINS CATHERINE AMUONOSU MARTINS OLADIPUPO MICHAEL MARTINS OLAITAN ADEOLA MARTINS OLALANWA MARTINS OLUWABUSOLA MASKOT LINKS VENTURE MASON TUNMISE HALIMA MATHEW SUNDAY MATIANO VENTURES MAXIFUND INV. & SEC PLC MB GLOBAL VENTURES MBA EVELYN MBACHU EKWUTOSI MBACHU MBACHU OZOEMENA NESTOR MBACHU RAPHAEL MADUBUBA DAWAH MBADIWE NDUBUISI HENRY MBAH EUNICE B. MBAH LILIAN CHIOMA MBAJEKWE AUGUSTINE CHIJIOKE MBANEFO CHIAMAKA MBANUGO AUGUSTINE UCHENNA MBC INSURANCE BROKERS LTD MBC SECURITIES NOMINEE "DPH" MBODI FELIX MBONU AZUBUIKE FIDELIS MC-BOYLE HOPE MEBAWONDU MARGARET OLORUNFUNMI MEDAHUNSI AKINOLA MEDAHUNSI CHRISTOPHER OLAJIDE MEDUOYE CLEMENT AYODEJI MEGA EQUITIES LTD MEGA EQUITIES NIGERIA LTD MEGA SHIELD MEGAWEALTH LIMITED MEGBULUBA EBIYEMI ORITSUWA MEMBERE ABIYE HENDERSON MENKITI EMMANUEL IKECHUKWU MERIFRIEND ASSOCIATES MESELE FOLUWASAYO JOSHUA MESH FADEKE OJUOLAPE MESHIOYE TUNDE MEON USOH SAMUEL MGBABAM FRIDAY MGBEAHURU PETER ENYEREIBE EMMA MGBEMENA IKE EMMA ROBINSON MGBEOKWERE CHUKWUMA MGBOH RAPHAEL OFOAGOZIE MGBONU EGBUNIWE MICAH KENNETH EZRA MICHAEL AKINADE ABEL MICHAEL IKHENOBA MICHAEL OLANIYI MICHAEL-MADUAKA DELE CHIBUZO MICHAELS RICK TOPE BUCKY

MICHEAL SUNDAY

MICHIKA YUSUF USMAN MIFTAH RIDWAN AJANI MIGDAD AJADI RASAKI MINAH LEGBORSI LEGBORSI MIRACLE ABIFADE OSAEOWOHAN MIRI DAMBE VONGDW MMO STANLEY CHUKWUJEKWU MOBAT ENTERPRISES MODU BENNETT OGUGUO CHIDI MODU NKECHI MODU NNEOMA MOGAHA GABRIEL CHUKWUELOFU MOGAJI EMMANUEL BAMIDELE MOGAJI VICTORIA OLUTAYO MOGBADEMU ADESANMI ALAO MOHAMMED ABDULLAHI MOHAMMED AMINU HALILU MOHAMMED BABA MOHAMMED FADILAH MOHAMMED GALI. MOHAMMED HADIZA ALIKO MOHAMMED HAFIZ USMAN MOHAMMED MARYAM ALIKO MOHAMMED MUSA J MOHAMMED SAGIRU SALISU MOHAMMED-ALIYU ADAMA MOJE ASSOCIATES VENTURES LIMITED MOJEKWU NELSON AMAECHI MOJUETAN PETER AGBOGIDI MOK EMMANUEL IFEANYI MOLOKWU AZUBUIKE AZIKIWE MOMODU DARLINGTON ALHAJI MOMODU LUCIA O. MOMODU OHIRHHEIME MARK MOMODU SAMUEL AIGBOKHAI MOMOH IBRAHIM GODWIN MOMOH RAPHAEL SADIK MONAKU DAVID MOGAR MONDALE IRONCHO MONDAY AYO BLESSING MONINA MATHIAS AKPOVETA MORADEYO KAMAR ADEOLA MORIAFEN DACOSTA AKPOMEDAYE OGBEN MORONKOLA TUNBOSUN ALABI DADA MORRISON HAMILTON MOSES JOHN FEMI MOSES NDIUWEM ANIETIE MOSES OLULANA LOYINMI MOSES ONYEBUCHI SAMSON MOSES SUNDAY OLUWASEUN MOSHOOD ISMAIL ADIGUN MOSURO ABDULRAHEEM MOYINWIN ADEGOKE SEHUBO MPAMA UCHE UDO MSHELIA PAUL MTAVIKILWA MUAZU SHEHU MUBARAK AYOMIDE OMO-IBRAHIM MUDASHIRU WAIDI KAYODE MUFUTAU NAJEEM ADEKUNLE MUHAMMAD AHMAD MUHAMMAD BABA CHIROMA MUHAMMAD BILKISU MUKHTAR MUHAMMAD HAMISU YADUDU MUHAMMAD HASSAN MUHAMMAD KAMILU BACHA MUHAMMAD SAMINU BALILI MUHAMMAD SARIYU GAFASA MUHAMMAD YABATA RAMAT BELLO MUHAMMADU JIBIRILLA MUHAMMED ISMAIL MUHAMMED MASHOOD OLAYINKA MUHAMMED MUKTAR MUHAMMED TUKUR ADAMU MUIBI ADETOKUNBO MUSTAPHA MUJAKPERUO VERA EKOREN MUKAILA KAFILAT AJOKE MUKTARI AUWALU MUNIR MOHAMMED AYOUR MUOGBOH OBINNA STAN & ROSELINE AYONDU MUOJIOFOR JOSEPH OKWUCHUKWU MUOKWE JOEL CHIMEZIE MUONEKE UCHE GLADYS MURAINO RAHMAN MURI AMINAT MURI WASIU AYINDE MUSA AGNES TALATU MUSA ALIYU MUSA DAWUUD

MUSA GANIYU ADETUNJI MUSA HALIMA-MUSA HAMISU MUSA HARUNA HALIYU MUSA IBRAHIM KATSINA MUSA MIFTAH MUSA MOHAMMED HAMIDU MUSA UMARU KABOJI MUSA YUSUF MUSA ZAIDAT ADESOLA MUSIBAU MUKAILA OLAMILEKAN MUSLIM DAHWD OPEYEMI MUSTAFA MOHAMMED HAMISU MUSTAPHA ADEWUNMI MUSTAPHA SAHEED BOLANLE MUSTAPHA SULEIMAN MUHAMMED MUSTAR SEED INVESTMENT CLUB MUTANA OAMEN MUTIU SHAMSIDEEN OLUSHILE MUYIWA RECOVERY ACCOUNT MUYIWA SAHEED OLASUPO N.T.C.N LTD NAABBA JAMEEL USMAN NABABA SANI NADEL ELECTRONICS CO.LTD NADI ADEOTI CECILIA NAJEEM SALAWA OLUWAKEMI NAME NANDUL TAMAR NANNA ENU IBITOLA NANNA TINUADE MUNIRAT NANSHAP ESTHER NANSHAP STEPHEN RICHARD NARASIMA PRASAD G NASIRU MUFUTAU AFOLABI NASIBU BABIU NAT LIBRARY OF NIG STAFF MULTI-PURP NATHAN EJIKE JOSIAH EJERE NATHAN WILFRED TOMBOFA NAZIRU MANSIR NDAFIAH A. LOVETH NDEDDE NDINANAKENKPO BENJAMIN NDIANEFO CHISOM CHIEBUKA NDIBE COLLINS NNONSO NDIDI EMMANUEL CHIEME NDIKA UCHENNA HARRISON NDIMELE MENYECHI MAUREEN NDIMELE UCHENNA NDU NYEKACHI KINGSLEY NDUBUISI COSMOS RICHARD NDUBUISI OKECHUKWU .H NDUBUISI PATRICK NDUKA ABEL ANYANSO NDUKA NWADIKE ABEL NDUKA RALUCHUKWU CHIDUME NDUKWU VIOLA NWANYISUNDAY NDULAKA O.M. NEM INSURANCE PLC NEMEITH NIGERIA PLC NESIAMA SAMSON NGENE IKECHUKWU CHRISTOPHER NGOESIONWU ERIC NGWAKWE CHIBUZOR NGWU AUGUSTINE TOCHUKWU NGWUOKE STANLEY SYLVESTER OBIORA NIHAQ INVESTMENTS LIMITED NIKI QUENTIN NINIOLA DAVID OCHE NIVAL CONSULTS LTD NJOKANMA FELIX NGOZICHUKWU NJOKU CHRISTIAN CHINONYEREM NJOKU JULIE UBA & MATHEW EMEKA NJOKU NATHAN MARSHALL N.IOKU NGOZI JOAN NJOKU OBINNA KELVIN & YETUNDE C. NJOKU OLUCHUKWU PROMISE NJOKU PEACE ONYINYECHI NKANU GOD'SWILL UMAH NKEMERE THERESA ADAKU NKEREUWEM JAMES NKONO GLORY MICHAEL NKWOR ONYENUCHE KELVIN NLEMCHI HYPOLITE UCHE NLEMOHA LOUIS NDUDIRI NMEZI CHARLES IKECHUKWU NMOYEM OKELEMAKA DAVID NNABUCHI EMMANUEL OSITA NNABUGU TOCHUKWU PROGRESS NNACHEBE DANIEL UCHECHUKWU NNACHI-IBIAM OGBONNE OGERI

ODESANYA OLASUNKANMI SULAIMON

NNACHOR GABRIEL ONYEDIKA NNADE EMMANUEL OGUCHI NNADI OGECHI CARL - A/C ES NNADOZIE EJIKE UGOCHUKWU NNADOZIE EZEKANACHI NNAJI COSMAS ANAGARAKU NNAJI DANIEL NNAJI KINGSLEY OKWUDIRI NNAJI MAUREEN CHINAEDUM NNAJI OBINNA C. NNAJI WILSON NNAJIDENWA LYNDA NGOZI NNAKWUZIE MIKE MADUEKE NNAMANI HARRISON NNABUIKE NNAMDI I. UZOKWE NNANTA MOSES IHEANACHO NNANTA UCHENWA SILAS A NNAOMA STEPHEN ODIHEMEREONWU NNEBECHI CELINA OKOLI NNOBADIM IKENNA NNOKE JUDITH NKECHI NNOLIM GEOFREY MMADUBUKO NNOLUM EDNA OKWU NNOROM HARISON U NNORUKA BENE NWAKAEGO NNORUKAH OGIDIKA NOIBI ANOTA AYOMIKU NOLA BASIRAT ADENIKE NOLA TAJUDEEN ADETUNJI NOMINEE "D" NORTHERN YARD LIMITED NOTIEMWONMWAN PATIENCE NSE CONSULT LIMITED NSIMA JOSEPH ETUKUDO NSOFOR EMMANUEL CHUKWUEMEKA NSUMEI SOLOMON EJIRO NTEKIM AMA SUNDAY NTEKIM BESSIE TARA NUBI ABIODUN OLUMUYIWA NUGA OLUDARE MOSES NUHU BELLO NURUDEEN ABOLORE MODINAT NUSIRAT A NWABISI AUGUSTINA NWABOGOR NNEKA NWABUDIKE ADENIKE GBEMISOLA NWABUDIKE LARRY CHIEDU NWABUISI JESSY NJIDEKA NWABUNIKE HARRISON CHIAGOZIE NWACHI NELSON MADULOSIE NWACHUKWU BERNICE C NWACHUKWU BLESSING NWACHUKWU CHUKWUEMEKA EMMANUEL NWACHUKWU EMEKA NWOSU NWACHUKWU EMEKA VICTOR NWACHUKWU EUGENE EZI-AMAH NWACHUKWU FRANCIS NWACHUKWU HYGINUS NWACHUKWU IFEOMACHUKWU NWACHUKWU IHEANYI CHIGOZIE NWACHUKWU IJEOMA NWACHUKWU MERCY NWACHUKWU VITALIS EMEKA NWADIANI CHRISTIE NKEMDILIM NWADIJE INNOCENT OFOR NWADIKE AKWIWU NWADIKE OBIAKU NWADINIGWE PAUL EKENE NWAECHE PETER SUNDAY NWAEFULU MICHAEL FIDELIS NWAEGBU GREGORY CHUKWUDI NWAEKE BENJAMIN NZERIBE NWAEKE KENNETH NNABUIFE NWAEZE GRACE NKECHINYERE NWAEZEAPU PASCAL CHIBUZO NWAFOR CHIMAOBI PRECIOUS NWAFOR CHINDIMA JOY NWAFOR CHIOMA JANET NWAFOR CHUKWUKA JOSHUA NWAFOR DIVINE CHIBUZO NWAFOR IFEOMA EUCHARIA NWAFOR IKECHUKWU R. NWAFOR NORA ANE NWAGBARA EZINNE CHIBUZOM NWAGBARA SAMUEL CHIGBOOH NWAGBO AMBROSE NWAGHODOH BRIAN CHUKWUEMEKE NWAGHODOH NOEL UGOCHUKWU

NWAGU EDITH AMUCHE

NWAIGBO CHILEZIEMANYA K NWAIWU UZOMA MODESTUS NWAKA IFY MARY NWAKANMA N KINGSLEY NWALA CHUKWUEMEKA P NWAMADI HENRY NWANDU FUNNAYA NWANERI MARTIN CHIGOZIE NWANGWU KINGSLEY NWANGWU KINGSLEY CHIKA NWANGWU UGOCHUKWU SAMUEL NWANKWO EMEKA OBIORA NWANKWO FRANCIS IKEMEFUNA NWANKWO GILBERT CHUKWUMA NWANKWO MACSIMEON UCHENNA NWANKWO MUBO ALICE NWANKWO NKEM MARTINS NWANMA COSTANCE CHIDINMA NWANOSIKE NOSAKHARE NWANYA EMEKA NWANYANWU VERONICA CHIKA NWAOCHEI JULIE OZOR NWAODU ETHELBERT CHUKWUDI NWAOGU CHIGOZIE CELESTINE NWAOGU GWACHINKPAM HOPE NWAOGU MIRIAM NWAOJIGBA CHUKWUEMEKA NWAOKOCHA EBERE NELLY NWAOKOCHA JEROME IKECHUKWU NWAOKOCHA M. ONYEBUCHI NWAOKOMA CHIMAOBI FELIX NWAOKORO EDWIN NWAOKORO LEVI NKEM NWAUSULOR CELESTINE CHUKWUMA NWEKE COLLINS CHUKWUNONSO NWEKE EMMANUEL FRANCIS NWEKE HENRIETTA NWEYE KINGSLEY ETONWANA NWEYE QUEENETH UKALINA NWEZE CHUKA PATRICK NWEZE EMMANUEL NWIGUBE GERALDINE NGOZI NWIGWE CATHERINE N NWIGWE CLETUS NWINEEDAM MARSHALL NORNUBARI NWODO JOSEPH NDUBUISI NWOGU CHIJIKE & MARY (MR & MRS) NWOGU EVELYN ONYEKACHI NWOKEDI EMMANUEL CHUKWUMA NWOKEDI N.E. NWOKEKE CHIKA CYRIL NWOKOCHA SUNNY CHIEKWEIRO NWOKOCHA VENATIUS AUGUSTINE NWOKOLO MARGARET NGOZI NWOKOLO NNEAMAKA JOAN NWOKOLO PAUL JOHNSON CHIBUZOR NWOKORO IJEOMA PEACE NWONWU FRANCISCA NWORIE FRIDAY CHUKWUMA NWOSA ELIZABETH QUEEN NWOSU ANTHONY NJIKEONYE NWOSU CATHRINE U NWOSU CHERECHI UGOCHUKWU NWOSU CHIJIOKE INNOCENT NWOSU DAVID CHINEDU NWOSU HYGINUS EMEKA JP NWOSU JAMES IZUCHUKWU NWOSU NDIDI MATHEW NWOSU OBINNA LAWRENCE NWOSU ZERIBE CHIKE NWOYE ANTHONY-GIDEON OBIORA NWOZOR EDWIN UWAKWE NZEKWE CHRISTIANA JOHN NZEWI TITUS CHUKWUMA NZIE RITA EKOK OAK BUSINESS AND FINANCE LIMITED OBA KAFILAT MOJISOLA OBABIRE AYODEJI OBABORI STEPHEN BAMIGBE OBA-DAINI OLUBUKOLA BOLAJI OBADEYI JAMES AREMU OBADIYA OLUWOLE JULIUS OBAIDU OLUWADAMILARE EXCEL OBALIM FRANCIS UCHENNA OBAMI STEPHEN ANATAKU OBAMI STEVE OBASA OLATUNDE STEPHEN

OBASA TOLULOPE

OBASEKI GODSWILL ARHUNDE

OBASI GERALDENE CHEKWUBE

OBASI JACOB OBATERU OLUFEMI OBATOSIN OLUWATOYIN ABIODUN OBAYEMI FEYISARA JANET OBAYEMI JONATHAN ADEWOLE OBAYOMI OLUWOLE OMOLOLU OBAZEE ELIZABETH OBAZU-OJEAGBASE ESTHER OBEH FELIX CHIMEZIE OBEMBE AKINOLA OLUKAYODE OBEMBE MAKANJUOLA AYINDE OBETA CHARLES OBEYA GODWIN (MR) OBEYA JOHN LINUS OBI BIBIANA AKUKANANWA OBI CHIDI CHRISTOPHER OBI CHINENYE VIVIAN OBI CHINWENDU DORATHTY OBI CHUKA OBINNA OBI COLLINS C OBI EMMANUEL OBI FIDELIS CHUKS OBI GERALD ONYEDIKA OBI NNAMDI & EBELE OBI PRINCE IFEANYI OBI RAPHAEL CHINEDU OBI THOMAS EDUM OBI WILSON AZUKA OBIAGWU DONALD OBIDEYI EFUNYEMI OLATUNDE OBIDIKE KEN -PAUL OBIDINMA CYIRACUS C OBIECHI FEBIAN NNAMDI OBIENYI CHRISTIAN NNAMDI OBIGWE ONYEDIKACHI BRIGHT OBLIUBU CHIPSON NZE OBIKE NDUBUISI EMMANUEL OBIKOYA KEHINDE HANNAH OBILA VIVIAN U. JOAN OBINNAKWELU FESTUS IZU OBINOMEN SANDRA OBIOHA ADANMA OBIOHA CHARLES OBIOKOR MARGRET METEHA OBIORA CAROL AYIABIMHE OBIORA EDWARD OBINNA OBIRE E. GLORY OBISANYA ADEBANJO AYODEJI OBIZOBA IKEMEFUNA CHRISTOPHER OBLA JOSEPH ELAGBAJE OBOH IGHO THOMPSON HON. OBOKO ALAGIAWEI OBOKO BELLO OBOKO IKIOGHA OBOKO MATAIKIOGA OBONG NKECHI OBOT CHARITY CLETUS OBOT ENOBONG ELKANAH OBOT GODWIN MICHAEL OBOUAYE OLUMESE CHRIS OBULE JALATH ODEY OBULUZO SIMON OBUSE VICTOR OCEAN COMMUNICATIONS LTD OCEANIC BANK/CROWNWEALTH /CLIENT-TRAD OCHADE BENEDICT OCHE ENE EUNICE OCHIABUTO EMEKA HAPPINESS OCHIGBO PATRIC AMEH OCHONMA EVEREST ONYEBUCHI OCHUKO EJUMEDIA MRS OCHUMBA DANIEL CHUKWUGOZIE ODAFI STANLEY ODAUDU AYO B. ODEBIYI ANTHONY ADENIYI ODEBIYI KUDIRAT .A ODEBUNMI OLUSEGUN MICHAEL ODEDEJI JACOB AKINSOLA ODEDEJI MOJISOLA FLORENCE ODEDERE ISAAC FOLORUNSO ODEGBAMI VICTORIA OMOLOLA ODEJIDE OLUBUNMI ADEOLA ODEJIMI OLUBISI ODEKOLA KAZEEM ATANDA ODELEYE ABIMBOLA ADERONKE ODEMAKINDE TEMITOPE (MISS) ODERHOHWO MARY CHOVWE FAVOUR ODERINDE ADEBUKOLA FOLAKE

ODERINDE JUMOKE APINKE

ODEY GABRIEL ODEYALE JAME OLUYINKA ODEYEMI BABATUNDE OLISAMEKA ODEYEMI ENITAN IDOWU ODEYEMI MO MRS ODEYINKA AKINRINOLA SUNDAY ODIACHI MIMI ADE ODIACHI OGECHI KENNETH ODIAGBE ABUMERE LAWRENCE ODIAKA CHINONSO BATHLOMEW ODIASE GREGORY & ADEDIWURA ODIGBO CHIKA FRANCA ODIGIE TRENSTER .E ODIHI DANIEL ODIHI HUMPREY ODIHI LINDA IFEOMA ODILI OZOEMEZIE PETER ODILINYE NWIKE SAMUEL ESTATE OF ODIONU DOMINIC OZOEMENA ODIONU VINCENT OBIEKEZIE ODITA ADIMABUA JONATHAN ODO KINGSLEY IFEANYI ODOFIN OLUWAFEMI ODOM MATTHEW NKAHEREONYE ODONMETA AYO BEMIGHO ODOZI STELLA EHENEDEN ODOZI UCHE ODUBANJO TAÍWO ADETUTU. ODUBELA SOLOMON OLUTUNBI ODUDU EHIMEN SAMUEL ODUESO ESTHER K. ODUESO ISAAC ADESANYA ODUFALU MOJISOLA MOSUNMOLA ODUFUWA ISAIAH SUNKANMI ODUGBO ZAKARI TAIRU ODUKALE ABIMBOLA ADEBOYE ODUKALE ENIOLA OLUMAYOWA ODUKALE TOKUNBO ABIODUN ODUM CHINENYE ANASTASIA ODUMADE PETER AFOLABI OLAREWAJU ODUMBO LAWRENCE OWOLABI AYODEJI ODUMOSU OLATUNDE OLUWASEUN ODUMOSU OLUWATOYIN OLATUNDE ODUNAIYA ABIOLA OLUBUNMI ODUNAYO AYOKUNLE SAMUEL ODUNEWU ADEWALE ADETAYO ODUNEWU ANJOLAOLUWA ABIGAEL ODUNEWU OLUWAGBOTEMI EMMANUEL ODUNGA OLUWAGBEMILEKE ODUNLAMI THEO OLU ODUNOWO ADEOLA OYEKUNLE ODUNOWO GBENGA KAZEEM ODUNSI EMMANUEL ADETOKUNBO ODUNSI ESHILOKUN PRINCE ADEMOLA ODUNSI OLUWASEUN ODUNAYO ODUNSI TITILAYO ADEFOLAKE ODUNTAN ADEDOYIN HELEN ODUNTAN LABIZAT DEMILADE (MISS) ODUNTAN MUIBI-ISHOLA ODUNTAN MUINATU-KEHINDE ODUNTAN OMOTAYO MORENIKE ODUNTAN USMAN ABIODUN ODUNUGA FELICIA ADEREMI ODUNUGA OLANIYI ODUNUKAN ADEKUNLE OLAYINKA ODUNUKAN ADETOUN OMOSHALEWA ODUOLA OLUGBENGA AKEEM ODUSAN OLUSHOLA ADEGBAYI ODUSANYA OLUGBENGA MARTINS ODUSELU ENDURANCE UTHMAN ODUSOGA OKANLAWON LAWRENCE ODUSOTE OLATUNBOSUN ANIKE ODUTAYO OLUYOMI ADEGOKE ODUUTAN ADAM ADEBADE ODUYE GANIYAT OLUWAFUNMBI F. ODUYEYE AYODELE ABIKE ODUYEYE OLUWASEUN JOSHUA ODUYIGA JULIANA OLUWAFUNMILAYO OFFEH HENRY OFFIAH KEVIN CHIJIOKE OFFIAH WILLIAM NNAIFE OFFIONG UBONG EDEM OFFOH HERBERT UCHECHUKWU OFFOR HERBERT UCHECHUKWU OFFOR JOSEPH CHIDIEBERE OFOBRUKWETA DORA EDIRIN OFOEGBU KINGSLEY OFOMA GAB UZOCHUKWU OFOMAJA ONAKORAME DANIEL

OFOMOLA OJO & CO OFOR DANIEL IKECHUKWU OFOR DAVID TOCHUKWU OFOR GIDEON UCHENNA OKORIE OFOR JOSEPH NNANNA OFORISHE ONOME RESIDENT OFUDJE B. JULIET OMAS OFUNGWU BEN OFUYA JOSHUA ARUBI OGAGAVWORIA WINSTON OKEOGHENE OGAH CYRIL ILEGHIEUMA OGA-ONU INNOCENT OGBAISI CHRIS & ISOKEN OGBARA SHAMSIDEEN O. OGBEBOR HENRY OGBECHIE DINMA DANIEL OGBECHIE NNEKA CHUKWUWETE OGBECHIE NONSO DAVID OGBEIDE OSAS CHURCHILL OGBEJELE PETER OMONKHEOA OGBO ENOCH ODE OGBOCHUKWU THELMA CHINENYE OGBODO GRACE OGBODO IDAH CHRISTIAN OGBODU JOSEPH OGBOGBO IJEOMA OGBOGBO NKECHI OGBOGBO NKIRUKA OGBOLE AJIMA MARK OGBONNA BARTHOLOMEW OGBONNA CHINONSO BENJAMIN OGBONNA CHRISTIE EBIERE OGBONNA GERALD **OGBONNA HENRY** OGBONNA LOIS ONYEDIKACHI OGBONNA SAMUEL CHIDIEBERE OGBONNA UCHE CHUKWU OGBORU DANIEL BRIGHT OGBU ANTHONIA OGBU ANTHONY IKECHUKWU OGBU SOLOMON OGUGUA OGBU SUNDAY EKPO OGBUAGU IFEANYI OGBUEHI EDWIN IFEANYI OGBUKA ESTHER NKEIRUKA OGBUMMAH WOGWUGWU THEOPHILUS OGEDEGBE DANIEL OMASAN OGEH AJIRI JOSEPH OGELEKA NWACHUKWU MATTHEW OGHENEKARO ROSE AGHOGHO OGHENEKOHWORHO IDOGHOR OGHOMWEN IYOBOSA JUDE OGHRE EMMANUEL OLUBAYO OGIDI ADEMOLA EBENEZER OGIEMWONYI VICTOR OMORUYI OGINNI AYODEJI JACOB OGIRIMA RUTH OGO STANLEY CHIDIEBERE OGODOBIRI SAMSON OGOEGBULEM NDUBUISI EMMANUEL OGOKE JUSTUS TASIE OGOKE PAUL TOCHUKWU OGO-OLUWA (ODO AGAMEGI-OGBO IJEBU) OGUBUIKE FAVOUR NMESOMA OGUEGO ANTHONY OGUGUA CHINEDU ISAAC OGUGUA UCHENNA G OGUH FOSTER OGHENERUEME OGUH GEORGE O. CHINWEIKE OGUIKE QUEEN LOVETH OGUJIUBA OKECHUKWU MICHEAL OGUN OLUREMI OGUN OLUSOJI TENIOLA OLUREMILEKUN OGUNADE ANTHONY ADESOJI OGUNBAMOWO YISAU OGUNBIYI BUKOLA OGUNBIYI KEHINDE TEMITOPE OGUNBIYI OLUBUNMI CATHERINE OGUNBIYI YUSUF GBENGA OGUNBONA OLATUNJI SUNDAY OGUNBONA OLUWAYEMISI OMOSHALEWA OGUNBOTE OLUWASHINA THOMAS OGUNBOWALE ABOSEDE GRACE OGUNBOWALE ANTHONY OLATUNJI OGUNDAPO OLUMIDE AMOS

OGUNDARE FUNMILOLA IYABODE

OGUNDEJI ADEGOKE DAVID OGUNDEJI AYODELE OGUNDEJI PETER TAIWO OGUNDELE SUNDAY TOPE OGUNDERO IYABOSOLA OGUNDERO MOYOSORE OGUNDERO OJUOLAPE OGUNDERO OLUFOLAKE OGUNDERO OLUMIDE ADEMOLA OGUNDIMU OLUGBOYEGA OGUNDIPE AYODELE OLUFEMI OGUNDIPE BILLY ALABI OGUNDIPE OLADAPO OYELOWO OGUNDIPE TEMITAYO AKINSODE OGUNDIYAN MODUPE AFOLAKE OGUNDIYAN OLATUNJI OLUWATOSIN OGUNFOWORA EBUNOLUWA JULIANA OGUNFOWORA FOLASADE ABIMBOLA OGUNFOWORA FOLASHADE ABIMBOLA OGUNFOWORA OLUMUYIWA OGUNFOWORA PELUMI ALEXANDRIA OGUNGBEMI GBENGA DAVID OGUNGBEMILE FAUSAT MOTUNRAYO OGUNJIMI ADENIYI KOLAWOLE OGUNJOBI KAYODE MICHAEL OGUNJOBI OLAYINKA OLAYEMI OGUNKA MERCY OGUNKOYA KAZEEM AFOLABI OGUNKUNLE GBENGA OGUNLADE JOHNSON AFOLABI OGUNLADE KEHINDE AMOS OGUNLANA OLANREWAJU OGUNLESI DOKUN **OGUNLESI JOSEPH** OGUNLEYE ABIMBOLA P. OGUNLEYE ADENIYI ADEKUNLE OGUNLEYE ADETUNWASE OGUNLEYE GABRIEL OLANREWAJU OGUNLEYE LAWRENCE ADEBOWALE OGUNLEYE OLABODE (DR.) OGUNLEYE OLADAPO JOEL OGUNLEYE OLAYINKA OLAIDE OGUNLEYE PATRICK FOLUSO OGUNLEYE SEGUN KELVIN OGUNLUSI OLUYOMI OLATUNDE OGUNLUSI TOMILOLA SAMUEL OGUNMEKAN JOHNSON ONASOLA OGUNMILUYI ADESOLA TOYIN OGUNMODEDE OMOLOLA GLORIA OGUNMOLA RAFIU BUKOLA OGUNMWOYI HENRY ATUMA OGUNNAIKE ADENIYI KAYODE OGUNNAIKE AGNES SUBUOLA OGUNNAIKE OLADELE OGUNNEYE ABUBAKRE AFOLABI OGUNNUBI ROBERTS OGUNNUSI MOFESOLA ADESOLA OGUNRINDE ADEMOLA OPEYEMI OGUNRINDE MOBOLAJI OLUYEMI OGUNRO OLUWASEUN OLUSEGUN OGUNSAKIN KAYODE OGUNSAN OLUWOLE JACOB OGUNSANYA MOJISOLA O.A OGUNSEYINDE OLUWASEUN ADEBAYO OGUNSOLA VIVIAN MODUPE OGUNSONA ADELAGUN OLUWADARE OGUNSULIRE BUKOLA OGUNSULIRE FELICIA MRS OGUNSULIRE OLATIMBO OGUNTADE SOJI OGUNTOBI RAPHAEL OLUFEMI OGUNTOYE OLUWATOPE LAWRENCE OGUNTOYINBO FRANCIS OPEYEMI OGUNTOYINBO IFEOLUWA VICTORIA OGUNTUNWASE BAMIDELE ABIODUN OGUNWALE BUKUNMI BENJAMIN OGUNWALE KEHINDE ABIBAT OGUNWEMIMO OLUWASEYI VICTOR OGUNWO FOI AKE BONKE OGUNYE IREAYO NATHANIEL OGUNYEMI GBOLAHAN KOLAWOLE OGUNYINKA OLUBUNMI OGUNYO ABIMBOLA MARIA OGUZIE CHRISTOPHER CHIJIOKE OGWARA ODANIBE THERESA OGWUCHE FRANCIS MARY OGWUCHE PHILOMINA OGWUDA IFEOMA MARY

OGWUEKE KEVIN .C.

OGWUEKE KEVIN CHRISTOPHER

OHAEGBU AUGUSTINE E. J. N OHAERI JUDE UZOMA OHAERI STELLA ONUWA OHAJI LAWRENCE OHANASIOBI IJEOMA MAUREEN OHANUGO AUGUSTINE ELOCHUKWU OHIOVBEUNU BENEDICT OMOIKHUDU OHIWERE STANLEY OHIWEREI EKEINDE OHIORENUAN OHIWEREI JANET ALERO OHUAKA CHISOM OHWEKEVWO ESE OHWOFASA JUSTINA ENOH OHWORHUADJEKE HELEN OIYUMAN SUNDAY ASIBHEWERE OJEAGA ALUGHE MATTHEW OJEAH LINCOLN CHIEDU OJEDIRAN BAMIDELE SUNDAY OJEDIRAN FESTUS SEGUN OJEDIRAN SEGUN FESTUS OJELABI ALICE BOLANLE OJELUA ALEX ODION OJEMEN BIBIANA OFURE OJEONU CYRIL OMOIKHOJE OJEWUNMI SAMUEL ALABI OJIAKO ADAOBI SYLVIA OJIAKO KENNEDY UCHENNA OJIEKHUDU ANDY IMOBHIO OJILE DAVID INYANDA OJILEKE ONYEKACHI OJIMAJO SAMSON MARVELOUS .A OJO ABIODUN OLUWATOSIN OJO ADEMOLA OJO ADEMOLA ABIODUN OJO BABATUNDE LANRE OJO EMMANUEL ABIODUN OJO FOLAKEMI JULIANA OJO KAFAYAT ADEOLA OJO LUTI OJO MICHAEL IBIKUNLE OJO MOFIFOLUWA OLUWADOLABOMI OJO MOSUNMOLA IBILOLA OJO OLADAPO OJO OLUWATOBILOBA OLANREWAJU OJO OSAGIATOR OJO OYEBOLA OJO SHOLA MARIA OJO UCHE LOIS OJOLO OLASUNKAMI OJORE-AKPALA TEA OJUEDERIE DAVID BEDEKEREMO OJUKWU CHIDUZIE RICHARD OJUMAH RICHARD OJUMORO EDWARD OJUMU JONATHAN OJUMU OMOSIMISOLA CHRISTABEL OJUROYE OLASIMBO IBIJOKE OJUROYE OLUWOLE OLAYINKA OKA CLEMENT FUNSO OKADIME FIDELIA E.O OKAFOR AMAKA OKAFOR BLESSING NKEONYERE OKAFOR CHARLES KAMSI OKAFOR CHUKWUEMEKA STEPHEN OKAFOR CHUKWUNAECHELUM OKAFOR ELVIS OBIDIKE OKAFOR EMMANUEL NKWACHUKWU OKAFOR FELIX IFEANYI OKAFOR IGNATIUS OKWUDILI OKAFOR JOHN OBIORAH OKAFOR KENE OKAFOR KENECHUKWU OBIAJULU OKAFOR LILIAN AMUCHE ADAEZE OKAFOR NATALIA MAKAROVA OKAFOR OGECHUKWU OKAFOR OKWUCHUKWU KENNETH OKAFOR PAUL O OKAFOR RITA AWECE OKAFOR UCHE MARIA OKAFOR UGOCHUKWU M OKAH-AVAE ONAKOME UTEJIRO OKAI IGANYA TABITHA OKAIMA OHIZUA OKALA EMEKA FESTUS

OKANDEJI ROSEMARY

OKAPARA NNABUNDO

OKE ABOSEDE VICTORIA

OKE AFOLUKE FATIMAT

OKE BENJAMIN SUNDAY

OKANLAWON SAMUEL ADEGOKE

OKE ELIJAH OLUWALEKE OKE GBEMISOLA OKE GBENGA OMOTOMIWA OKE MARY ODUNOLA OKE OLANIKE R. OKE OYELADE ADEOLA OKEBE GLORY E. OKECHUKWU C. CHIMA OKECHUKWU CHINEDU HENRY OKECHUKWU NGOZI ELIZABETH OKEDIJI EMMANUEL ADEBISI OKEGBENRO MUTIAT OKEGBUAN IGBINEDION OKEGUNNA FATAI AKIN OKEILE VICTORIA OHIMAI OKEKE AFAMEFUNA OKWUDILI OKEKE BENEDICT OSITA OKEKE CHINEDU GABRIEL OKEKE CHRISTIAN AMAECHI OKEKE CHUKWUNWEIKE IKECHUKWU OKEKE HENRY CHUKWUEMEKA OKEKE IFEANYI EMMANUEL OKEKE LETICIA NGOZI OKEKE M JOHN OKEKE MARIBEL UJU OKEKE OBIAGELI VERONICA OKEKE PETER OKEKE ROBERT ONYINYE MR & MRS OKEKE UCHENNA OKEKE UCHENNA ELIZABETH OKEKEUKO VICTORIA UCHECHUKWU OKELEYE ADENIKE ELIZABETH OKELEYE ENOCH ANJOLA-OLUWA OKELEYE GABRIEL OKELEYE RACHAEL OREOLUWA OKELOLA MOSES OYEBISI OKEME JANE .O. OKENA BONIFACE OGHENOVO WILFRED OKENWA FESTUS CHITOO OKENWA JULIET OKERE ADEPERO JOKE OKERE ALOYSIUS CHINONYE OKERE BERNADETTE OKERE MERCY OHANUNMA OKEREKE EZENWA MUNACHISO OKEREKE PRICILLIA EKENE OKERI PROSPER ELO OKESHINA DEBORAH ADEJOKE OKESOOTO IPADEOLA JONATHAN OKESOOTO JUMMAI OKESOTO JOHN OYEBAMIJI OKETAYO ADEOLU JOSHUA OKETOKI DELE OKEZIE CHINEDU OKEZIE PASCAL OKEZIE PASCAL O OKHADE PETER ONUWABHAGBE OKHUOFU DON ENEZEMHUDU OKI ISIAKA AYODELE OKI ONOME OGHENEVWAERE OKIRIMA AUGUSTINA OBUMA OKOAHABA INNOCENT BOLUM OKODUDU LILIAN TUWERE OKODUWA GODSWILL OKOFUAH SOLOMON OKOGBE OLAIFOTAPE EZEKIEL OKOH CHUKWUDI JOSEPH OKOH IJEOMA JACKSON OKOH JOSHUA IFEANYICHUKWU OKOI BESSIE EYONG OKOJI MAUREEN E OKOJIE SUNDAY OKOKHUNE GODWIN E. OKOKON EDWIN EDEM OKOLI CHINONSO ONYEJIAKU OKOLI CHUKWUEDOZIE OKOLI DAMION CHINWIKE OKOLI EBENEZAR ONYEMAEKE OKOLI FRANK EMEKA OKOLI FRANK JOVITA EMEKA OKOLI JOVITA FRANK EMEKA OKOLI PAUL C. OKOLIE ESTHER OKOLIE HENRY IFEANYI CHUKWU OKOLIE MARY EMLY OKOLO NJIDEKA JANE OKOLO NKENCHO OKOLO NNAMDI JEREMIAH OKOLODIBE IGNATIUS OKWUNNA OKON BASSEY OFFIONG

OKON EMMANUEL OKON ETIENOBONG MFON OKON FELIX EKEKOI-ESUA OKON KENTOROBONG MFOM OKON KINGSLEY MFON OKON MARCELINA ANIEFIOK OKON UDOM BASSEY NYONG OKONDU JOSEPH CHUKS OKONEDO JOSEPH MIRACLE OKONKWO AMBUS OKONKWO COLLINS CHUKWUDINMA OKONKWO DONATUS I. OKONKWO FRANCISCA NWABUNOR OKONKWO IFEANYI DAVID OKONKWO JUDE OBIORA OKONKWO LETICIA AGALA OKONKWO LILIAN AKUNNAYA(MRS) OKONKWO NDULUE CHIMEZIE OKONKWO NONSO JUDE OKONKWO ONUORA FEBIAN OKONKWODONATUS IFEBUNAWDU OKONOFUA LUCKY IRHIOGBE OKONYE LEONARD UCHEJIM OKORIE ERNEST OKORIE EZE HARRISON OKORIE FRIDAY JOSHUA OKORN EYA LOVINA OKORO FABIAN CHUKWUDUBEM OKORO GRACE NANCY OBIAJULUM OKORO JOHN B OKORO MICHAEL O OKOROAFOR CHINYERE NNENNA OKOROCHUKWU BARTHOLOMEW C. OKOROIGWE ESTHER ONYEKACHI OKORONKWO IJEOMA NWANGBO OKORONTA MICHAEL MARY OKOSUN CHRISTOPHER OKOSUN MICHAEL ENAHORO OKOTETE ESEOGHENE NANCY OKOTIE MARK OGHENEAKPOBO OKOYE CHUKWUMA SYLVANUS OKOYE IFEOMA THERESA OKOYE IGWE SANTOS OKOYE MERCY CHIZOBA OKOYE OBINNA CHARLES OKOYE PATIENCE NKEMDILIM OKPA OVAT EGBE OKPALA AMALACHUKWU CHIOMA OKPALA HUMPHRY CHUKS W/CMDR OKPALA NNAMDI EMMANUEL OKPALA ONYINYE LOVETH OKPALA VALENTINE UCHE OKPALAJI EMEKA JAMES OKPALANWOKIKE LOICY CHINYERE OKPARA ANTHONY IFEANYI OKPARA EDDIE CHIEMELE OKPARA JOSEPH OLUCHI OKPARA ONYEKWERE OKPLEWU PETER AGRISA OKPO JOSEPH IKECHUKWU OKPOCHI CHRISTOPHER OKPOKIRI BELEMA(ARC) OKPONOBI MARIAM OKPOR AUSTINE ANDREW OKPOTO O JAMES OKPUZOR PATRICK OBIAMAKA OKU AMARACHI OKUBA INNOCENT CHINEDU OKUBANJO OLUBAYODE OKUKU EMUE JEVOKE OKUKU OTOALELEN GODDAY OKUKU PATIENCE BOLA OKUNADE AKEEM SALISU OKUNADE OLAJUMOKE MAIMUNAT OKUNBOR THEOPHILUS OKUNEYE OMOLARA FISAYO OKUNGBURE OMOWUNMI OLUWATOSIN OKUNNOWO BABATUNDE D OKUNOLA DANIEL OLUWATORI SEUN OKUNOLA OLUWAKEMI OLAWANDE OKUNOREN JAMIU OLABODE OKUNOWO SHAMSIDEEN ABIMBOLA OKUNOYE PETER AYANDELE OKURUME SUNDAY MASCOT OKUSANYA OLUWOLE OKUSIPE OLUTOMISIN OMOLOLU OKUYEMI MODUPE ELIZABETH OKWAH HELEN OBUKOWHO OKWARA CHRISTIAN IKECHUKWU OKWARA IJEOMA

OKWARI TERRY OBO OKWEGBE ANDREW AJIRI OKWUADA SAMUEL KESSINGTON OKWUDEI ELIZABETH OKWUDIBA MARTIN OKWUKWE OKWUDILICHUKWU RICHARD OKWUDINKA EDITH CHIMEZE OKWUOBI NNAMDI PAT & NNEAMAKA T OKWUOHA JULIA AMECHI OKWUOKEI MARIA IFECHUKWUDE OKWUOLISE ALEXANDER EJIROGHENE OKWUOYIBO CHKWUDI JACOB OKWUTE OJONOMA LORETTA OLA KOLADE & FADAHUNSI O. OLUFEMI OLA NOGHAYIN BOSEDE OLA OLALEKAN ANTHONY OLABIRAN ADEJOKE-LARA OLABIRAN ADESODUN KOLAWOLE OLABIRAN SHOLA ADEFENWA OLABIYI OLADELE BENJAMIN OLABODE ENIOLA TOLUWALASE OLABODE JEREMIAH OLABODE OGUNLEYE OLABODE OLALEKAN OLAKOYEJO OLADAPO LATIFAT KEMI OLADAPO SAMUEL BABATUNDE OLADEINDE ADEJUMOKE IBILOLA OLADEINDE FEMI OLADEJI AKINYELE OLADEJI DAVID OLADEJI JOSEPH OLUKUNLE OLADEJI KASOPE OLADEJI OLUWATOYIN OLADEJI RASAK OLADEJI SINMISOLA OLADEJO HALIMA OLADEJO JUMOKE MOJISOLA OLADELE AYODEJI OLANREWAJU OLADELE MUKAİLA AYOFE OLADELE OLATEJU OYELEKE OLADEPO DARAMOSU OLAGUNJU OLADEPO RASHIDAT TITILOLA OLADIMEJI FOLASHADE OLADIMEJI OLUMIDE FEMI OLADIPO AYORINDE SAMUEL OLADIPO BUKOLA OLADIPO MUJIDAT ADESOYE OLADIPUPO KING ADEFEMI OLADIPUPO RACHEL OLUSINA OLADOKUN EBENEZER OLUWAFEMI OLADOKUN OLUSOLA SUNDAY OLADOYIN HELEN MODUPE OLADOYIN RHODALEEN TITILAYO OLADOYIN RICHARD TAIWO OLADUJA BABATUNDE JOSEPH OLADUNJOYE OYEYEMI MICHAEL OLAFIMIHAN NASIRU TITILOPE OLAFISOYE OLUWATOBI OPEYEMI OLAFUYI OLASUNKAMI OLAGBAJU OLANREWAJU GBEMIGA OLAGBOYE REBECCA AJIBOLA OLAGOKE SAMSON OLUSEGUN OLAGOROYE AYOMIDE MIRACLE OLAGOROYE OKE-IGBALAYE OLAITAN ABIGAEL BOLANCE OLAITAN DANIEL CHUKWUZURUM **JESUTOFUNMI** OLAITAN DEBORAH CHUKWUNEDUM OLAITAN ISIAKA ADEKUNLE OLAIYA FOLASHADE OLAJIDE DAVID SUNDAY OLAJIDE HILARY OPEYEMI OLAJIDE MICHAEL OLAYINKA OLAJIDE MOJISOLA ABOSEDE OLAJIDE OLAYIWOLA AWOWADE OLAJIDE OLUFUNKE DEBORAH OLAJIDE ROSEMARY EZEMWENGHIAN OLAJUMOKE ABISOYE OLAJUMOKE TOKUNBO OLUMIDE OLAJUWON MOBOLAJI OLUBUKOLA **OLAKITAN LANRE** OLALEKAN AJIROTUTU TAOREED OLALEKAN OLUBUNMI OLURONKE OLALEKAN TAOFEEK ADIO OLALEKAN TIJANI OLALEYE ADEYEMI ELIJAH

OLALEYE FELIX AKINADE

OLALEYE YAKUBU

OLALEYE OREOLUWA AYOOLUWA

OLAMIDE MOSES OLUWAKAYODE OLAMOUSI OLUWOLE AKINWUNMI OLANIRAN ABIODUN OLANIRAN NUSIRAT OLAYEMI OLANIYAN IDRIS ABAYOMI OLANIYAN OLURANTI JIDE OLANIYAN OLUWABUNMI JAMES OLANIYAN RABIU ADEMOLA OLANIYAN RAUFU ADEREMI OLANIYI OLUFOLAJIMI OLANIYI RASAQ KOLAWOLE OLANIYI SULE ADISA OLANREWAJU BABATUNDE AKANBI OLANREWAJU MICHAEL BORISADE OLANREWAJU RACHAEL ADENIKE OLANREWAJU SUNDAY CLEMENT OLANUBI OLANNI OLABUNMI OLAODE RACHAEL OLUFUNKE OLAOFE OLUFUNMILADE MONINUOLA OLAOYE RAPHAEL OLUKAYODE OLAREWAJU ADEGOKE THEOPHILUS OLASEGE KUDUS AKANBI OLASEGE OLAIDE SHUKURA OLASEINDE GRACE OMOBAMITALE OLASUBULUMI AKINTUNDE OLASUPO MARY FUNMILAYO OLATEJU IFEDAYO OLATEJU SARAFADEEN ADEKUNLE OLATEJU SARAFADEEN ADEKUNLE OLATIDOYE OLUSEUN OLABIYI **OLATIMBO AYINDE** OLATIMBO OGUNSULIRE OLATOMIRIN OLAWUNMI BOLATITO OLATUNDUN RASHEED OLABISI **OLATUNJI BOLANLE SEGUN** OLATUNJI BOLUWATIWI FAVOUR OLATUNJI FOLORUNSHO JACOB OLATUNJI KOLAWOLE OLATUNJI OLUSUYI MICHEAL OLATUNJI OLUWATOBI JOHNSON OLATUNJI PETER O. OLATUNJI TITILAYO OLUWASEUN OLATUNJI WAHEED AMOO OLAWALE OLUFEMI OLAYINKA OLAWOYIN MOTUNRAYO KARAMAT OLAWOYIN OLAKUNLE TAIWO OLAWUYI KOLAWOLE H. OLAWUYI SUNDAY ABAYOMI OLAYAN CHRISTOPHER UHIEMI OLAYANJU ESTHER .T. OLAYEMI ODUKEMI OLUFUNMILOLA OLAYEMI OLUKAYODE TEMITOPE OLAYEMI OLUSEGUN JACOB OLAYEMI ZAKARIYAH ARIMIYAH OLAYERI OLAJUMOKE MERCY **OLAYEYE EYITOLUWA OLAYEYE IRETOMIDE** OLAYEYE KEHINDE TEMITAYO OLAYEYE MOREWAOLUWA OLAYEYE RAOLAT TOLANI OLAYINKA LANRRAY SHERRIFF OLAYIWOLA ADEMOLA KAZEEM OLAYIWOLA ADEREMI M OLAYIWOLA SULAIMAN ABIODUN OLAYIWOLA SULAIMAN OLALEKAN OLAYIWOLE MICHAEL OLABODE OLAYODE ADEREMI OLEDIBE CAMILUS OBINNA OLIGBO VICTOR OLIKO FRANCISCO BIALOSA OLISA OLUSEGUN MICHAEL OLOBATUYI JOHNSON OLORUNFEMI OLOFINDAYO ONAOLAPO OLOGBON-ORI TAIWO ISMAIL OLOGUN COMFORT O. OLOJA KOLA OLOJA SUNDAY OLOJEDE FLORENCE AYODELE OLOJEDE IYABO (DR MRS). OLOKO SURAJUDEEN ABIMBOLA OLOKPA ERHERHE FRIDAY KRIS OLOKUTA MUINAT OLOMOLAIYE EBENEZER OBAMAYOWA OLONA OLADIMEJI OLONODE JUNJI OLANIRAN OLORE ADEWALE OLORIEGBE EKON EMEN RACHEAL

OLORUNDAHUNSI SUNDAY

OLORUNFEMI RACHEL KEHINDE

OLORUNOJE ISHOLA TAIWO OLAIYA

(ALHAJI) OLORUNTOBA SAMUEL OLUSEGUN OLORUNTOLA EDWARD TOKUNBO OLOTA OLUWAYOMI OMOTAYO OLOTU FISAYO MARY OLOTU PATIENCE URELIGHO OLOTU VICTOR OLOUKOTUN CHRISTIANA OLOWO EDWARD TAIWO OLOWODE KUDIRAT ADEJOKE OLOWOGBAYI INVESTMENT COM LTD OLOWOKANDI OLUFUNMILAYO RONKE OLOWOLABI TAYO BENSON OLOWOOKERE KAYODE GABRIEL OLOWOOKERE RONKE IDIAT OLOWOSEGUN TOYIN FAITH OLOWOSELU ADEGOKE ADEWUMI OLOWOYO PETER OLUWASEUN OLOWU ADEMOLA ABIODUN OLOYE TEMITOPE OLADIPO (NEE OSHUN) OLOYE WASIU ADEKUNLE OLOYEDE ADURAGBEMI SUNDAY OLOYEDE BENSON OLALERE OLOYEDE JOHN OLUWASEUN OLOYEDE OLUSOLA BABATUNDE OLOYEDE SEYI OLUBI ROTIMI OLUBIYI IYABO ABISOLA OLUBOWALE COMFORT YETUNDE OLUDARE ADANRI **OLUFEMI OYEDIRAN** OLUFEMI-BELLO MARGARET EDOGHOGHO OLUFEMI-TIMOTHY JULIET OMOWUMI OLUFIDIPE OYEYEMI OLUWASEUN OLUFOWOSHE AKINDELE OLUFUWA OLUFUNTO IBIYEMI OLUGBENGA ODEDIRAN OLUJIMI GEORGE OLAJIDE OLUKOGA AZEEZ ADEOLA OLUKOTUN ROTIMI OLUKOYA ADEYINKA OLUKOYA OLALEKAN OLUWATIMILEHIN OLUKUNLE MOBOLAJI SAMSON OLULADE EBENI ADEYINKA OLULANA RACHAEL OLUBUSOLA OLULODE OLUSOLA O. OLUMAGIN THOMAS ANINO OLUMILUA MICHEAL OLUMUYIWA OLUMUYIWA VICTORY TEMITOPE OLUOKUN ADEYEMI SUNDAY OLUPITAN TITUS OLAJIDE OLUSADA AKINOLA BANKOLE OLUSANYA OLUMIDE ADEYIGA OLUSANYA TEMIDAYO ENIOLA OLUSEGUN ALANI AYOFE OLUSEGUN OLUFUNSHO OLUSESAN DAVID TEMITOPE OLUSESAN ODUYOYE OLUSHOLA RAPHEAL OLUSOGA ANNE ADEDOYIN OLUSOLA SAMSON OLADAPO OLUTAYO IBIRONKE OLAMIDE OLUTOLA JOSHUA OLUMIDE OLUWA QUARTET INTERNATIONAL LTD OLUWADARAFUNMI EGBEYEMI OLUWADELE LALEKAN BOLUTIFE OLUWAFEMI JOLADE RUTH OLUWAGBEMI OLUBUSAYO MICHAEL OLUWAJEMISIN FAVOUR OLUWASEUN OLUWAKEMI IBRAHIM OLUWALUYI OLUWASEUN AYOOLA **OLUWANIRAN OLUWAKUNLE FESTUS** OLUWASEMILORE JONATHAN ODEYEMI OLUWATOSIN OLUWAPELUMI OLAWALE OLUWATUSIN EBENEZER ROTIMI OLUWAWOLE OMONIYI ABRAHAM OLUWAWOLE TEMITOPE EMMANUEL OLUWAYEMI OLUMIDE EYITAYO OLUWOLE GABBIEL AKANBI OLUWOLE OMOKAYODE OLUYADI OLUSEGUN AYODEJI OLUYADI SEGUN OLUYEMI OLUWOLE OLUFEMI OLY ALAWUBA ELIZABETH OLY-ALAWUBA JOHN IKENECHUKWU OLY-ALAWUBA MARILYN EBERECHUKWU OLY-ALAWUBA STEPHEN CHIZARAM OMACHOKO DAVID MARK OMADUDU JUDITH OMAKINWA RICHARD .T.

OMALVIEW INTERNATIONAL LTD OMAMOGHO VALENTINE OGHENERO OMANANYI TAIYE ADEIZA OMAR KEHINDE SHERIFFDEEN OMATSOGUWA SUSAN I. OME OBIOHA OGBAJIOGU OMEGAWATERS OMEKE OLIVER CHUKWUEMEKA OMELIEONWU ISIOMA PHILO OMENE GODWIN BOYITETE OMENE GRETA OMIDIRE DOLAPO OLUTOBI OMIJEH EUNICE OGHAGHARE OMIJIE MUYIBATU AJOKE OMIKUNLE ABIODUN ADELODUN OMIPIDAN JONAH OMOTAYO OMO-AGEGE IDONGESIT OMOANKHALEN JULIET OMOBUDE SUNDAY GARRY OMODAYO JOSEPH OLUTAYO OMODAYO OLUBUNMI F. OMODIAGBE DANIEL OMOEFE EMMANUELA OGBAISI OMOGBEHIN SOLA ZACH OMOGO CHIBUEZE VICTOR OMOGO OGBOLU FRANCIS OMOKANYE OLUSEGUN JOSEPH OMOKHODION ESTHER ONOHI OMOKHUALE PIETY OMOLADE LOKO (MRS) OMOLAJA MAJEOLAGBE OMOLOLU OMOLE ABRAHAM OLAMILEKAN OMOLE GRACE TOYIN OMOLEYE OLABISI (MRS) OMOLOLA OLAMIDE OMONIYI OLABIMPE JANET OMONUA PETER OMOPARIOLA EMMANUEL SINA OMOPARIOLA OLAWALE PHILIP OMOREGHA GIDEON OGOOLUWA OMOREGIE OSASUEHI. OMORODION ESOSA OMOSANYA OLUWASHOLA KIKE OMOSHEBI STEPHEN EKUNDAYO OMOSOLA ABASS ADENIYI OMOSOLA KIKELOMO FATIMA OMOTEHINWA OMOBORIOWO JOAD OMOTESHO FAUSAT ARINOLA OMOTESO ADEBAYO OPEYEMI OMOTOLANI ADETOUN LAIYENBI MUTIAT OMOTOSHO ABDUL WAHAB OMOTOSHO SEYIFUNMI J. OMOTUNDE LAWRENCE OLUWOLE OMOTUYI JANET BOSEDE OMOVIRO WILLIAMS OMOWARE EDAFE WILSON OMU AKPOR MEZINO OMUNGU ALAYE SMITH OMUOJINE EMMANUEL NDUDI ONABAJO TONIA ONABANJO EKO ONABIYI ABIODUN OLUMIDE ONABOLU AYODEJI OLUWAFEMI ONAH APPOLONIA CHINASA ONAH CHIZOBA S ONAIWU AUSTIN ONAKOMAYA ABIOLA ADEMOLU ONAKPOVHIE ONAGITE EMMANUEL ONALO PAUL OJOMAH ONANUGA IDOWU VERONICA ONANUGA MATHEW ADEWALE ONAOLA BABATUNDE ONASANYA ADETAYO ONASANYA BAKIU ADENIYI ONASANYA VICTOR OLAGUNJU A. ONASILE KAYODE KEHINDE ONI GRACE OLUWATOMIWA ONLJAMES OJO ONLIOSHUA AYOOLA OLABISI ONI OLATUNBUSUN OLUFEMI AKINKUNLE ONI OLAYINKA ABIODUN ONI OLUWASEUN ONI OLUWEAMUYIWA PETER ONIBANIYI TEMITOPE JOSEPH ONIBOKUN ADETUNJI VICTOR ONIFADE RUKAYAT BOLANLE ONIGBANJO ADENIYI SURAJUDEEN

ONIGBOGI OLUGBENGA

ONIKOYI MORILIAT ANIKE

ONILADO MODUPEOLUWA ITUNUOLUWA ONIMOLE LYDIA ONIROKO WAHEED AREMU ONIRU OLUMIDE SOLOMON ONITIRI LANRE ONIWINDE ADEBOYE TAIWO ONIYEMOFE EBRUBA FOLASHADE ONIYITAN MUYIWA ONOJA ENEMOYI SARAH ONOKPITE GODSPOWER OGHENEVBOGAGA ONONOGBO VINCENT O. ONOTOLE ANTHONIA OSEHI ONU EZI KALU ONU JOHN CYPRIAN ONUCHUKWU EMEKA ONUEGBU CHUKWUJEKWU LEONARD ONUEKWUSI AKWUGO ONUEKWUSI EUGENIA ONUEKWUSI JULIANA ONUEKWUSI NWANNEKA ONUEKWUSI UDOKA ONUH JOSEPH TOCHUKWU ONUH SHADRACK HANANIAH ONUKWUGHA SPIFF OKECHUKWU ONUOHA MARTINA UGO ONUOHA NGOZI ANGELA ONUORA NGOZI ONWOCHEI POLYCARP SUNDAY ONWOH MARY IFY ONWU PEGGY WIGWE ONWUAGANA BENJAMIN ONWUAGANA BENSON EMEKA ONWUAMA NKEM ONWUBUARIRI IHEOMA C. ONWUCHEKWA JULIE OGECHI ONWUCHEKWA VINCENT UCHE ONWUDIEEGWU CHIBUZO JULIUS ONWUDINJO FERDINAND CHIMEZIE ONWUDIWE ANTHONY UKACHUKWU ONWUEBUCHI CLARA ONWUEGBUNA AMECHI SUNDAY ONWUEGBUZIE SUSAN UZORCHIKWA ONWUEKWEIKPE MATTHEW NDUKAUBA ONWUFOR MICHAEL EMEKA ONWUKA AMANDA CHIDERAH ONWUKA CHUKWUDI MICHEAL ONWUKA DORIS ONWUKA PASCHAL NDUKWE ONWUKWE MICHAEL CHUKWUDI ONWUKWE SAMUEL ADUBISI ONYEAKA VERA UKAMAKA ONYEBEADI STELLA NGOZI ONYEBUCHI NATHAN IFENKWE ONYEBUENYI VERONICA NWANYIOMA ONYECHE GRACE ONYEHURUCHI HENRY IKECHI ONYEIBOR ANTHONY ONYEJE CHUKWUDI ONYEJEGBU AGBOR ONYEJEKWE ERNEST ONYEJEKWE JUDE ONYEJOSE FRANCIS IKECHUKWU ONYEKA OGBONNA PATRICK ONYEKWELE CHUKWUMERIJE ONYEKWELU CHUKWUNONSO OKWUDILI ONYEMACHI OBIOMA NGOZI AGNES ONYEMAEKE CHINWENDU MATILDA ONYEMARA EMMANUEL CHUKWUMA ONYEMEKEIHIA IFEANYI CARINA ONYENWEAKU UZOMA ONYENWESON SUNNY .C. ONYEOZIRI FAVOUR UGOCHUKWU ONYEOZIRI WINNER NMERI ONYEUKWU NKEMJIKA OSINACHI ONYEZE LAMBERT ANAEBOM OPADOKUN HENRY ADEGOKE OPAFEMI FIYIFOI UWA IFENNA OPAJOBI ADUNNI OLUMAYOWA OPARA EDWIN CHUKWUEMEKA MURPHY OPARA INNOCENT OPARA JANE JOVITA OPARA LEONARD EZENWA OPARA SUNDAY MICHEAL OPARAH STELLA IHUOMA (MRS) OPARA-NESTOR CHISOMAGA AZUBIKE OPARINDE CLEMENT OLUSEYI OPEBI OLUWABUNMI OMOTAYO

OPEKE SEGUN KAYODE

OPENE IJEOMA CHRISTOPHER OPEOLUWA DEBAYO DOHERTY EST OF OPEOLUWA IYABODE AYOKA OPITOKE CHARLES OPOKO AKUNNAYA PEARL OPUTA GEOFFREY UWADIEGWU ORAEGBU CHUKWUMA ORANAGWA UZOCHUKWU ANTHONT ORANYA OLUCHUKWU AUGUSTINE ORDUAH INNOCENT OREDIPE EMMANUEL KAYODE OREDIPE LATEEF ADEYEMI OREKOYA MODUPE ELIZABETH OREKOYA OLUSEGUN ADETOLA OREKYEH NWABUNWANNE RICHARD OREMADE OYEDEJI ORENUGA JUSTUS SOLA ORESANYA ADERIBIGBE SIMON ORETAN SAMUEL OLAJIDE OREYEJU FUNMILAYO ORHII EUGENIA AYAM ORHURHU BENSON ORIBAMISE BAYODE JULIUS ORIBAMISE CHARLIE OLAKUNLE ORIBAMISE ELIZABETH BOSEDE ORIBAMISE OJO STEPHEN ORIDOYE FOLAKE TITILOPE ORIERE MABEL ORIMOGUNJE BODE-THOMAS ORIOWO MARGARET MAYOWA ORISABIYI TAIWO ATANDA ORJI FIDELIA EBEKUCHI ORJI IFEOMA MARYANNE ORJI KALU JOSEPHINE **ORJI KINGSLEY** ORJI SUNDAY AZUBUIKE ORJI SUNDAY DESMOND ORJI UCHENNA SANDRA ORJI VICTOR CHUKWUEMEKA ORJICHUKWUENE UWAKWE DENNIS ORKPEH MAGDALENE ZAMBER OROGU ELOHOR PRECIOUS OROWOLE KOLAWOLE INUMIDUN ORUAMA BOKOLO ORUIGBO CHIMEZIE VALENTINE ORUKPE BENARD ORUMETEME OMOKARO OSABUOHIEN OSAYAMEN HARRISON OSADEBAMWEN EMOKARO OSADEBE MARIAN UNOMA OSAGBAEKHOMWEN GIFT OSAYANOMO OSAKA DANIEL OSAKWE JULIE ANASE OSARO UZAMA OSARIEMEN OSARUMWENSE AIMENOHO ROBERT OSARUMWENSE CHRISTOPHER OSASU OSAZUWA MOSES OSAZUWA OSEGBO PATRICIA OBIAGELI OSEH KEHINDE MICHAEL OSELE EUNICE EFOMO OSEMENE-ALHASSAN AUGUSTA OSENI OLANIKE ADUNNI OSENI OLAWALE SUNDAY OSHATOBA BOLATITO OSHIAME OMOLE AFISHIETU OSHINFADE BOLA TAYO OSHINOWO BABATUNDE ADEYEMI OSHINOWO SHAMSIDEEN .O OSHO OLUSEGUN SAMUEL OSHODI ABIOLA OLUMIDE OSHODI ASHABI FATIMOH OSHODI JACOB ADEGBOYEGA OSHODI KUDIRAT KOFOWOROLA OSHOMAH CATHERINE OSHUNGBUYI MICHAEL O. OSI JOHN MGBANA OSIGBEME TORITSEMOFE J. OSIKALU LUCIA FUNMILAYO OSINEYE BOI UWATIFF ESTHER OSINOWO OLAKUNLE OLUSEUN OSINUBI OLAWALE HAKEEM OSINUPEBI WOLE BOLARINWA OSOBA ADEYEMI SOLOMON OSOBA SAMUEL AYINLA(ESTATE OF -) OSOBASE CHRISTOPHER OSOBASE VICTOR OSOBU GABRIEL OSOBU OLALEKAN OSOBU OREOLUWA

OSOGHO-AJALA NDUKWE MICHAEL

OYEDELE AMOS

OSOLIKI ADEBOUN ADETORO OSONDU IJEOMA OSONDU VICTOR ONYEKA OSORDI AUSTIN ONOCHIE OSUAGWU CHIMA JOHNPIUS OSUJI NNABUEZE STANLEY OSUNBIYI OLUMIDE OLASUNKANMI OSUNBUNMI AYO & FUNMI OSUNDE EUNICE NKECHI OSUNDEYI MARY MORADEKE OSUNKOYA SUNDAY AFOLABI OSUNTOGUN BABATUNDE ADEDAYO OSUNTOKUN OLUSEUN OLUDARE OSUOCHA PERPETUA IFENWA OSUOHA A CHIMA OTAIRU ADBULGANIYU OTAKOYA OLUWASEUN ADETOUN OTARU KUBURAT IYABO OTASANYA ADENIKE ABIOLA OTEGBADE OLUWALEKE ADEYEMI OTEKAYI OLUFUNMILAYO DEBORAH OTENAIKE OLUWASEUN DARE **OTI ESTHER** OTI NWEZE OTIOCHA JAMES OKEY OTO AKOMHEN OTOLORIN OLUWATOBI OTOMEWO ANGELA OMEJEVWE OTONO MICHAEL OTTIH NNEOMA EILEEN OTTO OLUBAYO OLANIYI OTUADA LAURA OMAMUYOVWI OTUFOWORA TAIWO DANIEL OTUKOMAYA SAMUSIDEEN OYEKUNLE OTUN GANIYU AJANI OVADJE OGHENETEGA ANDREW OVEDHE WILFRED MEMENA OVIAWE TAIWO ABIMBOLA OVIE AGHOMI OVOH OGHALE BLESSING OVUEZIRIE EMMANUEL EHIDIAMEN O. OWANIKIN SOLOMON DOTUN OWATI ADEBOLA OWATI ADEBOLA TOYIN OWHERUO AYETUOMA MESHACH OWIE EGHO JOHN OWOADE ADEREMI OWOADE ADETUNJI OWOADE OLUFEMI ADEYEMI OWODEYI RASHEEDAT OWOEYE AFOLABI C OWOEYE ENIOLA TREASURE OWOEYE IBITADE OLUKAYODE OWOEYE ISREAL OMOTAYO OWOEYE SAMUEL OLUYEMI OWOJORI ODUNYEMI ABRAHAM OWOLABI ADEKUNLE KAREEM OWOLABI OLADAPO GBENGA OWOLABI OLUFUNMILAYO OYENIKE OWOLABI OLUSOLA JOHNSON OWOLABI OLUWASEGUN TOLULOPE OWOLAYO HARRISON OWOOLA ABIOLA WASIU OWOSENI ABIOLA **OWOYEMI TOLULOPE** OWOYOMI AYODEJI OLUSEGUN OWUAMALAM CHRISTIAN CHINAEYE OWUMI FAITH OWUNA HABIBA YAHAYA OYADOYE OMOTAYO LAWRENCE OYAKHIRE EFEILOMON RICH OYAMIENLEN GODFREY EHIKIOYA OYAREGBA OMOZUAFO SHAKA OYATOBO ENIOLA ABOSEDE OYAWALE SAMUEL ADEBAYO OYE SOLOMON KEHINDE OYE VICTOR IKE OYEBADE OLUWASEUN EMMANUEL OYEBAMIJI RASAKI AYOFE OYEBANJI GRACE ABIMBOLA OYEBANJI TEMITOPE ELIZABETH OYEBODE DADA OYEBODE OYEWUNMI OMOTOYOSI OYEDAPO JULIUS ABIODUN OYEDEJI ABRAHAM OYEDEJI AKINDELE OLAWUMI OYEDEJI MATHEW OYEBODE OYEDEJI TUNDE ABRAHAM OYEDELE ADETOYESE ADESOYE

OYEDIRAN ALICE MUBO OYEDIRAN OYEWOLE AYOBAMI OYEDIRAN SAMSON AKINLOLU OYEDOKUN ADEFISOYE TAIWO OYEDOKUN CHRISTIANAH OLUWEMIMO OYEDU ANAYO AMAECHI OYEFODUNRIN PRINCESS ABIKE ADEFUNKE OYEFOLU ROTIMI FRANCIS PATRICK OYEGBEMI VERONICA OLUFUNMILAYO OYEGOKE AYODELE OYEGOKE SAMSON ADEOLU OYEGUE UYINMWEN DESMOND OYEGUNJU ISIAKA AKINLOYE OYEGUNLE JOSEPH OLAJIDE OYEKA ELOBIKE ERNEST OYEKAN ADEMILEKAN ADEMIDIPUPO OYEKAN ADETOMIWA ADEYINKA OYEKAN IDIAT OLOLADE OYEKAN IFALADE AJASA OYEKAN PETER OYEGBADE OYEKAN WAHEED OYEKANMI ABAYOMI L OYEKANMI LYDIA IDOWU OYEKANMI OLUWAFEMI OLUWAPELUMI OYEKOLA TIMILEYIN ANU OYELADE A. OLADAPO OYELADE AANUOLUWAPO CHRISTOPHER OYELADE IFUEKO OYELADE OLUWAFEMI DANIELLA OYELADE TAYO SUNDAY OYELAKIN, OLADOSU OLALEKAN OYELAMI ABIODUN FEYISAYO OYELAMI GBENGA GABRIEL OYELAYO EYITAYO OYEYEMI OYELEKAN BOSE ESTHER OYELEKE FERANMI OYELEKE OLAWUMI OYELERE JOSEPH AYODELE OYELESE OLUFEMI OYELEYE DAVID AJIBADE OYELOLA BOLANLE WALIYAT OYELOLA OYETUNJI HASSAN OYENIRAN BASIRAT OYEYEMI OYENUGA ADETOMI BABATUNDE OYEPEJU ADEREMI ABRAHAM OYERINDE ADESINA OYERINDE SAHEED OYEKUNLE OYERO ENIOLA MUSHAFAU OYEROGBA EMMANUEL KEHINDE OYEROGBA VERONICA E. OYESANMI DAVID OLABODE OYESINA OLUWATOSIN TEMILOLUWA OYETADE STEPHEN OBALOLUWA OYETAN OLUMIDE OYETOLA OLUSHOLA DEBOLA OYETUNJI GBADEBO JOSIAH OYETUNMBI ALABA MORUFU OYEUSI EBENEZER OLUJIDE OYEWOLE DAVID & AYOBAMI OYEWOLE DAVID OYEBODE OYEWOLE EMMANUEL OYEBAMJI OYEWUSI TOLULOPE Y OYEYEMI ADEMOLA OYEYEMI DARE JOSHUA OYEYINKA PATRICK TOKUNBO OYIBOKA IFEOMA JENNIFER OYIBOTSA-DIARE ARIOVO FLORENCE OYIGWU SULE HABU OYINBO AYODELE OYINKI NATHAN WONARU OYINLOYE ADEJUWON PETERS OYINLOYE KUNLE OLANREWAJU OYINLOYE RUFUS OLAWALE OYINWOLA MOSUNMOLA OLATUNDE OZAH EMEKA THEOPHILUS OZOANI GEOFFREY CHUKWUMA OZOEMELAM NDUBUISLLUNDY OZOEMENA AUGUSTINE IKECHUKWU OZOEMENA BONIFACE OZOGBU FRANCIS & JULIET OZUE ERNEST BILIVI PAKOH GIDEON PAMICOL NOMINEES PAMSTAR INVESTMENT LIMITED PASTOR MRS GLAYS NWANKWO PATRICK DANIEL PATRICK UGOCHUKWU NNAMDI

PATRICK-BIENWI LEDUM

PAUL JAMES NNAJI PAUL OGOCHUKWU H O PAUL OKPE PAUL OWOLABI PAUL OZIEH JOSHUA CHUKWUNWIKE TOBI PAUL-INOFOMOH KENNETH EGBOMOADE PEDABO ASSOCIATES LTD PEMI YETUNDE TEMITOPE PENNY ATWORK VENTURES LIMITED PERTINENCE LIMITED PETERS ADENIKE MODUPE PETTERS ANNE-MARY PEWAN SHEDRACH BENJAMIN PH EMBASSY COOP INVEST&CREDIT S PHIL-EBOSIE ANENE & NENGI PHILIP VICTORIA .O PHILIPS SUNDAY PHILLIPS OYEWOLE ABAYOMI PITCHER ROBERT PIUS OLUWAFEMI SOLOMON PLATEAU INVESTMENT & PROPERTY DEV CO LTD PLUMSTEAD INV. LTD PML SECURITIES COMPANY LIMITED POLA NIG LTD POPOOLA ADESINA SAMUEL POPOOLA FRANCIS KAYODE POPOOLA FUNKE ANIKE POPOOLA OLADAYO POPOOLA OLUFELA POPOOLA OLUKUNLE IDOWU POPOOLA OLUTOPE BEATRICE POPOOLA SUNDAY AYOKUNLE POROKU ADEDAYO DANIEL PORTFOLIO MANAGER ACCOUNT PREYE OTHNIEL EBIKOLA PRINCE TRIUMPHANT INT'L SCH PRO CARE PLUS INC. PROFUND STOCKBROKERS LTD PROGRESSIVE NIPOST STAFF MULTI-PURPOSE PSL PORTFOLIO MANAGEMENT PU YI YANG & NEI PURPOSETODAY INV LTD PIC 019 LA PYRAMID SECURITIES LIMITED QUADRI BABAJIDE CHARLES QUDRI KUDIRAT DEOLA QUEENSPRIDE VENTURES RAFIU FATAI RAFIU MODINAT MORENIKE RAFIU OWOLABI AJAYI RAINBOW TRADING ACCOUNT RAJI ADETUNJI OYEKAN RAJI ISMAILA ADEWALE RAJI SAHEED OLANREWAJU RAJI WAREEZ OLALEKAN RASAK RISIKAT OMOLARA RASAQ ABIDEMI OLANREWAJU RASAQ TAJUDEEN RASHEED AKANNI KAREEM REDEEMERS UNIVERSITY REDEMPTION INVESTMENT LTD RENIER VAN ROOYEN REUBEN C UKAH REWANE ITUNU OPEYEMI REWARD - NOMINEE A/C REWARD SHARE MARGIN ACCOUNT RHAHOR OCHUKO DOROTHY RICHARDS DAVID RICHIES CAPITAL LIMITED RITE FOODS LIMITED RITT INVESTMENTS LIMITED ROBERT BLESSING DAVID ROBINSON EKENE AKABIO **ROB-SIL NIG ENTERPRISES** BOBSON SAMUEL ROLAND GABRIEL ROMEO TONYE ANTHONIA ROSSET GLOBAL VENTURES ROWET CAPITAL MANAGEMENT LTD ROWLANDS HENRY ADE ROYAL APOGEE LTD ROYAL CREST FINANCE LTD-DEPOSIT A/C ROYAL GUARANTY & TRUST LTD RUFAI DAMOLA SODIQ RUKAYYA SALEH MAINA

SADAUKI AISHATU PAMELA SADEX GRAPHIC COMPANY SADIKU HAMZAT SADIQ ABDULLAHI ADEOLA SADIQ DAVID OLALEKAN SADIQ DAVID OLALEKAN REMILEKUN SAFIYANU SHARIKU SAHEED HALIMAT SAINTS MULTI-PURPOSE COOP SOC LTD SAKA MUIDEEN ADEWALE SAKA NUSIRAT OMOBOLANLE SALAHUDEEN HAMMED OLUSOLA SALAKO TAOFIK & BADRU ISMAIL SALAM ABASS SALAMI JUSTIINA SOBALOJU SALAMI OLAYEMI MOJIDAT SALAMI OMETERE OLABISI SALAMI SIKIRU ADIO SALAMI TEMITOPE J SALAMI YUSUF BISI SALAMI YUSUFU BISI SALAU HAMMED KAYODE SALAU OMOYEMI IBRAHEEM SALAUDEEN OLAMIDE ABDLATEEF SALAWU ADEGBENGA SALAWU MURITALA SALAWU PAUL SALAWU RAMONI LAYI SALAWU RUKAYAT OLAIDE SALEH SHAMSUDDEEN ABDULLAHI SALIHU JAMILU HAMZA SALIHU JAMILU MUSA SALIMON HALIMAT AJOKE JAYEOLA SALISU MUHAMMAD ADEBAYO SALIU ISMAIL FOLORUNSHO SALIU REMI ITUNU SALMON IDRIS AKINRELE SAMBO ABBAS SANNI SAMEDE MAUREEN ESSE SAMM-PATT NIGERIA LIMITED SAMPOU TARI MRS SAMSON OLANIYI MOSES SAMUEL ABIMBOLA SAMUEL FLORA EMA SAMUEL GBEMINIYI OLANREWAJU SAMUEL JOSEPH KEHINDE SAMUEL OLUWASEGUN ABEL SAMUEL OLUWATOSIN OLUWADARASIMI SANDEY CHARLES OLUBUNMI SANGODOYIN BANJI SANGONIRAN OLUFEMI ADEDEJI SANGOWAWA OLUTOMI SANI LAWAL ALH. SANI MUHAMMAD AMINU SANI SALAMATU JUNAID SANKORE SECURITIES LIMITED SANNI ABIODUN CHRISTIANA SANNI KAFILAT MOSUMOLA AMOKE SANNI MUSILIMOT BOLANLE SANNI NAOMI EFO SANNI OLAYINKA MOYOSORE SANNI QUADRI IDOWU SANNI SIKIRU ADIGUN SANUSI ABDURRAHMAN SANUSI OLUWATOSIN ENIOLA AJOKE SANUSI ZAGE ZUBAIRU SANWOOLU OLUSEGUN OLUSEYI SANYAOLU FOYEKE ADENIKE SARUMI AFUSAT TITILAYO SARUMI ALAO SHAKIRU SARUMI BABATUNDE ABDULKABIR SARUMI GANIYAT OMOBOLANLE SARUMI OLANREWAJU RASHEED SARUMI OLUWAFISAYO JUMOKE SARUMI RAHEEMAT BOLUTIFE SARUMI RASAQ ADEDAYO SARUMI YINKA MOSHOOD SASA MICHAEL SUNDAY SAVAGE ADEBUKOLA ARIKE SAVAGE ELIZABETH NADU SAYYADI IBRAHIM SCA INVESTMENT LTD SCAB CONSULT LTD SCM INVESTMENT MANAGEMENT LTD A/C 3 SCOTT BABAWALE OLADIPO

RUNSEWE FOLAHAN ADEOLA

RUQAYA NASIR-USMAN

SAAIIO VENTURES

SADA KABIRU BELLO

SEAGIRT VENTURES LTD SECOYA LIMITED SEEDDIGIT LIMITED SEEDVEST LTD SEGUN OGUNRINDE SEKUMADE SUNDAY ALABI SELEEM ADEGUNWA SERAVAC NIGERIA LIMITED SERAVAC NIGERIA LTD SERIKI IDRIS ABIODUN SFS RESEARCH SHA GYANG DR. SHABI ABDUL-RAZAQ SHABU TERTSEA SHADRACK MOFOLUKE ADENIUNJU SHAH PUVESH SHAH SUSIIE SHAH VIDYUT SHAIBU ABACHI MOHAMMED SHAIBU AISHATU MUHAMMED SHAIBU HUSSEINI HASSAN SHAIBU OSENI T ALATU SHAREHOLDERS INVESTOR & OPERATORS SHARIF ABDULLAHI BABAJI SHEHU ABDULKADIR HAUWA SHEHU ABDULSAMAD KEHINDE SHEHU FATIMA MOHAMMED SHEHU MOHAMMED DAHA SHEHU UNEKU SHEIKH NASIRU QASIYUNI KABARA SHENOWO OLANIYI SHERIFF HAJJA AMNE SHITTU OLUWAKEMI OYEKUNBI SHITTU SEMIU OLAWALE SHITTU SULAIMON AYINLA SHOBANJO OLANREWAJU DILALAT SHOBOWALE BABATUNDE SHODA ISIWAT IYABODE SHODIPO BABATUNDE SHOEWU OLUWASEGUN SHOFOLAHAN ELIZABETH BUKOLA SHOFOLAHAN FRANCISCA BOLATITO SHOGBALA FASASI AYINLA OLALEKAN SHOGBAMU FATIMAH SHOKOYA YINUS ADEKUNLE SHOKUNBI KAMILU MUHAMMED SHOKUNBI OLUFEMI OLAKUNLE SHOLLYVEN COMMUNICATIONS SHOMORIN OLUWAKEMI SEUN SHONDE SAMUEL KOSEUNTI SHONEYE ROTIOLUWA .O SHONOWO FADEKE ISLAMIYAT SHOPEJU EFUNBOSEDE AYOTUNDE SHOPEJU EFUNREMI ADETUTU SHOWUNMI ADEJORO OMOWALE SHOWUNMI OLATUNJI A. SHOYEMI ADEDEJI SHOYODE IBUKUNOLUWA AMMAH SHOYOMBO OLUWATOBI SIMON SHOYOMBO SAIGE OLUWATONI SHYLLON ADETUNJI KAYODE SICOS FLOURISH INTERBIZ COY SIKIRU SAHEED ALIU SKINNER MOSES OMEIZA SKY PAVILION SKYEBANK PLC/READINGS INV LTD -TRADING SKYEBANK PLCREADINGS INV LTD TRADING SMART BOLA IDAYAT SMITH ASAHANKPO VICTOR SOARES ABATAN SOARES ABIODUN SOARES LAIWOLA SOARES LANRE SOARES OMOTIDOLO SOARES PAUL SOARES YEMISI SOBANDE OPEYEMI OLUBUKUNOLA SOBOWALE ADENRELE A. WAHEED SODIPE OLUWAGBEMILEKE OLUWASEGUN SODIPE WALE SAMUEL SOETAN A.OLUWOLE, EST OLUGBEMIGA & ORS(A SOFOLUKE SIGISMUND OLATUNJI SOKOYA MICHAEL SUNDAY SOLID KAY ENTERPRISES SOLID BASE CONTRACTORS LTD SOLOMON K. ADEOTI SOLOMON OLUSINA

SOMEFUN OLUFUNKE OLADUNNI

UMAR YAHAYA

SOMEFUN OLUGBENGA SEUN SONEYE FOLASADE OLAJUMOKE SONUGA MARIE STELLA SOOLA OLUYINKA OLUBUNMI SORETIRE OLUSOLA BOLAJOKO SOTOYINBO FOLUSO TITILAYO SOULEYMANE ALANI SOULMATE INDUSTRIES LIMITED SOWEMIMO ADEDAYO SOWEMIMO OLUSOLA OLABISI SOYINKA ABDULAI FATAI AYINDE SOYINKA TUNJI OLUSEGUN SOYOMBO OLUWATOBI TIMOTHY SPRING LIFE ASSURANCE PLC ST CLARE TRAVELS LTD STAR SISTERS LIMITED STEPHEN AUGUSTINA IFEOMA STEPHEN DAVID AKPAN STEVE JEMERIGBE STOCKMATCH INVESTMENT LIMITED STUDENTS PYE NIGERIA LTD SUBAIR RASAKI SULAIMAN IBRAHIM DAYYAB SULAIMAN IBRAHIM KASSIM SULAIMAN YEWANDE SAKIRAT SULAIMAN YUSUF SULAIMON ADEDEJI YUSSUF SULE ABIOLA SEKINAT SULE OYANAVHE OSILAMA SULEIMAN ABDULLAHI KABIR SULEIMAN AISHA JIBRIN SULEIMAN ARABA MARUF ADEKUNLE SULEMAN KABIRU SULIEMAN KABIRU SUNDAY DAVID CHUKWUDI SUNDAY GODWIN SEGUN SUNDAY OGBONNAYA OKEREKE SUNDAY OHIERO SUNDAY OLOJA SUNDAY VICTOR NDUBUISI SUNMOLA LASBAT ABIODUN (ALHAJI) SUNMON IBRAHIM OLAWOLE SUNMONU LANRE HAKEEM SUNMONU SULE AFOLABI AKANBI SUNNY OKUNDIA ADETOKUNBO ADEOLU SURAKAT MORUF AJASA OLALEKAN SYDNEY PHILLIPS LIMITED T & T TRADE TIMES TAFIDA FATIMA ISA TAFIDA KHADIJA ISA TAFIDA MARYAM ISA TAFIDA SADIQ ISA TAFIDA SADIYA ISA TAIRAT TIJANI TAIRAT TIJANI BOLANLE TAISUF LIMITED TAIWO ADETOUN OLAYEMI TAIWO AYOOLA AFONJA TAIWO KASHIMAWO AKANJI TAIWO MODUPE OLUYOMI TAIWO OLALEKAN MATTHEW TAIWO OLUFUNKE TAIWO OLUSEGUN MICHAEL TAIWO VICTOR OPEOLUWA TAJUDEEN NAJEEM AREMU TAJUDEEN TAIWO JAMIU TAJUDEEN TINUBU TEMILOLUWA TAMA IDRIS MUSA TAMUNO MAUREEN TANGALE EAST PROGRESSIVE ASSOC TANIMOMO ORITSEGBEMI OLUWANIMISOKAN TANIMOWO AYOMIDE TIMOTHY TANIMOWO AYOOLUWASUBOMI SAMUEL TANIMOWO OLUWABUSAYOMI THERESA TANIMOWO SAMUEL OLUMIDE TANKO ABUBAKAR DADIQ TARHENA MOSES KOLEDJO TARIAH SOIBIFA-A TAYLOR TITUS OLUSEGUN TECHBENIK LTD TEE A & WYE CREATION LTD TEME AMACHREE & IBIOKU TEMEDIE JOHN-NOBLE TEMISAN STEFANIA AMARA TEMISANRE DANIEL ATSENUWA - TESS TEMISANRE TUOYO G. TEN PLUS INVESTMENT LTD TENGAN AZUAKA TENGAN AZUAKU CLETUS

TENIOLA BUKOLA TENIOLA OLABODE TENIOLA TENPLUS INVESTMENT LTD TERIBA OLUMUYIWA TERSUGH JAMES VANDEFAN THE ANJI COMPANY LIMITED THE EATERY PLACE THE ESTATE OF EMIABATA KEHINDE LAWAL THE FUN PLACE THE LEISURE PLACE THELMA BASSEY THOMAS EDDY OKON TIAMIYU ADEYANJU RAMOTU TIAMIYU BUSURA TIJANI ADEGOKE AZEEZ TIJANI AJIMOTU MONYENI TIJANI ISMAIL MUHAMMOD AWWAL TIJANI LASISI AGBOOLA TIJANI MUIZ ADEYINKA TIJANI NABEEHA TIJANI NMAKA TIJANI TAYE-TAWO KANYINSOLA TIJANI, ADIJATU-KUBURA OLUWATOSIN TIJJANI ALIYAH UTHMAN TIJJANI BABAGANA TIJJANI KAZEEM ADESOLA TIJJANI RAKIYA TIMBO OGUNSULIRE TIME SQUARE GLOBAL VENTURES TIMOTHY JOHNSON OLUFEMI ADEOYE TIMOTHY PRECIOUS OLUWANIFEMI TIMOTHY(AMB) OLUFEMI TIMSTOWN CO NIGERIA LIMITED TINUBU TEMITAYO TITILOYE TEMITOPE O. TITUS AYO DELE EZEKIEL TOBYINBETTONI VICTORIA TOGUN MICHAEL OLUSHOLA TOM EDET PRINCEWILL TOMORI OLANREWAJU AKINWALE TONWE OSADIAYE GRACE TONY-GAY INVESTMENT LTD TOP NOTCH INTEGRATED SOLUTIONS LTD TOPMOST FIN.& INV. LTD.TRADED-STOCK-A/C TOYE DAVID OLUWADAMILOLA TRANSFORTE LIMITED TREVATE INVESTMENTS LTD TRUSTBANC CAPITAL ACCOUNT TSAFE ABDULLAHI BAWA TSAKPORHORE EMUOGHENERURU TSEUMAH GODDY TUBBS MARINE & ENERGY LIMITED TUDOR DEVELOPMENT LIMITED TURNER OMOYELE MICHEAL TWINKLE AND WINKLS KIDDIES CONCEPT UACL STAFF SOCIAL CLUB UAIB LIMITED UBA CHUKWUEMEKA MAC UBA UMAR UMAR UBABUDIKE OYIBO STEPHEN **UBAH UCHE EARNEST** UBAJEKWE CHUKWUELOKA **UBAJEKWE TIMOTHY** UBAK SAMUEL SYLVESTER UBANI JOSEPH LUCKY UBOGU FELIX NKWAONYE & OLUFUNMILAYO ITUN UCHE CLAUDIO IFEANYI UCHE GREG C. **UCHE METU** UCHE SHIRLEY ANADUAKA UCHE UDOCHUKWU ELISHA UCHE-ANYA ADAKU ANTHONIA UCHEBO PAUL CHUKWUEBUKA UCHENNA KALU UCHE-OKORO CHINYERE J F UCHIME IHUOMA FELICITY UDAZE BENJAMIN E. UDAZE EHIZUSI UDE EBELE 1 UDE IKENNA CHARLES UDE OKECHUKWU STANLEY UDEAGBALA VENESSA IFEOMA UDEAGWU RICHARD CHUKWUKADIBIA UDECHUKWU EMEKA ANTHONY

UDEH CYRIL NWABUEZE

UDEH DAVID UDEM CHINAZO STEPHNIE UDEM UZONNA DANIEL UDENTA KENNETH OKWUDILI UDEOGARANYA PATRICK OBINNA UDO GODWIN PATRICK UDO UDUAK AKPAN UDOAKA IDARESTI JOYCE UDODI JOHNSON EJIKE UDOFIA AKANINYENE EMMANUEL UDOFIA IME ASUQUO UDOGU OKECHUKWU CHARLES UDOH EDEM OKON UDOH EMMANUEL JOHN UDOH EVELYN ELIJAH UDOH HARDING UDOH HELEN LESOR UDOH LAWRENCE NELSON UDOIDIONG EMMANUEL HARRISON UDOJI UGOCHUKWU KINGSLEY UDOKA MATTHEW TITUS UDOMAH WILSON IKECHUKWU UDONSAK SAMUEL NAOMI UDOYE EMMANUEL O UDOYE MILLICENT CHIKAODILI UDU FIDELIS L. UDU INNOCENT UDU SOLOMON UDUM CYRIACUS CHRISTIAN UDUMAGA LYDIA OJONIMI UFFANG TOMMY INYANG UFONDU MADUABUROCHUKWU UFOT OKON JIMMY UGBAJA NDUBUEZE ROBERT UGBALA NDUBUISI TONI UGBEGWE REGINA EDIRIN UGBO ESOSA JOHAM UGBO OSAGUMWENRO UGBO OSAMAGIOGHOMWENWI UGHACHUKWU ISREAL BUNNA UGHE LINDA UGIOMOH PAUL OMOBA UGO EMMANUEL IKECHUKWU UGOEKE VICTORIA NDIDI UGOH LAETITIA I. MRS UGONABO EBELE EUCHARIA UGORJI CYNTHIA CHIUDO UGORJI KELECHI LOVEDAY UGOWE IYARE JOHN UGWAH OGUEJIOFOR MICHAEL UGWU ANSELEM IKECHUKWU UGWU CHIDI PETER UGWU GODFREY UGWU UGWU LAWRENCE OKAFOR UGWU VICTOR SUNDAY UGWUANYI NGOZIKA UGWUEZE GODWIN ANAYO UGWUNNA NDUKA MAURICE UGWUOTA FESTUS OKONKWO UHARA CHIGOZIE CHINYERE UHOMOHASABHOR GODWIN .E UJOMOH OGOCHUKWU MICHAEL UJU CAJETAN OGBONNAYA UKACHI CORNELUS OYEMAUCHECHI UKAGHA MAURICE UWANDU UKASOANYA UGOCHI JOY UKATTA ANNA - MARY ODIAKU UKATTA HENRY KELECHUKWU UKEJIANYA IFEOMA GLORIA UKEOMA IKECHUKWU CHIBUZOR UKO JOHN JOSEPH UKO WILLIAM OKODI UKONU PETER IKECHUKWU UKOT GRACE AKPANAM UKPONG CHRISTIANA LUCKY UKPONG EMMANUEL UDO UKPONG ENO GEORGE UKUESAN DAVID O. UKWATAR KARI IYETOR ULASI NWAMAKA MARYANN ULOH KELECHI REMMY UMANA MFONOBONG UBONG UMAR ALIYU RINJI UMAR FATIMA IBRAHIM UMAR HAYATU UMAR KUDRAT FUNMILAYO UMAR MOHAMMED ADABARA UMAR MUSA ABDULLAHI UMAR SANI YELWA UMAR YAHAYA

UMAR ZACHEAUS UMARU AZAGAKU TSOTAN UMEANO CHINONSO FABIAN UMEGBO CHINEDU VALENTINE UMEH UDOKA IFEANYI UMEH, CHINELO SYLVIA UMEOKANA CHIKE EBUBECHUKWU UMEOKONKWO CHUKWUMA DAVID UMEOKORO IFEANYICHUKWU JUDE UMISHI T DOMINIC UMO JOE UDO UMO MICHAEL AKPAN UMOBI BENJAMIN CHINEMELUM UMOH EFFIONG MATHEW UMOH GABRIEL O. UMOH IBORO UMOH ITORO MICHAEL UMOH LADY EMEM UMOH SUNDAY JOHN UMONAH ETIDO MONDAY UMO-OTONG UMO ETIM DR UMOREN BLESSING UKPONG UMOREN EDET JOSEPH UMOREN KEISHA UMORU IZEGBOYA DESMOND UMUDI FRANK UMUNNAKWE UGOCHUKWU C UNABAA IFEANYI C UNEKE I. FELICIA UNILORIN HEALTH CARE MULTI-P CO SOC UNION CAPITAL MARKETS LIMITED UNOARUMHI STELLA UNOKHUA PATRICK UNOZOR CHIMEZIE PATRICK UNUIGBE JACOB AGHOMO UNUIGBOJE IRIA IONE UNUIGBOJE ORDIA RYAN URUEBOR ABEL REMALIAH URUEBOR JOYCE OGHENEKOMENO USAK GODWIN EDET USIAPHRE PATRICK ONOME USMAN ABDULHAKEEM USMAN ABUBAKAR ADAMU USMAN AIYESATU USMAN AMINA BAKO USMAN CONCERN SUMAIYA USMAN FAROUK USMAN HAMZA USMAN KABIRU IBRAHIM USMAN OMOTAYO ISHAAQ USMAN UMAR MAIRIGA USMAN ZULAIHATU USMANA HUDSON ILIYA USOH ONYEDIKA C UTONWANNE IFEANYICHUKWU .A UTUK KOKO EDDIE GODSPEED UWADIAE F O S ADESUWA MR&MRS UWADIAE FLORENCE NKONYE UWAJEH ALEX NKENCHOR UWAJEH MAXWELL OGUGUA UWAKWE CHIDI PRINCEWILL UZAIRU JAFARU ALHASAN UZAMA FAITH OLUWATOYIN UZO TAMMY NWOKORO UZOCHUKWU CHIMA UZODIKE OBIORA UGOCHUKWU UZOETO BRIDGET UZOH AKAONYE BEN UZOKWE DAVID OKAFOR UZOKWE IFEANYI JOACHIN UZOMA GODSPOWER BUDUZHI UZOMA VICTORIA CHIKODI UZONDU EKE UZONG FELIX UZOR OLIVER EMEKA UZOR S NDUDI UZOSIKE UZOAMAKA JOY UZUH JOHN NDUKA VARGAS OBULOR & CHINYERE VETIVA NOMINEES A/C-FELIX NWABUKO VICBOL NIG LTD VICTOR ODEH & ASSOCIATES VICTOR OLU- AMINU VICTOR-AGOZUE PAMELA ONYEMAECHI VICTORIAN CLUB VINCENT MONSURAT MODESOLA VINCENT OLUWATOMI VINSTAR CONSULTING WAATE PETER NUBARIDO

YUSUF HABIBAT ONYIYI

WABARA KINGSLEY WABARA WADA ABUBAKAR WADA ASMAU MUSA WAHABI TAOFEEK OLANREWAJU WAILA SECURITIES AND FUNDS LTD. WAJERO OLUGBENGA AMBROSE WAMI CHIMENEM KELVIN WANAPIA NUHSODAH ILIYA WASIU ADEWALE AZEEZ WATSON MOSES WAZIRI HASSANA WEJINYA OSOBI CHINWEIKPE WELEBE IKECHI LAWRENCE WELI CHIKARU WEMA ASSET PORTFOLIO MGT A/C WICKLIFFE DAMILOLA DAVID WILLIAM ONWUKA WILLIAMS CHARLES TOLULOPE WILLIAMS DAVID ADEKUNLE ADEDEJI WILLIAMS OLADIPO WILLIAMS OLOLADE WILLIAMS OLUFEMI WILLIAMS PAUL DAYO WILLIAMS-OJO OLUWAYEMISI OLUWATOYIN WILLIE NWOKOYE

WILLIKI JOSHUA

WILLOUGHBY MARTIN ABAYOMI WOKE DON WOLE-OKE STEVEN OLATIWOLA WONDERLAND FUN FAIR WORLDWIDE COMM VENTURES WURAOLA AYODEJI KOLAWOLE WYSE BUILDERS & PARTNERS NIG. LTD XEMESIS ENTERPRISES XU WANG YADUDU AUWALU HAMISU YAHAYA ADO BICHI YAHAYA ALIYU ZUBAIRU YAHAYA BASHIR YAHAYA YAHAYA FA**I**ZU LAWAL YAHAYA IMRANA UMAR YAHAYA MOHAMMED AGEFU YAHAYA NAFIU YAHAYA UMARU YAKUBU ALI YAKUBU AMINU YAKUBU HALIMAT S. YAKUBU IDRIS

YAKUBU JEMEELAH

YAKUBU SHERIFAH

YALEGIN AUGUSTA .I

YAKUBU SHERIFF

YAKUBU JOSHUA SHARAH

YAMAH BOSEDE JANE YANMING ZHAO YARIMA FATIMA HAMZA YASHIM JACOB JOHN YELWA S. HAMISU YEMPEE INVESTMENTS LIMITED YER**I**MA ABBAS YEROKUN SOJI TIMOTHY YEWANDE AYOOLA AFONJA YIKE FENG YISA AISHA OIZA YOIL UNIQUE FARM LTD YOMI-FAKAYODE OLUFUNKE ABOSEDE YOUNG EMMANUEL YUBA RAYMOND AMIUNUMHENFO YUGUDA ABIODUN YUNUS ABIDEEN ABIODUN YUSSUF ZAINAB ADESHINA YUSUF ABDUL YUSUF ABDULLAH AYOADE YUSUF ADAMU YUSUF ADIJAT RANTI YUSUF AHMED HAMBALI YUSUF ALABI YUSUF BASHINU BURUM BURUM YUSUF BASHIR AHMED

YUSUF GLORY TAIWO

YUSUF HAFEES ADEKUNLE YUSUF HAMMED YUSUF MUHAMMADU INUWA YUSUF OLUSADE OMOLABAKE YUSUF OLUSOLA.A YUSUF RAMAT YUSUF SAKA YUSUF SAMAILA YUSUF TAIB OMOTAYO YUSUFF FAOSIYAT OMOTOYOSI YUSUFF OLUWATOYIN BILIKIS YUSUFF YESZIR OLUWASEHUN ZAKARI MOMOH SAMUEL ZANGIR GEORGE ZARAH HARUNA SHAYAU ZARMA AJIYA ZARMA FATIMA AJIYA ZARMA HAFSAT AJIYA ZARMA MUHAMMED AJIYA ZARMA NANAFATIMA AJIYA ZENITHBANK/AFRINVEST(W.A)/CLIENTS-TRDNG ZOMELO GBENGA SAMUEL ZUBAIR BABATUNDE ZUBAIR JIDE ZUBAIR MULKAHT

FIDSON WORD SEARCH

V C P Y G L 0 D J Α S Α В D D E P E Δ Y Y R S A Y Α L G S Т S Ν В S Α R 0 Т Т J Ε V M C Α 0 R M Α M 0 J C Y 0 J E X K M R M Ε Q E R Ε Α F Ν Н 0 T P P Т Y Ν X P 0 Q F Ε Т F N U T M E C W R Q ı M Ε Ν G Ε S C V J Α D Α M J D U Α C A Α V Ε Т R Α S В Ν D Ν Z C L Ν Α Τ 0 B R T 0 Α F W F U L Α V P 0 L 0 Ν Т E U C D P Т Н U 0 N М W L Ν Α X 0 X S C R D F Ε O В Ν G Y X F R C Ε F Α Ν M D A Z R Ε R 0 K N Α B L 0 0

Arthemed Asomex Astyfer Astvmin Aventra Avipol Avstat Ciprotab Clavamox Emal Ferobin Fidson Fidvite Fitulin Gascol Life Mannoll Meprasil Neutrosec Obanikoro Ranicef Tabufen Tribotan Tuxil Vitamin

NOTES	

Tuxil® Cough&Cold

...FOR COUGH-FREE NIGHTS &

REFRESHING MORNINGS





REPAIR® RECOVER

PEOPLE ALWAYS ASK, "HOW UNA DEY DO AM?"

...and we say to them, this country is not for the faint-hearted; complaining only doubles the 'wahala'. Some of us have become masters of our own - working hard and working smart, giving as much to the day as it requires.

Sure, the hustle takes its toll on the body. That's why we give it the goodness of amino acids and multivitamin in ASTYMIN, that helps us REPAIR & RECOVER from everyday fatigue... so that we can keep going, no shaking.

